Carvedilol/NNP protects/VBZ doxorubicin/NN induced/VBN cardiomyopathy/NN
carvedilol/NN protects/VBZ dysfunction/NN associated/VBN toxicity/NN
doxorubicin/NN toxicity/NN
carvedilol/NN protection/NN afford/VB minimizing/VBG limiting/VBG dysfunction/NN cardiomyopathy/NN
doxorubicin/NN therapy/NN accompanies/VBZ dysfunction/NN mitochondrial/JJ
doxorubicin/NN therapy/NN accompanies/VBZ dysfunction/NN
doxorubicin/NN therapy/NN patients/NNS cancer/NN
carvedilol/NN protection/NN afford/VB minimizing/VBG limiting/VBG dysfunction/NN accompanies/VBZ therapy/NN patients/NNS cancer/NN
carvedilol/NN protection/NN afford/VB minimizing/VBG limiting/VBG dysfunction/NN mitochondrial/JJ
carvedilol/NN protection/NN afford/VB minimizing/VBG limiting/VBG dysfunction/NN
indinavir/NN therapy/NN undergoing/VBG causing/VBG obstruction/NN ureteric/JJ
indinavir/NN therapy/NN undergoing/VBG causing/VBG obstruction/NN
indinavir/NN receiving/VBG describe/VBP HIV/NN
indinavir/NN receiving/VBG patients/NNS infected/JJ
indinavir/NN associated/VBN incidence/NN urolithiasis/NNS
indinavir/NN crystals/NNS caused/VBN obstruction/NN Ureteric/JJ
indinavir/NN crystals/NNS caused/VBN obstruction/NN
indinavir/NN therapy/NN receive/VBP patients/NNS enable/VB diagnosis/NN stones/NNS ureteric/JJ
indinavir/NN therapy/NN receive/VBP patients/NNS enable/VB diagnosis/NN stones/NNS
indinavir/NN therapy/NN receive/VBP patients/NNS enable/VB diagnosis/NN stones/NNS or/CC
indinavir/NN therapy/NN receive/VBP patients/NNS enable/VB diagnosis/NN stones/NNS obstruction/NN
indinavir/NN therapy/NN receive/VBP patients/NNS infection/NN HIV/NN
indinavir/NN therapy/NN receive/VBP patients/NNS infection/NN
pilsicainide/NN received/VBD convert/VB fibrillation/NN atrial/JJ
pilsicainide/NN received/VBD convert/VB fibrillation/NN
sodium/NN blocker/NN pilsicainide/NN received/VBD convert/VB fibrillation/NN atrial/JJ
sodium/NN blocker/NN pilsicainide/NN received/VBD convert/VB fibrillation/NN
sodium/NN blocker/NN pilsicainide/NN received/VBD developed/VBD death/NN sudden/JJ
sodium/NN blocker/NN pilsicainide/NN received/VBD developed/VBD death/NN cardiac/JJ
sodium/NN blocker/NN pilsicainide/NN received/VBD developed/VBD death/NN
pilsicainide/NN effective/JJ terminate/VB fibrillation/NN atrial/JJ
pilsicainide/NN effective/JJ terminate/VB fibrillation/NN
terbinafine/JJ metoprolol/JJ drug/NN induced/VBN report/VB bradycardia/NN sinus/JJ
terbinafine/JJ metoprolol/JJ drug/NN induced/VBN report/VB bradycardia/NN
metoprolol/JJ drug/NN induced/VBN report/VB bradycardia/NN sinus/JJ
metoprolol/JJ drug/NN induced/VBN report/VB bradycardia/NN
metoprolol/JJ 200/CD man/NN mg/JJ year/NN day/NN prescribed/VBN onychomycosis/NNS
terbinafine/NN mg/NN course/NN 90/CD prescribed/VBN day/NN disease/NN coronary/JJ
terbinafine/NN mg/NN course/NN 90/CD prescribed/VBN day/NN disease/NN artery/NN
terbinafine/NN mg/NN course/NN 90/CD prescribed/VBN day/NN disease/NN
terbinafine/NN mg/NN course/NN 90/CD prescribed/VBN onychomycosis/NNS
metoprolol/JJ 200/CD man/NN mg/JJ year/NN day/NN disease/NN coronary/JJ
metoprolol/JJ 200/CD man/NN mg/JJ year/NN day/NN disease/NN artery/NN
metoprolol/JJ 200/CD man/NN mg/JJ year/NN day/NN disease/NN
terbinafine/JJ therapy/NN day/NN brought/VBN room/NN decrease/NN status/NN confusion/NN
terbinafine/NN metoprolol/NN interaction/NN relationship/NN indicates/VBZ score/NN 7/CD scale/NN adverse/JJ
terbinafine/NN metoprolol/NN interaction/NN relationship/NN indicates/VBZ score/NN 7/CD scale/NN drug/NN
terbinafine/NN metoprolol/NN interaction/NN relationship/NN indicates/VBZ score/NN 7/CD scale/NN reaction/NN
terbinafine/NN metoprolol/NN interaction/NN relationship/NN bradycardia/NN sinus/NNS
terbinafine/NN metoprolol/NN interaction/NN relationship/NN bradycardia/NN
metoprolol/NN interaction/NN relationship/NN indicates/VBZ score/NN 7/CD scale/NN adverse/JJ
metoprolol/NN interaction/NN relationship/NN indicates/VBZ score/NN 7/CD scale/NN drug/NN
metoprolol/NN interaction/NN relationship/NN indicates/VBZ score/NN 7/CD scale/NN reaction/NN
metoprolol/NN interaction/NN relationship/NN bradycardia/NN sinus/NNS
metoprolol/NN interaction/NN relationship/NN bradycardia/NN
terbinafine/NN decreased/VBN clearance/NN leading/VBG accumulation/NN resulted/VBN bradycardia/NN sinus/NNS
terbinafine/NN decreased/VBN clearance/NN leading/VBG accumulation/NN resulted/VBN bradycardia/NN
metoprolol/NNP clearance/NN leading/VBG accumulation/NN resulted/VBN bradycardia/NN sinus/NNS
metoprolol/NNP clearance/NN leading/VBG accumulation/NN resulted/VBN bradycardia/NN
metoprolol/JJ accumulation/NN resulted/VBN bradycardia/NN sinus/NNS
metoprolol/JJ accumulation/NN resulted/VBN bradycardia/NN
creatinine/NN levels/NNS augment/VB affect/VB ability/NN induce/VB injury/NN acute/JJ
creatinine/NN levels/NNS augment/VB affect/VB ability/NN induce/VB injury/NN kidney/NN
creatinine/NN levels/NNS augment/VB affect/VB ability/NN induce/VB injury/NN
urea/NN creatinine/NN levels/NNS augment/VB affect/VB ability/NN induce/VB injury/NN acute/JJ
urea/NN creatinine/NN levels/NNS augment/VB affect/VB ability/NN induce/VB injury/NN kidney/NN
urea/NN creatinine/NN levels/NNS augment/VB affect/VB ability/NN induce/VB injury/NN
urea/NN creatinine/NN levels/NNS augment/VB affect/VB increase/VB score/NN acute/JJ
urea/NN creatinine/NN levels/NNS augment/VB affect/VB increase/VB score/NN tubular/JJ
urea/NN creatinine/NN levels/NNS augment/VB affect/VB increase/VB score/NN necrosis/NNS
creatinine/NN levels/NNS augment/VB affect/VB increase/VB score/NN acute/JJ
creatinine/NN levels/NNS augment/VB affect/VB increase/VB score/NN tubular/JJ
creatinine/NN levels/NNS augment/VB affect/VB increase/VB score/NN necrosis/NNS
cisplatin/NN involved/VBN induced/VBN mediating/VBG process/NN necrotic/JJ
cisplatin/NN therapy/NN induced/VBN nephrotoxicity/NN
dexmedetomidine/NN administration/NN year/NN syncope/NN
aminoglycosides/NNS trials/NNS indicate/VBP ranges/VBZ risk/NN developing/VBG failure/NN acute/JJ
aminoglycosides/NNS trials/NNS indicate/VBP ranges/VBZ risk/NN developing/VBG failure/NN renal/JJ
aminoglycosides/NNS trials/NNS indicate/VBP ranges/VBZ risk/NN developing/VBG failure/NN
aminoglycoside/NN levels/NNS therapy/NN disease/NN liver/NN
aminoglycoside/NN levels/NNS therapy/NN disease/NN
creatinine/NN clearance/NN therapy/NN duration/NN increase/VB risk/NN nephrotoxicity/NN
creatinine/NN clearance/NN therapy/NN disease/NN liver/NN
creatinine/NN clearance/NN therapy/NN disease/NN
Levodopa/NNP induced/VBN improved/VBN dyskinesias/NNS
dopamine/JJ agonist/NN challenge/NN evaluated/VBN severity/NN disability/NN motor/NN
dopamine/JJ agonist/NN challenge/NN evaluated/VBN severity/NN disability/NN
dopamine/JJ agonist/NN challenge/NN evaluated/VBN severity/NN dyskinesias/NNS patients/NNS disease/NN Parkinson/NNP
dopamine/JJ agonist/NN challenge/NN evaluated/VBN severity/NN dyskinesias/NNS patients/NNS disease/NN Parkinson/NNP '/POS
dopamine/JJ agonist/NN challenge/NN evaluated/VBN severity/NN dyskinesias/NNS patients/NNS disease/NN s/JJ
dopamine/JJ agonist/NN challenge/NN evaluated/VBN severity/NN dyskinesias/NNS patients/NNS disease/NN
fluoxetine/NN administration/NN apomorphine/NN agonist/NN challenge/NN evaluated/VBN severity/NN disability/NN motor/NN
fluoxetine/NN administration/NN apomorphine/NN agonist/NN challenge/NN evaluated/VBN severity/NN disability/NN
levodopa/NN dyskinesias/NNS patients/NNS disease/NN Parkinson/NNP
levodopa/NN dyskinesias/NNS patients/NNS disease/NN Parkinson/NNP '/POS
levodopa/NN dyskinesias/NNS patients/NNS disease/NN s/JJ
levodopa/NN dyskinesias/NNS patients/NNS disease/NN
levodopa/NN dyskinesias/NNS
apomorphine/NN agonist/NN challenge/NN evaluated/VBN severity/NN disability/NN motor/NN
apomorphine/NN agonist/NN challenge/NN evaluated/VBN severity/NN disability/NN
dopamine/JJ agonist/NN challenge/NN evaluated/VBN severity/NN dyskinesias/NNS
apomorphine/NN agonist/NN challenge/NN evaluated/VBN severity/NN dyskinesias/NNS patients/NNS disease/NN Parkinson/NNP
apomorphine/NN agonist/NN challenge/NN evaluated/VBN severity/NN dyskinesias/NNS patients/NNS disease/NN Parkinson/NNP '/POS
apomorphine/NN agonist/NN challenge/NN evaluated/VBN severity/NN dyskinesias/NNS patients/NNS disease/NN s/JJ
apomorphine/NN agonist/NN challenge/NN evaluated/VBN severity/NN dyskinesias/NNS patients/NNS disease/NN
levodopa/NN dyskinesias/NNS severity/NN disability/NN motor/NN
levodopa/NN dyskinesias/NNS severity/NN disability/NN
fluoxetine/NN administration/NN apomorphine/NN agonist/NN challenge/NN evaluated/VBN severity/NN dyskinesias/NNS patients/NNS disease/NN Parkinson/NNP
fluoxetine/NN administration/NN apomorphine/NN agonist/NN challenge/NN evaluated/VBN severity/NN dyskinesias/NNS patients/NNS disease/NN Parkinson/NNP '/POS
fluoxetine/NN administration/NN apomorphine/NN agonist/NN challenge/NN evaluated/VBN severity/NN dyskinesias/NNS patients/NNS disease/NN s/JJ
fluoxetine/NN administration/NN apomorphine/NN agonist/NN challenge/NN evaluated/VBN severity/NN dyskinesias/NNS patients/NNS disease/NN
fluoxetine/JJ treatment/NN was/VBD improvement/NN apomorphine/NN induced/VBN modification/NN disability/NN motor/NN
fluoxetine/JJ treatment/NN was/VBD improvement/NN apomorphine/NN induced/VBN modification/NN disability/NN
apomorphine/NN induced/VBN modification/NN disability/NN motor/NN
apomorphine/NN induced/VBN modification/NN disability/NN
apomorphine/NN induced/VBN modification/NN disability/NN parkinsonian/JJ
fluoxetine/JJ treatment/NN was/VBD improvement/NN apomorphine/NN induced/VBN modification/NN disability/NN parkinsonian/JJ
dopamine/JJ agonist/JJ levodopa/JJ dyskinesias/NNS reduce/VB disability/NN motor/NN
dopamine/JJ agonist/JJ levodopa/JJ dyskinesias/NNS reduce/VB disability/NN
dopamine/JJ agonist/JJ levodopa/JJ dyskinesias/NNS reduce/VB disability/NN parkinsonian/NN
fluoxetine/NN transmission/NN reduce/VB disability/NN motor/NN
fluoxetine/NN transmission/NN reduce/VB disability/NN
levodopa/JJ dyskinesias/NNS reduce/VB disability/NN parkinsonian/NN
levodopa/JJ dyskinesias/NNS
dopamine/JJ agonist/JJ levodopa/JJ dyskinesias/NNS
levodopa/JJ dyskinesias/NNS reduce/VB disability/NN motor/NN
levodopa/JJ dyskinesias/NNS reduce/VB disability/NN
fluoxetine/NN transmission/NN reduce/VB disability/NN parkinsonian/NN
MIP/NNP inhibition/NN replicate/VB pilocarpine/NN model/NN seizures/NNS
inositol/JJ sensitive/JJ pilocarpine/NN model/NN seizures/NNS
lithium/NN effects/NNS replicate/VB pilocarpine/NN model/NN seizures/NNS
mefenamic/JJ acid/NN non/NN effect/NN investigate/VB designed/VBN seizures/NNS
acid/NN non/NN effect/NN investigate/VB designed/VBN seizures/NNS
indomethacin/NN non/NN effect/NN investigate/VB designed/VBN seizures/NNS
ibuprofen/NN non/NN effect/NN investigate/VB designed/VBN seizures/NNS
Indomethacin/NNP failed/VBD seizures/NNS
ibuprofen/NN kg/NN failed/VBD seizures/NNS
Mefenamic/NNP mg/VBP prevented/VBD seizures/NNS
acid/CD Mefenamic/NNP mg/VBP prevented/VBD seizures/NNS
Mefenamic/NNP mg/VBP prevented/VBD seizures/NNS rats/NNS seizure/NN
acid/CD Mefenamic/NNP mg/VBP prevented/VBD seizures/NNS rats/NNS seizure/NN
Mefenamic/NNP mg/VBP prevented/VBD seizures/NNS damage/NN brain/NN
Mefenamic/NNP mg/VBP prevented/VBD seizures/NNS damage/NN
acid/CD Mefenamic/NNP mg/VBP prevented/VBD seizures/NNS damage/NN brain/NN
acid/CD Mefenamic/NNP mg/VBP prevented/VBD seizures/NNS damage/NN
pilocarpine/NN induced/VBN damage/NN brain/NN
pilocarpine/NN induced/VBN damage/NN
Niacin/NNP extended/VBD release/NN product/NN approved/VBN treatment/NN hypercholesterolemia/NN dyslipidemia/NN
extended/VBD release/NN product/NN approved/VBN treatment/NN hypercholesterolemia/NN dyslipidemia/NN
release/NN product/NN approved/VBN treatment/NN hypercholesterolemia/NN dyslipidemia/NN
lovastatin/NN product/NN approved/VBN treatment/NN hypercholesterolemia/NN dyslipidemia/NN
Niacin/NNP extended/VBD release/NN product/NN approved/VBN treatment/NN hypercholesterolemia/NN
extended/VBD release/NN product/NN approved/VBN treatment/NN hypercholesterolemia/NN
release/NN product/NN approved/VBN treatment/NN hypercholesterolemia/NN
lovastatin/NN product/NN approved/VBN treatment/NN hypercholesterolemia/NN
niacin/JJ dyslipidemia/JJ
extended/JJ lovastatin/NN dyslipidemia/JJ
release/NN lovastatin/NN dyslipidemia/JJ
lovastatin/NN dyslipidemia/JJ
creatine/NN increase/NN phosphokinase/VBP observed/JJ myopathy/RB
metformin/NN suppresses/NNS treatment/NN left/VBD
metformin/NN suppresses/NNS treatment/NN left/VBD dysfunction/NN ventricular/NN
metformin/NN suppresses/NNS treatment/NN left/VBD dysfunction/NN
metformin/NN suppresses/NNS treatment/NN left/VBD dysfunction/NN infarction/NN myocardial/JJ
metformin/NN suppresses/NNS treatment/NN left/VBD dysfunction/NN infarction/NN
AMP/NNP activation/NN has/VBZ effect/NN infarction/NN myocardial/JJ
AMP/NNP activation/NN has/VBZ effect/NN infarction/NN
metformin/NN treatment/NN has/VBZ effect/NN infarction/NN myocardial/JJ
metformin/NN treatment/NN has/VBZ effect/NN infarction/NN
metformin/NN treatment/NN effect/NN activities/NNS infarction/NN myocardial/JJ
metformin/NN treatment/NN effect/NN activities/NNS infarction/NN
metformin/NN treatment/NN dysfunction/NN cardiac/JJ
metformin/NN treatment/NN dysfunction/NN
metformin/NN kg/NN 25/CD treated/VBN groups/NNS lower/JJR dysfunction/NN left/JJ
metformin/NN kg/NN 25/CD treated/VBN groups/NNS lower/JJR dysfunction/NN ventricular/NN
metformin/NN kg/NN 25/CD treated/VBN groups/NNS lower/JJR dysfunction/NN
isoproterenol/JJ mRNA/NN lowered/VBD myeloid/VBD 88/CD factor/NN tumor/NN
isoproterenol/JJ mRNA/NN lowered/VBD myeloid/VBD 88/CD factor/NN necrosis/NN
metformin/NN treatment/NN reduces/VBZ post/NN dysfunction/NNS myocardial/JJ
metformin/NN treatment/NN reduces/VBZ post/NN dysfunction/NNS infarction/NN
levodopa/NN effect/NN Pharmacodynamics/NNS patients/NNS parkinsonian/NN
levodopa/NN i/FW effects/NNS examined/VBN patients/NNS parkinsonian/NN
levodopa/NN examined/VBN patients/NNS parkinsonian/NN
Phenylalanine/RB reduced/VBD effects/NNS hypotensive/NN
amino/JJ acid/NN reduced/VBD effects/NNS hypotensive/NN
acid/NN reduced/VBD effects/NNS hypotensive/NN
Phenytoin/NNP induced/VBN injury/NN hepatic/JJ
Phenytoin/NNP induced/VBN injury/NN
FZP/NNP toxocity/NN
FZP/NNP toxocity/NN Signs/NNS included/VBD salivation/NN
FZP/NNP toxocity/NN Signs/NNS included/VBD salivation/NN tremors/NNS muscle/NN
FZP/NNP toxocity/NN Signs/NNS included/VBD salivation/NN tremors/NNS
FZP/NNP use/NN relevant/JJ situations/NNS is/VBZ excitability/NN epilepsy/NN
Amiodarone/NNP induced/VBN coma/NN myxoedema/NN
Amiodarone/NNP induced/VBN coma/NN
amiodarone/JJ therapy/NN fibrillation/NN atrial/JJ
amiodarone/JJ therapy/NN fibrillation/NN
amiodarone/NN cases/NNS induced/VBN coma/NN myxoedema/NN
amiodarone/NN cases/NNS induced/VBN coma/NN
amiodarone/NN case/NN represents/VBZ significant/JJ disease/NN thyroid/NN
amiodarone/NN case/NN represents/VBZ significant/JJ disease/NN
amiodarone/NN case/NN represents/VBZ significant/JJ coma/NN myxoedema/NN
amiodarone/NN case/NN represents/VBZ significant/JJ coma/NN
NADPH/NNP number/NN catalepsy/NN
nitric/NN inhibition/NN Sub/NNP catalepsy/NN
oxide/NN synthesis/NN Sub/NNP catalepsy/NN
NG/NNP RATIONALE/NNP induces/VBZ catalepsy/RB
nitro/NN NG/NNP RATIONALE/NNP induces/VBZ catalepsy/RB
L/NNP RATIONALE/NNP induces/VBZ catalepsy/RB
arginine/NN induces/VBZ catalepsy/RB
L/NNP arginine/NN induces/VBZ catalepsy/RB
NOARG/NNP L/NNP arginine/NN induces/VBZ catalepsy/RB
nitric/NN inhibitor/NN arginine/NN induces/VBZ catalepsy/RB
oxide/NN synthase/NN inhibitor/NN arginine/NN induces/VBZ catalepsy/RB
dopamine/JJ receptors/NNS block/VB drugs/NNS cause/VBP catalepsy/RB
L/NNP effects/NNS investigate/VB induced/VBN catalepsy/NN
NOARG/VBG investigate/VB induced/VBN catalepsy/NN
L/NNP NOARG/VBG induced/VBN catalepsy/RB
NOARG/VBG induced/VBN catalepsy/RB
L/NNP tolerance/NN produced/VBD NOARG/VBG induced/VBN catalepsy/RB
NOARG/VBG NOARG/VBG induced/VBN catalepsy/RB
Angiotensin/NNP used/VBD treat/VB failure/NN hypertension/NN
converting/VBG used/VBD treat/VB failure/NN hypertension/NN
enzyme/JJ inhibitors/NNS converting/VBG used/VBD treat/VB failure/NN hypertension/NN
ACE/NNP inhibitors/NNS converting/VBG used/VBD treat/VB failure/NN hypertension/NN
inhibitors/NNS converting/VBG used/VBD treat/VB failure/NN hypertension/NN
Angiotensin/NNP used/VBD treat/VB failure/NN hypertension/NN congestive/JJ
Angiotensin/NNP used/VBD treat/VB failure/NN heart/NN
Angiotensin/NNP used/VBD treat/VB failure/NN
converting/VBG used/VBD treat/VB failure/NN hypertension/NN congestive/JJ
converting/VBG used/VBD treat/VB failure/NN heart/NN
converting/VBG used/VBD treat/VB failure/NN
enzyme/JJ inhibitors/NNS converting/VBG used/VBD treat/VB failure/NN hypertension/NN congestive/JJ
enzyme/JJ inhibitors/NNS converting/VBG used/VBD treat/VB failure/NN heart/NN
enzyme/JJ inhibitors/NNS converting/VBG used/VBD treat/VB failure/NN
ACE/NNP inhibitors/NNS converting/VBG used/VBD treat/VB failure/NN hypertension/NN congestive/JJ
ACE/NNP inhibitors/NNS converting/VBG used/VBD treat/VB failure/NN heart/NN
ACE/NNP inhibitors/NNS converting/VBG used/VBD treat/VB failure/NN
inhibitors/NNS converting/VBG used/VBD treat/VB failure/NN hypertension/NN congestive/JJ
inhibitors/NNS converting/VBG used/VBD treat/VB failure/NN heart/NN
inhibitors/NNS converting/VBG used/VBD treat/VB failure/NN
MK/NNP actions/NNS model/NN epilepticus/NNS status/NN
MK/NNP actions/NNS model/NN epilepticus/NNS
801/CD actions/NNS model/NN epilepticus/NNS status/NN
801/CD actions/NNS model/NN epilepticus/NNS
pilocarpine/NN lithium/NN coadministration/NN models/NNS seizure/NN
pilocarpine/NN dose/NN administration/NN models/NNS seizure/NN
N/NNP aspartate/NN 801/CD tested/VBN rats/NNS using/VBG models/NNS seizure/NN
methyl/NN aspartate/NN 801/CD tested/VBN rats/NNS using/VBG models/NNS seizure/NN
D/NNP methyl/NN aspartate/NN 801/CD tested/VBN rats/NNS using/VBG models/NNS seizure/NN
aspartate/NN 801/CD tested/VBN rats/NNS using/VBG models/NNS seizure/NN
NMDA/NNP aspartate/NN 801/CD tested/VBN rats/NNS using/VBG models/NNS seizure/NN
lithium/NN coadministration/NN models/NNS seizure/NN
MK/NNP tested/VBN rats/NNS using/VBG models/NNS seizure/NN
801/CD tested/VBN rats/NNS using/VBG models/NNS seizure/NN
pilocarpine/VBP suggesting/VBG control/VBP seizures/NNS
pilocarpine/NN treated/VBN rats/NNS pilocarpine/VBP suggesting/VBG control/VBP seizures/NNS
lithium/NN produced/VBN 801/CD pretreatment/NN pilocarpine/VBP suggesting/VBG control/VBP seizures/NNS
MK/NNP pretreatment/NN pilocarpine/VBP suggesting/VBG control/VBP seizures/NNS
801/CD pretreatment/NN pilocarpine/VBP suggesting/VBG control/VBP seizures/NNS
pilocarpine/VBP occurred/VBD periods/NNS activity/NN seizure/NN
lithium/NN 801/CD effect/NN pilocarpine/VBP occurred/VBD periods/NNS activity/NN seizure/NN
MK/NNP effect/NN pilocarpine/VBP occurred/VBD periods/NNS activity/NN seizure/NN
801/CD effect/NN pilocarpine/VBP occurred/VBD periods/NNS activity/NN seizure/NN
pilocarpine/NN lithium/NN induced/VBN seizures/NNS
pilocarpine/NN lithium/NN induced/VBN seizures/NNS block/VB easy/JJ difficult/JJ terminate/VB block/VB lethality/NN seizures/NNS
pilocarpine/NN prior/RB anticonvulsants/NNS administration/NN induced/VBN seizures/NNS
pilocarpine/NN prior/RB anticonvulsants/NNS administration/NN induced/VBN seizures/NNS block/VB easy/JJ difficult/JJ terminate/VB block/VB lethality/NN seizures/NNS
lithium/NN induced/VBN seizures/NNS
lithium/NN induced/VBN seizures/NNS block/VB easy/JJ difficult/JJ terminate/VB block/VB lethality/NN seizures/NNS
pilocarpine/NN 30/CD Administration/NNP reduced/VBD activity/NN seizure/NN
MK/NNP Administration/NNP 30/CD epilepticus/NNS status/NN
MK/NNP Administration/NNP 30/CD epilepticus/NNS
801/CD 30/CD epilepticus/NNS status/NN
801/CD 30/CD epilepticus/NNS
MK/NNP Administration/NNP reduced/VBD activity/NN seizure/NN
801/CD 30/CD Administration/NNP reduced/VBD activity/NN seizure/NN
NMDA/NNP receptors/NNS activation/NN plays/VBZ role/NN damage/NN brain/NN
NMDA/NNP receptors/NNS activation/NN plays/VBZ role/NN damage/NN
lithium/JJ model/NN damage/NN brain/NN
lithium/JJ model/NN damage/NN
NMDA/NNP receptors/NNS activation/NN plays/VBZ role/NN epilepticus/NNS status/NN
NMDA/NNP receptors/NNS activation/NN plays/VBZ role/NN epilepticus/NNS
pilocarpine/NN model/NN damage/NN brain/NN
pilocarpine/NN model/NN damage/NN
NMDA/NN doses/NNS synergistic/JJ resulting/VBG epilepticus/NNS status/NN
NMDA/NN doses/NNS synergistic/JJ resulting/VBG epilepticus/NNS
Valproic/JJ acid/NN effective/JJ treatment/NN types/NNS epilepsy/NN
acid/NN effective/JJ treatment/NN types/NNS epilepsy/NN
VPA/NNP acid/NN effective/JJ treatment/NN types/NNS epilepsy/NN
VPA/NNP therapy/NN withdrawal/NN showed/VBD loss/NN weight/NN
VPA/NNP therapy/NN withdrawal/NN showed/VBD loss/NN
5/CD granisetron/NN prevention/NN nausea/NN
hydroxytryptamine/JJ granisetron/NN prevention/NN nausea/NN
5/CD granisetron/NN prevention/NN nausea/NN vomiting/NN
hydroxytryptamine/JJ granisetron/NN prevention/NN nausea/NN vomiting/NN
granisetron/NN prevention/NN nausea/NN vomiting/NN
granisetron/NN prevention/NN nausea/NN
granisetron/NN doses/NNS effects/NNS assess/VB induced/VBN nausea/NN vomiting/NN
Kytril/NNP granisetron/NN doses/NNS effects/NNS assess/VB induced/VBN nausea/NN vomiting/NN
granisetron/NN doses/NNS effects/NNS assess/VB induced/VBN nausea/NN
Kytril/NNP granisetron/NN doses/NNS effects/NNS assess/VB induced/VBN nausea/NN
granisetron/NN doses/NNS RESULTS/NNS kg/NN recorded/VBN response/NN </NNP vomiting/NN
granisetron/NN doses/NNS RESULTS/NNS kg/NN recorded/VBN response/NN rescue/NN vomiting/JJ
granisetron/NN dose/NN effective/JJ vomiting/NN
granisetron/NN dose/NN effective/JJ vomiting/NN %/NN patients/NNS received/VBD prevented/VBD vomiting/NN
H/CD 2/CD O/NNP reduced/VBD prevented/VBD loss/NN weight/NN
H/CD 2/CD O/NNP reduced/VBD prevented/VBD loss/NN
2/CD O/NNP reduced/VBD prevented/VBD loss/NN weight/NN
2/CD O/NNP reduced/VBD prevented/VBD loss/NN
O/NNP reduced/VBD prevented/VBD loss/NN weight/NN
O/NNP reduced/VBD prevented/VBD loss/NN
2/CD O/NNP reduced/VBD prevented/VBD loss/NN weight/NN
2/CD O/NNP reduced/VBD prevented/VBD loss/NN
acetylcholine/NN acid/NN injection/NN acid/NN accelerated/VBD mouse/NN convulsive/JJ
5/CD turnover/NN hydroxytryptamine/NN accelerated/VBD mouse/NN convulsive/JJ
hydroxytryptamine/NN accelerated/VBD mouse/NN convulsive/JJ
5/CD hydroxytryptamine/NN accelerated/VBD mouse/NN convulsive/JJ
HT/NNP 5/CD hydroxytryptamine/NN accelerated/VBD mouse/NN convulsive/JJ
gamma/NN synthesis/NN suppressed/VBD accelerated/VBD mouse/NN convulsive/JJ
aminobutyric/JJ acid/NN injection/NN acid/NN accelerated/VBD mouse/NN convulsive/JJ
acid/NN injection/NN acid/NN accelerated/VBD mouse/NN convulsive/JJ
Fluoxetine/NNP improves/VBZ deficits/NNS memory/NN
Fluoxetine/NNP improves/VBZ deficits/NNS
phenytoin/NN case/NN seizures/NNS
DPH/NNP case/NN seizures/NNS
DPH/NNP concentration/NN normal/JJ presented/VBD rash/NN
DPH/NNP treatment/NN presented/VBD rash/NN
DPH/NNP injection/NN had/VBD normal/JJ presented/VBD rash/NN
DPH/NNP treatment/NN patient/NN alert/VB increase/NN seizures/NNS
DPH/NNP eliminating/VBG alert/VB increase/NN seizures/NNS
guanosine/VBP renin/NN mediated/VBN nephropathy/RB
3/CD guanosine/VBP renin/NN mediated/VBN nephropathy/RB
'/POS 3/CD guanosine/VBP renin/NN mediated/VBN nephropathy/RB
5/CD excretion/NN 3/CD guanosine/VBP renin/NN mediated/VBN nephropathy/RB
'/POS 5/CD excretion/NN 3/CD guanosine/VBP renin/NN mediated/VBN nephropathy/RB
-/JJ excretion/NN 3/CD guanosine/VBP renin/NN mediated/VBN nephropathy/RB
cyclic/JJ excretion/NN 3/CD guanosine/VBP renin/NN mediated/VBN nephropathy/RB
monophosphate/NN excretion/NN 3/CD guanosine/VBP renin/NN mediated/VBN nephropathy/RB
cGMP/NN excretion/NN 3/CD guanosine/VBP renin/NN mediated/VBN nephropathy/RB
DMTU/NNP reduced/VBD damage/NN tubular/JJ
DMTU/NNP reduced/VBD damage/NN
superoxide/JJ anions/NNS play/VBP have/VBP differ/VBP nephropathy/NN
DMTU/NNP SOD/NNP have/VBP differ/VBP nephropathy/NN
DMTU/NNP SOD/NNP differ/VBP nephropathy/NN
prostaglandins/NNS role/NN nephropathy/NN
Salicylate/JJ nephropathy/NN
prostaglandins/NNS development/NN nephropathy/NN
bilirubin/NN deposition/NN leading/VBG unconjugated/VBN hyperbilirubinemia/NN
glucuronyl/JJ transferase/NN absence/NN unconjugated/VBN hyperbilirubinemia/NN
aspirin/NN damage/NN evidence/NN accompanied/VBN jj/NNP jJ/VBP rats/NNS incidence/NN hematuria/NN
aspirin/NN jj/NN treated/VBN p/VBN lesions/NNS increase/NN rats/NNS incidence/NN hematuria/NN
prostaglandin/NN synthesis/NN changes/NNS accompanied/VBN evidence/NN damage/NN renal/JJ
prostaglandin/NN synthesis/NN changes/NNS accompanied/VBN evidence/NN damage/NN
prostaglandin/NN synthesis/NN changes/NNS accompanied/VBN jj/NNP jJ/VBP rats/NNS incidence/NN hematuria/NN
creatinine/NN rats/NNS jJ/VBP jj/NNP accompanied/VBN evidence/NN damage/NN renal/JJ
creatinine/NN rats/NNS jJ/VBP jj/NNP accompanied/VBN evidence/NN damage/NN
creatinine/NN rats/NNS incidence/NN hematuria/NN
prostaglandin/NN synthesis/NN contributes/VBZ lead/VB pathological/VB lesions/NNS deterioration/NN
prostaglandin/NN synthesis/NN contributes/VBZ lead/VB pathological/VB lesions/NNS deterioration/NN function/NN of/IN
prostaglandin/NN synthesis/NN contributes/VBZ lead/VB pathological/VB lesions/NNS deterioration/NN function/NN renal/JJ
prostaglandin/NN synthesis/NN contributes/VBZ lead/VB pathological/VB lesions/NNS deterioration/NN function/NN
prostaglandin/NN synthesis/NN inhibition/NN lead/VB pathological/VB lesions/NNS deterioration/NN
prostaglandin/NN synthesis/NN inhibition/NN lead/VB pathological/VB lesions/NNS deterioration/NN function/NN of/IN
prostaglandin/NN synthesis/NN inhibition/NN lead/VB pathological/VB lesions/NNS deterioration/NN function/NN renal/JJ
prostaglandin/NN synthesis/NN inhibition/NN lead/VB pathological/VB lesions/NNS deterioration/NN function/NN
prostaglandin/NN synthesis/NN contributes/VBZ lead/VB pathological/VB
prostaglandin/NN synthesis/NN contributes/VBZ lead/VB pathological/VB lesions/NNS renal/JJ
prostaglandin/NN synthesis/NN contributes/VBZ lead/VB pathological/VB lesions/NNS medullary/NN
prostaglandin/NN synthesis/NN contributes/VBZ lead/VB pathological/VB lesions/NNS
prostaglandin/NN synthesis/NN inhibition/NN lead/VB pathological/VB
prostaglandin/NN synthesis/NN inhibition/NN lead/VB pathological/VB lesions/NNS renal/JJ
prostaglandin/NN synthesis/NN inhibition/NN lead/VB pathological/VB lesions/NNS medullary/NN
prostaglandin/NN synthesis/NN inhibition/NN lead/VB pathological/VB lesions/NNS
calcium/NN Nissl/NNP served/VBD detect/VB damage/NN neuronal/JJ
calcium/NN Nissl/NNP served/VBD detect/VB damage/NN
MK/NNP induced/VBN protects/VBZ damage/NN brain/NN
MK/NNP induced/VBN protects/VBZ damage/NN
801/CD augments/NNS pilocarpine/JJ MK/NNP induced/VBN protects/VBZ damage/NN brain/NN
801/CD augments/NNS pilocarpine/JJ MK/NNP induced/VBN protects/VBZ damage/NN
pilocarpine/JJ MK/NNP induced/VBN protects/VBZ damage/NN brain/NN
pilocarpine/JJ MK/NNP induced/VBN protects/VBZ damage/NN
pentobarbital/NN Scopolamine/NNP prevented/VBD development/NN pilocarpine/NN induced/VBN seizure/NN
Scopolamine/NNP prevented/VBD development/NN pilocarpine/NN induced/VBN seizure/NN
pentobarbital/JJ Scopolamine/JJ blocked/VBD pilocarpine/NN seizure/NN
pentobarbital/JJ Scopolamine/JJ blocked/VBD pilocarpine/NN treatment/NN augmented/VBN seizure/NN
Scopolamine/JJ blocked/VBD pilocarpine/NN seizure/NN
Scopolamine/JJ blocked/VBD pilocarpine/NN treatment/NN augmented/VBN seizure/NN
MK/NNP Pentobarbital/NNP 801/CD protected/VBN damage/NN brain/NN
MK/NNP Pentobarbital/NNP 801/CD protected/VBN damage/NN
801/CD protected/VBN damage/NN brain/NN
801/CD protected/VBN damage/NN
MK/NNP appeared/VBD protected/VBN damage/NN brain/NN
MK/NNP appeared/VBD protected/VBN damage/NN
801/CD MK/NNP appeared/VBD protected/VBN damage/NN brain/NN
801/CD MK/NNP appeared/VBD protected/VBN damage/NN
scopolamine/NNP Pentobarbital/NNP 801/CD protected/VBN damage/NN brain/NN
scopolamine/NNP Pentobarbital/NNP 801/CD protected/VBN damage/NN
Pentobarbital/NNP 801/CD protected/VBN damage/NN brain/NN
Pentobarbital/NNP 801/CD protected/VBN damage/NN
pilocarpine/NN protected/VBN damage/NN brain/NN
pilocarpine/NN protected/VBN damage/NN
NMDA/NNP receptor/NN cause/VB mechanism/NN elevation/NN transmission/NN propagated/VBN initiated/VBN epilepticus/NNS status/NN
NMDA/NNP receptor/NN cause/VB mechanism/NN elevation/NN transmission/NN propagated/VBN initiated/VBN epilepticus/NNS
NMDA/NNP receptor/NN cause/VB damage/NN brain/NN
NMDA/NNP receptor/NN cause/VB damage/NN
pilocarpine/NN induced/VBN epilepticus/NNS initiated/VBN propagated/VBN transmission/NN elevation/NN mechanism/NN cause/VB damage/NN brain/NN
pilocarpine/NN induced/VBN epilepticus/NNS initiated/VBN propagated/VBN transmission/NN elevation/NN mechanism/NN cause/VB damage/NN
cytarabine/NN encephalopathy/NN Acute/JJ
cytarabine/NN encephalopathy/NN
cytarabine/NN treatment/NN leukemia/NN acute/JJ
cytarabine/NN treatment/NN leukemia/NN lymphoblastic/JJ
cytarabine/NN treatment/NN leukemia/NN
PEG/NNP chemotherapy/NN encephalopathy/NN Acute/JJ
PEG/NNP chemotherapy/NN encephalopathy/NN
asparaginase/JJ cytarabine/NN encephalopathy/NN Acute/JJ
asparaginase/JJ cytarabine/NN encephalopathy/NN
PEG/NNP chemotherapy/NN encephalopathy/NN cytarabine/NN treatment/NN leukemia/NN acute/JJ
PEG/NNP chemotherapy/NN encephalopathy/NN cytarabine/NN treatment/NN leukemia/NN lymphoblastic/JJ
PEG/NNP chemotherapy/NN encephalopathy/NN cytarabine/NN treatment/NN leukemia/NN
asparaginase/JJ cytarabine/NN treatment/NN leukemia/NN acute/JJ
asparaginase/JJ cytarabine/NN treatment/NN leukemia/NN lymphoblastic/JJ
asparaginase/JJ cytarabine/NN treatment/NN leukemia/NN
cytarabine/NN administration/NN sided/VBD encephalopathy/NN acute/JJ
cytarabine/NN administration/NN sided/VBD encephalopathy/NN
artesunate/NN treatment/NN anemia/NN
artesunate/NN described/VBN recommended/VBD drug/NN treatment/NN malaria/NN
artesunate/NN malaria/NN
alfentanil/NN inhibition/NN Increase/NNP fasciculations/NNS muscle/NN
alfentanil/NN inhibition/NN Increase/NNP fasciculations/NNS
alfentanil/JJ group/NN greater/JJR incidence/NN fasciculations/NNS muscle/NN
alfentanil/JJ group/NN greater/JJR incidence/NN fasciculations/NNS
H/NNP cm/NN O/NNP +/JJ higher/JJR pressure/NN fasciculations/NNS muscle/NN
H/NNP cm/NN O/NNP +/JJ higher/JJR pressure/NN fasciculations/NNS
2/CD H/NNP cm/NN O/NNP +/JJ higher/JJR pressure/NN fasciculations/NNS muscle/NN
2/CD H/NNP cm/NN O/NNP +/JJ higher/JJR pressure/NN fasciculations/NNS
O/NNP +/JJ higher/JJR pressure/NN fasciculations/NNS muscle/NN
O/NNP +/JJ higher/JJR pressure/NN fasciculations/NNS
H/NNP cm/VBP +/JJ higher/JJR pressure/NN fasciculations/NNS muscle/NN
H/NNP cm/VBP +/JJ higher/JJR pressure/NN fasciculations/NNS
2/CD H/NNP cm/VBP +/JJ higher/JJR pressure/NN fasciculations/NNS muscle/NN
2/CD H/NNP cm/VBP +/JJ higher/JJR pressure/NN fasciculations/NNS
O/RB cm/VBP +/JJ higher/JJR pressure/NN fasciculations/NNS muscle/NN
O/RB cm/VBP +/JJ higher/JJR pressure/NN fasciculations/NNS
alfentanil/JJ group/NN higher/JJR pressure/NN fasciculations/NNS muscle/NN
alfentanil/JJ group/NN higher/JJR pressure/NN fasciculations/NNS
Alfentanil/JJ micrograms/NNS kg/VBP fasciculations/NNS muscle/NN
Alfentanil/JJ micrograms/NNS kg/VBP fasciculations/NNS
denopamine/NN Improvement/NNP failure/NN cardiac/JJ
denopamine/NN Improvement/NNP failure/NN
TA/NNP denopamine/NN Improvement/NNP failure/NN cardiac/JJ
TA/NNP denopamine/NN Improvement/NNP failure/NN
064/CD TA/NNP denopamine/NN Improvement/NNP failure/NN cardiac/JJ
064/CD TA/NNP denopamine/NN Improvement/NNP failure/NN
denopamine/NN beta/NN agonist/NN improving/VBG failure/NN cardiac/JJ
denopamine/NN beta/NN agonist/NN improving/VBG failure/NN
denopamine/NN doses/NNS induced/VBN arrhythmias/NNS
denopamine/NN trials/NNS warrant/VBP treatment/NN failure/NN cardiac/JJ
denopamine/NN trials/NNS warrant/VBP treatment/NN failure/NN
methotrexate/JJ enhancement/NN images/NNS patients/NNS leukoencephalopathy/NN developed/VBN leukemia/NN acute/JJ
methotrexate/JJ enhancement/NN images/NNS patients/NNS leukoencephalopathy/NN developed/VBN leukemia/NN lymphoblastic/JJ
methotrexate/JJ enhancement/NN images/NNS patients/NNS leukoencephalopathy/NN developed/VBN leukemia/NN
warfarin/NN fibrillation/NN atrial/JJ
warfarin/NN fibrillation/NN
warfarin/NN fibrillation/NN aged/VBN People/NNS rate/NN hemorrhage/NN stroke/NN
warfarin/NN 76/CD older/JJR fibrillation/NN atrial/JJ
warfarin/NN 76/CD older/JJR fibrillation/NN
warfarin/NN 76/CD aged/VBN people/NNS determine/VB incidence/NN hemorrhage/NN stroke/NN
warfarin/NN admitted/VBN network/NN June/NNP fibrillation/NN atrial/JJ
warfarin/NN admitted/VBN network/NN June/NNP fibrillation/NN
warfarin/NN use/NN obtained/VBN strokes/VBZ
warfarin/NN initiation/NN rate/NN stroke/NN
warfarin/NN rate/NN stroke/NN
warfarin/NN treatment/NN is/VBZ demonstrating/VBG low/JJ rate/NN stroke/NN
cholecystokinin/NN seizures/NNS
cholecystokinin/NN seizures/NNS
cholecystokinin/JJ ester/NN administration/NN enhanced/VBD latency/NN seizures/NNS
octapeptide/JJ ester/NN administration/NN enhanced/VBD latency/NN seizures/NNS
CCK/NNP ester/NN administration/NN enhanced/VBD latency/NN seizures/NNS
8/CD CCK/NNP ester/NN administration/NN enhanced/VBD latency/NN seizures/NNS
cholecystokinin/NN octapeptide/NN ester/NN administration/NN enhanced/VBD latency/NN seizures/NNS
octapeptide/NN ester/NN administration/NN enhanced/VBD latency/NN seizures/NNS
CCK/NNP ester/NN administration/NN enhanced/VBD latency/NN seizures/NNS
8/CD CCK/NNP ester/NN administration/NN enhanced/VBD latency/NN seizures/NNS
diazepam/NN 8/CD seizures/NNS
Paclitaxel/NNP acid/NN cancer/NN breast/NN
Paclitaxel/NNP acid/NN cancer/NN
folinic/JJ fluorouracil/JJ acid/NN cancer/NN breast/NN
folinic/JJ fluorouracil/JJ acid/NN cancer/NN
acid/NN cancer/NN breast/NN
acid/NN cancer/NN
5/CD Paclitaxel/NNP acid/NN cancer/NN breast/NN
5/CD Paclitaxel/NNP acid/NN cancer/NN
fluorouracil/JJ acid/NN cancer/NN breast/NN
fluorouracil/JJ acid/NN cancer/NN
paclitaxel/NN acid/NN Fluorouracil/NNP therapies/NNS patients/NNS breast/NN
paclitaxel/NN acid/NN Fluorouracil/NNP therapies/NNS patients/NNS cancer/NN
Taxol/NNP Bristol/NNP acid/NN Fluorouracil/NNP therapies/NNS patients/NNS breast/NN
Taxol/NNP Bristol/NNP acid/NN Fluorouracil/NNP therapies/NNS patients/NNS cancer/NN
folinic/JJ acid/NN Fluorouracil/NNP therapies/NNS patients/NNS breast/NN
folinic/JJ acid/NN Fluorouracil/NNP therapies/NNS patients/NNS cancer/NN
acid/NN Fluorouracil/NNP therapies/NNS patients/NNS breast/NN
acid/NN Fluorouracil/NNP therapies/NNS patients/NNS cancer/NN
5/CD therapies/NNS patients/NNS breast/NN
5/CD therapies/NNS patients/NNS cancer/NN
Fluorouracil/NNP therapies/NNS patients/NNS breast/NN
Fluorouracil/NNP therapies/NNS patients/NNS cancer/NN
Paclitaxel/NNP cytotoxicity/NN
5/CD Paclitaxel/NNP cytotoxicity/NN
fluorouracil/JJ have/JJ cytotoxicity/NN
paclitaxel/JJ mg/NN trial/NN performed/VBD 2/CD cancer/NN breast/NN
paclitaxel/JJ mg/NN trial/NN performed/VBD 2/CD cancer/NN
folinic/JJ mg/NN followed/VBD day/NN hours/NNS mg/NN trial/NN performed/VBD 2/CD cancer/NN breast/NN
folinic/JJ mg/NN followed/VBD day/NN hours/NNS mg/NN trial/NN performed/VBD 2/CD cancer/NN
acid/NN mg/NN followed/VBD day/NN hours/NNS mg/NN trial/NN performed/VBD 2/CD cancer/NN breast/NN
acid/NN mg/NN followed/VBD day/NN hours/NNS mg/NN trial/NN performed/VBD 2/CD cancer/NN
5/CD hour/NN followed/VBD day/NN hours/NNS mg/NN trial/NN performed/VBD 2/CD cancer/NN breast/NN
5/CD hour/NN followed/VBD day/NN hours/NNS mg/NN trial/NN performed/VBD 2/CD cancer/NN
fluorouracil/JJ hour/NN followed/VBD day/NN hours/NNS mg/NN trial/NN performed/VBD 2/CD cancer/NN breast/NN
fluorouracil/JJ hour/NN followed/VBD day/NN hours/NNS mg/NN trial/NN performed/VBD 2/CD cancer/NN
granulocyte/JJ colony/NN required/VBN patients/NNS follow/VB neutropenia/NN
colony/NN required/VBN patients/NNS follow/VB neutropenia/NN
stimulating/JJ follow/VB neutropenia/NN
factor/NN stimulating/JJ follow/VB neutropenia/NN
granulocyte/JJ colony/NN required/VBN patients/NNS follow/VB stimulating/JJ neutropenia/NN
colony/NN required/VBN patients/NNS follow/VB stimulating/JJ neutropenia/NN
stimulating/JJ neutropenia/NN
factor/NN stimulating/JJ neutropenia/NN
chlorpromazine/VBD induced/VBN patients/NNS schizophrenic/JJ
chlorpromazine/NN plays/NNS EPS/NNP patients/NNS schizophrenic/JJ
chlorpromazine/NN treated/VBN gene/NN inpatients/NNS schizophrenic/JJ
chlorpromazine/NN induced/VBN schizophrenia/NN
remifentanil/JJ i/NN anesthesia/NN induced/VBN anesthesia/NN maintaining/VBG reinforced/VBD sinus/NNS compare/VB amount/NN bleeding/NN
propofol/JJ anesthesia/NN induced/VBN anesthesia/NN maintaining/VBG reinforced/VBD sinus/NNS compare/VB amount/NN bleeding/NN
indinavir/NN treated/VBN leukocyturia/NNP associated/VBN function/NN virus/NN human/JJ
indinavir/NN treated/VBN leukocyturia/NNP associated/VBN function/NN virus/NN immunodeficiency/JJ
indinavir/NN treated/VBN leukocyturia/NNP associated/VBN function/NN virus/NN
indinavir/NN treated/VBN type/NN
indinavir/NN treated/VBN type/NN 1/CD
indinavir/NN treated/VBN children/NNS infected/JJ
indinavir/NN treated/VBN leukocyturia/NNP
indinavir/NN monitor/VB study/NN DESIGN/NNP nephrotoxicity/NN cohort/NN type/NN human/JJ
indinavir/NN monitor/VB study/NN DESIGN/NNP nephrotoxicity/NN cohort/NN type/NN immunodeficiency/JJ
indinavir/NN monitor/VB study/NN DESIGN/NNP nephrotoxicity/NN cohort/NN type/NN virus/NN
indinavir/NN monitor/VB study/NN DESIGN/NNP nephrotoxicity/NN cohort/NN type/NN
indinavir/NN monitor/VB study/NN DESIGN/NNP nephrotoxicity/NN cohort/NN type/NN 1/CD
indinavir/NN monitor/VB study/NN DESIGN/NNP children/NNS infected/JJ
indinavir/NN treated/VBN children/NNS DESIGN/NNP nephrotoxicity/NN cohort/NN type/NN human/JJ
indinavir/NN treated/VBN children/NNS DESIGN/NNP nephrotoxicity/NN cohort/NN type/NN immunodeficiency/JJ
indinavir/NN treated/VBN children/NNS DESIGN/NNP nephrotoxicity/NN cohort/NN type/NN virus/NN
indinavir/NN treated/VBN children/NNS DESIGN/NNP nephrotoxicity/NN cohort/NN type/NN
indinavir/NN treated/VBN children/NNS DESIGN/NNP nephrotoxicity/NN cohort/NN type/NN 1/CD
indinavir/NN treated/VBN children/NNS infected/JJ
creatinine/NN ratio/NN increase/NN associated/VBN leukocyturia/NNP
creatinine/NN ratio/NN increase/NN associated/VBN associated/VBN' hematuria/NN
creatinine/NN levels/NNS had/VBD Children/NNP leukocyturia/NN
creatinine/NN levels/NNS had/VBD leukocyturia/NN
indinavir/NN >/NNS level/NN h/NNP L/NNP curve/NN found/VBN incidence/NN leukocyturia/NN
creatinine/NN levels/NNS decreased/VBD disappeared/VBD leukocyturia/NN
creatinine/JJ ratios/NNS //VBZ decreased/VBD disappeared/VBD leukocyturia/NN
indinavir/NN treated/VBN Children/NNP CONCLUSIONS/NNS have/VBP incidence/NN leukocyturia/NN
creatinine/NN levels/NNS increase/NN had/VBD Children/NNP leukocyturia/NN
Indinavir/NNP monitored/VBN children/NNS factors/NNS leukocyturia/NN
indinavir/JJ L/NNP curve/NN area/NN years/NNS age/NN leukocyturia/NN
creatinine/NN concentration/NN rose/VBD hypotension/NN
creatinine/NN concentration/NN rose/VBD hypotension/NN
labetalol/NN induces/VBZ tachycardia/NN hypertension/NN
labetalol/NN induces/VBZ tachycardia/NN
methoxyflurane/JJ anesthesia/NN developed/VBN syndrome/NN hepatic/JJ
methoxyflurane/JJ anesthesia/NN developed/VBN syndrome/NN insufficiency/NN
methoxyflurane/JJ anesthesia/NN developed/VBN syndrome/NN
methoxyflurane/JJ anesthesia/NN operated/VBN cholecystitis/NNS acute/JJ
methoxyflurane/JJ anesthesia/NN operated/VBN cholecystitis/NNS
methadone/JJ group/NN patients/NNS presented/VBD torsades/NNS
methadone/JJ group/NN patients/NNS presented/VBD torsades/NNS de/IN
methadone/JJ group/NN patients/NNS presented/VBD torsades/NNS pointes/NNS
methadone/JJ dose/NN variability/JJ %/NN analysis/NN interactions/NNS hypokalemia/NN
potassium/VBP contribute/VBP QT/VB
potassium/VBP contribute/VBP QT/VB prolongation/NN
bisphosphonates/VBZ caused/VBN Osteoporosis/NNP
biphosphonate/NN Alendronate/NNP effective/JJ treatment/NN osteoporosis/NNS
Alendronate/NNP effective/JJ treatment/NN osteoporosis/NNS
bisphosphonate/NN CONCLUSION/NNP conclude/VBP report/VB patients/NNS osteoporosis/NN
bisphosphonate/NN considered/VBN ascribing/VBG osteoporosis/NN
bisphosphonate/NN CONCLUSION/NNP conclude/VBP report/VB pain/NN
bisphosphonate/NN considered/VBN pain/NN
DOX/NNP dose/NN associated/VBN disarrangement/NN cardiac/JJ
DOX/NNP dose/NN associated/VBN disarrangement/NN
Mannitol/NNP Cisplatin/VBN Rates/NNS Toxicity/NNP Receiving/NNP Cancer/NNP
Mannitol/NNP Cisplatin/VBN Rates/NNS Toxicity/NNP Renal/NNP
Mannitol/NNP Cisplatin/VBN Rates/NNS Toxicity/NNP
Cisplatin/VBN Rates/NNS Toxicity/NNP Receiving/NNP Cancer/NNP
Cisplatin/VBN Rates/NNS Toxicity/NNP Renal/NNP
Cisplatin/VBN Rates/NNS Toxicity/NNP
cisplatin/NN use/NN complications/NNS One/CD dose/NN limiting/VBG nephrotoxicity/RB
mannitol/NN use/NN toxicity/NN
mannitol/NN cisplatin/NN rates/NNS induced/VBN patients/NNS cancer/NN
mannitol/NN cisplatin/NN rates/NNS induced/VBN nephrotoxicity/RB
cisplatin/NN rates/NNS induced/VBN patients/NNS cancer/NN
cisplatin/NN rates/NNS induced/VBN patients/NNS cancer/NN
cisplatin/NN rates/NNS induced/VBN nephrotoxicity/RB
cisplatin/NN rates/NNS induced/VBN nephrotoxicity/RB
cisplatin/NN single/JJ receiving/VBG collected/VBN patients/NNS cancer/NN
cisplatin/NN We/PRP RESULTS/NNS had/VBD head/NN
cisplatin/NN We/PRP RESULTS/NNS had/VBD head/NN and/CC
cisplatin/NN We/PRP RESULTS/NNS had/VBD head/NN neck/NN
cisplatin/NN We/PRP RESULTS/NNS had/VBD cancer/NN
cisplatin/NN We/PRP RESULTS/NNS had/VBD cancer/NN malignancy/NN
mannitol/JJ receive/VB Patients/NNS likely/JJ develop/VB nephrotoxicity/NN
mannitol/NN quantities/NNS available/JJ given/VBN patients/NNS risk/NN nephrotoxicity/NN
cisplatin/NN schedule/NN those/DT hypertension/NN
mannitol/NN addition/NN benefit/VB suggests/VBZ risk/NN nephrotoxicity/NN
mannitol/NN addition/NN benefit/VB suggests/VBZ risk/NN patients/NNS receiving/VBG schedule/NN those/DT hypertension/NN
cisplatin/NN schedule/NN receiving/VBG patients/NNS risk/NN nephrotoxicity/NN
amphotericin/NN B/NN incorporating/VBG Attenuation/NNP nanosphere/NN nephrotoxicity/JJ
B/NN incorporating/VBG Attenuation/NNP nanosphere/NN nephrotoxicity/JJ
amphotericin/NN B/NN incorporating/VBG nanosphere/NN 718/CD effective/JJ has/VBZ toxicity/NN
B/NN incorporating/VBG nanosphere/NN 718/CD effective/JJ has/VBZ toxicity/NN
Fungizone/NNP that/DT 718/CD toxicity/NN
amphotericin/NNP B/NNP study/NN vivo/NN compared/VBD' compared/VBD toxicity/NN
B/NNP study/NN vivo/NN compared/VBD' compared/VBD toxicity/NN
amphotericin/NNP B/NNP compared/VBD toxicity/NN
B/NNP compared/VBD toxicity/NN
sodium/NN deoxycholate/NN B/NNP compared/VBD toxicity/NN
deoxycholate/NN B/NNP compared/VBD toxicity/NN
D/NNP deoxycholate/NN B/NNP compared/VBD toxicity/NN
AmB/VBN B/NNP compared/VBD toxicity/NN
amphotericin/NNP B/NNP incorporation/NN suggest/VBP attenuates/VBZ nephrotoxicity/NN
B/NNP incorporation/NN suggest/VBP attenuates/VBZ nephrotoxicity/NN
amphotericin/NNP B/NNP nephrotoxicity/NN
B/NNP nephrotoxicity/NN
apigenin/NN prevent/VB amnesia/NN
cocaine/NN patients/NNS I/NN Utility/NNP pain/NN chest/NN
cocaine/NN patients/NNS I/NN Utility/NNP pain/NN
cocaine/NN patients/NNS difficult/JJ infarction/NN diagnosis/NN make/VB associated/JJ pain/NN chest/NN
cocaine/NN patients/NNS difficult/JJ infarction/NN diagnosis/NN make/VB associated/JJ pain/NN
cocaine/NN patients/NNS difficult/JJ infarction/NN diagnosis/NN make/VB abnormalities/NNS associated/VBN necrosis/NNS myocardial/JJ
cocaine/NN patients/NNS difficult/JJ infarction/NN diagnosis/NN make/VB abnormalities/NNS associated/VBN necrosis/NNS
cocaine/NN pain/NN chest/NN
cocaine/NN pain/NN
cocaine/NN patients/NNS MB/NNP CK/NNP associated/VBN pain/NN chest/NN
cocaine/NN patients/NNS MB/NNP CK/NNP associated/VBN pain/NN
cocaine/NN patients/NNS MB/NNP necrosis/NNS
hydrochlorothiazide/JJ therapy/NN Comparison/NNP study/NN therapy/NN adults/NNS hypertensive/JJ
valsartan/NN Comparison/NNP study/NN therapy/NN adults/NNS hypertensive/JJ
hydrochlorothiazide/NN valsartan/NN efficacy/NN investigated/VBN study/NN OBJECTIVE/NNP combinations/NNS patients/NNS hypertension/NN essential/JJ
hydrochlorothiazide/NN valsartan/NN efficacy/NN investigated/VBN study/NN OBJECTIVE/NNP combinations/NNS patients/NNS hypertension/NN
HCTZ/NNP valsartan/NN efficacy/NN investigated/VBN study/NN OBJECTIVE/NNP combinations/NNS patients/NNS hypertension/NN essential/JJ
HCTZ/NNP valsartan/NN efficacy/NN investigated/VBN study/NN OBJECTIVE/NNP combinations/NNS patients/NNS hypertension/NN
valsartan/NN efficacy/NN investigated/VBN study/NN OBJECTIVE/NNP combinations/NNS patients/NNS hypertension/NN essential/JJ
valsartan/NN efficacy/NN investigated/VBN study/NN OBJECTIVE/NNP combinations/NNS patients/NNS hypertension/NN
VAL/NNP valsartan/NN efficacy/NN investigated/VBN study/NN OBJECTIVE/NNP combinations/NNS patients/NNS hypertension/NN essential/JJ
VAL/NNP valsartan/NN efficacy/NN investigated/VBN study/NN OBJECTIVE/NNP combinations/NNS patients/NNS hypertension/NN
HCTZ/NNP 1/CD randomized/VBN Patients/NNS hypertension/NN essential/JJ
HCTZ/NNP 1/CD randomized/VBN Patients/NNS hypertension/NN
HCTZ/CD 160/CD VAL/NNP 5/CD 1/CD randomized/VBN Patients/NNS hypertension/NN essential/JJ
HCTZ/CD 160/CD VAL/NNP 5/CD 1/CD randomized/VBN Patients/NNS hypertension/NN
VAL/NNP 1/CD randomized/VBN Patients/NNS hypertension/NN essential/JJ
VAL/NNP 1/CD randomized/VBN Patients/NNS hypertension/NN
VAL/NNP 5/CD 1/CD randomized/VBN Patients/NNS hypertension/NN essential/JJ
VAL/NNP 5/CD 1/CD randomized/VBN Patients/NNS hypertension/NN
VAL/NNP combinations/NNP lower/JJR incidence/NN hypokalemia/NN
VAL/NNP HCTZ/NNP therapies/NNS associated/VBN associated/VBN hypokalemia/NN
diltiazem/NN Comparison/NNP induced/VBN nephropathy/RB
sodium/NN chloride/NN Comparison/NNP induced/VBN nephropathy/RB
chloride/NN Comparison/NNP induced/VBN nephropathy/RB
contrast/NN Comparison/NNP induced/VBN nephropathy/RB
Contrast/NNP INTRODUCTION/NNP increases/VBZ nephropathy/NN
Misoprostol/NNP associated/VBN symptoms/NNS headache/NN
desogestrel/VBP gestodene/VBP progestagens/NN containing/VBG used/VBD women/NNS higher/JJR incidence/NN thromboembolism/NN venous/JJ
desogestrel/VBP gestodene/VBP progestagens/NN containing/VBG used/VBD women/NNS higher/JJR incidence/NN thromboembolism/NN
desogestrel/VBP gestodene/VBP progestagens/NN containing/VBG used/VBD women/NNS higher/JJR incidence/NN thromboembolism/NN VTE/NNP
gestodene/VBP progestagens/NN containing/VBG used/VBD women/NNS higher/JJR incidence/NN thromboembolism/NN venous/JJ
gestodene/VBP progestagens/NN containing/VBG used/VBD women/NNS higher/JJR incidence/NN thromboembolism/NN
gestodene/VBP progestagens/NN containing/VBG used/VBD women/NNS higher/JJR incidence/NN thromboembolism/NN VTE/NNP
progestagens/NNS gestodene/VBP progestagens/NN containing/VBG used/VBD women/NNS higher/JJR incidence/NN thromboembolism/NN venous/JJ
progestagens/NNS gestodene/VBP progestagens/NN containing/VBG used/VBD women/NNS higher/JJR incidence/NN thromboembolism/NN
progestagens/NNS gestodene/VBP progestagens/NN containing/VBG used/VBD women/NNS higher/JJR incidence/NN thromboembolism/NN VTE/NNP
progestagens/NN containing/VBG used/VBD women/NNS higher/JJR incidence/NN thromboembolism/NN venous/JJ
progestagens/NN containing/VBG used/VBD women/NNS higher/JJR incidence/NN thromboembolism/NN
progestagens/NN containing/VBG used/VBD women/NNS higher/JJR incidence/NN thromboembolism/NN VTE/NNP
progestagen/NN users/NNS VTE/NNP
OCs/NN use/NN associated/VBN VTE/NNP cases/NNS recorded/VBN deep/JJ
OCs/NN use/NN associated/VBN VTE/NNP cases/NNS recorded/VBN deep/JJ thrombosis/NNS vein/NN
OCs/NN use/NN associated/VBN VTE/NNP cases/NNS recorded/VBN deep/JJ thrombosis/NNS
OCs/NN use/NN associated/VBN VTE/NNP cases/NNS recorded/VBN deep/JJ thrombosis/VBZ venous/NNS
OCs/NN use/NN associated/VBN VTE/NNP cases/NNS recorded/VBN deep/JJ thrombosis/VBZ
OCs/NN use/NN associated/VBN VTE/NNP cases/NNS recorded/VBN deep/JJ thrombosis/NNS 35/CD thrombosis/NNS
desogestrel/NN users/NNS higher/JJR risk/NN VTE/NNP
desogestrel/NN gestodene/NN users/NNS higher/JJR risk/NN VTE/NNP
gestodene/NN users/NNS higher/JJR risk/NN VTE/NNP
ethinyloestradiol/NN higher/JJR risk/NN VTE/NNP
ethinyloestradiol/NN higher/JJR risk/NN VTE/NNP
progestagens/NNS users/NNS higher/JJR risk/NN VTE/NNP
desogestrel/NN 1/CD 49/CD odds/NNS 3/CD ratios/NNS VTE/NNP
ethinyloestradiol/NN 1/CD 49/CD odds/NNS 3/CD ratios/NNS VTE/NNP
progestagens/NN 18/CD odds/NNS 3/CD ratios/NNS VTE/NNP
Cyclophosphamide/JJ cardiotoxicity/NN
CYA/NNP doses/NNS occur/VB cardiotoxicity/NN
CYA/NNP doses/NNS occur/VB described/VBN factors/NNS development/NN cardiotoxicity/NN
CYA/NNP dose/NN calculated/VBD patients/NNS determine/VB correlated/VBN cardiotoxicity/RB
CYA/NNP incidence/NN correlated/VBN cardiotoxicity/RB
CYA/NNP dose/NN calculated/VBD correlates/VBZ toxicity/NN
CYA/NNP incidence/NN correlated/VBN determine/VB patients/NNS calculated/VBD correlates/VBZ toxicity/NN
CYA/NNP mg/NNS receive/VB were/VBD patients/NNS underwent/VBD total/NN transplants/NNS anemia/NN aplastic/JJ
CYA/NNP mg/NNS receive/VB were/VBD patients/NNS underwent/VBD total/NN transplants/NNS anemia/NN
CYA/NNP mg/NNS receive/VB were/VBD patients/NNS underwent/VBD total/NN syndrome/NN severe/JJ
CYA/NNP mg/NNS receive/VB were/VBD patients/NNS underwent/VBD total/NN syndrome/NN combined/VBN
CYA/NNP mg/NNS receive/VB were/VBD patients/NNS underwent/VBD total/NN syndrome/NN immunodeficiency/JJ
CYA/NNP mg/NNS receive/VB were/VBD patients/NNS underwent/VBD total/NN syndrome/NN
CYA/NNP mg/NNS receive/VB were/VBD patients/NNS underwent/VBD total/NN Wiskott/NNP
CYA/NNP mg/NNS receive/VB were/VBD patients/NNS underwent/VBD total/NN Wiskott/NNP syndrome/NN Aldrich/NNP
CYA/NNP mg/NNS receive/VB were/VBD patients/NNS underwent/VBD total/NN Wiskott/NNP syndrome/NN
CYA/NNP consistent/JJ symptoms/NNS had/VBD days/NNS cardiotoxicity/RB
CYA/NNP doses/NNS receiving/VBG days/NNS cardiotoxicity/RB
CYA/NNP related/VBN thought/VBN Cardiotoxicity/NNP
CYA/NNP cardiotoxicity/NN
CYA/NNP cardiotoxicity/NN correlates/VBZ calculated/VBN prepared/VBN grafting/VBG d/SYM days/NNS incidence/NN cardiotoxicity/NN
CYA/NNP dosage/NNP correlates/VBZ cardiotoxicity/NN
CYA/NNP dosage/NNP correlates/VBZ calculated/VBN prepared/VBN grafting/VBG d/SYM days/NNS incidence/NN cardiotoxicity/NN
CYA/NNP dose/NN grafting/VBG prepared/VBN calculated/VBN correlates/VBZ cardiotoxicity/NN
CYA/NNP dose/NN grafting/VBG d/SYM days/NNS incidence/NN cardiotoxicity/NN
CYA/NNP dosage/NN calculated/VBN patients/NNS cardiotoxicity/NN incidence/NN days/NNS d/SYM grafting/VBG prepared/VBN calculated/VBN correlates/VBZ cardiotoxicity/NN
CYA/NNP dosage/NN calculated/VBN patients/NNS cardiotoxicity/NN
CYA/NNP cardiotoxicity/NN correlates/VBZ calculated/VBN prepared/VBN patients/NNS anemia/NN aplastic/JJ
CYA/NNP cardiotoxicity/NN correlates/VBZ calculated/VBN prepared/VBN patients/NNS anemia/NN
CYA/NNP dosage/NNP correlates/VBZ calculated/VBN prepared/VBN patients/NNS anemia/NN aplastic/JJ
CYA/NNP dosage/NNP correlates/VBZ calculated/VBN prepared/VBN patients/NNS anemia/NN
CYA/NNP dose/NN grafting/VBG prepared/VBN patients/NNS anemia/NN aplastic/JJ
CYA/NNP dose/NN grafting/VBG prepared/VBN patients/NNS anemia/NN
CYA/NNP dosage/NN calculated/VBN patients/NNS cardiotoxicity/NN incidence/NN days/NNS d/SYM grafting/VBG prepared/VBN patients/NNS anemia/NN aplastic/JJ
CYA/NNP dosage/NN calculated/VBN patients/NNS cardiotoxicity/NN incidence/NN days/NNS d/SYM grafting/VBG prepared/VBN patients/NNS anemia/NN
CYA/NNP cardiotoxicity/NN correlates/VBZ calculated/VBN prepared/VBN patients/NNS anemia/NN immunodeficiencies/NNS
CYA/NNP dosage/NNP correlates/VBZ calculated/VBN prepared/VBN patients/NNS anemia/NN immunodeficiencies/NNS
CYA/NNP dose/NN grafting/VBG prepared/VBN patients/NNS anemia/NN immunodeficiencies/NNS
CYA/NNP dosage/NN calculated/VBN patients/NNS cardiotoxicity/NN incidence/NN days/NNS d/SYM grafting/VBG prepared/VBN patients/NNS anemia/NN immunodeficiencies/NNS
Viracept/VB irregular/VB
Viracept/VB warning/NN heartbeat/NN
Viracept/NN cause/VB beat/NN irregular/NN
Viracept/NN cause/VB beat/NN heart/NN
Viracept/NN cause/VB beat/NN
bilirubin/NN value/NN plasma/NN sex/NN Factors/NNS associated/VBN development/NN failure/NN fulminant/JJ
bilirubin/NN value/NN plasma/NN sex/NN Factors/NNS associated/VBN development/NN failure/NN hepatic/JJ
bilirubin/NN value/NN plasma/NN sex/NN Factors/NNS associated/VBN development/NN failure/NN
Nifedipine/NNP induced/VBN neuropathy/NN autonomic/JJ
Nifedipine/NNP induced/VBN neuropathy/NN
nifedipine/VBP 40/CD slowed/VBD min/NN rate/NN have/VB flutter/NN atrial/JJ
nifedipine/VBP 40/CD slowed/VBD min/NN rate/NN have/VB flutter/NN
pethidine/NN infusion/NN induced/VBN dysfunction/NNS Cerebellar/NN
pethidine/NN infusion/NN induced/VBN dysfunction/NNS Cerebellar/NN and/CC
pethidine/NN infusion/NN induced/VBN dysfunction/NNS Cerebellar/NN oculomotor/NN
pethidine/NN infusion/NN induced/VBN dysfunction/NNS
Pethidine/NNP opioid/NN gains/VBZ control/NN pain/NN
pethidine/NN cause/VB patients/NNS renal/NN impaired/VBN
pethidine/NN cause/VB patients/NNS renal/NN
pethidine/NN cause/VB patients/NNS renal/NN and/CC
pethidine/NN cause/VB patients/NNS renal/NN function/NN liver/NN
pethidine/NN cause/VB patients/NNS renal/NN function/NN
pethidine/NN cause/VB metabolite/NN neurotoxic/JJ
norpethidine/JJ cause/VB patients/NNS those/DT need/VBP control/NN pain/NN
norpethidine/JJ cause/VB resulting/VBG attack/NN irritability/NN
pethidine/NN cause/VB resulting/VBG attack/NN irritability/NN seizure/NN
pethidine/NN cause/VB resulting/VBG attack/NN irritability/NN
norpethidine/JJ cause/VB patients/NNS renal/NN impaired/VBN
norpethidine/JJ cause/VB patients/NNS renal/NN
norpethidine/JJ cause/VB patients/NNS renal/NN and/CC
norpethidine/JJ cause/VB patients/NNS renal/NN function/NN liver/NN
norpethidine/JJ cause/VB patients/NNS renal/NN function/NN
norpethidine/JJ cause/VB metabolite/NN neurotoxic/JJ
pethidine/NN cause/VB patients/NNS those/DT need/VBP control/NN pain/NN
dexamethasone/NN lenalidomide/NN efficacy/NN data/NNS Real/NNP myeloma/NN multiple/JJ
dexamethasone/NN lenalidomide/NN efficacy/NN data/NNS Real/NNP myeloma/NN
dexamethasone/NN lenalidomide/NN efficacy/NN data/NNS Real/NNP myeloma/NN treated/VBN practice/NN study/NN Group/NNP Myeloma/NNP
lenalidomide/NN efficacy/NN data/NNS Real/NNP myeloma/NN multiple/JJ
lenalidomide/NN efficacy/NN data/NNS Real/NNP myeloma/NN
lenalidomide/NN efficacy/NN data/NNS Real/NNP myeloma/NN treated/VBN practice/NN study/NN Group/NNP Myeloma/NNP
dexamethasone/NN Lenalidomide/NN standard/NN care/NN myeloma/NN multiple/JJ
dexamethasone/NN Lenalidomide/NN standard/NN care/NN myeloma/NN
dexamethasone/NN Lenalidomide/NN standard/NN care/NN myeloma/NN RRMM/NNP
Lenalidomide/NN standard/NN care/NN myeloma/NN multiple/JJ
Lenalidomide/NN standard/NN care/NN myeloma/NN
Lenalidomide/NN standard/NN care/NN myeloma/NN RRMM/NNP
RD/NNP Lenalidomide/NN standard/NN care/NN myeloma/NN multiple/JJ
RD/NNP Lenalidomide/NN standard/NN care/NN myeloma/NN
RD/NNP Lenalidomide/NN standard/NN care/NN myeloma/NN RRMM/NNP
RD/NNP received/VBD patients/NNS RRMM/CD
RD/NNP effective/JJ RRMM/NNP
sumatriptan/NN use/NN occurring/VBG published/VBN vasospasm/NN infarction/NN myocardial/JJ
sumatriptan/NN use/NN occurring/VBG published/VBN vasospasm/NN infarction/NN
sumatriptan/NN use/NN occurring/VBG published/VBN vasospasm/NN coronary/JJ
sumatriptan/NN use/NN occurring/VBG published/VBN vasospasm/NN
sumatriptan/NN use/NN occurring/VBG published/VBN vasospasm/NN ischemia/NN myocardial/JJ
sumatriptan/NN use/NN occurring/VBG published/VBN vasospasm/NN ischemia/NN
sumatriptan/NN treated/VBN migraine/NN
diazinon/NN exposed/VBN Incidence/NNP tumours/NNS
organophosphate/JJ diazinon/NN exposed/VBN Incidence/NNP tumours/NNS
Diazinon/NNP associated/VBN examined/VBN associated/VBN risk/NN cancer/NN
diazinon/NN associated/VBN risk/NN cancer/NN
organophosphate/NN insecticide/NN Diazinon/NNP associated/VBN examined/VBN associated/VBN risk/NN cancer/NN
organophosphate/NN insecticide/NN Diazinon/NNP associated/VBN cancer/NN lung/NN
organophosphate/NN insecticide/NN Diazinon/NNP associated/VBN cancer/NN
diazinon/JJ exposure/NN information/NN cancer/NN
diazinon/JJ exposure/NN used/VBD evaluate/VB risk/NN tumour/NN
diazinon/NN use/VB reported/VBN Carolina/NNP METHODS/NNS assessed/VBN incidence/NN cancer/NN
Metformin/NNP protects/VBZ seizures/NNS impairments/NNS learning/NN
Metformin/NNP protects/VBZ seizures/NNS impairments/NNS learning/NN and/CC
Metformin/NNP protects/VBZ seizures/NNS impairments/NNS learning/NN memory/NN
Metformin/NNP protects/VBZ seizures/NNS impairments/NNS
Metformin/NNP protects/VBZ seizures/NNS
pentylenetetrazole/NN induced/VBN damage/NN seizures/NNS impairments/NNS learning/NN
pentylenetetrazole/NN induced/VBN damage/NN seizures/NNS impairments/NNS learning/NN and/CC
pentylenetetrazole/NN induced/VBN damage/NN seizures/NNS impairments/NNS learning/NN memory/NN
pentylenetetrazole/NN induced/VBN damage/NN seizures/NNS impairments/NNS
metformin/NN effects/NNS evaluate/VB designed/VBN observed/VBD impairment/NN cognitive/JJ
metformin/NN effects/NNS evaluate/VB designed/VBN observed/VBD impairment/NN
metformin/NN effects/NNS evaluate/VB seizures/NNS
metformin/NN suppressed/VBD ameliorated/VBD impairment/NN cognitive/JJ
metformin/NN suppressed/VBD ameliorated/VBD impairment/NN
metformin/NN agent/NN treatment/NN medicine/NN impairment/NN cognitive/JJ
metformin/NN agent/NN treatment/NN medicine/NN impairment/NN
metformin/NN agent/NN treatment/NN medicine/NN impairment/NN induced/VBN seizures/NNS
metformin/NN agent/NN treatment/NN epilepsy/NN
theophylline/NN asthma/NN
oxitropium/NN effect/NN Comparison/NNP theophylline/NN asthma/NN
bromide/JJ effect/NN Comparison/NNP theophylline/NN asthma/NN
theophylline/NN effects/NNS preparation/NN asthma/NN
oxitropium/NN bromide/NN drug/NN effects/NNS preparation/NN asthma/NN
bromide/NN drug/NN effects/NNS preparation/NN asthma/NN
oxitropium/NN effects/NNS reported/VBD as/IN subjects/NNS reporting/VBG nausea/NN tremors/NNS
oxitropium/NN effects/NNS reported/VBD as/IN subjects/NNS reporting/VBG nausea/NN vomiting/NN
oxitropium/NN effects/NNS reported/VBD as/IN subjects/NNS reporting/VBG nausea/NN
theophylline/VB asthma/NN
Oxitropium/NNP proves/VBZ alternative/NN theophylline/VB asthma/NN
aminonucleoside/JJ nephrosis/NNS
aminonucleoside/JJ nephrosis/NNS function/VBP glomerular/VBP
aminonucleoside/JJ nephrosis/NNS function/VBP sclerosis/NN
puromycin/NN model/NN studied/VBN relationship/NN dysfunction/NN mesangial/JJ
puromycin/NN model/NN studied/VBN relationship/NN dysfunction/NN
aminonucleoside/NN model/NN studied/VBN relationship/NN dysfunction/NN mesangial/JJ
aminonucleoside/NN model/NN studied/VBN relationship/NN dysfunction/NN
puromycin/NN model/NN studied/VBN relationship/NN dysfunction/NN sclerosis/NN glomerular/NN
puromycin/NN model/NN studied/VBN relationship/NN dysfunction/NN sclerosis/NN
aminonucleoside/NN model/NN studied/VBN relationship/NN dysfunction/NN sclerosis/NN glomerular/NN
aminonucleoside/NN model/NN studied/VBN relationship/NN dysfunction/NN sclerosis/NN
PAN/NNP model/NN studied/VBN relationship/NN dysfunction/NN mesangial/JJ
PAN/NNP model/NN studied/VBN relationship/NN dysfunction/NN
PAN/NNP model/NN studied/VBN relationship/NN dysfunction/NN sclerosis/NN glomerular/NN
PAN/NNP model/NN studied/VBN relationship/NN dysfunction/NN sclerosis/NN
carbon/NN given/VBN proteinuric/JJ
PAN/NNP rats/NNS glomeruli/NN %/NN //NNS found/VBN sclerosis/NN glomerular/NN
PAN/NNP rats/NNS glomeruli/NN %/NN //NNS found/VBN sclerosis/NN
PAN/NNP treatment/NN change/VB conclude/VBP caused/VBN develop/VB sclerosis/NN
PAN/NNP model/NN Similar/JJ nephrosis/VBZ
PAN/NNP model/NN Similar/JJ nephrosis/VBZ related/VBN development/NN sclerosis/NN glomerular/NN
PAN/NNP model/NN Similar/JJ nephrosis/VBZ related/VBN development/NN sclerosis/NN
succinylcholine/NN administration/NN blockade/NN neuromuscular/NN
succinylcholine/NN administration/NN blockade/NN
simvastatin/NN telaprevir/NN treated/VBN Rhabdomyolysis/NNS patient/NN hepatitis/NNP
simvastatin/NN telaprevir/NN treated/VBN Rhabdomyolysis/NNS patient/NN C/NNP
simvastatin/NN telaprevir/NN treated/VBN Rhabdomyolysis/NNS patient/NN virus/NN
simvastatin/NN telaprevir/NN treated/VBN Rhabdomyolysis/NNS patient/NN infected/JJ
telaprevir/NN treated/VBN Rhabdomyolysis/NNS patient/NN hepatitis/NNP
telaprevir/NN treated/VBN Rhabdomyolysis/NNS patient/NN C/NNP
telaprevir/NN treated/VBN Rhabdomyolysis/NNS patient/NN virus/NN
telaprevir/NN treated/VBN Rhabdomyolysis/NNS patient/NN infected/JJ
ribavirin/JJ interferon/NN received/VBD man/NN infection/NN hepatitis/NNP
ribavirin/JJ interferon/NN received/VBD man/NN infection/NN C/NNP
ribavirin/JJ interferon/NN received/VBD man/NN infection/NN virus/NN
ribavirin/JJ interferon/NN received/VBD man/NN infection/NN
telaprevir/NN interferon/NN received/VBD man/NN infection/NN hepatitis/NNP
telaprevir/NN interferon/NN received/VBD man/NN infection/NN C/NNP
telaprevir/NN interferon/NN received/VBD man/NN infection/NN virus/NN
telaprevir/NN interferon/NN received/VBD man/NN infection/NN
pegylated/JJ interferon/NN received/VBD man/NN infection/NN hepatitis/NNP
pegylated/JJ interferon/NN received/VBD man/NN infection/NN C/NNP
pegylated/JJ interferon/NN received/VBD man/NN infection/NN virus/NN
pegylated/JJ interferon/NN received/VBD man/NN infection/NN
interferon/NN received/VBD man/NN infection/NN hepatitis/NNP
interferon/NN received/VBD man/NN infection/NN C/NNP
interferon/NN received/VBD man/NN infection/NN virus/NN
interferon/NN received/VBD man/NN infection/NN
simvastatin/NN discontinued/VBN toxicity/NN
alkylxanthines/NNS Effect/NN failure/NN acute/JJ
alkylxanthines/NNS Effect/NN failure/NN renal/JJ
alkylxanthines/NNS Effect/NN failure/NN
Adenosine/JJ antagonists/NNS shown/VBN benefit/NN models/NNS ischaemic/JJ nephrotoxic/JJ
Adenosine/JJ antagonists/NNS shown/VBN benefit/NN models/NNS ischaemic/JJ
Adenosine/JJ antagonists/NNS shown/VBN benefit/NN models/NNS failure/NN acute/JJ
Adenosine/JJ antagonists/NNS shown/VBN benefit/NN models/NNS failure/NN renal/JJ
Adenosine/JJ antagonists/NNS shown/VBN benefit/NN models/NNS failure/NN
Adenosine/JJ antagonists/NNS shown/VBN benefit/NN models/NNS failure/NN ARF/NNP
alkylxanthines/NNS effects/NNS examined/VBN rats/NNS developing/VBG failure/NN acute/JJ
alkylxanthines/NNS effects/NNS examined/VBN rats/NNS developing/VBG failure/NN renal/JJ
alkylxanthines/NNS effects/NNS examined/VBN rats/NNS developing/VBG failure/NN
8/CD examined/VBN rats/NNS developing/VBG failure/NN acute/JJ
8/CD examined/VBN rats/NNS developing/VBG failure/NN renal/JJ
8/CD examined/VBN rats/NNS developing/VBG failure/NN
phenyltheophylline/JJ 8/CD examined/VBN rats/NNS developing/VBG failure/NN acute/JJ
phenyltheophylline/JJ 8/CD examined/VBN rats/NNS developing/VBG failure/NN renal/JJ
phenyltheophylline/JJ 8/CD examined/VBN rats/NNS developing/VBG failure/NN
adenosine/JJ antagonists/NNS examined/VBN rats/NNS developing/VBG failure/NN acute/JJ
adenosine/JJ antagonists/NNS examined/VBN rats/NNS developing/VBG failure/NN renal/JJ
adenosine/JJ antagonists/NNS examined/VBN rats/NNS developing/VBG failure/NN
theophylline/JJ phenyltheophylline/JJ 8/CD examined/VBN rats/NNS developing/VBG failure/NN acute/JJ
theophylline/JJ phenyltheophylline/JJ 8/CD examined/VBN rats/NNS developing/VBG failure/NN renal/JJ
theophylline/JJ phenyltheophylline/JJ 8/CD examined/VBN rats/NNS developing/VBG failure/NN
enprofylline/JJ phenyltheophylline/JJ 8/CD examined/VBN rats/NNS developing/VBG failure/NN acute/JJ
enprofylline/JJ phenyltheophylline/JJ 8/CD examined/VBN rats/NNS developing/VBG failure/NN renal/JJ
enprofylline/JJ phenyltheophylline/JJ 8/CD examined/VBN rats/NNS developing/VBG failure/NN
creatinine/NN urea/NN biochemical/JJ degree/NN necrosis/NNS
p/NNS analysis/NN functional/JJ biochemical/JJ degree/NN necrosis/NNS
aminohippuric/JJ clearances/NNS analysis/NN functional/JJ biochemical/JJ degree/NN necrosis/NNS
acid/JJ clearances/NNS analysis/NN functional/JJ biochemical/JJ degree/NN necrosis/NNS
urea/NN biochemical/JJ degree/NN necrosis/NNS
alkylxanthines/NNS noted/VBN effect/NN lack/NN indicates/VBZ plays/VBZ role/NN ARF/NNP
adenosine/NN plays/VBZ role/NN ARF/NNP
ecstasy/JJ users/NNS generation/NN prognosis/NN cause/NN Given/VBN record/NN memory/NN impaired/VBN
ecstasy/JJ users/NNS generation/NN prognosis/NN cause/NN Given/VBN record/NN memory/NN
fluocinolone/NN Safety/NN acetonide/VBP implant/NN retinochoroidopathy/NN birdshot/JJ
fluocinolone/NN Safety/NN acetonide/VBP implant/NN retinochoroidopathy/NN
acetonide/VBP implant/NN retinochoroidopathy/NN birdshot/JJ
acetonide/VBP implant/NN retinochoroidopathy/NN
fluocinolone/JJ acetonide/JJ implant/NN outcomes/NNS report/VB patients/NNS retinochoroidopathy/NN birdshot/JJ
fluocinolone/JJ acetonide/JJ implant/NN outcomes/NNS report/VB patients/NNS retinochoroidopathy/NN
acetonide/JJ implant/NN outcomes/NNS report/VB patients/NNS retinochoroidopathy/NN birdshot/JJ
acetonide/JJ implant/NN outcomes/NNS report/VB patients/NNS retinochoroidopathy/NN
fluocinolone/JJ implant/NN helps/VBZ control/VB inflammation/NN
acetonide/NN implant/NN helps/VBZ control/VB inflammation/NN
fluocinolone/JJ implant/NN helps/VBZ control/VB treatment/NN cases/NNS retinochoroidopathy/NN birdshot/JJ
fluocinolone/JJ implant/NN helps/VBZ control/VB treatment/NN cases/NNS retinochoroidopathy/NN
acetonide/NN implant/NN helps/VBZ control/VB treatment/NN cases/NNS retinochoroidopathy/NN birdshot/JJ
acetonide/NN implant/NN helps/VBZ control/VB treatment/NN cases/NNS retinochoroidopathy/NN
meloxicam/VB due/JJ developed/VBD arthritis/NN rheumatoid/JJ
meloxicam/VB due/JJ developed/VBD arthritis/NN
propranolol/NN daily/NN year/NN treatment/NN angina/NN
propranolol/NN evidence/NN accepted/VBN cause/NN disorder/NN conduction/NN
propranolol/NN evidence/NN accepted/VBN cause/NN disorder/NN
olanzapine/NN comparison/NN episode/NN schizophrenia/NN
risperidone/NN comparison/NN episode/NN schizophrenia/NN
olanzapine/NN outcomes/NNS OBJECTIVE/NNP schizophrenia/NN
risperidone/NN olanzapine/NN outcomes/NNS OBJECTIVE/NNP schizophrenia/NN
olanzapine/NN assigned/VBN METHOD/NNP subjects/NNS schizophrenia/NN
olanzapine/NN assigned/VBN METHOD/NNP subjects/NNS schizophrenia/NN disorder/NN schizophreniform/NN
olanzapine/NN assigned/VBN METHOD/NNP subjects/NNS schizophrenia/NN disorder/NN
olanzapine/NN assigned/VBN METHOD/NNP subjects/NNS schizophrenia/NN disorder/NN schizoaffective/JJ
olanzapine/NN assigned/VBN METHOD/NNP subjects/NNS schizophrenia/NN disorder/NN
risperidone/NN olanzapine/NN assigned/VBN METHOD/NNP subjects/NNS schizophrenia/NN disorder/NN schizophreniform/NN
risperidone/NN olanzapine/NN assigned/VBN METHOD/NNP subjects/NNS schizophrenia/NN disorder/NN
risperidone/NN olanzapine/NN assigned/VBN METHOD/NNP subjects/NNS schizophrenia/NN disorder/NN schizoaffective/JJ
risperidone/NN olanzapine/NN assigned/VBN METHOD/NNP subjects/NNS schizophrenia/NN disorder/NN
risperidone/NN olanzapine/NN assigned/VBN METHOD/NNP subjects/NNS schizophrenia/NN
lithium/NN treated/VBN depression/NN manic/JJ
lithium/NN treated/VBN depression/NN
glucose/NN negative/JJ polyuria/NN
glucose/NN negative/JJ polyuria/NN polydipsia/NN
glucose/NN concentrations/NNS remained/VBD indicated/VBD induced/VBN insipidus/NNS nephrogenic/JJ
glucose/NN concentrations/NNS remained/VBD indicated/VBD induced/VBN insipidus/NNS diabetes/NN
glucose/NN concentrations/NNS remained/VBD indicated/VBD induced/VBN insipidus/NNS
glucose/NN concentrations/NNS remained/VBD polyuric/JJ
lithium/NN likely/JJ insipidus/NNS induced/VBN indicated/VBD remained/VBD recovery/NN hyperglycaemia/NN
glucose/NN concentrations/NNS remained/VBD recovery/NN hyperglycaemia/NN
K/NNP +/NN Na/NN ouabain/NN administration/NN suggested/VBN mimic/VB symptoms/NNS mania/NN bipolar/JJ
K/NNP +/NN Na/NN ouabain/NN administration/NN suggested/VBN mimic/VB symptoms/NNS mania/NN
Na/NN ouabain/NN administration/NN suggested/VBN mimic/VB symptoms/NNS mania/NN bipolar/JJ
Na/NN ouabain/NN administration/NN suggested/VBN mimic/VB symptoms/NNS mania/NN
ouabain/JJ hyperlocomotion/NN
zolmitriptan/NN took/VBD had/VBD migraines/NNS
zolmitriptan/NN times/NNS days/NNS headache/NN migraine/NN
zolmitriptan/NN times/NNS days/NNS headache/NN
benzodiazepine/JJ flumazenil/NN Administration/NNP unmask/VB seizures/NNS
benzodiazepine/JJ intoxication/NN seizures/NNS
sodium/NN nitrite/VBP rats/NNS percent/NN had/VBD thrombosis/NNS
nitrite/VBP rats/NNS percent/NN had/VBD thrombosis/NNS
quinacrine/NN hydrochloride/NN nitrite/VBP rats/NNS percent/NN had/VBD thrombosis/NNS
hydrochloride/NN nitrite/VBP rats/NNS percent/NN had/VBD thrombosis/NNS
sodium/NN nitrite/VBP rats/NNS percent/NN had/VBD have/VB thrombosis/NNS atrial/JJ
sodium/NN nitrite/VBP rats/NNS percent/NN had/VBD have/VB thrombosis/NNS
nitrite/VBP rats/NNS percent/NN had/VBD have/VB thrombosis/NNS atrial/JJ
nitrite/VBP rats/NNS percent/NN had/VBD have/VB thrombosis/NNS
tacrolimus/NNS induced/VBN crisis/NN scleroderma/JJ
tacrolimus/NNS induced/VBN crisis/NN renal/JJ
tacrolimus/NNS induced/VBN crisis/NN
prednisolone/NN tacrolimus/NNS induced/VBN crisis/NN scleroderma/JJ
prednisolone/NN tacrolimus/NNS induced/VBN crisis/NN renal/JJ
prednisolone/NN tacrolimus/NNS induced/VBN crisis/NN
corticosteroid/VBD recognized/VBN factor/NN SRC/NNP
cyclosporine/NN patients/NNS SSc/NNP
tacrolimus/NNS induced/VBN SRC/NNP
corticosteroids/NNS tacrolimus/NNS induced/VBN SRC/NNP
chlorhexidine/NN diphosphanilate/NN study/NN agent/NN burns/NNS
diphosphanilate/NN study/NN agent/NN burns/NNS
Chlorhexidine/JJ phosphanilate/NN evaluated/VBN wound/VBD burn/NN
phosphanilate/NN evaluated/VBN wound/VBD burn/NN
CHP/NNP phosphanilate/NN evaluated/VBN wound/VBD burn/NN
CHP/NNP concentrations/NNS each/DT treated/VBN site/NN burn/VBP
CHP/NNP concentrations/NNS each/DT treated/VBN site/NN agent/NN used/VBN treatment/NN wounds/NNS burn/JJ
silver/NN 1/CD cent/NN 2/CD cent/JJ cream/NN 25/CD site/NN burn/VBP
sulphadiazine/NN cream/NN 25/CD site/NN burn/VBP
silver/NN 1/CD cent/NN 2/CD cent/JJ cream/NN 25/CD site/NN agent/NN used/VBN treatment/NN wounds/NNS burn/JJ
sulphadiazine/NN cream/NN 25/CD site/NN agent/NN used/VBN treatment/NN wounds/NNS burn/JJ
AgSD/NNP cream/NN 25/CD site/NN burn/VBP
AgSD/NNP cream/NN 25/CD site/NN agent/NN used/VBN treatment/NN wounds/NNS burn/JJ
AgSD/NNP closest/JJS tolerance/NN pain/NN
AgSD/NNP statistically/RB differed/VBD closest/JJS tolerance/NN pain/NN
Lindane/NNP insecticide/NN effects/NNS neurotoxic/JJ
gamma/NN Lindane/NNP insecticide/NN effects/NNS neurotoxic/JJ
hexachlorocyclohexane/NN gamma/NN Lindane/NNP insecticide/NN effects/NNS neurotoxic/JJ
dopamine/NN GABA/NNP concentration/NN measuring/VBG onset/NN seizures/NNS
GABA/NNP concentration/NN measuring/VBG onset/NN seizures/NNS
D/NNP Effect/NN damage/NN renal/JJ
D/NNP Effect/NN damage/NN
Glucarates/NNP Effect/NN damage/NN renal/JJ
Glucarates/NNP Effect/NN damage/NN
aminoglycoside/JJ antibiotics/NNS injection/NN failure/NN develop/VBP rats/NNS Dehydrated/JJ
kanamycin/NN induced/VBN failure/NN renal/JJ
kanamycin/NN induced/VBN failure/NN
2/CD administration/NN dilactone/VBP failure/NN renal/JJ
2/CD administration/NN dilactone/VBP failure/NN
5/CD 2/CD administration/NN dilactone/VBP failure/NN renal/JJ
5/CD 2/CD administration/NN dilactone/VBP failure/NN
di/FW 2/CD administration/NN dilactone/VBP failure/NN renal/JJ
di/FW 2/CD administration/NN dilactone/VBP failure/NN
O/NNP 2/CD administration/NN dilactone/VBP failure/NN renal/JJ
O/NNP 2/CD administration/NN dilactone/VBP failure/NN
acetyl/NN 2/CD administration/NN dilactone/VBP failure/NN renal/JJ
acetyl/NN 2/CD administration/NN dilactone/VBP failure/NN
D/NNP 2/CD administration/NN dilactone/VBP failure/NN renal/JJ
D/NNP 2/CD administration/NN dilactone/VBP failure/NN
glucaro/NN 2/CD administration/NN dilactone/VBP failure/NN renal/JJ
glucaro/NN 2/CD administration/NN dilactone/VBP failure/NN
1/CD 2/CD administration/NN dilactone/VBP failure/NN renal/JJ
1/CD 2/CD administration/NN dilactone/VBP failure/NN
4/CD 2/CD administration/NN dilactone/VBP failure/NN renal/JJ
4/CD 2/CD administration/NN dilactone/VBP failure/NN
6/CD 4/CD 2/CD administration/NN dilactone/VBP failure/NN renal/JJ
6/CD 4/CD 2/CD administration/NN dilactone/VBP failure/NN
3/CD 6/CD 4/CD 2/CD administration/NN dilactone/VBP failure/NN renal/JJ
3/CD 6/CD 4/CD 2/CD administration/NN dilactone/VBP failure/NN
dilactone/VBP failure/NN renal/JJ
dilactone/VBP failure/NN
D/NNP effective/JJ damage/NN renal/JJ
D/NNP effective/JJ damage/NN
Glucarates/NNP effective/JJ damage/NN renal/JJ
Glucarates/NNP effective/JJ damage/NN
aminoglycoside/NN antibitocis/NNS antibiotics/NNS induced/VBN damage/NN renal/JJ
aminoglycoside/NN antibitocis/NNS antibiotics/NNS induced/VBN damage/NN
D/NNP obtained/VBN damages/NNS renal/JJ
D/NNP obtained/VBN damages/NNS
glucarate/NN D/NNP obtained/VBN damages/NNS renal/JJ
glucarate/NN D/NNP obtained/VBN damages/NNS
D/NNP had/VBD ability/NN prevent/VB damage/NN renal/JJ
D/NNP had/VBD ability/NN prevent/VB damage/NN
Glucarates/NNP had/VBD ability/NN prevent/VB damage/NN renal/JJ
Glucarates/NNP had/VBD ability/NN prevent/VB damage/NN
monosaccharides/NNS spared/VBN lesions/NNS renal/JJ
monosaccharides/NNS spared/VBN lesions/NNS
D/NNP glucarates/NNS nephrotoxicity/NN
glucarates/NNS nephrotoxicity/NN
tacrolimus/NNS discontinuation/NN occurred/VBD Deterioration/NNP
tacrolimus/NNS discontinuation/NN occurred/VBD Deterioration/NNP vision/NN of/IN
tacrolimus/NNS discontinuation/NN occurred/VBD Deterioration/NNP vision/NN
nitric/JJ oxide/NN derived/VBN cell/NN Loss/NN hallmark/NN dysfunction/NN arterial/JJ
nitric/JJ oxide/NN derived/VBN cell/NN Loss/NN hallmark/NN dysfunction/NN
oxide/NN derived/VBN cell/NN Loss/NN hallmark/NN dysfunction/NN arterial/JJ
oxide/NN derived/VBN cell/NN Loss/NN hallmark/NN dysfunction/NN
NO/RB oxide/NN derived/VBN cell/NN Loss/NN hallmark/NN dysfunction/NN arterial/JJ
NO/RB oxide/NN derived/VBN cell/NN Loss/NN hallmark/NN dysfunction/NN
Nomega/NNP role/NN hypertension/NN
nitro/NN role/NN hypertension/NN
L/NNP role/NN hypertension/NN
arginine/JJ hypertension/NN
LNNA/NNP hypertension/NN
LNNA/NNP hypertension/NN
LNNA/NNP weeks/NNS elevated/VBD hypertension/NN
LNNA/NNP rats/NNS hypertensive/NN
hexamethonium/NN blockade/NN caused/VBD fall/NN rats/NNS hypertensive/NN
histamine/JJ receptors/NNS Blockade/NNP reduce/VB immunization/NN induced/VBN encephalopathy/RB
histamine/JJ receptors/NNS Blockade/NNP reduce/VB immunization/NN pertussis/NN
gamma/NN isoniazid/NN microinjection/NN produced/VBN seizures/NNS
vinyl/NN Susceptibility/NNP seizures/NNS
GABA/NNP vinyl/NN Susceptibility/NNP seizures/NNS
isoniazid/NN microinjection/NN produced/VBN seizures/NNS
Pilocarpine/NNP reproduces/VBZ sequelae/NN epilepsy/NN temporal/JJ
Pilocarpine/NNP reproduces/VBZ sequelae/NN epilepsy/NN lobe/NN
Pilocarpine/NNP reproduces/VBZ sequelae/NN epilepsy/NN
gamma/NN activity/NN manipulating/VBG effects/NNS inhibition/NN nigra/NN seizures/NNS
aminobutyric/JJ acid/NN gamma/NN activity/NN manipulating/VBG effects/NNS inhibition/NN nigra/NN seizures/NNS
acid/NN gamma/NN activity/NN manipulating/VBG effects/NNS inhibition/NN nigra/NN seizures/NNS
GABA/NNP gamma/NN activity/NN manipulating/VBG effects/NNS inhibition/NN nigra/NN seizures/NNS
GABA/NNP activity/NN inhibitor/NN micrograms/NNS resulted/VBD seizures/NNS epilepticus/NNS status/NN
GABA/NNP activity/NN inhibitor/NN micrograms/NNS resulted/VBD seizures/NNS epilepticus/NNS
L/NNP enzyme/NN activity/NN inhibitor/NN micrograms/NNS resulted/VBD seizures/NNS epilepticus/NNS status/NN
L/NNP enzyme/NN activity/NN inhibitor/NN micrograms/NNS resulted/VBD seizures/NNS epilepticus/NNS
glutamic/JJ decarboxylase/NN activity/NN inhibitor/NN micrograms/NNS resulted/VBD seizures/NNS epilepticus/NNS status/NN
glutamic/JJ decarboxylase/NN activity/NN inhibitor/NN micrograms/NNS resulted/VBD seizures/NNS epilepticus/NNS
acid/JJ decarboxylase/NN activity/NN inhibitor/NN micrograms/NNS resulted/VBD seizures/NNS epilepticus/NNS status/NN
acid/JJ decarboxylase/NN activity/NN inhibitor/NN micrograms/NNS resulted/VBD seizures/NNS epilepticus/NNS
pilocarpine/NN doses/NNS kg/NN activity/NN inhibitor/NN micrograms/NNS resulted/VBD seizures/NNS epilepticus/NNS status/NN
pilocarpine/NN doses/NNS kg/NN activity/NN inhibitor/NN micrograms/NNS resulted/VBD seizures/NNS epilepticus/NNS
isoniazid/NN microinjections/NNS pretreated/VBN animals/NNS resulted/VBD seizures/NNS epilepticus/NNS status/NN
isoniazid/NN microinjections/NNS pretreated/VBN animals/NNS resulted/VBD seizures/NNS epilepticus/NNS
L/NNP enzyme/NN activity/NN inhibitor/NN micrograms/NNS resulted/VBD seizures/NNS
glutamic/JJ decarboxylase/NN activity/NN inhibitor/NN micrograms/NNS resulted/VBD seizures/NNS
acid/JJ decarboxylase/NN activity/NN inhibitor/NN micrograms/NNS resulted/VBD seizures/NNS
GABA/NNP activity/NN inhibitor/NN micrograms/NNS resulted/VBD seizures/NNS
isoniazid/NN microinjections/NNS pretreated/VBN animals/NNS resulted/VBD seizures/NNS
isoniazid/NN injections/NNS augment/VB seizures/NNS
gamma/NN transaminase/NNP inhibitor/NN Application/NNP suppressed/VBD appearance/NN seizures/NNS
vinyl/NN transaminase/NNP inhibitor/NN Application/NNP suppressed/VBD appearance/NN seizures/NNS
GABA/NNP D/NNP vinyl/NN transaminase/NNP inhibitor/NN Application/NNP suppressed/VBD appearance/NN seizures/NNS
D/NNP vinyl/NN transaminase/NNP inhibitor/NN Application/NNP suppressed/VBD appearance/NN seizures/NNS
L/NNP D/NNP vinyl/NN transaminase/NNP inhibitor/NN Application/NNP suppressed/VBD appearance/NN seizures/NNS
4/CD vinyl/NN transaminase/NNP inhibitor/NN Application/NNP suppressed/VBD appearance/NN seizures/NNS
amino/JJ transaminase/NNP inhibitor/NN Application/NNP suppressed/VBD appearance/NN seizures/NNS
hex/NN amino/JJ transaminase/NNP inhibitor/NN Application/NNP suppressed/VBD appearance/NN seizures/NNS
5/CD amino/JJ transaminase/NNP inhibitor/NN Application/NNP suppressed/VBD appearance/NN seizures/NNS
enoic/JJ acid/NN 5/CD amino/JJ transaminase/NNP inhibitor/NN Application/NNP suppressed/VBD appearance/NN seizures/NNS
acid/NN 5/CD amino/JJ transaminase/NNP inhibitor/NN Application/NNP suppressed/VBD appearance/NN seizures/NNS
GABA/NNP transaminase/NNP inhibitor/NN Application/NNP suppressed/VBD appearance/NN seizures/NNS
gamma/NN Microinjections/NNS failed/VBD prevent/VB development/NN convulsions/NNS
vinyl/NN gamma/NN Microinjections/NNS failed/VBD prevent/VB development/NN convulsions/NNS
GABA/NNP gamma/NN Microinjections/NNS failed/VBD prevent/VB development/NN convulsions/NNS
GABA/NNP regulation/NN subjected/VBN seizures/NNS
doxorubicin/NN immunocytoma/NN
doxorubicin/NN nephrotoxicity/NN effect/NN cardiotoxicity/RB
doxorubicin/NN nephrotoxicity/NN
doxorubicin/NN induced/VBN activity/NN studied/VBN Antitumor/NNP inbred/VBD bearing/VBG immunocytoma/NN
doxorubicin/NN induced/VBN activity/NN cardiotoxicity/NN
doxorubicin/NN induced/VBN activity/NN nephrotoxicity/NN
doxorubicin/NN injections/NNS treated/VBN Animals/NNS tumor/NN
doxorubicin/NN kg/NN observed/VBN regression/NNP Tumor/NNP
doxorubicin/VBN mg/NN induced/VBN disappearance/NN tumor/NN
doxorubicin/VBN mg/NN dose/NN observed/VBN scored/VBD evidence/NN cardiotoxicity/NN
doxorubicin/JJ kg/NN dose/NN seen/VBN evidence/NN damage/NN renal/JJ
doxorubicin/JJ kg/NN dose/NN seen/VBN evidence/NN damage/NN
calcium/NN antagonist/NN Effects/NNPS induced/VBN ischemia/NN myocardial/JJ
calcium/NN antagonist/NN Effects/NNPS induced/VBN ischemia/NN
CD/NNP induced/VBN ischemia/NN myocardial/JJ
CD/NNP induced/VBN ischemia/NN
832/CD CD/NNP induced/VBN ischemia/NN myocardial/JJ
832/CD CD/NNP induced/VBN ischemia/NN
isoproterenol/NN 832/CD CD/NNP induced/VBN stenosis/NNS coronary/JJ
isoproterenol/NN 832/CD CD/NNP induced/VBN stenosis/NNS
calcium/NN antagonist/NN Effects/NNPS induced/VBN stenosis/NNS coronary/JJ
calcium/NN antagonist/NN Effects/NNPS induced/VBN stenosis/NNS
CD/NNP induced/VBN stenosis/NNS coronary/JJ
CD/NNP induced/VBN stenosis/NNS
832/CD CD/NNP induced/VBN stenosis/NNS coronary/JJ
832/CD CD/NNP induced/VBN stenosis/NNS
nifedipine/NN those/DT compared/VBN studied/VBN dogs/NNS stenosis/NNS coronary/JJ
nifedipine/NN those/DT compared/VBN studied/VBN dogs/NNS stenosis/NNS
CD/NNP Effects/NNPS induced/VBD studied/VBN ischemia/NN myocardial/JJ
CD/NNP Effects/NNPS induced/VBD studied/VBN ischemia/NN
832/CD Effects/NNPS induced/VBD studied/VBN ischemia/NN myocardial/JJ
832/CD Effects/NNPS induced/VBD studied/VBN ischemia/NN
nifedipine/NN those/DT compared/VBN studied/VBN ischemia/NN myocardial/JJ
nifedipine/NN those/DT compared/VBN studied/VBN ischemia/NN
isoproterenol/NN 832/CD Effects/NNPS induced/VBD studied/VBN dogs/NNS stenosis/NNS coronary/JJ
isoproterenol/NN 832/CD Effects/NNPS induced/VBD studied/VBN dogs/NNS stenosis/NNS
ISO/NNP isoproterenol/NN 832/CD Effects/NNPS induced/VBD studied/VBN dogs/NNS stenosis/NNS coronary/JJ
ISO/NNP isoproterenol/NN 832/CD Effects/NNPS induced/VBD studied/VBN dogs/NNS stenosis/NNS
diltiazem/NN nifedipine/NN those/DT compared/VBN studied/VBN ischemia/NN myocardial/JJ
diltiazem/NN nifedipine/NN those/DT compared/VBN studied/VBN ischemia/NN
diltiazem/NN nifedipine/NN those/DT compared/VBN studied/VBN dogs/NNS stenosis/NNS coronary/JJ
diltiazem/NN nifedipine/NN those/DT compared/VBN studied/VBN dogs/NNS stenosis/NNS
CD/NNP Effects/NNPS induced/VBD studied/VBN dogs/NNS stenosis/NNS coronary/JJ
CD/NNP Effects/NNPS induced/VBD studied/VBN dogs/NNS stenosis/NNS
832/CD Effects/NNPS induced/VBD studied/VBN dogs/NNS stenosis/NNS coronary/JJ
832/CD Effects/NNPS induced/VBD studied/VBN dogs/NNS stenosis/NNS
ISO/NNP infusion/NN periods/NNS 3/CD increased/VBD presence/NN stenosis/NNS coronary/JJ
ISO/NNP infusion/NN periods/NNS 3/CD increased/VBD presence/NN stenosis/NNS artery/NN
ISO/NNP infusion/NN periods/NNS 3/CD increased/VBD presence/NN stenosis/NNS
ISO/NNP infusion/NN stenosis/NNS
ISO/NN infusion/NN infused/VBN performed/VBN infusion/NN stenosis/NNS
CD/NNP doses/NNS infused/VBN performed/VBN infusion/NN stenosis/NNS
832/CD CD/NNP doses/NNS infused/VBN performed/VBN infusion/NN stenosis/NNS
nifedipine/NN CD/NNP doses/NNS infused/VBN performed/VBN infusion/NN stenosis/NNS
diltiazem/NN CD/NNP doses/NNS infused/VBN performed/VBN infusion/NN stenosis/NNS
ISO/NNP infusion/NNP stenosis/NNS
CD/NNP nifedipine/VB contrast/NN +/VBD mV/NN min/NN infusion/NNP stenosis/NNS
832/CD CD/NNP nifedipine/VB contrast/NN +/VBD mV/NN min/NN infusion/NNP stenosis/NNS
nifedipine/VB contrast/NN +/VBD mV/NN min/NN infusion/NNP stenosis/NNS
ISO/NNP infusion/NNP stenosis/NNS
Diltiazem/RB prevented/VBD decrease/NN segmental/NN shortening/VBG infusion/NNP stenosis/NNS
CD/NNP improves/VBZ ischemia/NN myocardial/JJ
CD/NNP improves/VBZ ischemia/NN
832/CD CD/NNP improves/VBZ ischemia/NN myocardial/JJ
832/CD CD/NNP improves/VBZ ischemia/NN
CD/NNP property/NN plays/VBZ suggest/VBP improves/VBZ ischemia/NN myocardial/JJ
CD/NNP property/NN plays/VBZ suggest/VBP improves/VBZ ischemia/NN
832/CD CD/NNP property/NN plays/VBZ suggest/VBP improves/VBZ ischemia/NN myocardial/JJ
832/CD CD/NNP property/NN plays/VBZ suggest/VBP improves/VBZ ischemia/NN
CD/NNP effects/NNS role/NN plays/VBZ suggest/VBP improves/VBZ ischemia/NN myocardial/JJ
CD/NNP effects/NNS role/NN plays/VBZ suggest/VBP improves/VBZ ischemia/NN
832/CD role/NN plays/VBZ suggest/VBP improves/VBZ ischemia/NN myocardial/JJ
832/CD role/NN plays/VBZ suggest/VBP improves/VBZ ischemia/NN
ISO/NNP infusion/NNP stenosis/NNS
CD/NNP improves/VBZ infusion/NNP stenosis/NNS
832/CD CD/NNP improves/VBZ infusion/NNP stenosis/NNS
CD/NNP property/NN plays/VBZ suggest/VBP improves/VBZ infusion/NNP stenosis/NNS
832/CD CD/NNP property/NN plays/VBZ suggest/VBP improves/VBZ infusion/NNP stenosis/NNS
CD/NNP effects/NNS role/NN plays/VBZ suggest/VBP improves/VBZ infusion/NNP stenosis/NNS
832/CD role/NN plays/VBZ suggest/VBP improves/VBZ infusion/NNP stenosis/NNS
cocaine/NN users/NNS Prevalence/NNP disease/NN heart/NN
cocaine/NN users/NNS Prevalence/NNP disease/NN
cocaine/NN users/NNS determine/VB prevalence/NN disease/NN heart/NN
cocaine/NN users/NNS determine/VB prevalence/NN disease/NN
cocaine/NN users/NNS users/NNS determine/VB prevalence/NN disease/NN heart/NN
cocaine/NN users/NNS users/NNS determine/VB prevalence/NN disease/NN
cocaine/NN users/NNS common/JJ artery/NN coronary/JJ
cocaine/NN users/NNS common/JJ artery/NN
cocaine/NN users/NNS common/JJ artery/NN or/CC
cocaine/NN users/NNS common/JJ artery/NN disease/NN myocardial/JJ
cocaine/NN users/NNS common/JJ artery/NN disease/NN
S/NNP BACKGROUND/NNP 23121/CD retardation/NN rats/NNS studies/NNS toxicity/NN
53482/CD BACKGROUND/NNP 23121/CD retardation/NN rats/NNS studies/NNS toxicity/NN
S/NNP 53482/CD BACKGROUND/NNP 23121/CD retardation/NN rats/NNS studies/NNS toxicity/NN
23121/CD retardation/NN rats/NNS studies/NNS toxicity/NN
S/NNP rats/NNS exposure/NN RESULTS/NNS produced/VBD similar/JJ patterns/NNS toxicity/NN
53482/CD exposure/NN RESULTS/NNS produced/VBD similar/JJ patterns/NNS toxicity/NN
phosphate/NN binder/NN switching/VBG hypercalcemic/JJ
calcium/NN reabsorption/NN parameters/NNS compared/VBN results/NNS patients/NNS matched/VBN age/NN etiology/NN disease/NN renal/JJ
calcium/NN reabsorption/NN parameters/NNS compared/VBN results/NNS patients/NNS matched/VBN age/NN etiology/NN disease/NN
calcium/NN reabsorption/NN parameters/NNS compared/VBN identify/VB factors/NNS associated/VBN development/NN hypercalcemia/NN
calcium/NN values/NNS experiencing/VBG episodes/NNS hypercalcemic/JJ
calcium/NN concentration/NN exhibited/VBD patients/NNS group/NN hypercalcemic/JJ
capsaicin/NN post/NN
capsaicin/NN neuralgia/NN herpetic/JJ
capsaicin/NN neuralgia/NN
capsaicin/NN evaluate/VB capsaicin/VBP patients/NNS post/NN
capsaicin/NN evaluate/VB capsaicin/VBP patients/NNS treated/VBN neuralgia/NN herpetic/JJ
capsaicin/NN evaluate/VB capsaicin/VBP patients/NNS treated/VBN neuralgia/NN
capsaicin/NN evaluate/VB capsaicin/VBP patients/NNS treated/VBN neuralgia/NN PHN/NNP
capsaicin/VBP patients/NNS post/NN
capsaicin/VBP patients/NNS treated/VBN neuralgia/NN herpetic/JJ
capsaicin/VBP patients/NNS treated/VBN neuralgia/NN
capsaicin/VBP patients/NNS treated/VBN neuralgia/NN PHN/NNP
capsaicin/NN PHN/NNP
nitroglycerin/NN reversed/VBN ischemia/NN
calcium/NN nitroglycerin/NN reversed/VBN ischemia/NN
calcium/NN nitroglycerin/NN reversed/VBN ischemia/NN induced/VBN spasm/NN coronary/JJ
calcium/NN nitroglycerin/NN reversed/VBN ischemia/NN induced/VBN spasm/NN artery/NN
calcium/NN nitroglycerin/NN reversed/VBN ischemia/NN induced/VBN spasm/NN
nitroglycerin/NN reversed/VBN ischemia/NN induced/VBN spasm/NN coronary/JJ
nitroglycerin/NN reversed/VBN ischemia/NN induced/VBN spasm/NN artery/NN
nitroglycerin/NN reversed/VBN ischemia/NN induced/VBN spasm/NN
amlodipine/JJ loss/NN report/VBP case/NN female/NN hypertension/NN
amlodipine/JJ loss/NN
amlodipine/JJ loss/NN sensation/NN of/IN
amlodipine/JJ loss/NN sensation/NN taste/NN
amlodipine/JJ loss/NN sensation/NN
Penicillamine/NNP related/VBN abnormalities/NNS presentation/NN anxiety/NN
zinc/NN acetate/NN dermatitis/NNS related/VBN abnormalities/NNS presentation/NN anxiety/NN
acetate/NN dermatitis/NNS related/VBN abnormalities/NNS presentation/NN anxiety/NN
zinc/NN acetate/NN dermatitis/NNS lichenoid/JJ
zinc/NN acetate/NN dermatitis/NNS
acetate/NN dermatitis/NNS lichenoid/JJ
acetate/NN dermatitis/NNS
zinc/NN acetate/NN dermatitis/NNS related/VBN patient/NN Wilson/NNP
zinc/NN acetate/NN dermatitis/NNS related/VBN patient/NN disease/NN
acetate/NN dermatitis/NNS related/VBN patient/NN Wilson/NNP
acetate/NN dermatitis/NNS related/VBN patient/NN disease/NN
Penicillamine/NNP related/VBN patient/NN Wilson/NNP
Penicillamine/NNP related/VBN patient/NN disease/NN
copper/NN metabolism/NN toxicity/NN tissues/NNS disorders/NNS neurologic/NN hepatic/NN
copper/NN metabolism/NN toxicity/NN tissues/NNS disorders/NNS neurologic/NN
copper/NN metabolism/NN toxicity/NN tissues/NNS disorders/NNS neurologic/NN and/CC
copper/NN metabolism/NN toxicity/NN tissues/NNS disorders/NNS neurologic/NN psychiatric/JJ
copper/NN metabolism/NN toxicity/NN tissues/NNS disorders/NNS
copper/NN accumulation/NN metabolism/NN toxicity/NN tissues/NNS disorders/NNS neurologic/NN hepatic/NN
copper/NN accumulation/NN metabolism/NN toxicity/NN tissues/NNS disorders/NNS neurologic/NN
copper/NN accumulation/NN metabolism/NN toxicity/NN tissues/NNS disorders/NNS neurologic/NN and/CC
copper/NN accumulation/NN metabolism/NN toxicity/NN tissues/NNS disorders/NNS neurologic/NN psychiatric/JJ
copper/NN accumulation/NN metabolism/NN toxicity/NN tissues/NNS disorders/NNS
copper/NN metabolism/NN disorder/NN disease/NN Wilson/NNP
copper/NN metabolism/NN disorder/NN disease/NN Wilson/NNP '/POS
copper/NN metabolism/NN disorder/NN disease/NN s/JJ
copper/NN metabolism/NN disorder/NN disease/NN
copper/NN accumulation/NN metabolism/NN disorder/NN disease/NN Wilson/NNP
copper/NN accumulation/NN metabolism/NN disorder/NN disease/NN Wilson/NNP '/POS
copper/NN accumulation/NN metabolism/NN disorder/NN disease/NN s/JJ
copper/NN accumulation/NN metabolism/NN disorder/NN disease/NN
copper/NN metabolism/NN toxicity/NN
copper/NN accumulation/NN metabolism/NN toxicity/NN
zinc/NN acetate/NN permitted/VBD interrupted/VBN appearance/NN dermatitis/NNS lichenoid/JJ
zinc/NN acetate/NN permitted/VBD interrupted/VBN appearance/NN dermatitis/NNS
acetate/NN permitted/VBD interrupted/VBN appearance/NN dermatitis/NNS lichenoid/JJ
acetate/NN permitted/VBD interrupted/VBN appearance/NN dermatitis/NNS
zinc/NN acetate/NN therapy/NN represented/VBD treatment/NN patient/NN Wilson/NNP
zinc/NN acetate/NN therapy/NN represented/VBD treatment/NN patient/NN Wilson/NNP '/POS
zinc/NN acetate/NN therapy/NN represented/VBD treatment/NN patient/NN s/JJ
zinc/NN acetate/NN therapy/NN represented/VBD treatment/NN patient/NN disease/NN
acetate/NN therapy/NN represented/VBD treatment/NN patient/NN Wilson/NNP
acetate/NN therapy/NN represented/VBD treatment/NN patient/NN Wilson/NNP '/POS
acetate/NN therapy/NN represented/VBD treatment/NN patient/NN s/JJ
acetate/NN therapy/NN represented/VBD treatment/NN patient/NN disease/NN
penicillamine/VBP represented/VBD treatment/NN patient/NN Wilson/NNP
penicillamine/VBP represented/VBD treatment/NN patient/NN Wilson/NNP '/POS
penicillamine/VBP represented/VBD treatment/NN patient/NN s/JJ
penicillamine/VBP represented/VBD treatment/NN patient/NN disease/NN
zinc/NN acetate/NN safety/NN allowed/VBD line/NN evidence/NN efficacy/NN drug/NN treatment/NN disease/NN Wilson/NNP
zinc/NN acetate/NN safety/NN allowed/VBD line/NN evidence/NN efficacy/NN drug/NN treatment/NN disease/NN Wilson/NNP '/POS
zinc/NN acetate/NN safety/NN allowed/VBD line/NN evidence/NN efficacy/NN drug/NN treatment/NN disease/NN s/JJ
zinc/NN acetate/NN safety/NN allowed/VBD line/NN evidence/NN efficacy/NN drug/NN treatment/NN disease/NN
acetate/NN safety/NN allowed/VBD line/NN evidence/NN efficacy/NN drug/NN treatment/NN disease/NN Wilson/NNP
acetate/NN safety/NN allowed/VBD line/NN evidence/NN efficacy/NN drug/NN treatment/NN disease/NN Wilson/NNP '/POS
acetate/NN safety/NN allowed/VBD line/NN evidence/NN efficacy/NN drug/NN treatment/NN disease/NN s/JJ
acetate/NN safety/NN allowed/VBD line/NN evidence/NN efficacy/NN drug/NN treatment/NN disease/NN
penicillamine/NN most/JJS conceivable/JJ seem/VB develop/VB lesion/NN skin/NN
penicillamine/NN most/JJS conceivable/JJ seem/VB develop/VB lesion/NN
penicillamine/NN Wilson/NNP
penicillamine/NN Wilson/NNP '/POS
penicillamine/NN s/JJ
penicillamine/NN disease/NN
I/PRP leading/VBG factor/NN cardiotoxicity/NN
131/NNP HA/NNP factor/NN cardiotoxicity/NN
HA/NNP factor/NN cardiotoxicity/NN
warfarin/NN users/NNS 0/CD MB/NNP
warfarin/NN users/NNS 0/CD MB/NNP TIA/NNP RESULTS/NNS analysis/NN ICH/NNP IS/NNS
warfarin/NN users/NNS 0/CD MB/NNP frequent/JJ TIA/NNP IS/VBZ
warfarin/NN users/NNS 0/CD MB/NNP TIA/NNP
warfarin/NN users/NNS 0/CD MB/NNP frequent/JJ TIA/NNP
warfarin/NN MB/NNP
warfarin/NN users/NNS none/NN 0/NNP nonusers/NNS users/NNS excess/NN MB/NNP
warfarin/NN MB/NNP excess/NN users/NNS nonusers/NNS 0/NNP none/NN users/NNS TIA/NNP IS/NNP
warfarin/NN users/NNS TIA/NNP IS/NNP
warfarin/NN MB/NNP excess/NN users/NNS nonusers/NNS 0/NNP none/NN users/NNS TIA/NNP
warfarin/NN users/NNS TIA/NNP
warfarin/NN users/NNS MB/NNP
warfarin/NN users/NNS MB/NNP excess/NN CONCLUSIONS/NNS suggests/VBZ increase/VB MB/NNP
warfarin/NN risk/NN increase/VB suggests/VBZ CONCLUSIONS/NNS excess/NN MB/NNP
warfarin/NN risk/NN increase/VB MB/NNP
NCQ/NNP treated/VBN cells/NNS observed/VBN necrosis/NNS
436/CD NCQ/NNP treated/VBN cells/NNS observed/VBN necrosis/NNS
NCQ/NNP treated/VBN cells/NNS observed/VBN had/VBD inducing/VBG concentrations/NNS necrosis/NNS
436/CD NCQ/NNP treated/VBN cells/NNS observed/VBN had/VBD inducing/VBG concentrations/NNS necrosis/NNS
NCQ/NNP 344/NNP had/VBD observed/VBN necrosis/NNS
344/NNP had/VBD observed/VBN necrosis/NNS
NCQ/NNP 344/NNP had/VBD inducing/VBG concentrations/NNS necrosis/NNS
344/NNP had/VBD inducing/VBG concentrations/NNS necrosis/NNS
NCQ/NNP ability/NN contribute/VB induce/VB anemia/NN aplastic/JJ
NCQ/NNP ability/NN contribute/VB induce/VB anemia/NN
436/CD NCQ/NNP ability/NN contribute/VB induce/VB anemia/NN aplastic/JJ
436/CD NCQ/NNP ability/NN contribute/VB induce/VB anemia/NN
NCQ/NNP ability/NN contribute/VB anemia/NN aplastic/JJ
NCQ/NNP ability/NN contribute/VB anemia/NN
436/CD NCQ/NNP ability/NN contribute/VB anemia/NN aplastic/JJ
436/CD NCQ/NNP ability/NN contribute/VB anemia/NN
NCQ/NNP NCQ/NNP ability/NN contribute/VB induce/VB anemia/NN aplastic/JJ
NCQ/NNP NCQ/NNP ability/NN contribute/VB induce/VB anemia/NN
344/CD NCQ/NNP NCQ/NNP ability/NN contribute/VB induce/VB anemia/NN aplastic/JJ
344/CD NCQ/NNP NCQ/NNP ability/NN contribute/VB induce/VB anemia/NN
NCQ/NNP NCQ/NNP ability/NN contribute/VB anemia/NN aplastic/JJ
NCQ/NNP NCQ/NNP ability/NN contribute/VB anemia/NN
344/CD NCQ/NNP NCQ/NNP ability/NN contribute/VB anemia/NN aplastic/JJ
344/CD NCQ/NNP NCQ/NNP ability/NN contribute/VB anemia/NN
Bepridil/NNP induced/VBN bradycardia/NN anti/NNS effect/NN tachycardial/JJ
Bepridil/NNP compound/NN treatment/NN attacks/NNS anginal/JJ
Bepridil/NNP compound/NN treatment/NN attacks/NNS
Curcumin/NNP prevents/VBZ maleate/NN induced/VBN nephrotoxicity/RB
oxygen/NN consumption/NN alterations/NNS relation/VBG induced/VBN nephrotoxicity/RB
curcumin/NN effect/NN injury/NN renal/JJ
curcumin/NN effect/NN injury/NN
sodium/NN gelatinase/NN excretion/NN besides/NNS necrosis/NNS
glucose/NN gelatinase/NN excretion/NN included/VBD' included/VBD injury/NN renal/JJ
glucose/NN gelatinase/NN excretion/NN included/VBD' included/VBD injury/NN
glucose/NN gelatinase/NN excretion/NN glucosaminidase/NN upregulation/NN molecule/NN kidney/NN
glucose/NN gelatinase/NN excretion/NN glucosaminidase/NN upregulation/NN molecule/NN injury/NN
sodium/NN gelatinase/NN excretion/NN included/VBD' included/VBD injury/NN renal/JJ
sodium/NN gelatinase/NN excretion/NN included/VBD' included/VBD injury/NN
sodium/NN gelatinase/NN excretion/NN glucosaminidase/NN upregulation/NN molecule/NN kidney/NN
sodium/NN gelatinase/NN excretion/NN glucosaminidase/NN upregulation/NN molecule/NN injury/NN
glucose/NN gelatinase/NN excretion/NN besides/NNS necrosis/NNS
curcumin/NN able/JJ attenuate/VB maleate/NN induced/VBN and/CC nephropathy/RB
Levetiracetam/VB phenobarbital/VB cats/NNS epilepsy/NN idiopathic/JJ
Levetiracetam/VB phenobarbital/VB cats/NNS epilepsy/NN
phenobarbital/VB cats/NNS epilepsy/NN idiopathic/JJ
phenobarbital/VB cats/NNS epilepsy/NN
levetiracetam/NN administered/VBN epilepsy/NN idiopathic/JJ
levetiracetam/NN administered/VBN epilepsy/NN
phenobarbital/JJ treatment/NN adjunct/JJ epilepsy/NN idiopathic/JJ
phenobarbital/JJ treatment/NN adjunct/JJ epilepsy/NN
phenobarbital/NN controlled/VBN have/VB epilepsy/NN idiopathic/JJ
phenobarbital/NN controlled/VBN have/VB epilepsy/NN
phenobarbital/NN treated/VBN suspected/VBN have/VB epilepsy/NN idiopathic/JJ
phenobarbital/NN treated/VBN suspected/VBN have/VB epilepsy/NN
levetiracetam/NN treatment/NN initiation/NN compared/VBN frequencies/VBZ Seizure/NNP
levetiracetam/NN frequency/NN seizure/NN
levetiracetam/NN frequency/NN mo/VBZ //RB seizures/NNS
levetiracetam/NN frequency/NN higher/JJR frequency/NN seizure/NN
levetiracetam/NN frequency/NN higher/JJR mo/NN seizures/NNS
levetiracetam/NN frequency/NN higher/JJR classified/VBN responded/VBN levetiracetam/VB ie/NN frequency/NN seizure/NN
levetiracetam/NN treatment/NN initiation/NN higher/JJR frequency/NN seizure/NN
levetiracetam/NN treatment/NN initiation/NN higher/JJR frequency/NN mo/VBZ //RB seizures/NNS
levetiracetam/NN treatment/NN initiation/NN higher/JJR frequency/NN seizure/NN
levetiracetam/NN treatment/NN initiation/NN higher/JJR mo/NN seizures/NNS
levetiracetam/NN treatment/NN initiation/NN higher/JJR classified/VBN responded/VBN levetiracetam/VB ie/NN frequency/NN seizure/NN
levetiracetam/VB responded/VBN classified/VBN higher/JJR frequency/NN seizure/NN
levetiracetam/VB responded/VBN classified/VBN higher/JJR frequency/NN mo/VBZ //RB seizures/NNS
levetiracetam/VB responded/VBN classified/VBN higher/JJR frequency/NN seizure/NN
levetiracetam/VB responded/VBN classified/VBN higher/JJR mo/NN seizures/NNS
levetiracetam/VB ie/NN frequency/NN seizure/NN
levetiracetam/NN tolerated/VBN suggested/VBD useful/JJ adjunct/NN phenobarbital/VB cats/NNS epilepsy/NN idiopathic/JJ
levetiracetam/NN tolerated/VBN suggested/VBD useful/JJ adjunct/NN phenobarbital/VB cats/NNS epilepsy/NN
phenobarbital/VB cats/NNS epilepsy/NN idiopathic/JJ
phenobarbital/VB cats/NNS epilepsy/NN
metronidazole/JJ toxicity/NN
naloxone/NN training/NN Reversal/NNP amnesia/NN
naloxone/NN role/NN deficit/NN retention/NN
naloxone/NN role/NN deficit/NN
scopolamine/NN role/NN deficit/NN retention/NN
scopolamine/NN role/NN deficit/NN
methyl/RB scopolamine/JJ Scopolamine/JJ induced/VBN as/RB amnesia/NN
scopolamine/JJ Scopolamine/JJ induced/VBN as/RB amnesia/NN
Naloxone/NNP injected/VBD prior/RB training/NN attenuated/VBN deficit/NN retention/NN
Naloxone/NNP injected/VBD prior/RB training/NN attenuated/VBN deficit/NN
naloxone/NN administration/NN single/JJ attenuated/VBD amnesia/NN
scopolamine/NN responsible/JJ appear/VBP increase/NN sensitivity/NN pain/NN
naloxone/NN pre/NN sensitivity/NN increase/NN appear/VBP responsible/JJ scopolamine/NN induced/VBN deficit/NN retention/NN
naloxone/NN pre/NN sensitivity/NN increase/NN appear/VBP responsible/JJ scopolamine/NN induced/VBN deficit/NN
naloxone/NN post/NN state/NN increase/NN appear/VBP responsible/JJ scopolamine/NN induced/VBN deficit/NN retention/NN
naloxone/NN post/NN state/NN increase/NN appear/VBP responsible/JJ scopolamine/NN induced/VBN deficit/NN
naloxone/NN influence/NN responsible/JJ scopolamine/NN induced/VBN deficit/NN retention/NN
naloxone/NN influence/NN responsible/JJ scopolamine/NN induced/VBN deficit/NN
scopolamine/NN induced/VBN deficit/NN retention/NN
scopolamine/NN induced/VBN deficit/NN
naloxone/NN pre/NN sensitivity/NN pain/NN
naloxone/NN post/NN state/NN increase/NN sensitivity/NN pain/NN
naloxone/NN influence/NN responsible/JJ appear/VBP increase/NN sensitivity/NN pain/NN
Testosterone/JJ streptozotocin/NNS induced/VBN impairment/NN memory/NN
Testosterone/JJ streptozotocin/NNS induced/VBN impairment/NN
testosterone/NN effects/NNS study/VB induced/VBN impairment/NN memory/NN
testosterone/NN effects/NNS study/VB induced/VBN impairment/NN
testosterone/JJ replacement/NN attenuated/VBN impaired/VBN
testosterone/JJ replacement/NN attenuated/VBN impaired/VBN memory/NN the/DT
testosterone/JJ replacement/NN attenuated/VBN impaired/VBN memory/NN
testosterone/JJ replacement/NN attenuated/VBN impaired/VBN impairment/NN memory/NN
testosterone/JJ replacement/NN attenuated/VBN impaired/VBN impairment/NN
Testosterone/JJ ameliorates/NNS CONCLUSION/NNP impairment/NN memory/NN
Testosterone/JJ ameliorates/NNS CONCLUSION/NNP impairment/NN
Serotonin/NNP reuptake/VBP inhibitors/NNS paranoia/NN
serotonin/JJ fluoxetine/NN exacerbation/NN paranoid/JJ
serotonin/JJ inhibitors/NNS associated/VBN exacerbations/NNS paranoid/JJ
serotonin/JJ inhibitors/NNS associated/VBN exacerbations/NNS present/VB disorders/NNS depressive/NN
serotonin/JJ inhibitors/NNS associated/VBN exacerbations/NNS present/VB disorders/NNS
serotonin/JJ inhibitors/NNS associated/VBN exacerbations/NNS present/VB disorders/NNS atypicality/NN course/NN psychosis/NNS
serotonin/JJ inhibitors/NNS associated/VBN exacerbations/NNS present/VB disorders/NNS atypicality/NN course/NN onset/NN course/NN psychosis/NNS
dopamine/NN release/NN HT/NNP mechanisms/NNS apply/VB remain/VBP pharmacology/NN paranoia/NN
serotonin/JJ blockers/NNS call/VB exacerbations/NNS paranoid/JJ
serotonin/JJ blockers/NNS call/VB raise/VB considerations/NNS paranoia/NN
monoHER/NN administration/NN interval/NN influence/NN cardiotoxicity/NN
doxorubicin/NN monoHER/NN administration/NN interval/NN influence/NN cardiotoxicity/NN
doxorubicin/NN protection/NN administration/NN interval/NN influence/NN cardiotoxicity/NN
doxorubicin/NN continues/VBZ known/VBN cardiotoxicity/RB
DOX/NNP doxorubicin/NN continues/VBZ known/VBN cardiotoxicity/RB
DOX/NNP induced/VBN results/NNS cardiac/JJ
DOX/NNP induced/VBN results/NNS damage/NN
DOX/NNP induced/VBN results/NNS cardiac/JJ
DOX/NNP induced/VBN results/NNS damage/NN
iron/NN properties/NNS scavenging/NN induced/VBN cardiotoxicity/RB
monohydroxyethylrutoside/NN showed/VBD DOX/NNP induced/VBN cardiotoxicity/RB
monoHER/NN monohydroxyethylrutoside/NN showed/VBD DOX/NNP induced/VBN cardiotoxicity/RB
flavonoid/JJ monohydroxyethylrutoside/NN showed/VBD DOX/NNP induced/VBN cardiotoxicity/RB
DOX/NNP induced/VBN cardiotoxicity/RB
DOX/NNP treatment/NN induced/VBN damage/NN cardiac/JJ
DOX/NNP treatment/NN induced/VBN damage/NN
azimilide/JJ sotalol/JJ dl/NN induced/VBN prolongation/NNP initiate/VB pointes/NNS torsade/JJ
azimilide/JJ sotalol/JJ dl/NN induced/VBN prolongation/NNP initiate/VB pointes/NNS de/NNP
azimilide/JJ sotalol/JJ dl/NN induced/VBN prolongation/NNP initiate/VB pointes/NNS
azimilide/JJ sotalol/JJ dl/NN induced/VBN prolongation/NNP initiate/VB pointes/NNS TdP/NNP
azimilide/JJ sotalol/JJ dl/NN induced/VBN prolongation/NNP QT/NNP
azimilide/JJ sotalol/JJ dl/NN induced/VBN prolongation/NNP
azimilide/JJ sotalol/JJ dl/NN EADs/VBZ produced/VBD rabbits/NNS seen/VBN prolongation/NNS QT/NNP
azimilide/JJ sotalol/JJ dl/NN EADs/VBZ produced/VBD rabbits/NNS seen/VBN prolongation/NNS
nicotine/NN effects/NNS investigates/VBZ anxiety/NN
Nicotine/JJ pretreatment/NN blocked/VBD caffeine/NN induced/VBN anxiety/NN
nicotine/NN anxiety/NN
alanine/JJ >/NNS jaundice/JJ
alanine/JJ >/NNS jaundice/JJ limits/NNS patients/NNS hepatitis/NN
alanine/JJ >/NNS jaundice/JJ limits/NNS patients/NNS %/NN observed/VBN anemia/JJ
NVP/NNP therapy/NN associated/VBN rash/NN therapy/NN neuropathy/NN peripheral/JJ
NVP/NNP therapy/NN associated/VBN rash/NN therapy/NN neuropathy/NN
d/LS therapy/NN rash/NN
4/CD therapy/NN rash/NN
T/NNP therapy/NN rash/NN
diclofenac/NN treatment/NN dysmenorrhea/NN
glyceryl/NN comparison/NN trinitrate/VBP diclofenac/NN treatment/NN dysmenorrhea/NN
trinitrate/VBP diclofenac/NN treatment/NN dysmenorrhea/NN
prostaglandins/NNS hypersecretion/NN caused/VBN uterine/NN characterized/VBN syndrome/NN dysmenorrhea/NN
diclofenac/NN comparison/NN dysmenorrhea/NN
DCF/NNP efficacy/NN resolution/NN dysmenorrhea/NN
glyceryl/JJ trinitrate/NN efficacy/NN resolution/NN dysmenorrhea/NN
trinitrate/NN efficacy/NN resolution/NN dysmenorrhea/NN
GTN/NNP efficacy/NN resolution/NN dysmenorrhea/NN
NO/JJ donor/NN efficacy/NN resolution/NN dysmenorrhea/NN
DCF/NNP continued/VBD effective/JJ reducing/VBG pain/NN pelvic/JJ
DCF/NNP continued/VBD effective/JJ reducing/VBG pain/NN
GTN/NNP scores/NNS remained/VBD effective/JJ reducing/VBG pain/NN pelvic/JJ
GTN/NNP scores/NNS remained/VBD effective/JJ reducing/VBG pain/NN
GTN/NNP hour/NN higher/JJR more/JJR remained/VBD effective/JJ reducing/VBG pain/NN pelvic/JJ
GTN/NNP hour/NN higher/JJR more/JJR remained/VBD effective/JJ reducing/VBG pain/NN
GTN/NNP hours/NNS 6/CD 23/CD 7/CD 20/CD 5/CD DFC/NNP GTN/NNP hour/NN higher/JJR more/JJR remained/VBD effective/JJ reducing/VBG pain/NN pelvic/JJ
GTN/NNP hours/NNS 6/CD 23/CD 7/CD 20/CD 5/CD DFC/NNP GTN/NNP hour/NN higher/JJR more/JJR remained/VBD effective/JJ reducing/VBG pain/NN
DCF/NNP increased/VBN' increased/VBN Headache/NNP
DCF/NNP comparison/NN tolerability/JJ treatment/NN dysmenorrhea/NN
GTN/NNP has/VBZ tolerability/JJ treatment/NN dysmenorrhea/NN
Glucose/JJ metabolism/NN patients/NNS schizophrenia/NN
glucose/NN test/NN metabolism/NN patients/NNS schizophrenia/NN
glucose/NN metabolism/NN affecting/VBG remains/VBZ increasing/VBG incidence/NN mellitus/NNS diabetes/NN
glucose/NN metabolism/NN affecting/VBG remains/VBZ increasing/VBG incidence/NN mellitus/NNS
glucose/NN metabolism/NN affecting/VBG increasing/VBG factors/NNS diabetes/NN
glucose/NN metabolism/NN affecting/VBG remains/VBZ increasing/VBG patients/NNS schizophrenia/NN
glucose/NN test/NN using/VBG evaluated/VBN schizophrenia/NN
olanzapine/JJ either/RB treated/VBN matched/VBN subjects/NNS disorder/NN schizophrenia/NN schizoaffective/NN
olanzapine/JJ either/RB treated/VBN matched/VBN subjects/NNS disorder/NN
risperidone/NN either/RB treated/VBN matched/VBN subjects/NNS disorder/NN schizophrenia/NN
olanzapine/JJ either/RB treated/VBN matched/VBN subjects/NNS disorder/NN schizophrenia/NN
clozapine/JJ either/RB treated/VBN matched/VBN subjects/NNS disorder/NN schizophrenia/NN
clozapine/JJ either/RB treated/VBN matched/VBN subjects/NNS disorder/NN schizophrenia/NN schizoaffective/NN
clozapine/JJ either/RB treated/VBN matched/VBN subjects/NNS disorder/NN
risperidone/NN either/RB treated/VBN matched/VBN subjects/NNS disorder/NN schizophrenia/NN schizoaffective/NN
risperidone/NN either/RB treated/VBN matched/VBN subjects/NNS disorder/NN
glucose/NN index/NN insulin/NN
glucose/NN index/NN sensitivity/NN
glucose/NN assessment/NN resistance/NN insulin/NN
glucose/NN assessment/NN resistance/NN
glucose/NN effectiveness/NN glucose/NN index/NN insulin/NN
glucose/NN effectiveness/NN glucose/NN index/NN sensitivity/NN
glucose/NN effectiveness/NN glucose/NN assessment/NN resistance/NN insulin/NN
glucose/NN effectiveness/NN glucose/NN assessment/NN resistance/NN
risperidone/NNP difference/NN index/NN insulin/NN
risperidone/NNP difference/NN index/NN sensitivity/NN
risperidone/NNP difference/NN was/VBD subjects/NNS received/VBD exhibiting/VBG resistance/NN insulin/NN
risperidone/NNP difference/NN was/VBD subjects/NNS received/VBD exhibiting/VBG resistance/NN
risperidone/NN treated/VBN subjects/NNS resistance/NN exhibiting/VBG received/VBD subjects/NNS was/VBD difference/NN index/NN insulin/NN
risperidone/NN treated/VBN subjects/NNS resistance/NN exhibiting/VBG received/VBD subjects/NNS was/VBD difference/NN index/NN sensitivity/NN
risperidone/NN treated/VBN subjects/NNS resistance/NN insulin/NN
risperidone/NN treated/VBN subjects/NNS resistance/NN
risperidone/NN risperidone/NN treated/VBN subjects/NNS resistance/NN exhibiting/VBG received/VBD subjects/NNS was/VBD difference/NN index/NN insulin/NN
risperidone/NN risperidone/NN treated/VBN subjects/NNS resistance/NN exhibiting/VBG received/VBD subjects/NNS was/VBD difference/NN index/NN sensitivity/NN
risperidone/NN risperidone/NN treated/VBN subjects/NNS resistance/NN insulin/NN
risperidone/NN risperidone/NN treated/VBN subjects/NNS resistance/NN
risperidone/NN 001/NNP exhibiting/VBG received/VBD subjects/NNS was/VBD difference/NN index/NN insulin/NN
risperidone/NN 001/NNP exhibiting/VBG received/VBD subjects/NNS was/VBD difference/NN index/NN sensitivity/NN
risperidone/NN 001/NNP exhibiting/VBG resistance/NN insulin/NN
risperidone/NN 001/NNP exhibiting/VBG resistance/NN
risperidone/NNP 4/CD differed/VBD assessment/NN resistance/NN insulin/NN
risperidone/NNP 4/CD differed/VBD assessment/NN resistance/NN
risperidone/NN clozapine/VB differed/VBD assessment/NN resistance/NN insulin/NN
risperidone/NN clozapine/VB differed/VBD assessment/NN resistance/NN
risperidone/NN risperidone/NN clozapine/VB differed/VBD assessment/NN resistance/NN insulin/NN
risperidone/NN risperidone/NN clozapine/VB differed/VBD assessment/NN resistance/NN
risperidone/NN displayed/VBD resistance/NN insulin/NN
risperidone/NN displayed/VBD resistance/NN
glucose/NN effectiveness/NN resistance/NN insulin/NN
glucose/NN effectiveness/NN resistance/NN
midazolam/NN Fentanyl/NNP myoclonus/NNS
Fentanyl/NNP myoclonus/NNS
midazolam/NN fentanyl/NN effectiveness/NN compare/VB prevent/VB etomidate/NN myoclonus/NNS
midazolam/NN fentanyl/NN combination/NN fentanyl/NN effectiveness/NN compare/VB prevent/VB etomidate/NN myoclonus/NNS
fentanyl/NN effectiveness/NN compare/VB prevent/VB etomidate/NN myoclonus/NNS
fentanyl/NN combination/NN fentanyl/NN effectiveness/NN compare/VB prevent/VB etomidate/NN myoclonus/NNS
etomidate/JJ injection/NN minutes/NNS severity/NN observed/VBN evaluated/VBN movements/NNS Myoclonic/JJ
etomidate/JJ injection/NN minutes/NNS severity/NN observed/VBN evaluated/VBN movements/NNS
etomidate/JJ injection/NN due/JJ pain/NN
midazolam/NN fentanyl/NN fentanyl/NN pretreatment/NN effective/JJ preventing/VBG etomidate/NN myoclonus/NNS
fentanyl/NN pretreatment/NN effective/JJ preventing/VBG etomidate/NN myoclonus/NNS
fentanyl/NN fentanyl/NN pretreatment/NN effective/JJ preventing/VBG etomidate/NN myoclonus/NNS
All/DT trans/NNS myositis/NNS patient/NN leukemia/NN acute/JJ
All/DT trans/NNS myositis/NNS patient/NN leukemia/NN promyelocytic/JJ
All/DT trans/NNS myositis/NNS patient/NN leukemia/NN
trans/NNS myositis/NNS patient/NN leukemia/NN acute/JJ
trans/NNS myositis/NNS patient/NN leukemia/NN promyelocytic/JJ
trans/NNS myositis/NNS patient/NN leukemia/NN
retinoic/JJ acid/NN trans/NNS myositis/NNS patient/NN leukemia/NN acute/JJ
retinoic/JJ acid/NN trans/NNS myositis/NNS patient/NN leukemia/NN promyelocytic/JJ
retinoic/JJ acid/NN trans/NNS myositis/NNS patient/NN leukemia/NN
acid/NN trans/NNS myositis/NNS patient/NN leukemia/NN acute/JJ
acid/NN trans/NNS myositis/NNS patient/NN leukemia/NN promyelocytic/JJ
acid/NN trans/NNS myositis/NNS patient/NN leukemia/NN
All/DT associated/VBN acid/NN component/NN therapy/NN leukemia/NN promyelocytic/JJ acute/JJ
All/DT associated/VBN acid/NN component/NN therapy/NN leukemia/NN promyelocytic/JJ
All/DT associated/VBN acid/NN component/NN therapy/NN leukemia/NN
trans/JJ acid/NN component/NN therapy/NN leukemia/NN promyelocytic/JJ acute/JJ
trans/JJ acid/NN component/NN therapy/NN leukemia/NN promyelocytic/JJ
trans/JJ acid/NN component/NN therapy/NN leukemia/NN
retinoic/JJ acid/NN component/NN therapy/NN leukemia/NN promyelocytic/JJ acute/JJ
retinoic/JJ acid/NN component/NN therapy/NN leukemia/NN promyelocytic/JJ
retinoic/JJ acid/NN component/NN therapy/NN leukemia/NN
acid/NN component/NN therapy/NN leukemia/NN promyelocytic/JJ acute/JJ
acid/NN component/NN therapy/NN leukemia/NN promyelocytic/JJ
acid/NN component/NN therapy/NN leukemia/NN
All/DT associated/VBN acid/NN component/NN therapy/NN leukemia/NN APL/NNP
trans/JJ acid/NN component/NN therapy/NN leukemia/NN APL/NNP
retinoic/JJ acid/NN component/NN therapy/NN leukemia/NN APL/NNP
acid/NN component/NN therapy/NN leukemia/NN APL/NNP
ATRA/NNP acid/NN component/NN therapy/NN leukemia/NN promyelocytic/JJ acute/JJ
ATRA/NNP acid/NN component/NN therapy/NN leukemia/NN promyelocytic/JJ
ATRA/NNP acid/NN component/NN therapy/NN leukemia/NN
ATRA/NNP acid/NN component/NN therapy/NN leukemia/NN APL/NNP
L/NNP bradykinesia/NNP rigidity/NNP
DOPA/NNP February/NNP bradykinesia/NNP rigidity/NNP
L/NNP bradykinesia/NNP
DOPA/NNP February/NNP bradykinesia/NNP
L/NNP bradykinesia/NNP February/NNP pallidotomy/NN underwent/VBD patients/NNS disease/NN Parkinson/NNP
L/NNP bradykinesia/NNP February/NNP pallidotomy/NN underwent/VBD patients/NNS disease/NN Parkinson/NNP '/POS
L/NNP bradykinesia/NNP February/NNP pallidotomy/NN underwent/VBD patients/NNS disease/NN s/JJ
L/NNP bradykinesia/NNP February/NNP pallidotomy/NN underwent/VBD patients/NNS disease/NN
DOPA/NNP February/NNP pallidotomy/NN underwent/VBD patients/NNS disease/NN Parkinson/NNP
DOPA/NNP February/NNP pallidotomy/NN underwent/VBD patients/NNS disease/NN Parkinson/NNP '/POS
DOPA/NNP February/NNP pallidotomy/NN underwent/VBD patients/NNS disease/NN s/JJ
DOPA/NNP February/NNP pallidotomy/NN underwent/VBD patients/NNS disease/NN
hydrochlorothiazide/NN mg/NN administered/VBN month/NN patients/NNS hypertensive/JJ
timolol/JJ maleate/NN mg/NN mg/NN administered/VBN month/NN patients/NNS hypertensive/JJ
maleate/NN mg/NN mg/NN administered/VBN month/NN patients/NNS hypertensive/JJ
propranolol/NN loading/NN induced/VBN confirmed/VBN absence/NN MR/NNP
phosphorus/NN poisoning/NN
phosphorus/NN known/VBN cause/VB hepatotoxicity/RB
phosphorus/NN Poisoning/VBG
phosphorus/NN poisoning/NN presented/VBD highlighting/VBG feature/NN hepatotoxicity/NN
phosphorus/NN hepatotoxicity/NN
phosphorus/NN poisoning/NN
phosphorus/NN hepatotoxicity/NN feature/NN highlighting/VBG presented/VBD poisoning/NN
angiotensin/NN therapy/NN use/NN caused/VBD Syncope/NNP
angiotensin/NN therapy/NN use/NN caused/VBD hyperkalemia/NN
spironolactone/NN inhibitor/NN converting/VBG caused/VBD Syncope/NNP
aldosterone/JJ antagonist/NN spiranolactone/NN doses/NNS considered/VBN cause/NN hyperkalemia/NN
potassium/NN using/VBG patients/NNS possibility/NN hyperkalemia/NN
potassium/NN using/VBG patients/NNS have/VBP disturbance/NN renal/JJ
potassium/NN using/VBG patients/NNS have/VBP disturbance/NN
aspirin/NN discuss/VB adults/NNS risk/NN disease/NN coronary/JJ
aspirin/NN discuss/VB adults/NNS risk/NN disease/NN heart/NN
aspirin/NN discuss/VB adults/NNS risk/NN disease/NN
aspirin/NN taking/VBG prevention/NN infarctions/NNS myocardial/JJ
aspirin/NN taking/VBG prevention/NN infarctions/NNS
aspirin/NN control/NN prevention/NN disease/NN cardiovascular/JJ
aspirin/NN control/NN prevention/NN disease/NN
aspirin/NN reviews/NNS SELECTION/NNP CVD/NNP
aspirin/NN reviews/NNS SELECTION/NNP selected/VBN answer/VB questions/NNS decrease/VB CVD/NNP
aspirin/NN decrease/VB questions/NNS answer/VB selected/VBN SELECTION/NNP reviews/NNS aspirin/NN control/NN prevention/NN disease/NN cardiovascular/JJ
aspirin/NN decrease/VB questions/NNS answer/VB selected/VBN SELECTION/NNP reviews/NNS aspirin/NN control/NN prevention/NN disease/NN
aspirin/NN decrease/VB questions/NNS answer/VB selected/VBN SELECTION/NNP CVD/NNP
aspirin/NN decrease/VB CVD/NNP
aspirin/NN increase/VB bleeding/NN strokes/NNS hemorrhagic/NN
aspirin/NN increase/VB bleeding/NN strokes/NNS
aspirin/NN use/NN reduces/VBZ number/NN events/NNS CVD/NNP
aspirin/NN use/NN reduces/VBZ CVD/NNP
Aspirin/NNP seem/VB affect/VB mortality/NN CVD/NNP
aspirin/NN use/NN increases/VBZ risk/NN events/NNS bleeding/VBG
aspirin/NN use/NN strokes/NNS hemorrhagic/JJ
aspirin/NN use/NN strokes/NNS
aspirin/NN prevention/NN CVD/NNP
Aspirin/NNP reduces/VBZ risk/NN infarction/NN myocardial/JJ
Aspirin/NNP reduces/VBZ risk/NN infarction/NN
Aspirin/NN use/NN increases/VBZ risk/NN events/NNS bleeding/VBG
Hydroxytyrosol/NNP ameliorates/VBZ induced/VBN stress/NN dysfunction/NN mitochondrial/JJ
Hydroxytyrosol/NNP ameliorates/VBZ induced/VBN stress/NN dysfunction/NN
doxorubicin/NN stress/NN dysfunction/NN mitochondrial/JJ
doxorubicin/NN stress/NN dysfunction/NN
Hydroxytyrosol/NNP ameliorates/VBZ induced/VBN cardiotoxicity/RB
doxorubicin/NN stress/NN induced/VBN cardiotoxicity/RB
Hydroxytyrosol/NNP ameliorates/VBZ induced/VBN rats/NNS cancer/NN breast/NN
Hydroxytyrosol/NNP ameliorates/VBZ induced/VBN rats/NNS cancer/NN
doxorubicin/NN stress/NN induced/VBN rats/NNS cancer/NN breast/NN
doxorubicin/NN stress/NN induced/VBN rats/NNS cancer/NN
doxorubicin/NN drugs/NNS effect/NN potentiate/VB shown/VBN involved/VBN processes/NNS cancer/NN
doxorubicin/NN drugs/NNS effect/NN potentiate/VB shown/VBN involved/VBN processes/NNS cancer/NN disease/NN cardiovascular/JJ
doxorubicin/NN drugs/NNS effect/NN potentiate/VB shown/VBN involved/VBN processes/NNS cancer/NN disease/NN
Doxorubicin/NNP causes/VBZ cardiotoxicity/NN characterized/VBN increases/NNS stress/NN dysfunction/NN mitochondrial/NN
Doxorubicin/NNP causes/VBZ cardiotoxicity/NN characterized/VBN increases/NNS stress/NN dysfunction/NN
Doxorubicin/NNP causes/VBZ cardiotoxicity/NN
hydroxytyrosol/NN ameliorated/VBN toxicity/NN cardiac/JJ
hydroxytyrosol/NN ameliorated/VBN toxicity/NN
doxorubicin/NN associated/VBN ameliorated/VBN toxicity/NN cardiac/JJ
doxorubicin/NN associated/VBN ameliorated/VBN toxicity/NN
hydroxytyrosol/NN rats/NNS cancer/NN breast/NN
hydroxytyrosol/NN rats/NNS cancer/NN
doxorubicin/NN associated/VBN ameliorated/VBN hydroxytyrosol/NN rats/NNS cancer/NN breast/NN
doxorubicin/NN associated/VBN ameliorated/VBN hydroxytyrosol/NN rats/NNS cancer/NN
hydroxytyrosol/NN mg/NN groups/NNS divided/VBN Thirty/NNP rats/NNS bearing/VBG tumors/NNS breast/NN
hydroxytyrosol/NN mg/NN groups/NNS divided/VBN Thirty/NNP rats/NNS bearing/VBG tumors/NNS
hydroxytyrosol/NN doxorubicin/NN groups/NNS divided/VBN Thirty/NNP rats/NNS bearing/VBG tumors/NNS breast/NN
hydroxytyrosol/NN doxorubicin/NN groups/NNS divided/VBN Thirty/NNP rats/NNS bearing/VBG tumors/NNS
doxorubicin/NN groups/NNS divided/VBN Thirty/NNP rats/NNS bearing/VBG tumors/NNS breast/NN
doxorubicin/NN groups/NNS divided/VBN Thirty/NNP rats/NNS bearing/VBG tumors/NNS
doxorubicin/NN groups/NNS divided/VBN Thirty/NNP rats/NNS bearing/VBG tumors/NNS breast/NN
doxorubicin/NN groups/NNS divided/VBN Thirty/NNP rats/NNS bearing/VBG tumors/NNS
Hydroxytyrosol/NNP improved/VBD disturbances/NNS cardiac/JJ
Hydroxytyrosol/NNP improved/VBD disturbances/NNS
hydroxytyrosol/NN protect/VB damage/NN heart/NN
hydroxytyrosol/NN protect/VB damage/NN
amitriptyline/NNP therapy/NN syndrome/NN neuroleptic/JJ
amitriptyline/NNP therapy/NN syndrome/NN malignant/JJ
amitriptyline/NNP therapy/NN syndrome/NN
amitriptyline/NNP therapy/NN syndrome/NN disorders/NNS serotonin/NN
amitriptyline/NNP therapy/NN syndrome/NN disorders/NNS syndrome/NN
amitriptyline/NNP therapy/NN course/NN developed/VBN remission/NN depression/NN unipolar/NN
amitriptyline/NNP therapy/NN course/NN developed/VBN remission/NN depression/NN
glycopyrrolate/NN hyperhidrosis/VBZ gustatory/RB
glycopyrrolate/NN hyperhidrosis/VBZ
glycopyrrolate/NN applying/VBG excellent/JJ sweating/NN
glycopyrrolate/NN applying/VBG excellent/JJ reduced/VBN sweating/NN
glycopyrrolate/JJ patients/NNS throat/NN mouth/NN dry/JJ
glycopyrrolate/JJ patients/NNS throat/NN mouth/NN
glycopyrrolate/JJ patient/NN headache/NN patients/NNS throat/NN mouth/NN dry/JJ
glycopyrrolate/JJ patient/NN headache/NN patients/NNS throat/NN mouth/NN
glycopyrrolate/JJ pad/NN application/NN appeared/VBD tolerated/JJ method/NN treatment/NN sympathectomy/NN moderate/JJ symptoms/NNS hyperhidrosis/NNS gustatory/JJ
glycopyrrolate/JJ pad/NN application/NN appeared/VBD tolerated/JJ method/NN treatment/NN sympathectomy/NN moderate/JJ symptoms/NNS hyperhidrosis/NNS
cocaine/NN contributes/VBZ impairment/NN Mitochondrial/JJ
cocaine/NN contributes/VBZ impairment/NN
MitoQ/NN contributes/VBZ impairment/NN Mitochondrial/JJ
MitoQ/NN contributes/VBZ impairment/NN
MitoQ/NN contributes/VBZ cocaine/NN dysfunction/NN cardiac/JJ
MitoQ/NN contributes/VBZ cocaine/NN dysfunction/NN
cocaine/NN exposure/NN short/JJ detectable/JJ suggesting/VBG late/JJ abnormalities/NNS mitochondrial/JJ
cocaine/NN exposure/NN short/JJ detectable/JJ suggesting/VBG late/JJ abnormalities/NNS
cocaine/NN response/NN late/JJ abnormalities/NNS mitochondrial/JJ
cocaine/NN response/NN late/JJ abnormalities/NNS
MitoQ/RB shown/VBN prevent/VB abnormalities/NNS dysfunction/NN characterized/VBN dysfunction/NN diastolic/JJ
MitoQ/RB shown/VBN prevent/VB abnormalities/NNS dysfunction/NN characterized/VBN dysfunction/NN
MitoQ/RB shown/VBN prevent/VB abnormalities/NNS mitochondrial/JJ
MitoQ/RB shown/VBN prevent/VB abnormalities/NNS
MitoQ/RB shown/VBN prevent/VB abnormalities/NNS dysfunction/NN cardiac/JJ
MitoQ/RB shown/VBN prevent/VB abnormalities/NNS dysfunction/NN
cocaine/NN demonstrate/VBP extend/VBP due/JJ defect/NN mitochondrial/JJ
cocaine/NN demonstrate/VBP extend/VBP due/JJ defect/NN
contrast/NN Incidence/NNP nephropathy/NN patients/NNS cancer/NN
contrast/NN related/VBN factors/NNS frequency/NN determine/VB induced/VBN cancer/NN
irinotecan/NN more/JJR more/JJR' patients/NNS hypertension/NN
bevacizumab/JJ //JJ irinotecan/NN more/JJR more/JJR' patients/NNS hypertension/NN
irinotecan/NN combination/NN Hypertension/NNP
bevacizumab/JJ irinotecan/NN combination/NN Hypertension/NNP
bevacizumab/NN Hypertension/NN
alcohol/NN association/NN use/VBP progression/NN HIV/NN
alcohol/NN association/NN use/VBP progression/NN disease/NN
alcohol/NN consumption/NN association/NN effects/NNS progression/NN HIV/NN
alcohol/NN consumption/NN association/NN effects/NNS progression/NN disease/NN
Topotecan/NNP combination/NN radiotherapy/NN glioblastoma/NN
Topotecan/NNP option/NN exhibits/VBZ inhibition/NN glioma/NN
topotecan/JJ mg/NN radiotherapy/NN combination/NN assessed/VBD adults/NNS GBM/NNP
amiodarone/NN dronedarone/NN effects/NNS animals/NNS infarction/NN myocardial/JJ
amiodarone/NN dronedarone/NN effects/NNS animals/NNS infarction/NN
dronedarone/NN effects/NNS animals/NNS infarction/NN myocardial/JJ
dronedarone/NN effects/NNS animals/NNS infarction/NN
amiodarone/VB related/VBN compound/NN effects/NNS compared/VBN compared/VBN' stimulation/NN dogs/NNS infarction/NN myocardial/JJ
amiodarone/VB related/VBN compound/NN effects/NNS compared/VBN compared/VBN' stimulation/NN dogs/NNS infarction/NN
amiodarone/NN those/DT compared/VBN compared/VBN' stimulation/NN dogs/NNS infarction/NN myocardial/JJ
amiodarone/NN those/DT compared/VBN compared/VBN' stimulation/NN dogs/NNS infarction/NN
dronedarone/NN effects/NNS compared/VBN compared/VBN' stimulation/NN dogs/NNS infarction/NN myocardial/JJ
dronedarone/NN effects/NNS compared/VBN compared/VBN' stimulation/NN dogs/NNS infarction/NN
amiodarone/NN dronedarone/NN reduced/VBD exercise/NN induced/VBN tachycardia/NN
amiodarone/NN dronedarone/NN reduced/VBD exercise/NN induced/VBN tachycardia/NN
dronedarone/NN reduced/VBD exercise/NN induced/VBN tachycardia/NN
dronedarone/NN reduced/VBD exercise/NN induced/VBN tachycardia/NN
dronedarone/NN suitable/JJ treatment/NN arrhythmias/NNS
rifampin/NN use/NN associated/VBN complication/NN failure/NN Renal/JJ
rifampin/NN use/NN associated/VBN complication/NN failure/NN
rifampin/NN failure/NN developed/VBD leprosy/NNP
trimethaphan/NN induced/VBN accompanied/VBN bradycardia/NN
carbamazepine/VB woman/NN epileptic/JJ
carbamazepine/JJ toxicity/NN bone/NN
carbamazepine/JJ toxicity/NN marrow/NN
carbamazepine/JJ toxicity/NN
cyclosporin/NN A/NN tablets/NNS Long/NNP hypertension/NN patients/NNS psoriasis/NNS
A/NN tablets/NNS Long/NNP hypertension/NN patients/NNS psoriasis/NNS
nifedipine/NN efficacy/JJ Long/NNP hypertension/NN
nifedipine/NN efficacy/JJ Long/NNP hypertension/NN patients/NNS psoriasis/NNS
calcium/NN blocker/NN months/NNS treated/VBN cyclosporin/NN course/NN hypertension/NN
cyclosporin/NN course/NN hypertension/NN patients/NNS psoriatic/JJ
A/DT therapy/NN treated/VBN cyclosporin/NN course/NN hypertension/NN patients/NNS psoriatic/JJ
nifedipine/JJ release/VBP patients/NNS hypertension/NN
nifedipine/JJ release/VBP patients/NNS psoriatic/JJ
calcium/NN blocker/NN months/NNS treated/VBN cyclosporin/NN course/NN hypertension/NN patients/NNS psoriatic/JJ
blood/NN levels/NNS included/VBD 9/CD development/NN hyperplasia/NN gingival/JJ
blood/NN levels/NNS included/VBD 9/CD development/NN hyperplasia/NN
urea/NN levels/NNS included/VBD 9/CD development/NN hyperplasia/NN gingival/JJ
urea/NN levels/NNS included/VBD 9/CD development/NN hyperplasia/NN
nitrogen/NN levels/NNS included/VBD 9/CD development/NN hyperplasia/NN gingival/JJ
nitrogen/NN levels/NNS included/VBD 9/CD development/NN hyperplasia/NN
cyclosporin/NN A/NN treatment/NN sustained/VBD useful/JJ patients/NNS psoriatic/JJ
A/NN treatment/NN sustained/VBD useful/JJ patients/NNS psoriatic/JJ
nifedipine/NN useful/JJ patients/NNS hypertensive/JJ
nifedipine/NN useful/JJ patients/NNS psoriatic/JJ
Piperacillin/NNP tazobactam/NNP seizure/NN
//NNP tazobactam/NNP seizure/NN
tazobactam/NNP seizure/NN
piperacillin/NN use/NN goes/VBZ neurotoxicity/NN
piperacillin/NN associated/VBN neurotoxicity/NN
piperacillin/JJ tazobactam/NN doses/NNS seizure/NN given/VBN report/VBP 57/CD woman/NN end/NN
piperacillin/JJ tazobactam/NN doses/NNS seizure/NN given/VBN report/VBP 57/CD disease/NN stage/NN
piperacillin/JJ tazobactam/NN doses/NNS seizure/NN given/VBN report/VBP 57/CD disease/NN renal/JJ
piperacillin/JJ tazobactam/NN doses/NNS seizure/NN given/VBN report/VBP 57/CD disease/NN
//JJ tazobactam/NN doses/NNS seizure/NN given/VBN report/VBP 57/CD woman/NN end/NN
//JJ tazobactam/NN doses/NNS seizure/NN given/VBN report/VBP 57/CD disease/NN stage/NN
//JJ tazobactam/NN doses/NNS seizure/NN given/VBN report/VBP 57/CD disease/NN renal/JJ
//JJ tazobactam/NN doses/NNS seizure/NN given/VBN report/VBP 57/CD disease/NN
tazobactam/NN doses/NNS seizure/NN given/VBN report/VBP 57/CD woman/NN end/NN
tazobactam/NN doses/NNS seizure/NN given/VBN report/VBP 57/CD disease/NN stage/NN
tazobactam/NN doses/NNS seizure/NN given/VBN report/VBP 57/CD disease/NN renal/JJ
tazobactam/NN doses/NNS seizure/NN given/VBN report/VBP 57/CD disease/NN
piperacillin/JJ tazobactam/NN doses/NNS seizure/NN given/VBN bronchiectasis/NNS infection/NN secondary/JJ
piperacillin/JJ tazobactam/NN doses/NNS seizure/NN given/VBN bronchiectasis/NNS infection/NN
//JJ tazobactam/NN doses/NNS seizure/NN given/VBN bronchiectasis/NNS infection/NN secondary/JJ
//JJ tazobactam/NN doses/NNS seizure/NN given/VBN bronchiectasis/NNS infection/NN
tazobactam/NN doses/NNS seizure/NN given/VBN bronchiectasis/NNS infection/NN secondary/JJ
tazobactam/NN doses/NNS seizure/NN given/VBN bronchiectasis/NNS infection/NN
piperacillin/JJ tazobactam/NN doses/NNS seizure/NN given/VBN bronchiectasis/NNS
//JJ tazobactam/NN doses/NNS seizure/NN given/VBN bronchiectasis/NNS
tazobactam/NN doses/NNS seizure/NN given/VBN bronchiectasis/NNS
ammonia/NN levels/NNS electrolyte/NN revealed/VBD leukocytosis/VBZ
Piperacillin/NNP considered/VBN patients/NNS uremic/JJ
Piperacillin/NNP considered/VBN encephalopathy/RB
piperacillin/NN removing/VBG inefficient/JJ terminate/VB piperacillin/NN induced/VBN encephalopathy/RB
piperacillin/NN induced/VBN encephalopathy/RB
gentamicin/NN treated/VBN Animals/NNS BACKGROUND/NNP show/VB areas/NNS fibrosis/NN
clentiazem/NN effect/NN injury/NN cardiac/JJ
clentiazem/NN effect/NN injury/NN
epinephrine/NN clentiazem/NN effect/NN injury/NN cardiac/JJ
epinephrine/NN clentiazem/NN effect/NN injury/NN
calcium/NN antagonist/NN clentiazem/NN effects/NNS induced/VBN cardiomyopathy/RB
1/CD clentiazem/NN effects/NNS induced/VBN cardiomyopathy/RB
5/CD clentiazem/NN effects/NNS induced/VBN cardiomyopathy/RB
benzothiazepine/JJ antagonist/NN clentiazem/NN effects/NNS induced/VBN cardiomyopathy/RB
clentiazem/NN effects/NNS induced/VBN cardiomyopathy/RB
epinephrine/NN infusion/NN 2/CD died/VBD observed/JJ lesions/NNS fibrosis/NN
epinephrine/NN infusion/NN 2/CD died/VBD observed/JJ lesions/NNS ischemic/JJ
epinephrine/NN infusion/NN 2/CD died/VBD observed/JJ lesions/NNS
clentiazem/NN Treatment/NNP prevented/VBD attenuated/VBD lesions/NNS fibrosis/NN
epinephrine/NN prevented/VBD attenuated/VBD lesions/NNS fibrosis/NN
clentiazem/NN Treatment/NNP prevented/VBD attenuated/VBD lesions/NNS ischemic/JJ
clentiazem/NN Treatment/NNP prevented/VBD attenuated/VBD lesions/NNS
epinephrine/NN prevented/VBD attenuated/VBD lesions/NNS ischemic/JJ
epinephrine/NN prevented/VBD attenuated/VBD lesions/NNS
clentiazem/NN attenuated/VBD epinephrine/NN induced/VBN injury/NN cardiac/JJ
clentiazem/NN attenuated/VBD epinephrine/NN induced/VBN injury/NN
epinephrine/NN induced/VBN injury/NN cardiac/JJ
epinephrine/NN induced/VBN injury/NN
digoxin/NN hypokalemia/NN
digoxin/NN hypokalemia/NN excess/NN factors/NNS context/NN occurred/VBD Consistent/NNP TdP/NNP
amiodarone/JJ therapy/NN context/NN tone/NN resulted/VBD amiodarone/NN induced/VBN proarrhythmia/NN
amiodarone/NN induced/VBN proarrhythmia/NN
amiodarone/JJ therapy/NN absence/NN induce/VB hypokalemia/NN hypomagnesemia/NN
amiodarone/JJ therapy/NN absence/NN induce/VB hypokalemia/NN
dexamethasone/NN Bortezomib/NN myeloma/NN multiple/JJ
dexamethasone/NN Bortezomib/NN myeloma/NN
Bortezomib/NN myeloma/NN multiple/JJ
Bortezomib/NN myeloma/NN
dexamethasone/NN therapy/NN myeloma/NN multiple/JJ
dexamethasone/NN therapy/NN myeloma/NN
dexamethasone/NN MM/NNP
dex/NN dexamethasone/NN therapy/NN myeloma/NN multiple/JJ
dex/NN dexamethasone/NN therapy/NN myeloma/NN
dex/NN dexamethasone/NN MM/NNP
Bortezomib/NNP dexamethasone/NN therapy/NN myeloma/NN multiple/JJ
Bortezomib/NNP dexamethasone/NN therapy/NN myeloma/NN
Bortezomib/NNP dexamethasone/NN MM/NNP
bort/NN Bortezomib/NNP dexamethasone/NN therapy/NN myeloma/NN multiple/JJ
bort/NN Bortezomib/NNP dexamethasone/NN therapy/NN myeloma/NN
bort/NN Bortezomib/NNP dexamethasone/NN MM/NNP
dex/NN bort/NN combination/NN investigated/VBN study/NN stem/VBP MM/NNP
bort/NN combination/NN investigated/VBN study/NN stem/VBP MM/NNP
bort/NN day/NN mg/NN bort/NN combination/NN investigated/VBN study/NN stem/VBP MM/NNP
dex/NN treatment/NN patients/NNS MM/NNP
Bort/NN treatment/NN patients/NNS MM/NNP
pentazocine/JJ morphine/JJ induced/VBN analgesia/NN effect/NN effect/NN' effect/NN cataleptic/JJ
NA/NNP receptors/NNS stimulating/VBG drugs/NNS failed/VBD found/VBN enhanced/VBD induced/VBN catalepsy/RB
MA/NNP chronically/NNP used/VBN subjects/NNS Studies/NNS revealed/VBN systems/NNS abnormalities/NNS metabolic/JJ
MA/NNP chronically/NNP used/VBN subjects/NNS Studies/NNS revealed/VBN systems/NNS abnormalities/NNS
MA/NNP abuse/NN associated/VBN related/VBN cognitive/VB
MA/NNP abuse/NN associated/VBN related/VBN cognitive/VB impairment/NN
MA/NNP abusers/NNS had/VBD hippocampal/VB hypertrophy/NN
ACC/NNP have/VBP activity/NN seizures/NNS
9653/CD have/VBP activity/NN seizures/NNS
phenytoin/NN sodium/NN 9653/CD have/VBP activity/NN seizures/NNS
sodium/NN 9653/CD have/VBP activity/NN seizures/NNS
ACC/NNP have/VBP activity/NN tachycardia/NN ventricular/NN
ACC/NNP have/VBP activity/NN tachycardia/NN
9653/CD have/VBP activity/NN tachycardia/NN ventricular/NN
9653/CD have/VBP activity/NN tachycardia/NN
phenytoin/NN sodium/NN 9653/CD have/VBP activity/NN tachycardia/NN ventricular/NN
phenytoin/NN sodium/NN 9653/CD have/VBP activity/NN tachycardia/NN
sodium/NN 9653/CD have/VBP activity/NN tachycardia/NN ventricular/NN
sodium/NN 9653/CD have/VBP activity/NN tachycardia/NN
ACC/NNP doses/NNS necessary/JJ convert/VB arrhythmia/NN
9653/CD doses/NNS necessary/JJ convert/VB arrhythmia/NN
phenytoin/NN sodium/NN 9653/CD doses/NNS necessary/JJ convert/VB arrhythmia/NN
sodium/NN 9653/CD doses/NNS necessary/JJ convert/VB arrhythmia/NN
phenytoin/JJ sodium/NN arrhythmias/NNS
sodium/NN arrhythmias/NNS
ACC/NNP studies/NNS toxicity/NN
9653/CD studies/NNS toxicity/NN
phenytoin/NN sodium/NN 9653/CD studies/NNS toxicity/NN
sodium/NN 9653/CD studies/NNS toxicity/NN
valproate/JJ induced/NNS encephalopathy/NN
valproate/NN migraine/NN hemiplegic/JJ
valproate/NN migraine/NN
valproate/NN started/VBN had/VBD number/NN admissions/NNS hemiparesis/NNS
N/NNP D/NNP titre/JJ encephalopathy/JJ
methyl/NN D/NNP titre/JJ encephalopathy/JJ
D/NNP titre/JJ encephalopathy/JJ
aspartate/JJ antibodies/NNS present/JJ showed/VBD consistent/JJ D/NNP titre/JJ encephalopathy/JJ
NMDA/NNP antibodies/NNS present/JJ showed/VBD consistent/JJ D/NNP titre/JJ encephalopathy/JJ
valproate/NN aetiologies/NNS induced/VBN receptor/NN encephalopathy/NN
NMDA/NN encephalopathy/NN
NMDA/NN encephalopathy/NN receptor/NN induced/VBN aetiologies/NNS associated/JJ present/NN encephalitis/NN
valproate/NN aetiologies/NNS associated/JJ present/NN encephalitis/NN
citalopram/NN concentration/NN associated/VBN somnolence/NN
citalopram/NN concentration/NN associated/VBN somnolence/NN difficulties/NNS movement/NN
citalopram/NN concentration/NN associated/VBN somnolence/NN difficulties/NNS
desmethylfluoxetine/NN concentration/NN hyperkinetic/JJ
desmethylfluoxetine/NN concentration/NN delirium/JJ
L/NNP induced/VBN produced/VBD cell/NN -/VB hernias/NNS
norepinephrine/NN produced/VBD cell/NN -/VB hernias/NNS
Ecstasy/NNP drug/NN associated/VBN dysfunction/NN psychobiological/JJ
Ecstasy/NNP drug/NN associated/VBN dysfunction/NN
MDMA/NNP Ecstasy/NNP drug/NN associated/VBN dysfunction/NN psychobiological/JJ
MDMA/NNP Ecstasy/NNP drug/NN associated/VBN dysfunction/NN
ecstasy/NN observations/NNS line/NN increases/NNS anxiety/NN
Mefenamic/JJ acid/NN induced/VBN hypothyroidism/NN
acid/NN induced/VBN hypothyroidism/NN
mefenamic/JJ acid/NN use/VB patients/NNS hypothyroid/JJ
acid/NN use/VB patients/NNS hypothyroid/JJ
mefenamic/JJ acid/NN use/VB prudent/JJ seem/VB corrected/VBN hypothyroidism/NN
acid/NN use/VB prudent/JJ seem/VB corrected/VBN hypothyroidism/NN
cocaine/NN presenting/VBG admitted/VBN receive/VBP syndrome/NN acute/JJ
cocaine/NN presenting/VBG admitted/VBN receive/VBP syndrome/NN coronary/JJ
cocaine/NN presenting/VBG admitted/VBN receive/VBP syndrome/NN
cocaine/NN efficacious/NNS associated/JJ pain/NN account/VB vasospasm/NN coronary/JJ
cocaine/NN efficacious/NNS associated/JJ pain/NN account/VB vasospasm/NN
cocaine/NN efficacious/NNS associated/JJ pain/NN account/VB some/DT ischemia/NN
cocaine/NN result/VB discharged/VBN patients/NNS ECG/NN ischemic/JJ
cocaine/NN patients/NNS ECG/NN ischemic/JJ
methotrexate/JJ consequence/NN P/NNP protocols/NNS acute/JJ
methotrexate/JJ consequence/NN P/NNP protocols/NNS lymphoblastic/JJ
methotrexate/JJ consequence/NN P/NNP protocols/NNS leukemia/NN
methotrexate/NN led/VBN children/NNS leukemia/NN acute/JJ
methotrexate/NN led/VBN children/NNS leukemia/NN lymphoblastic/JJ
methotrexate/NN led/VBN children/NNS leukemia/NN
MTX/NNP methotrexate/NN led/VBN children/NNS leukemia/NN acute/JJ
MTX/NNP methotrexate/NN led/VBN children/NNS leukemia/NN lymphoblastic/JJ
MTX/NNP methotrexate/NN led/VBN children/NNS leukemia/NN
MTX/NNP administration/NN frequency/NN therapy/NN modifications/NNS led/VBN children/NNS leukemia/NN acute/JJ
MTX/NNP administration/NN frequency/NN therapy/NN modifications/NNS led/VBN children/NNS leukemia/NN lymphoblastic/JJ
MTX/NNP administration/NN frequency/NN therapy/NN modifications/NNS led/VBN children/NNS leukemia/NN
methotrexate/NN led/VBN neurotoxicity/NN
MTX/NNP methotrexate/NN led/VBN neurotoxicity/NN
MTX/NNP administration/NN frequency/NN therapy/NN modifications/NNS led/VBN neurotoxicity/NN
ginsenosides/NNS Effects/NNPS hyperalgesia/NN
Re/NNP effects/NNS ginsenosides/NNS OIH/NNP
Rg/NNP effects/NNS ginsenosides/NNS OIH/NNP
1/CD Rg/NNP effects/NNS ginsenosides/NNS OIH/NNP
and/CC effects/NNS ginsenosides/NNS OIH/NNP
Rb/NNP ginsenosides/NNS OIH/NNP
1/CD ginsenosides/NNS OIH/NNP
ginsenosides/NNS OIH/NNP
Re/NNP inhibited/VBD OIH/NNP
acetic/JJ acid/NN test/NN inhibited/VBD OIH/NNP
acid/NN test/NN inhibited/VBD OIH/NNP
Rg/NNP failed/VBD prevent/VB OIH/NNP
1/CD Rg/NNP failed/VBD prevent/VB OIH/NNP
and/CC Rg/NNP failed/VBD prevent/VB OIH/NNP
Rb/NNP ginsenosides/NNS Rg/NNP failed/VBD prevent/VB OIH/NNP
1/CD ginsenosides/NNS Rg/NNP failed/VBD prevent/VB OIH/NNP
ginsenosides/NNS Rg/NNP failed/VBD prevent/VB OIH/NNP
acetic/JJ acid/NN OIH/NNP
acid/NN OIH/NNP
Rg/NNP showed/VBD tendency/NN aggravate/VB OIH/NNP
1/CD Rg/NNP showed/VBD tendency/NN aggravate/VB OIH/NNP
ginsenoside/NN contribute/VB reversal/NN OIH/NNP
Re/NNP ginsenoside/NN contribute/VB reversal/NN OIH/NNP
Rb/NNP Rg/NNP ginsenoside/NN contribute/VB reversal/NN OIH/NNP
1/CD Rb/NNP Rg/NNP ginsenoside/NN contribute/VB reversal/NN OIH/NNP
Rg/NNP ginsenoside/NN contribute/VB reversal/NN OIH/NNP
1/CD Rg/NNP ginsenoside/NN contribute/VB reversal/NN OIH/NNP
triglyceride/NN accumulation/NN dose/NN observed/VBN liver/NN depression/NN
triglyceride/NN output/NN liver/NN depression/NN
tetracycline/NN dose/NN observed/VBN liver/NN depression/NN
oleic/JJ acid/NN provision/NN observed/VBN liver/NN depression/NN
acid/NN provision/NN observed/VBN liver/NN depression/NN
triglyceride/NN output/NN depression/NN
tetracycline/NN effects/NNS resistant/JJ depression/NN
triglyceride/NN secretion/NN accounted/VBD liver/NN fatty/NN
triglyceride/NN secretion/NN accounted/VBD liver/NN
triglyceride/NN %/NN accounted/VBD liver/NN fatty/NN
triglyceride/NN %/NN accounted/VBD liver/NN
triglyceride/NN production/NN involved/VBN indicating/VBG triglyceride/NN %/NN accounted/VBD liver/NN fatty/NN
triglyceride/NN production/NN involved/VBN indicating/VBG triglyceride/NN %/NN accounted/VBD liver/NN
mesna/NN prevention/NN bladder/NN lesions/NNS
mesna/NN prevention/NN bladder/NN of/IN
mesna/NN prevention/NN bladder/NN the/DT
mesna/NN prevention/NN bladder/NN urinary/JJ
mesna/NN prevention/NN bladder/NN
cyclophosphamide/JJ developed/VBD characterized/VBN detachment/NN urothelium/NN edema/NN
cyclophosphamide/JJ developed/VBD characterized/VBN detachment/NN urothelium/NN edema/NN owing/VBG damage/VB bed/NN necroses/NNS
cyclophosphamide/JJ developed/VBD characterized/VBN cystitis/NNS
cocaine/NN intoxication/NN pallidus/VBZ infarction/NN haemorrhagic/JJ
cocaine/NN intoxication/NN pallidus/VBZ infarction/NN
cocaine/NN intoxication/NN pallidus/VBZ infarction/NN globus/NNS of/IN
cocaine/NN intoxication/NN pallidus/VBZ infarction/NN globus/NNS the/DT
cocaine/NN intoxication/NN pallidus/VBZ infarction/NN globus/NNS
cocaine/NN intoxication/NN pallidus/VBZ
alcohol/NN cocaine/NN intoxication/NN pallidus/VBZ infarction/NN haemorrhagic/JJ
alcohol/NN cocaine/NN intoxication/NN pallidus/VBZ infarction/NN
alcohol/NN cocaine/NN intoxication/NN pallidus/VBZ infarction/NN globus/NNS of/IN
alcohol/NN cocaine/NN intoxication/NN pallidus/VBZ infarction/NN globus/NNS the/DT
alcohol/NN cocaine/NN intoxication/NN pallidus/VBZ infarction/NN globus/NNS
alcohol/NN cocaine/NN intoxication/NN pallidus/VBZ
Cocaine/NNP factor/NN stroke/NN ischemic/JJ
Cocaine/NNP factor/NN stroke/NN ischemic/JJ and/CC
Cocaine/NNP factor/NN stroke/NN ischemic/JJ haemorrhagic/JJ
Cocaine/NNP factor/NN stroke/NN
alcohol/NN pallidus/VBZ case/NN 31/CD man/NN ischemia/NN
alcohol/NN pallidus/VBZ case/NN 31/CD man/NN ischemia/NN globus/NNS of/IN
alcohol/NN pallidus/VBZ case/NN 31/CD man/NN ischemia/NN globus/NNS the/DT
alcohol/NN pallidus/VBZ case/NN 31/CD man/NN ischemia/NN globus/NNS
alcohol/NN pallidus/VBZ
cocaine/NN use/NN infarcts/NNS basal/JJ
cocaine/NN use/NN infarcts/NNS ganglia/NN
cocaine/NN use/NN infarcts/NNS
ethanol/NN use/NN cocaine/NN related/VBN dysfunction/NN arrhythmia/NN cardiac/JJ
ethanol/NN use/NN cocaine/NN related/VBN dysfunction/NN arrhythmia/NN
ethanol/NN use/NN cocaine/NN related/VBN dysfunction/NN arrhythmia/NN causes/NNS hypoperfusion/NN cerebral/JJ
ethanol/NN use/NN cocaine/NN related/VBN dysfunction/NN arrhythmia/NN causes/NNS hypoperfusion/NN
cocaine/NN related/VBN dysfunction/NN arrhythmia/NN causes/NNS hypoperfusion/NN cerebral/JJ
cocaine/NN related/VBN dysfunction/NN arrhythmia/NN causes/NNS hypoperfusion/NN
cocaine/NN related/VBN dysfunction/NN arrhythmia/NN cardiac/JJ
cocaine/NN related/VBN dysfunction/NN arrhythmia/NN
cocaine/NN related/VBN dysfunction/NN respiratory/JJ
cocaine/NN related/VBN dysfunction/NN
ethanol/NN use/NN cocaine/NN related/VBN dysfunction/NN respiratory/JJ
ethanol/NN use/NN cocaine/NN related/VBN dysfunction/NN
etoposide/NN therapy/NN glioma/NN malignant/JJ
etoposide/NN therapy/NN glioma/NN
etoposide/NN therapy/NN dysfunction/NN Acute/JJ
etoposide/NN therapy/NN dysfunction/NN neurologic/JJ
etoposide/NN therapy/NN dysfunction/NN
Etoposide/NNP used/VBN treatment/NN tumors/NNS
VP/NNP Etoposide/NNP used/VBN treatment/NN tumors/NNS
16/CD VP/NNP Etoposide/NNP used/VBN treatment/NN tumors/NNS
213/CD 16/CD VP/NNP Etoposide/NNP used/VBN treatment/NN tumors/NNS
Etoposide/NNP used/VBN treatment/NN tumors/NNS malignancies/NNS hematologic/JJ
Etoposide/NNP used/VBN treatment/NN tumors/NNS malignancies/NNS
VP/NNP Etoposide/NNP used/VBN treatment/NN tumors/NNS malignancies/NNS hematologic/JJ
VP/NNP Etoposide/NNP used/VBN treatment/NN tumors/NNS malignancies/NNS
16/CD VP/NNP Etoposide/NNP used/VBN treatment/NN tumors/NNS malignancies/NNS hematologic/JJ
16/CD VP/NNP Etoposide/NNP used/VBN treatment/NN tumors/NNS malignancies/NNS
213/CD 16/CD VP/NNP Etoposide/NNP used/VBN treatment/NN tumors/NNS malignancies/NNS hematologic/JJ
213/CD 16/CD VP/NNP Etoposide/NNP used/VBN treatment/NN tumors/NNS malignancies/NNS
etoposide/NN therapy/NN toxicity/NN
etoposide/NN therapy/NN glioma/NN malignant/JJ
etoposide/NN therapy/NN glioma/NN
alpha/NNP alanine/NN induced/VBN cardiotoxicity/RB
fluoro/NN alanine/NN induced/VBN cardiotoxicity/RB
beta/NN fluoro/NN alanine/NN induced/VBN cardiotoxicity/RB
alanine/NN induced/VBN cardiotoxicity/RB
5/CD Fluorouracil/NNP induced/VBN cardiotoxicity/RB
Fluorouracil/NNP induced/VBN cardiotoxicity/RB
5/CD treatment/NN malignancies/NNS
fluorouracil/JJ treatment/NN malignancies/NNS
5/CD treatment/NN malignancies/NNS
FU/NNP 5/CD treatment/NN malignancies/NNS
5/CD occurring/VBG Cardiotoxicity/RB
fluorouracil/JJ treatment/NN 5/CD occurring/VBG Cardiotoxicity/RB
5/CD treatment/NN 5/CD occurring/VBG Cardiotoxicity/RB
FU/NNP 5/CD treatment/NN 5/CD occurring/VBG Cardiotoxicity/RB
alpha/JJ alanine/NN level/NN observed/JJ induced/VBN cardiotoxicity/RB
fluoro/NN alanine/NN level/NN observed/JJ induced/VBN cardiotoxicity/RB
beta/NN fluoro/NN alanine/NN level/NN observed/JJ induced/VBN cardiotoxicity/RB
alanine/NN level/NN observed/JJ induced/VBN cardiotoxicity/RB
FBAL/NNP alanine/NN level/NN observed/JJ induced/VBN cardiotoxicity/RB
5/CD man/NN year/NN induced/VBN cardiotoxicity/RB
FU/NNP 5/CD man/NN year/NN induced/VBN cardiotoxicity/RB
FBAL/NNP concentration/NN occurred/VBD pain/NN precordial/JJ
FBAL/NNP concentration/NN occurred/VBD pain/NN
FBAL/NNP concentration/NN occurred/VBD pain/NN block/NN right/JJ
FBAL/NNP concentration/NN occurred/VBD pain/NN block/NN bundle/NN
FBAL/NNP concentration/NN occurred/VBD pain/NN block/NN branch/NN
FBAL/NNP concentration/NN occurred/VBD pain/NN block/NN
5/CD induced/VBN cardiotoxicity/RB
FU/NNP 5/CD induced/VBN cardiotoxicity/RB
5/CD administration/NN induced/VBN cardiotoxicity/RB
FU/NNP abandoned/VBN considered/VBN due/JJ 5/CD induced/VBN cardiotoxicity/RB
FBAL/NNP related/VBN 5/CD induced/VBN cardiotoxicity/RB
5/CD induced/VBN cardiotoxicity/RB
FU/NNP 5/CD induced/VBN cardiotoxicity/RB
5/CD induced/VBN cardiotoxicity/RB
FU/NNP 5/CD induced/VBN cardiotoxicity/RB
cyclophosphamide/JJ adriamycin/JJ platinum/NN Treatment/NNP cancer/NN ovarian/NN
cyclophosphamide/JJ adriamycin/JJ platinum/NN Treatment/NNP cancer/NN
adriamycin/JJ platinum/NN Treatment/NNP cancer/NN ovarian/NN
adriamycin/JJ platinum/NN Treatment/NNP cancer/NN
hexamethylmelamine/JJ adriamycin/JJ platinum/NN Treatment/NNP cancer/NN ovarian/NN
hexamethylmelamine/JJ adriamycin/JJ platinum/NN Treatment/NNP cancer/NN
cis/NN combination/NN Treatment/NNP cancer/NN ovarian/NN
cis/NN combination/NN Treatment/NNP cancer/NN
platinum/NN Treatment/NNP cancer/NN ovarian/NN
platinum/NN Treatment/NNP cancer/NN
cyclophosphamide/NN m/NN m/NNP mg/NN combination/NN treated/VBN patients/NNS cancer/NN ovarian/NN
cyclophosphamide/NN m/NN m/NNP mg/NN combination/NN treated/VBN patients/NNS cancer/NN
adriamycin/CD m/NNP mg/NN combination/NN treated/VBN patients/NNS cancer/NN ovarian/NN
adriamycin/CD m/NNP mg/NN combination/NN treated/VBN patients/NNS cancer/NN
hexamethylmelamine/NN mg/NN m/NN m/NNP mg/NN combination/NN treated/VBN patients/NNS cancer/NN ovarian/NN
hexamethylmelamine/NN mg/NN m/NN m/NNP mg/NN combination/NN treated/VBN patients/NNS cancer/NN
HMM/NNP hexamethylmelamine/NN mg/NN m/NN m/NNP mg/NN combination/NN treated/VBN patients/NNS cancer/NN ovarian/NN
HMM/NNP hexamethylmelamine/NN mg/NN m/NN m/NNP mg/NN combination/NN treated/VBN patients/NNS cancer/NN
CPDD/NNP combination/NN treated/VBN patients/NNS cancer/NN ovarian/NN
CPDD/NNP combination/NN treated/VBN patients/NNS cancer/NN
cisplatinum/NN combination/NN treated/VBN patients/NNS cancer/NN ovarian/NN
cisplatinum/NN combination/NN treated/VBN patients/NNS cancer/NN
HMM/NNP toxicity/NN gastrointestinal/JJ
HMM/NNP toxicity/NN
levomepromazine/NN risperidone/NN administration/NN developed/VBD patient/NN failure/NN chronic/JJ
levomepromazine/NN risperidone/NN administration/NN developed/VBD patient/NN failure/NN renal/JJ
levomepromazine/NN risperidone/NN administration/NN developed/VBD patient/NN failure/NN
levomepromazine/NN risperidone/NN administration/NN developed/VBD patient/NN CRF/NNP
risperidone/NN administration/NN developed/VBD patient/NN failure/NN chronic/JJ
risperidone/NN administration/NN developed/VBD patient/NN failure/NN renal/JJ
risperidone/NN administration/NN developed/VBD patient/NN failure/NN
risperidone/NN administration/NN developed/VBD patient/NN CRF/NNP
cocaine/NN exposure/NN linked/VBN hemorrhage/NN
cocaine/NN exposure/NN increases/VBZ incidence/NN cysts/NNS subependymal/JJ
cocaine/NN exposure/NN increases/VBZ incidence/NN cysts/NNS
cocaine/NN group/NN was/VBD history/NN abuse/NN cocaine/NN
cocaine/NN group/NN was/VBD history/NN abuse/NN
cocaine/NN exposed/VBN infants/NNS cysts/NNS subependymal/JJ
cocaine/NN exposed/VBN infants/NNS cysts/NNS
cocaine/NN prenatally/NN exposed/VBN incidence/NN formation/NN subependymal/JJ
cocaine/NN prenatally/NN exposed/VBN incidence/NN formation/NN cyst/NN
bilirubin/NN gender/NN end/NN
bilirubin/NN gender/NN score/NN stage/NN
bilirubin/NN gender/NN score/NN liver/NN
bilirubin/NN gender/NN score/NN disease/NN
TAC/NN level/NN gender/NN end/NN
TAC/NN level/NN gender/NN score/NN stage/NN
TAC/NN level/NN gender/NN score/NN liver/NN
TAC/NN level/NN gender/NN score/NN disease/NN
bilirubin/NN gender/NN included/VBD factors/NNS associated/VBN seizures/NNS
oestrogen/NN therapy/NN receiving/VBG Prevention/NN disease/NN endometrial/JJ
oestrogen/NN therapy/NN receiving/VBG Prevention/NN disease/NN
oestrogen/NN therapy/NN receiving/VBG women/NNS described/VBN patients/NNS disease/NN endometrial/JJ
oestrogen/NN therapy/NN receiving/VBG women/NNS described/VBN patients/NNS disease/NN
progestagen/NN associated/VBN hyperplasia/NNP
norethisterone/NN days/NNS courses/NNS caused/VBD cases/NNS hyperplasia/NN
norethisterone/NN days/NNS courses/NNS caused/VBD cases/NNS 6/CD cases/NNS hyperplasia/NN
oestrogen/NN therapy/NN problems/NNS demonstrated/VBD cases/NNS carcinoma/NN endometrial/JJ
oestrogen/NN therapy/NN problems/NNS demonstrated/VBD cases/NNS carcinoma/NN
oestrogen/NN therapy/NN problems/NNS demonstrated/VBD malignancy/NN
progestagen/NN low/NN seem/VB increase/VB risk/NN hyperplasia/NN carcinoma/NN
oestrogen/NN therapy/NN low/NN seem/VB increase/VB risk/NN hyperplasia/NN carcinoma/NN
progestagen/NN low/NN seem/VB increase/VB risk/NN hyperplasia/NN endometrial/JJ
progestagen/NN low/NN seem/VB increase/VB risk/NN hyperplasia/NN
oestrogen/NN therapy/NN low/NN seem/VB increase/VB risk/NN hyperplasia/NN endometrial/JJ
oestrogen/NN therapy/NN low/NN seem/VB increase/VB risk/NN hyperplasia/NN
lidocaine/NN safety/NN Clinical/VB associated/JJ infarction/NN myocardial/JJ
lidocaine/NN safety/NN Clinical/VB associated/JJ infarction/NN
lidocaine/NN safety/NN evaluate/VB induced/VBN infarction/NN myocardial/JJ
lidocaine/NN safety/NN evaluate/VB induced/VBN infarction/NN
lidocaine/NN safety/NN evaluate/VB induced/VBN infarction/NN MI/NNP
lidocaine/NN received/VBD MI/NNP
lidocaine/VB associated/JJ MI/NNP
lidocaine/NN administration/NN experienced/VBD died/VBD patients/NNS received/VBD lidocaine/VB associated/JJ MI/NNP
lidocaine/VB received/VBD patients/NNS died/VBD exhibited/VBD bradydysrhythmias/NNS
lidocaine/NN administration/NN experienced/VBD died/VBD exhibited/VBD bradydysrhythmias/NNS
cocaine/NN setting/NN lidocaine/VB received/VBD patients/NNS died/VBD exhibited/VBD bradydysrhythmias/NNS tachycardia/NN ventricular/NN
cocaine/NN setting/NN lidocaine/VB received/VBD patients/NNS died/VBD exhibited/VBD bradydysrhythmias/NNS tachycardia/NN
cocaine/NN setting/NN lidocaine/VB received/VBD patients/NNS died/VBD exhibited/VBD bradydysrhythmias/NNS
lidocaine/VB received/VBD patients/NNS died/VBD exhibited/VBD bradydysrhythmias/NNS tachycardia/NN ventricular/NN
lidocaine/VB received/VBD patients/NNS died/VBD exhibited/VBD bradydysrhythmias/NNS tachycardia/NN
lidocaine/NN administration/NN experienced/VBD died/VBD exhibited/VBD bradydysrhythmias/NNS tachycardia/NN ventricular/NN
lidocaine/NN administration/NN experienced/VBD died/VBD exhibited/VBD bradydysrhythmias/NNS tachycardia/NN
lidocaine/VB received/VBD patients/NNS died/VBD exhibited/VBD bradydysrhythmias/NNS fibrillation/NN ventricular/NN
lidocaine/VB received/VBD patients/NNS died/VBD exhibited/VBD bradydysrhythmias/NNS fibrillation/NN
lidocaine/NN administration/NN experienced/VBD died/VBD exhibited/VBD bradydysrhythmias/NNS fibrillation/NN ventricular/NN
lidocaine/NN administration/NN experienced/VBD died/VBD exhibited/VBD bradydysrhythmias/NNS fibrillation/NN
lidocaine/VB received/VBD patients/NNS died/VBD experienced/VBD seizures/NNS
lidocaine/NN administration/NN experienced/VBD seizures/NNS
cocaine/NN setting/NN lidocaine/VB received/VBD patients/NNS died/VBD exhibited/VBD bradydysrhythmias/NNS fibrillation/NN ventricular/NN
cocaine/NN setting/NN lidocaine/VB received/VBD patients/NNS died/VBD exhibited/VBD bradydysrhythmias/NNS fibrillation/NN
cocaine/NN setting/NN lidocaine/VB received/VBD patients/NNS died/VBD experienced/VBD seizures/NNS
lidocaine/NN enhance/VB associated/VBN cardiovascular/NNS
lidocaine/NN enhance/VB associated/VBN cardiovascular/NNS or/CC
lidocaine/NN enhance/VB associated/VBN cardiovascular/NNS toxicity/NN central/JJ
lidocaine/NN enhance/VB associated/VBN cardiovascular/NNS toxicity/NN nervous/JJ
lidocaine/NN enhance/VB associated/VBN cardiovascular/NNS toxicity/NN system/NN
lidocaine/NN enhance/VB associated/VBN cardiovascular/NNS toxicity/NN
lidocaine/NN use/NN toxicity/NN enhance/VB associated/VBN cardiovascular/NNS
lidocaine/NN use/NN toxicity/NN enhance/VB associated/VBN cardiovascular/NNS or/CC
lidocaine/NN use/NN toxicity/NN enhance/VB associated/VBN cardiovascular/NNS toxicity/NN central/JJ
lidocaine/NN use/NN toxicity/NN enhance/VB associated/VBN cardiovascular/NNS toxicity/NN nervous/JJ
lidocaine/NN use/NN toxicity/NN enhance/VB associated/VBN cardiovascular/NNS toxicity/NN system/NN
lidocaine/NN use/NN toxicity/NN enhance/VB associated/VBN cardiovascular/NNS toxicity/NN
lidocaine/NN enhance/VB associated/VBN MI/NNP
lidocaine/NN use/NN toxicity/NN enhance/VB associated/VBN MI/NNP
lidocaine/NN enhance/VB toxicity/NN
lidocaine/NN use/NN toxicity/NN
cocaine/NN toxicity/NN enhance/VB associated/VBN cardiovascular/NNS
cocaine/NN toxicity/NN enhance/VB associated/VBN cardiovascular/NNS or/CC
cocaine/NN toxicity/NN enhance/VB associated/VBN cardiovascular/NNS toxicity/NN central/JJ
cocaine/NN toxicity/NN enhance/VB associated/VBN cardiovascular/NNS toxicity/NN nervous/JJ
cocaine/NN toxicity/NN enhance/VB associated/VBN cardiovascular/NNS toxicity/NN system/NN
cocaine/NN toxicity/NN enhance/VB associated/VBN cardiovascular/NNS toxicity/NN
cocaine/NN patients/NNS enhance/VB associated/VBN cardiovascular/NNS
cocaine/NN patients/NNS enhance/VB associated/VBN cardiovascular/NNS or/CC
cocaine/NN patients/NNS enhance/VB associated/VBN cardiovascular/NNS toxicity/NN central/JJ
cocaine/NN patients/NNS enhance/VB associated/VBN cardiovascular/NNS toxicity/NN nervous/JJ
cocaine/NN patients/NNS enhance/VB associated/VBN cardiovascular/NNS toxicity/NN system/NN
cocaine/NN patients/NNS enhance/VB associated/VBN cardiovascular/NNS toxicity/NN
cocaine/NN toxicity/NN
cocaine/NN patients/NNS enhance/VB toxicity/NN
ethambutol/NN tuberculosis/NNP
ethambutol/NN tuberculosis/NNP node/NN of/IN
ethambutol/NN tuberculosis/NNP node/NN the/DT
ethambutol/NN tuberculosis/NNP node/NN lung/NN
ethambutol/NN tuberculosis/NNP node/NN lung/NN or/CC
ethambutol/NN tuberculosis/NNP node/NN lung/NN lymph/NN
ethambutol/NN tuberculosis/NNP node/NN
dobutamine/JJ echocardiography/NN safety/NN assess/VB study/VB associated/JJ pain/NN chest/NN
dobutamine/JJ echocardiography/NN safety/NN assess/VB study/VB associated/JJ pain/NN
Dobutamine/JJ echocardiography/NN test/NN evaluating/VBG ischemia/NN
dobutamine/NN administration/NN concern/NN conducted/VBD study/VB associated/JJ pain/NN chest/NN
dobutamine/NN administration/NN concern/NN conducted/VBD study/VB associated/JJ pain/NN
cocaine/NN toxicity/NN
dobutamine/NN administered/VBN patients/NNS pain/NN chest/NN
dobutamine/NN administered/VBN patients/NNS pain/NN
dobutamine/NN treatment/NN pointes/VBZ patient/NN cardiomyopathy/NN dilated/JJ
dobutamine/NN treatment/NN pointes/VBZ patient/NN cardiomyopathy/NN
dobutamine/NN treatment/NN pointes/VBZ patient/NN cardiomyopathy/NN failure/NN congestive/JJ
dobutamine/NN treatment/NN pointes/VBZ patient/NN cardiomyopathy/NN failure/NN heart/NN
dobutamine/NN treatment/NN pointes/VBZ patient/NN cardiomyopathy/NN failure/NN
dobutamine/NN treatment/NN pointes/VBZ tachycardia/NN ventricular/NN
dobutamine/NN treatment/NN pointes/VBZ tachycardia/NN
dobutamine/JJ dose/NN cycle/NN tachycardia/NN torsade/VB dilated/VB cardiomyopathy/NN developed/VBD prolongation/NN QT/NNP
dobutamine/JJ dose/NN cycle/NN tachycardia/NN torsade/VB dilated/VB cardiomyopathy/NN developed/VBD prolongation/NN
dobutamine/JJ dose/NN cycle/NN tachycardia/NN torsade/VB dilated/VB cardiomyopathy/NN arrhythmias/NNS ventricular/NN
dobutamine/JJ dose/NN cycle/NN tachycardia/NN torsade/VB dilated/VB cardiomyopathy/NN arrhythmias/NNS
dobutamine/JJ dose/NN cycle/NN tachycardia/NN torsade/VB dilated/VB
dobutamine/JJ dose/NN cycle/NN tachycardia/NN torsade/VB dilated/VB cardiomyopathy/NN
dobutamine/JJ dose/NN cycle/NN tachycardia/NN torsade/VB dilated/VB secondary/JJ case/NN 56/CD woman/NN failure/NN heart/NN
dobutamine/JJ dose/NN cycle/NN tachycardia/NN torsade/VB dilated/VB secondary/JJ case/NN 56/CD woman/NN failure/NN
dobutamine/JJ dose/NN cycle/NN tachycardia/NN ventricular/NN
dobutamine/JJ dose/NN cycle/NN tachycardia/NN
dobutamine/NN tachycardia/NN torsade/NN report/NN supports/VBZ occur/VB arrhythmias/NNS
dobutamine/NN tachycardia/NN ventricular/NN
dobutamine/NN tachycardia/NN
Amiodarone/NNP requiring/VBG fibrillation/NN infarction/NN myocardial/JJ
Amiodarone/NNP requiring/VBG fibrillation/NN infarction/NN
Amiodarone/NNP requiring/VBG fibrillation/NN atrial/JJ
Amiodarone/NNP requiring/VBG fibrillation/NN
amiodarone/NN patients/NNS fibrillation/NN atrial/JJ
amiodarone/NN patients/NNS fibrillation/NN
amiodarone/NN patients/NNS fibrillation/NN AF/NNP
amiodarone/JJ therapy/NN bradyarrhythmia/NN Reports/NNS infrequent/JJ studies/NNS assessing/VBG use/NN management/NN patients/NNS arrhythmias/NNS ventricular/NN
amiodarone/JJ therapy/NN bradyarrhythmia/NN Reports/NNS infrequent/JJ studies/NNS assessing/VBG use/NN management/NN patients/NNS arrhythmias/NNS
amiodarone/NN patients/NNS AF/NNP MI/NN
amiodarone/NN patients/NNS AF/NNP
propranolol/NN Modification/NNP hypoglycaemia/NN
Thalidomide/JJ neuropathy/NN
Thalidomide/JJ neuropathy/NN treated/VBN cancer/NN prostate/NN
Thalidomide/JJ neuropathy/NN treated/VBN cancer/NN
thalidomide/JJ evaluated/VBN using/VBG neuropathy/NNP
androgen/NN men/NNS Sixty/CD cancer/NN prostate/NN
androgen/NN men/NNS Sixty/CD cancer/NN
thalidomide/NN underwent/NNS trial/NN Sixty/CD cancer/NN prostate/NN
thalidomide/NN underwent/NNS trial/NN Sixty/CD cancer/NN
thalidomide/NN complication/NN Neuropathy/NNP
prostaglandin/NN bupivacaine/NN effects/NNS E/VBD release/NN pain/NN
E/VBD release/NN pain/NN
2/CD release/NN pain/NN
prostaglandin/NN bupivacaine/NN effects/NNS E/VBD model/NN pain/NN
E/VBD model/NN pain/NN
2/CD release/NN E/VBD model/NN pain/NN
lidocaine/NN bupivacaine/NN effects/NNS E/VBD release/NN pain/NN
lidocaine/NN bupivacaine/NN effects/NNS E/VBD model/NN pain/NN
bupivacaine/NN effects/NNS E/VBD release/NN pain/NN
bupivacaine/NN effects/NNS E/VBD model/NN pain/NN
prostaglandin/NN E/NN bupivacaine/JJ production/NN effects/NNS expression/NN increases/VBZ pain/NN postoperative/JJ
prostaglandin/NN E/NN bupivacaine/JJ production/NN effects/NNS expression/NN increases/VBZ pain/NN
E/NN bupivacaine/JJ production/NN effects/NNS expression/NN increases/VBZ pain/NN postoperative/JJ
E/NN bupivacaine/JJ production/NN effects/NNS expression/NN increases/VBZ pain/NN
2/CD E/NN bupivacaine/JJ production/NN effects/NNS expression/NN increases/VBZ pain/NN postoperative/JJ
2/CD E/NN bupivacaine/JJ production/NN effects/NNS expression/NN increases/VBZ pain/NN
PGE/NNP E/NN bupivacaine/JJ production/NN effects/NNS expression/NN increases/VBZ pain/NN postoperative/JJ
PGE/NNP E/NN bupivacaine/JJ production/NN effects/NNS expression/NN increases/VBZ pain/NN
2/CD PGE/NNP E/NN bupivacaine/JJ production/NN effects/NNS expression/NN increases/VBZ pain/NN postoperative/JJ
2/CD PGE/NNP E/NN bupivacaine/JJ production/NN effects/NNS expression/NN increases/VBZ pain/NN
bupivacaine/NN RESULTS/NNS reported/VBD pain/NN
rofecoxib/NN group/NN reported/VBD pain/NN
PGE/NNP levels/NNS h/NN reported/VBD pain/NN
2/CD levels/NNS h/NN reported/VBD pain/NN
bupivacaine/NN reported/VBD pain/NN
PGE/NN pain/NN
2/CD production/NN PGE/NN pain/NN
PGE/NN associated/VBN injury/NN tissue/NN
PGE/NN associated/VBN injury/NN
2/CD production/NN PGE/NN associated/VBN injury/NN tissue/NN
2/CD production/NN PGE/NN associated/VBN injury/NN
bupivacaine/JJ stimulates/NNS COX/VBP expression/NN injury/NN associated/VBN PGE/NN pain/NN
bupivacaine/JJ stimulates/NNS COX/VBP expression/NN injury/NN tissue/NN
bupivacaine/JJ stimulates/NNS COX/VBP expression/NN injury/NN
tyrosine/JJ kinase/JJ receptors/NNS expression/NN examined/VBN inflammation/NN urinary/JJ
tyrosine/JJ kinase/JJ receptors/NNS expression/NN examined/VBN inflammation/NN bladder/NN
tyrosine/JJ kinase/JJ receptors/NNS expression/NN examined/VBN inflammation/NN
isoproterenol/NN dosages/NNS effects/NNS associated/VBN mortality/NN reduced/VBD indicated/VBD had/VBD little/RB severity/NN infarction/NN
Flecainide/NNP started/VBN fibrillation/NN atrial/JJ
Flecainide/NNP started/VBN fibrillation/NN
sodium/NN channels/NNS interact/NN cause/VB delirium/NN
flecainide/NN prescribed/VBN occur/VB toxicity/NN
flecainide/JJ concentrations/NNS monitored/VBN occur/VB toxicity/NN
paroxetine/NN prescribed/VBN occur/VB toxicity/NN
trimethoprim/NN sulfamethoxazole/NN toxicity/NN drug/NN
trimethoprim/NN sulfamethoxazole/NN toxicity/NN
sulfamethoxazole/NN toxicity/NN drug/NN
sulfamethoxazole/NN toxicity/NN
trimethoprim/NN sulfamethoxazole/NN toxicity/NN drug/NN
trimethoprim/NN sulfamethoxazole/NN toxicity/NN
cephalexin/NN sulfamethoxazole/NN toxicity/NN drug/NN
cephalexin/NN sulfamethoxazole/NN toxicity/NN
trimethoprim/NN prescribed/VBN estimate/VB risk/NN liver/NN
trimethoprim/NN prescribed/VBN estimate/VB risk/NN liver/NN blood/NN
trimethoprim/NN prescribed/VBN estimate/VB risk/NN liver/NN skin/NN
trimethoprim/NN prescribed/VBN estimate/VB risk/NN liver/NN and/CC
trimethoprim/NN prescribed/VBN estimate/VB risk/NN liver/NN disorders/NNS renal/JJ
trimethoprim/NN prescribed/VBN estimate/VB risk/NN liver/NN disorders/NNS
sulfamethoxazole/NN prescribed/VBN estimate/VB risk/NN liver/NN
sulfamethoxazole/NN prescribed/VBN estimate/VB risk/NN liver/NN blood/NN
sulfamethoxazole/NN prescribed/VBN estimate/VB risk/NN liver/NN skin/NN
sulfamethoxazole/NN prescribed/VBN estimate/VB risk/NN liver/NN and/CC
sulfamethoxazole/NN prescribed/VBN estimate/VB risk/NN liver/NN disorders/NNS renal/JJ
sulfamethoxazole/NN prescribed/VBN estimate/VB risk/NN liver/NN disorders/NNS
TMP/NNP sulfamethoxazole/NN prescribed/VBN estimate/VB risk/NN liver/NN
TMP/NNP sulfamethoxazole/NN prescribed/VBN estimate/VB risk/NN liver/NN blood/NN
TMP/NNP sulfamethoxazole/NN prescribed/VBN estimate/VB risk/NN liver/NN skin/NN
TMP/NNP sulfamethoxazole/NN prescribed/VBN estimate/VB risk/NN liver/NN and/CC
TMP/NNP sulfamethoxazole/NN prescribed/VBN estimate/VB risk/NN liver/NN disorders/NNS renal/JJ
TMP/NNP sulfamethoxazole/NN prescribed/VBN estimate/VB risk/NN liver/NN disorders/NNS
SMZ/NNP TMP/NNP sulfamethoxazole/NN prescribed/VBN estimate/VB risk/NN liver/NN
SMZ/NNP TMP/NNP sulfamethoxazole/NN prescribed/VBN estimate/VB risk/NN liver/NN blood/NN
SMZ/NNP TMP/NNP sulfamethoxazole/NN prescribed/VBN estimate/VB risk/NN liver/NN skin/NN
SMZ/NNP TMP/NNP sulfamethoxazole/NN prescribed/VBN estimate/VB risk/NN liver/NN and/CC
SMZ/NNP TMP/NNP sulfamethoxazole/NN prescribed/VBN estimate/VB risk/NN liver/NN disorders/NNS renal/JJ
SMZ/NNP TMP/NNP sulfamethoxazole/NN prescribed/VBN estimate/VB risk/NN liver/NN disorders/NNS
trimethoprim/NN alone/RB 266/CD sulfamethoxazole/NN prescribed/VBN estimate/VB risk/NN liver/NN
trimethoprim/NN alone/RB 266/CD sulfamethoxazole/NN prescribed/VBN estimate/VB risk/NN liver/NN blood/NN
trimethoprim/NN alone/RB 266/CD sulfamethoxazole/NN prescribed/VBN estimate/VB risk/NN liver/NN skin/NN
trimethoprim/NN alone/RB 266/CD sulfamethoxazole/NN prescribed/VBN estimate/VB risk/NN liver/NN and/CC
trimethoprim/NN alone/RB 266/CD sulfamethoxazole/NN prescribed/VBN estimate/VB risk/NN liver/NN disorders/NNS renal/JJ
trimethoprim/NN alone/RB 266/CD sulfamethoxazole/NN prescribed/VBN estimate/VB risk/NN liver/NN disorders/NNS
cephalexin/NN sulfamethoxazole/NN prescribed/VBN estimate/VB risk/NN liver/NN
cephalexin/NN sulfamethoxazole/NN prescribed/VBN estimate/VB risk/NN liver/NN blood/NN
cephalexin/NN sulfamethoxazole/NN prescribed/VBN estimate/VB risk/NN liver/NN skin/NN
cephalexin/NN sulfamethoxazole/NN prescribed/VBN estimate/VB risk/NN liver/NN and/CC
cephalexin/NN sulfamethoxazole/NN prescribed/VBN estimate/VB risk/NN liver/NN disorders/NNS renal/JJ
cephalexin/NN sulfamethoxazole/NN prescribed/VBN estimate/VB risk/NN liver/NN disorders/NNS
TMP/NNP exposed/VBN disorders/NNS experienced/VBD SMZ/VBP SMZ/NNP seven/CD multiforme/NN erythema/NN
TMP/NNP exposed/VBN disorders/NNS experienced/VBD SMZ/VBP SMZ/NNP seven/CD multiforme/NN
SMZ/NNP seven/CD multiforme/NN erythema/NN
SMZ/NNP seven/CD multiforme/NN
TMP/NNP exposed/VBN Johnson/NNP Stevens/NNP seven/CD multiforme/NN erythema/NN
TMP/NNP exposed/VBN Johnson/NNP Stevens/NNP seven/CD multiforme/NN
SMZ/VBP SMZ/NNP seven/CD multiforme/NN erythema/NN
SMZ/VBP SMZ/NNP seven/CD multiforme/NN
melatonin/NN effects/NNS cortex/NN induced/VBN dysplasia/NN cortical/JJ
melatonin/NN effects/NNS cortex/NN induced/VBN dysplasia/NN
melatonin/NN effects/NNS investigate/VB BCNU/NNS induced/VBN dysplasia/NN cortical/JJ
melatonin/NN effects/NNS investigate/VB BCNU/NNS induced/VBN dysplasia/NN
linezolid/JJ therapy/NN associated/VBN vision/NN loss/NN
linezolid/JJ therapy/NN associated/VBN vision/NN of/IN
linezolid/JJ therapy/NN associated/VBN vision/NN
linezolid/NN drugs/NNS tuberculous/VBZ presented/VBD loss/NN
linezolid/NN drugs/NNS tuberculous/VBZ presented/VBD loss/NN vision/NN of/IN
linezolid/NN drugs/NNS tuberculous/VBZ presented/VBD loss/NN vision/NN
ethambutol/NN linezolid/NN drugs/NNS tuberculous/VBZ presented/VBD loss/NN
ethambutol/NN linezolid/NN drugs/NNS tuberculous/VBZ presented/VBD loss/NN vision/NN of/IN
ethambutol/NN linezolid/NN drugs/NNS tuberculous/VBZ presented/VBD loss/NN vision/NN
linezolid/NN drug/NN extensively/JJ
linezolid/NN drug/NN
linezolid/NN drugs/NNS tuberculous/VBZ presented/VBD tuberculosis/NNP resistant/NNP
linezolid/NN drugs/NNS tuberculous/VBZ presented/VBD tuberculosis/NNP
linezolid/NN drugs/NNS tuberculous/VBZ presented/VBD tuberculosis/NNP XDR/NNP
linezolid/NN drugs/NNS tuberculous/VBZ presented/VBD tuberculosis/NNP XDR/NNP TB/NN
ethambutol/NN linezolid/NN drug/NN extensively/JJ
ethambutol/NN linezolid/NN drug/NN
ethambutol/NN linezolid/NN drugs/NNS tuberculous/VBZ presented/VBD tuberculosis/NNP resistant/NNP
ethambutol/NN linezolid/NN drugs/NNS tuberculous/VBZ presented/VBD tuberculosis/NNP
ethambutol/NN linezolid/NN drugs/NNS tuberculous/VBZ presented/VBD tuberculosis/NNP XDR/NNP
ethambutol/NN linezolid/NN drugs/NNS tuberculous/VBZ presented/VBD tuberculosis/NNP XDR/NNP TB/NN
Ethambutol/NNP induced/VBN suspected/VBN neuropathy/NN toxic/JJ
Ethambutol/NNP induced/VBN suspected/VBN neuropathy/NN optic/JJ
Ethambutol/NNP induced/VBN suspected/VBN neuropathy/NN
ethambutol/NN withdrawn/VBN suspected/VBN neuropathy/NN toxic/JJ
ethambutol/NN withdrawn/VBN suspected/VBN neuropathy/NN optic/JJ
ethambutol/NN withdrawn/VBN suspected/VBN neuropathy/NN
ethambutol/NN withdrawal/NN occurred/VBD Deterioration/NNP
ethambutol/NN withdrawal/NN occurred/VBD Deterioration/NNP vision/NN of/IN
ethambutol/NN withdrawal/NN occurred/VBD Deterioration/NNP vision/NN
levodopa/NN characterize/VB dynamics/NNS patients/NNS PD/NNP
levodopa/NN suggest/VBP confirm/VBP predictor/NN dysphagia/NN
levodopa/NN suggest/VBP confirm/VBP predictor/NN alterations/NNS PD/NNP
dexamethasone/NN bortezomib/NN Combination/NNP stem/VBP transplantation/NN myeloma/NN multiple/JJ
dexamethasone/NN bortezomib/NN Combination/NNP stem/VBP transplantation/NN myeloma/NN
bortezomib/NN Combination/NNP stem/VBP transplantation/NN myeloma/NN multiple/JJ
bortezomib/NN Combination/NNP stem/VBP transplantation/NN myeloma/NN
thalidomide/NN bortezomib/NN Combination/NNP stem/VBP transplantation/NN myeloma/NN multiple/JJ
thalidomide/NN bortezomib/NN Combination/NNP stem/VBP transplantation/NN myeloma/NN
dexamethasone/NN bortezomib/NN regimen/NN safety/NN analyzed/VBD patients/NNS MM/NNP
bortezomib/NN regimen/NN safety/NN analyzed/VBD patients/NNS MM/NNP
thalidomide/NN bortezomib/NN regimen/NN safety/NN analyzed/VBD patients/NNS MM/NNP
imipramine/NN induced/VBN Hypertension/NNP neuroblastoma/NN
Imipramine/NNP given/VBN occurrence/NN hypertension/NN 4/CD girl/NN neuroblastoma/NN
Imipramine/NNP given/VBN control/VB disorder/NN behavior/NN
Imipramine/NNP given/VBN control/VB disorder/NN
salbutamol/NN inhaled/VBD asthmatics/NNS
salbutamol/NN doses/NNS produce/VBP response/NN patients/NNS asthma/NN
salbutamol/JJ dose/NN treatment/NN 14/CD given/VBN patients/NNS asthmatic/JJ
salbutamol/NN 14/CD given/VBN patients/NNS asthmatic/JJ
K/NNP metabolic/JJ responses/NNS chronotropic/NN tremor/NN
Glu/NNP K/NNP metabolic/JJ responses/NNS chronotropic/NN tremor/NN
doxorubicin/NN hearts/NNS treated/VBD hypertrophic/JJ
doxorubicin/NN given/VBN toxicity/NN using/VBG determined/VBN schedule/NN exerted/VBN toxicity/NN
doxorubicin/NN given/VBN toxicity/NN
ICRF/NNP protection/NN determined/VBN schedule/NN exerted/VBN toxicity/NN
187/CD ICRF/NNP protection/NN determined/VBN schedule/NN exerted/VBN toxicity/NN
ICRF/NNP protection/NN determined/VBN using/VBG toxicity/NN
187/CD ICRF/NNP protection/NN determined/VBN using/VBG toxicity/NN
ICRF/NNP provided/VBN protection/NN demonstrated/VBD induced/VBN cardiotoxicity/RB
187/VBZ result/NN induced/VBN cardiotoxicity/RB
HCl/NN exposure/NN effect/NN determined/VBD determining/VBG concentration/NN bupivacaine/NN caused/VBD myocyte/VBP become/VB arrhythmic/JJ
N/NNP form/NN given/VBN cardiotoxicity/NN
2/CD conjugates/NN form/NN given/VBN cardiotoxicity/NN
hydroxypropyl/NN 2/CD conjugates/NN form/NN given/VBN cardiotoxicity/NN
methacrylamide/JJ conjugates/NN form/NN given/VBN cardiotoxicity/NN
N/NNS doxorubicin/NN cardiotoxicity/NN
2/CD cardiotoxicity/NN
hydroxypropyl/NN 2/CD cardiotoxicity/NN
methacrylamide/VBP cardiotoxicity/NN
HPMA/NNP conjugates/NNS methacrylamide/VBP cardiotoxicity/NN
N/NNS doxorubicin/NN cardiotoxicity/NN methacrylamide/VBP used/VBN evaluate/VB toxicity/NN
2/CD cardiotoxicity/NN methacrylamide/VBP used/VBN evaluate/VB toxicity/NN
hydroxypropyl/NN 2/CD cardiotoxicity/NN methacrylamide/VBP used/VBN evaluate/VB toxicity/NN
methacrylamide/VBP used/VBN evaluate/VB toxicity/NN
HPMA/NNP conjugates/NNS methacrylamide/VBP used/VBN evaluate/VB toxicity/NN
doxorubicin/NN cardiotoxicity/NN methacrylamide/VBP used/VBN evaluate/VB toxicity/NN
DOX/NNP doxorubicin/NN cardiotoxicity/NN methacrylamide/VBP used/VBN evaluate/VB toxicity/NN
HPMA/NNP copolymer/NNP mixture/NN DOX/NN received/VBD animals/NNS observed/VBN deaths/NNS related/VBN cardiotoxicity/NN
HPMA/NNP copolymer/NNP mixture/NN DOX/NN received/VBD animals/NNS observed/VBN revealed/VBD heart/NN consistent/JJ cardiotoxicity/JJ
K/NNP induced/VBN Nephropathy/RB
Na/NNP Expression/NNP Decreased/VBN K/NNP induced/VBN Nephropathy/RB
K/NNP Na/NNP expression/NN related/VBN nephropathy/RB
Na/NNP expression/NN related/VBN nephropathy/RB
caproate/VB related/VBD effect/NN Hyperglycemic/JJ
caproate/NN derivatives/NNS amounts/NNS feeding/NN resulted/VBD hyperglycemia/NN glucosuria/NN
glucose/NN curve/NN hyperglycemia/NN
amino/JJ derivatives/NNS amounts/NNS feeding/NN resulted/VBD hyperglycemia/NN glucosuria/NN
caproate/NN derivatives/NNS amounts/NNS feeding/NN resulted/VBD hyperglycemia/NN
glucose/NN curve/NN hyperglycemia/NN glucosuria/NN
Levodopa/NNP induced/VBN disease/NN Parkinson/NNP
Levodopa/NNP induced/VBN disease/NN Parkinson/NNP '/POS
Levodopa/NNP induced/VBN disease/NN s/JJ
Levodopa/NNP induced/VBN disease/NN
tiapride/NN tetrabenazine/NN therapy/NN induced/VBN patient/NN disease/NN Huntington/NNP
tiapride/NN tetrabenazine/NN therapy/NN induced/VBN patient/NN disease/NN Huntington/NNP '/POS
tiapride/NN tetrabenazine/NN therapy/NN induced/VBN patient/NN disease/NN s/JJ
tiapride/NN tetrabenazine/NN therapy/NN induced/VBN patient/NN disease/NN
tetrabenazine/NN therapy/NN induced/VBN patient/NN disease/NN Huntington/NNP
tetrabenazine/NN therapy/NN induced/VBN patient/NN disease/NN Huntington/NNP '/POS
tetrabenazine/NN therapy/NN induced/VBN patient/NN disease/NN s/JJ
tetrabenazine/NN therapy/NN induced/VBN patient/NN disease/NN
tiapride/NN tetrabenazine/NN therapy/NN induced/VBN stage/NN cancer/NN breast/NN
tiapride/NN tetrabenazine/NN therapy/NN induced/VBN stage/NN cancer/NN
tetrabenazine/NN therapy/NN induced/VBN stage/NN cancer/NN breast/NN
tetrabenazine/NN therapy/NN induced/VBN stage/NN cancer/NN
tiapride/NN therapy/NN initiation/NN occurred/VBD disease/NN Huntington/NNP
tiapride/NN therapy/NN initiation/NN occurred/VBD disease/NN Huntington/NNP '/POS
tiapride/NN therapy/NN initiation/NN occurred/VBD disease/NN s/JJ
tiapride/NN therapy/NN initiation/NN occurred/VBD disease/NN
tetrabenazine/NN tiapride/NN therapy/NN initiation/NN occurred/VBD disease/NN Huntington/NNP
tetrabenazine/NN tiapride/NN therapy/NN initiation/NN occurred/VBD disease/NN Huntington/NNP '/POS
tetrabenazine/NN tiapride/NN therapy/NN initiation/NN occurred/VBD disease/NN s/JJ
tetrabenazine/NN tiapride/NN therapy/NN initiation/NN occurred/VBD disease/NN
erdosteine/NN protection/NN induced/VBZ nephrotoxicity/RB
oxygen/NN species/NNS production/NN promotes/VBZ stress/NN vancomycin/NN examine/VB investigate/VB role/NN erdosteine/NN antioxidant/VBN tissue/NN VCM/NN induced/VBN impairment/NN renal/JJ
oxygen/NN species/NNS production/NN promotes/VBZ stress/NN vancomycin/NN examine/VB investigate/VB role/NN erdosteine/NN antioxidant/VBN tissue/NN VCM/NN induced/VBN impairment/NN
erdosteine/NN antioxidant/VBN tissue/NN VCM/NN induced/VBN impairment/NN renal/JJ
erdosteine/NN antioxidant/VBN tissue/NN VCM/NN induced/VBN impairment/NN
superoxide/JJ dismutase/NN excretion/NNS NAG/NNP marker/NN injury/NN renal/JJ
superoxide/JJ dismutase/NN excretion/NNS NAG/NNP marker/NN injury/NN tubular/JJ
superoxide/JJ dismutase/NN excretion/NNS NAG/NNP marker/NN injury/NN
malondialdehyde/JJ excretion/NNS NAG/NNP marker/NN injury/NN renal/JJ
malondialdehyde/JJ excretion/NNS NAG/NNP marker/NN injury/NN tubular/JJ
malondialdehyde/JJ excretion/NNS NAG/NNP marker/NN injury/NN
MDA/NNP malondialdehyde/JJ excretion/NNS NAG/NNP marker/NN injury/NN renal/JJ
MDA/NNP malondialdehyde/JJ excretion/NNS NAG/NNP marker/NN injury/NN tubular/JJ
MDA/NNP malondialdehyde/JJ excretion/NNS NAG/NNP marker/NN injury/NN
Erdosteine/NNP showed/VBD induced/VBN nephrotoxicity/RB
erdosteine/JJ groups/NNS control/NN those/DT were/VBD dilatation/NN lumens/NNS atrophy/NN
VCM/NNP necrosis/NNS lumens/NNS atrophy/NN
erdosteine/JJ groups/NNS control/NN those/DT were/VBD dilatation/NN lumens/NNS necrosis/NNS
erdosteine/JJ groups/NNS control/NN those/DT were/VBD dilatation/NN lumens/NNS desquamation/NN
VCM/NNP necrosis/NNS lumens/NNS desquamation/NN
VCM/NNP necrosis/NNS
erdosteine/NN modulation/NN induced/VBN nephrotoxicity/RB
erdosteine/NN modulation/NN induced/VBN reduces/VBZ VCM/NNP induced/VBN damage/NN kidney/NN
erdosteine/NN modulation/NN induced/VBN reduces/VBZ VCM/NNP induced/VBN damage/NN
propranolol/NN isomers/NNS properties/NNS arrhythmias/NNS cardiac/JJ
propranolol/NN isomers/NNS properties/NNS arrhythmias/NNS
propranolol/NN isomers/NNS capable/JJ preventing/VBG adrenaline/NN induced/VBN arrhythmias/NNS cardiac/JJ
propranolol/NN isomers/NNS capable/JJ preventing/VBG adrenaline/NN induced/VBN arrhythmias/NNS
propranolol/NN +/NNP -/NNP dose/NN anaesthetized/VBN cats/NNS induced/VBN arrhythmias/NNS cardiac/JJ
propranolol/NN +/NNP -/NNP dose/NN anaesthetized/VBN cats/NNS induced/VBN arrhythmias/NNS
propranolol/NN +/NNP that/DT 4/CD kg/NN +/NNP -/NNP dose/NN anaesthetized/VBN cats/NNS induced/VBN arrhythmias/NNS cardiac/JJ
propranolol/NN +/NNP that/DT 4/CD kg/NN +/NNP -/NNP dose/NN anaesthetized/VBN cats/NNS induced/VBN arrhythmias/NNS
propranolol/NN isomers/NNS capable/JJ reversing/VBG tachycardia/NN ventricular/NN
propranolol/NN isomers/NNS capable/JJ reversing/VBG tachycardia/NN
direct/JJ inhibitor/NN using/VBG mandates/VBZ treatment/NN HIT/NNP
thrombin/NN inhibitor/NN using/VBG mandates/VBZ treatment/NN HIT/NNP
inhibitor/NN using/VBG mandates/VBZ treatment/NN HIT/NNP
Direct/JJ inhibitors/NNS appropriate/JJ based/VBN heparin/VB patients/NNS history/NN HIT/NNP
thrombin/NN inhibitors/NNS appropriate/JJ based/VBN heparin/VB patients/NNS history/NN HIT/NNP
inhibitors/NNS appropriate/JJ based/VBN heparin/VB patients/NNS history/NN HIT/NNP
busulfan/NN Dose/NNP neurotoxicity/NN
Busulfan/NNP known/VBN neurotoxic/JJ
Busulfan/NNP known/VBN remains/VBZ neurotoxicity/NN
busulfan/NN receiving/VBG children/NNS study/NN report/VBP transplantation/NN tumors/NNS tumors/NNS brain/NN
busulfan/NN receiving/VBG children/NNS study/NN report/VBP transplantation/NN tumors/NNS tumors/NNS
busulfan/NN receiving/VBG children/NNS study/NN report/VBP transplantation/NN tumors/NNS
busulfan/NN dose/NN taken/VBN was/VBD difference/NN terms/NNS incidence/NN neurotoxicity/JJ
busulfan/NN m/NN dose/NN v/NN mg/NN 600/CD given/VBN had/VBD symptoms/NNS neurological/JJ
busulfan/NN m/NN dose/NN v/NN mg/NN 600/CD given/VBN had/VBD symptoms/NNS
clonazepam/NN infusion/NN given/VBN had/VBD symptoms/NNS neurological/JJ
clonazepam/NN infusion/NN given/VBN had/VBD symptoms/NNS
Busulfan/NN levels/NNS measured/VBN mg/VBP disease/NN assay/RB fluid/NN children/NNS system/NN central/JJ
Busulfan/NN levels/NNS measured/VBN mg/VBP disease/NN assay/RB fluid/NN children/NNS system/NN nervous/JJ
Busulfan/NN levels/NNS measured/VBN mg/VBP disease/NN assay/RB fluid/NN children/NNS system/NN
Busulfan/NN levels/NNS measured/VBN mg/VBP disease/NN
busulfan/VBN m/NN mg/VBP disease/NN assay/RB fluid/NN children/NNS system/NN central/JJ
busulfan/VBN m/NN mg/VBP disease/NN assay/RB fluid/NN children/NNS system/NN nervous/JJ
busulfan/VBN m/NN mg/VBP disease/NN assay/RB fluid/NN children/NNS system/NN
busulfan/VBN m/NN mg/VBP disease/NN
busulfan/JJ fluid/NN busulfan/VBN m/NN mg/VBP disease/NN assay/RB fluid/NN children/NNS system/NN central/JJ
busulfan/JJ fluid/NN busulfan/VBN m/NN mg/VBP disease/NN assay/RB fluid/NN children/NNS system/NN nervous/JJ
busulfan/JJ fluid/NN busulfan/VBN m/NN mg/VBP disease/NN assay/RB fluid/NN children/NNS system/NN
busulfan/JJ fluid/NN busulfan/VBN m/NN mg/VBP disease/NN
clonazepam/NN busulfan/VBN m/NN mg/VBP disease/NN assay/RB fluid/NN children/NNS system/NN central/JJ
clonazepam/NN busulfan/VBN m/NN mg/VBP disease/NN assay/RB fluid/NN children/NNS system/NN nervous/JJ
clonazepam/NN busulfan/VBN m/NN mg/VBP disease/NN assay/RB fluid/NN children/NNS system/NN
clonazepam/NN busulfan/VBN m/NN mg/VBP disease/NN
clonazepam/NN prevented/VBN children/NNS dependent/JJ dose/NN neurotoxicity/NN
busulfan/NN neurotoxicity/NN
busulfan/NN dose/NN followed/VBN neurotoxicity/NN
busulfan/NN dose/NN followed/VBN neurotoxicity/NN close/JJ incidence/NN neurotoxicity/JJ
rapamycin/NN inhibitors/NNS target/NN treated/VBN patients/NNS complication/NN Proteinuria/NNP
tacrolimus/NNS developed/VBD proteinuria/NN
tacrolimus/NNS developed/VBD amyloidosis/NNS
propranolol/NNP effects/NNS 76/CD induced/VBN hypertrophy/NN heart/NN
propranolol/NNP effects/NNS 76/CD induced/VBN hypertrophy/NN
ornithine/JJ activity/NN blockers/NNS hearts/NNS hypertrophied/JJ
ornithine/JJ activity/NN blockers/NNS hearts/NNS
propranolol/NN stop/VB pattern/NN heart/NN hypertrophied/JJ
propranolol/NN beta/NN have/VBP potency/NN prevent/VB producing/VBG hypertrophy/NN heart/NN
propranolol/NN beta/NN have/VBP potency/NN prevent/VB producing/VBG hypertrophy/NN
lidocaine/VBP phase/NN infarction/NN myocardial/JJ
lidocaine/VBP phase/NN infarction/NN
lidocaine/JJ placebo/NN trial/NN double/JJ entered/VBD patients/NNS infarction/NN myocardial/JJ
lidocaine/JJ placebo/NN trial/NN double/JJ entered/VBD patients/NNS infarction/NN
Lidocaine/NNP prevent/VB tachycardia/NN ventricular/NN
Lidocaine/NNP prevent/VB tachycardia/NN
lidocaine/NN number/NN reduction/NN was/VBD prevent/VB tachycardia/NN ventricular/NN
lidocaine/NN number/NN reduction/NN was/VBD prevent/VB tachycardia/NN
Lidocaine/NNP prevent/VB was/VBD reduction/NN number/NN arrhythmias/NNS
lidocaine/NN number/NN arrhythmias/NNS
lidocaine/NN level/NN administration/NN patients/NNS infarction/NN myocardial/JJ
lidocaine/NN level/NN administration/NN patients/NNS infarction/NN
lidocaine/NN level/NN higher/JJR infarction/NN
lidocaine/JJ group/NN hypotension/NN patients/NNS died/VBN asystole/NN
lidocaine/JJ received/VBN nine/CD hypotension/NN patients/NNS died/VBN asystole/NN
lidocaine/NN had/VBN asystole/NN
lidocaine/JJ prophylactically/NN administration/NN advocate/NN hours/NNS infarction/NN myocardial/JJ
lidocaine/JJ prophylactically/NN administration/NN advocate/NN hours/NNS infarction/NN
estrogen/NN phenotypes/NNS hemorrhagic/JJ
estrogen/NN phenotypes/NNS separation/NN growth/NN tumor/NN
estrogen/NN phenotypes/NNS separation/NN tumor/NN
estrogen/JJ rat/NN administration/NN induces/VBZ growth/NN tumors/NNS pituitary/JJ
estrogen/JJ rat/NN administration/NN induces/VBZ growth/NN tumors/NNS
estrogen/JJ rat/NN administration/NN induces/VBZ growth/NN tumors/NNS hemorrhagic/JJ
diethylstilbestrol/NNP treatment/NN weeks/NNS caused/VBD grow/VB become/VB hemorrhagic/JJ
DES/NNP treatment/NN weeks/NNS caused/VBD grow/VB become/VB hemorrhagic/JJ
DES/NNP exhibited/VBD exhibited/VBD phenotype/NN hemorrhagic/JJ
methylprednisolone/NN therapy/NN received/VBD patients/NNS arthritis/NN rheumatoid/JJ
methylprednisolone/NN therapy/NN received/VBD patients/NNS arthritis/NN
MP/NNP therapy/NN received/VBD patients/NNS arthritis/NN rheumatoid/JJ
MP/NNP therapy/NN received/VBD patients/NNS arthritis/NN
MP/NNP contraindicated/VBN patients/NNS disease/NN heart/NN
MP/NNP contraindicated/VBN patients/NNS disease/NN
verapamil/NN increased/VBD patients/NNS syndromes/NNS chest/NN
verapamil/NN increased/VBD patients/NNS syndromes/NNS pain/NN
angiotensin/NN system/NN patients/NNS diabetes/NN type/NN
angiotensin/NN system/NN patients/NNS diabetes/NN type/NN 1/CD
angiotensin/NN system/NN patients/NNS diabetes/NN
angiotensin/NN system/NN renin/NN blockade/NN retard/VB progression/NN nephropathy/NN
angiotensin/NN system/NN renin/NN blockade/NN retard/VB suggesting/VBG involved/VBN pathogenesis/NNS nephropathy/NN diabetic/JJ
angiotensin/NN system/NN renin/NN blockade/NN retard/VB suggesting/VBG involved/VBN pathogenesis/NNS nephropathy/NN
angiotensin/NN system/NN renin/NN blockade/NN retard/VB suggesting/VBG involved/VBN pathogenesis/NNS nephropathy/NN nephropathy/NN diabetic/JJ
angiotensin/NN system/NN renin/NN blockade/NN retard/VB suggesting/VBG involved/VBN pathogenesis/NNS nephropathy/NN nephropathy/NN
streptozotocin/NN diabetes/NNP
STZ/NNP streptozotocin/NN diabetes/NNP
streptozotocin/NN contributes/VBZ development/NN fibrosis/NN
STZ/NNP streptozotocin/NN contributes/VBZ development/NN fibrosis/NN
calcium/NN pathogenesis/NNS disease/NN cardiovascular/JJ
calcium/NN pathogenesis/NNS disease/NN
calcium/NN importance/NN recognition/NN stimulated/VBN blocking/VBG treatment/NN variety/NN diseases/NNS cardiovascular/JJ
calcium/NN importance/NN recognition/NN stimulated/VBN blocking/VBG treatment/NN variety/NN diseases/NNS
calcium/NN channel/NN use/NN stimulated/VBN recognition/NN importance/NN calcium/NN pathogenesis/NNS disease/NN cardiovascular/JJ
calcium/NN channel/NN use/NN stimulated/VBN recognition/NN importance/NN calcium/NN pathogenesis/NNS disease/NN
channel/NN use/NN stimulated/VBN recognition/NN importance/NN calcium/NN pathogenesis/NNS disease/NN cardiovascular/JJ
channel/NN use/NN stimulated/VBN recognition/NN importance/NN calcium/NN pathogenesis/NNS disease/NN
blocking/VBG stimulated/VBN recognition/NN importance/NN calcium/NN pathogenesis/NNS disease/NN cardiovascular/JJ
blocking/VBG stimulated/VBN recognition/NN importance/NN calcium/NN pathogenesis/NNS disease/NN
agents/NNS blocking/VBG stimulated/VBN recognition/NN importance/NN calcium/NN pathogenesis/NNS disease/NN cardiovascular/JJ
agents/NNS blocking/VBG stimulated/VBN recognition/NN importance/NN calcium/NN pathogenesis/NNS disease/NN
calcium/NN channel/NN use/NN stimulated/VBN blocking/VBG treatment/NN variety/NN diseases/NNS cardiovascular/JJ
calcium/NN channel/NN use/NN stimulated/VBN blocking/VBG treatment/NN variety/NN diseases/NNS
channel/NN use/NN stimulated/VBN blocking/VBG treatment/NN variety/NN diseases/NNS cardiovascular/JJ
channel/NN use/NN stimulated/VBN blocking/VBG treatment/NN variety/NN diseases/NNS
blocking/VBG treatment/NN variety/NN diseases/NNS cardiovascular/JJ
blocking/VBG treatment/NN variety/NN diseases/NNS
agents/NNS blocking/VBG treatment/NN variety/NN diseases/NNS cardiovascular/JJ
agents/NNS blocking/VBG treatment/NN variety/NN diseases/NNS
dihydropyridine/NN controls/VBZ angina/NN
dihydropyridine/NN controls/VBZ angina/NN hypertension/NN
nifedipine/NN controls/VBZ angina/NN hypertension/NN
nifedipine/NN controls/VBZ angina/NN
nitrendipine/NN possible/JJ dosage/NN offers/VBZ therapy/NN hypertension/NN
nisoldipine/NN nitrendipine/NN possible/JJ dosage/NN offers/VBZ therapy/NN hypertension/NN
nisoldipine/NN properties/NNS led/VBN angina/NN
nimodipine/VB treatment/NN hemorrhage/NN headache/NN migraine/JJ
nimodipine/VB treatment/NN hemorrhage/NN headache/NN
nimodipine/VB treatment/NN hemorrhage/NN stroke/NN
nimodipine/VB treatment/NN hemorrhage/NN subarachnoid/JJ
nimodipine/VB treatment/NN hemorrhage/NN
nimodipine/VB treatment/NN hemorrhage/NN dementia/NN
dihydropyridine/JJ blockers/NNS tolerated/JJ effects/NNS headache/NN edema/NN anorexia/NN
dihydropyridine/JJ blockers/NNS tolerated/JJ effects/NNS headache/NN edema/NN nausea/NN
dihydropyridine/JJ blockers/NNS tolerated/JJ effects/NNS headache/NN flushing/NN
dihydropyridine/JJ blockers/NNS tolerated/JJ effects/NNS headache/NN edema/NN dizziness/NN
dihydropyridine/JJ blockers/NNS tolerated/JJ effects/NNS headache/NN
dihydropyridine/JJ blockers/NNS tolerated/JJ effects/NNS headache/NN edema/NN
dihydropyridine/JJ blockers/NNS tolerated/JJ effects/NNS headache/NN palpitations/NNS
calcium/NN blockers/NNS tolerated/JJ effects/NNS headache/NN palpitations/NNS
channel/NN blockers/NNS tolerated/JJ effects/NNS headache/NN palpitations/NNS
blockers/NNS tolerated/JJ effects/NNS headache/NN palpitations/NNS
diphenylhydantoin/NN taking/VBG patient/NN developed/VBD rash/NN skin/NN
diphenylhydantoin/NN taking/VBG patient/NN developed/VBD rash/NN
diphenylhydantoin/NN treatment/NN complication/NN known/VBN well/NN rash/NN Skin/NN
diphenylhydantoin/NN treatment/NN complication/NN known/VBN well/NN rash/NN
diphenylhydantoin/NN ingestion/NN relation/NN occurrence/NN rash/NN skin/NN
diphenylhydantoin/NN ingestion/NN relation/NN occurrence/NN rash/NN
methamphetamine/NN dose/NN neurotoxic/JJ
dopamine/NNP levels/NNS reduction/NN indicated/VBN depressive/NN
HVA/NNP dopamine/NNP levels/NNS reduction/NN indicated/VBN depressive/NN
DOPAC/NNP dopamine/NNP levels/NNS reduction/NN indicated/VBN depressive/NN
serotonin/JJ hydroxylase/JJ administration/NN tyrosine/VBP depressive/NN
tyrosine/VBP depressive/NN
morphine/NN synergy/NN Studies/NNS pain/NN inflammatory/JJ neuropathic/JJ
morphine/NN synergy/NN Studies/NNS pain/NN
sodium/NN blocker/NN synergy/NN Studies/NNS pain/NN inflammatory/JJ neuropathic/JJ
sodium/NN blocker/NN synergy/NN Studies/NNS pain/NN
CNSB/NNP blocker/NN synergy/NN Studies/NNS pain/NN inflammatory/JJ neuropathic/JJ
CNSB/NNP blocker/NN synergy/NN Studies/NNS pain/NN
002/CD CNSB/NNP blocker/NN synergy/NN Studies/NNS pain/NN inflammatory/JJ neuropathic/JJ
002/CD CNSB/NNP blocker/NN synergy/NN Studies/NNS pain/NN
morphine/NN models/NNS pain/NN inflammatory/JJ neuropathic/JJ
morphine/NN models/NNS pain/NN
sodium/NN blocker/NN properties/NNS given/VBN and/CC combinations/NNS morphine/NN models/NNS pain/NN inflammatory/JJ neuropathic/JJ
sodium/NN blocker/NN properties/NNS given/VBN and/CC combinations/NNS morphine/NN models/NNS pain/NN
CNSB/NNP effect/NN blocker/NN properties/NNS given/VBN and/CC combinations/NNS morphine/NN models/NNS pain/NN inflammatory/JJ neuropathic/JJ
CNSB/NNP effect/NN blocker/NN properties/NNS given/VBN and/CC combinations/NNS morphine/NN models/NNS pain/NN
002/CD CNSB/NNP effect/NN blocker/NN properties/NNS given/VBN and/CC combinations/NNS morphine/NN models/NNS pain/NN inflammatory/JJ neuropathic/JJ
002/CD CNSB/NNP effect/NN blocker/NN properties/NNS given/VBN and/CC combinations/NNS morphine/NN models/NNS pain/NN
streptozotocin/NN inflammation/NN paw/NN carrageenan/NN using/VBG heat/NN models/NNS pain/NN
STZ/NNP inflammation/NN paw/NN carrageenan/NN using/VBG heat/NN models/NNS pain/NN
CNSB/NNP doses/NNS curves/NNS constructed/VBN effect/NN using/VBG carrageenan/NN paw/NN inflammation/NN
002/CD CNSB/NNP doses/NNS curves/NNS constructed/VBN effect/NN using/VBG carrageenan/NN paw/NN inflammation/NN
CNSB/NNP doses/NNS curves/NNS constructed/VBN effect/NN using/VBG carrageenan/NN induced/VBN neuropathy/NN diabetic/JJ
CNSB/NNP doses/NNS curves/NNS constructed/VBN effect/NN using/VBG carrageenan/NN induced/VBN neuropathy/NN
002/CD CNSB/NNP doses/NNS curves/NNS constructed/VBN effect/NN using/VBG carrageenan/NN induced/VBN neuropathy/NN diabetic/JJ
002/CD CNSB/NNP doses/NNS curves/NNS constructed/VBN effect/NN using/VBG carrageenan/NN induced/VBN neuropathy/NN
carrageenan/NN induced/VBN neuropathy/NN diabetic/JJ
carrageenan/NN induced/VBN neuropathy/NN
morphine/NN doses/NNS curves/NNS constructed/VBN effect/NN using/VBG carrageenan/NN induced/VBN neuropathy/NN diabetic/JJ
morphine/NN doses/NNS curves/NNS constructed/VBN effect/NN using/VBG carrageenan/NN induced/VBN neuropathy/NN
CNSB/NNP doses/NNS curves/NNS constructed/VBN effect/NN using/VBG heat/NN models/NNS pain/NN
002/CD CNSB/NNP doses/NNS curves/NNS constructed/VBN effect/NN using/VBG heat/NN models/NNS pain/NN
morphine/NN doses/NNS curves/NNS constructed/VBN effect/NN using/VBG carrageenan/NN paw/NN inflammation/NN
morphine/NN doses/NNS curves/NNS constructed/VBN effect/NN using/VBG heat/NN models/NNS pain/NN
carrageenan/NN using/VBG heat/NN models/NNS pain/NN
streptozotocin/NN inflammation/NN
STZ/NNP inflammation/NN
CNSB/NNP model/NN neuropathy/NN
002/CD CNSB/NNP model/NN neuropathy/NN
CNSB/NNP model/NN doses/NNS calculated/VBN cause/VB 7/CD reversal/NN hyperalgesia/NN
002/CD CNSB/NNP model/NN doses/NNS calculated/VBN cause/VB 7/CD reversal/NN hyperalgesia/NN
STZ/NNP 1/CD 14/CD doses/NNS model/NN neuropathy/NN
morphine/NN CNSB/NNP model/NN neuropathy/NN
carrageenan/NN model/NN 1/CD 83/CD doses/NNS model/NN neuropathy/NN
morphine/NN CNSB/NNP model/NN doses/NNS calculated/VBN cause/VB 7/CD reversal/NN hyperalgesia/NN
CNSB/NNP combination/NN given/VBN dose/NN 37/CD 1/CD model/NN neuropathy/NN
002/CD CNSB/NNP combination/NN given/VBN dose/NN 37/CD 1/CD model/NN neuropathy/NN
morphine/NN values/VBZ dose/NN 37/CD 1/CD model/NN neuropathy/NN
carrageenan/NN model/NN dose/NN 37/CD 1/CD model/NN neuropathy/NN
CNSB/NNP administration/NN reversal/NN hyperalgesia/NN models/NNS inflammatory/JJ neuropathic/JJ
002/CD CNSB/NNP administration/NN reversal/NN hyperalgesia/NN models/NNS inflammatory/JJ neuropathic/JJ
CNSB/NNP administration/NN reversal/NN hyperalgesia/NN
002/CD CNSB/NNP administration/NN reversal/NN hyperalgesia/NN
morphine/NN antinociception/NN increased/VBN co/NN reversal/NN hyperalgesia/NN models/NNS inflammatory/JJ neuropathic/JJ
morphine/NN antinociception/NN increased/VBN co/NN reversal/NN hyperalgesia/NN
triglycerides/NNPS changes/NNS MATERIALS/NNP les/NNP cancer/NN prostate/NN
triglycerides/NNPS changes/NNS MATERIALS/NNP les/NNP cancer/NN
TG/NNP triglycerides/NNPS changes/NNS MATERIALS/NNP les/NNP cancer/NN prostate/NN
TG/NNP triglycerides/NNPS changes/NNS MATERIALS/NNP les/NNP cancer/NN
cyproterone/JJ acetate/NN les/NNP cancer/NN prostate/NN
cyproterone/JJ acetate/NN les/NNP cancer/NN
acetate/NN les/NNP cancer/NN prostate/NN
acetate/NN les/NNP cancer/NN
CPA/NNP acetate/NN les/NNP cancer/NN prostate/NN
CPA/NNP acetate/NN les/NNP cancer/NN
cholesterols/NNS changes/NNS MATERIALS/NNP les/NNP cancer/NN prostate/NN
cholesterols/NNS changes/NNS MATERIALS/NNP les/NNP cancer/NN
C/NNP changes/NNS MATERIALS/NNP les/NNP cancer/NN prostate/NN
C/NNP changes/NNS MATERIALS/NNP les/NNP cancer/NN
CPA/NNP treatment/NN years/NNS period/NN found/VBN affected/VBN disease/NN coronary/JJ
CPA/NNP treatment/NN years/NNS period/NN found/VBN affected/VBN disease/NN heart/NN
CPA/NNP treatment/NN years/NNS period/NN found/VBN affected/VBN disease/NN
cholesterol/NN changes/NNS mediated/VBN %/NN coronary/NNP
cholesterol/NN changes/NNS mediated/VBN %/NN coronary/NNP arteriosclerosis/VBZ
estrogen/NN caused/VBN effect/NN hyperglyceridemic/JJ
estrogen/NN caused/VBN effect/NN
cholesterol/NN changes/NNS mediated/VBN %/NN coronary/NNP A/NNP known/VBN effect/NN hyperglyceridemic/JJ
cholesterol/NN changes/NNS mediated/VBN %/NN coronary/NNP A/NNP known/VBN effect/NN
estrogen/NN caused/VBN effect/NN known/VBN A/NNP coronary/NNP
estrogen/NN caused/VBN effect/NN known/VBN A/NNP coronary/NNP arteriosclerosis/VBZ
carbamazepine/JJ therapy/NN induced/VBN Asterixis/NNS
carbamazepine/NN adding/VBG triggered/VBN asterixis/NNS
CBZ/NNP carbamazepine/NN adding/VBG triggered/VBN asterixis/NNS
CBZ/NNP used/VBN consider/VBP sign/NN neurotoxicity/NN
lithium/NN drugs/NNS used/VBN consider/VBP sign/NN neurotoxicity/NN
CBZ/NNP used/VBN consider/VBP asterixis/NNS
clozapine/NN lithium/NN drugs/NNS used/VBN consider/VBP sign/NN neurotoxicity/NN
halothane/JJ anaesthesia/NN became/VBD developed/VBD bradycardia/NN
halothane/JJ anaesthesia/NN became/VBD hypotensive/NN
halothane/JJ anaesthesia/NN enhanced/VBN bradycardia/NN
halothane/JJ anaesthesia/NN enhanced/VBN bradycardia/NN hypotension/NN
methotrexate/NN treatment/NN cause/VB toxicity/NN hepatic/JJ
methotrexate/NN treatment/NN cause/VB toxicity/NN hepatic/JJ and/CC
methotrexate/NN treatment/NN cause/VB toxicity/NN hepatic/JJ renal/JJ
methotrexate/NN treatment/NN cause/VB toxicity/NN
MTX/NNP HD/NNP methotrexate/NN treatment/NN cause/VB toxicity/NN hepatic/JJ
MTX/NNP HD/NNP methotrexate/NN treatment/NN cause/VB toxicity/NN hepatic/JJ and/CC
MTX/NNP HD/NNP methotrexate/NN treatment/NN cause/VB toxicity/NN hepatic/JJ renal/JJ
MTX/NNP HD/NNP methotrexate/NN treatment/NN cause/VB toxicity/NN
methotrexate/NN treatment/NN lymphoma/NNP Burkitt/NNP
methotrexate/NN treatment/NN lymphoma/NNP
MTX/NNP HD/NNP methotrexate/NN treatment/NN lymphoma/NNP Burkitt/NNP
MTX/NNP HD/NNP methotrexate/NN treatment/NN lymphoma/NNP
MTX/NNP therapy/NN year/NN transplantation/NN atresia/NN biliary/JJ
MTX/NNP therapy/NN year/NN transplantation/NN atresia/NN
olanzapine/NN mania/NN bipolar/JJ
olanzapine/NN mania/NN
olanzapine/JJ placebo/NN efficacy/NN compared/VBD treatment/NN mania/NN bipolar/JJ
olanzapine/JJ placebo/NN efficacy/NN compared/VBD treatment/NN mania/NN
olanzapine/NN randomized/VBN total/NN diagnosis/NN disorder/NNP bipolar/NNP
olanzapine/NN randomized/VBN total/NN diagnosis/NN disorder/NNP
olanzapine/NN randomized/VBN total/NN manic/JJ
Olanzapine/NNP demonstrated/VBD treatment/NN mania/NN bipolar/JJ
Olanzapine/NNP demonstrated/VBD treatment/NN mania/NN
ondansetron/NN peri/NNS depression/NN
ondansetron/NN prophylaxis/NNS used/VBN anaesthetic/NN presented/VBD woman/NN history/NN nausea/NN postoperative/JJ
ondansetron/NN prophylaxis/NNS used/VBN anaesthetic/NN presented/VBD woman/NN history/NN nausea/NN
ondansetron/NN prophylaxis/NNS used/VBN anaesthetic/NN presented/VBD woman/NN history/NN nausea/NN and/CC
ondansetron/NN prophylaxis/NNS used/VBN anaesthetic/NN presented/VBD woman/NN history/NN nausea/NN vomiting/NN
serotonin/NN antagonist/NN use/NN related/VBN developed/VBN disorder/NN major/JJ
serotonin/NN antagonist/NN use/NN related/VBN developed/VBN disorder/NN depression/NN
serotonin/NN antagonist/NN use/NN related/VBN developed/VBN disorder/NN
serotonin/NN antagonists/NNS infusion/NN Anaesthesia/NNP provided/VBD nausea/NN
propofol/JJ infusion/NN Anaesthesia/NNP provided/VBD nausea/NN
serotonin/NN antagonists/NNS infusion/NN Anaesthesia/NNP provided/VBD exacerbation/NN disorder/NN depression/NN
serotonin/NN antagonists/NNS infusion/NN Anaesthesia/NNP provided/VBD exacerbation/NN disorder/NN
propofol/JJ infusion/NN Anaesthesia/NNP provided/VBD exacerbation/NN disorder/NN depression/NN
propofol/JJ infusion/NN Anaesthesia/NNP provided/VBD exacerbation/NN disorder/NN
dopamine/NN hyperprolactinemia/NN
dopamine/JJ antagonist/NN haloperidol/NN induced/VBN Hyperprolactinemia/NNP
dopamine/JJ concentrations/NNS increased/VBD months/NNS hyperprolactinemia/NN
DA/NNP dopamine/JJ concentrations/NNS increased/VBD months/NNS hyperprolactinemia/NN
DA/NNP concentrations/NNS increase/NN produced/VBD months/NNS hyperprolactinemia/NN
DA/NNP response/NN lost/VBN followed/VBN 9/CD month/NN hyperprolactinemia/JJ
norepinephrine/NN change/NN metabolites/NNS months/NNS hyperprolactinemia/NN
norepinephrine/NN change/NN metabolites/NNS months/NNS hyperprolactinemia/NN
NE/NNP norepinephrine/NN change/NN metabolites/NNS months/NNS hyperprolactinemia/NN
NE/NNP norepinephrine/NN change/NN metabolites/NNS months/NNS hyperprolactinemia/NN
5/CD decrease/NN metabolites/NNS months/NNS hyperprolactinemia/NN
hydroxyindoleacetic/JJ acid/NN metabolites/NNS months/NNS hyperprolactinemia/NN
acid/NN metabolites/NNS months/NNS hyperprolactinemia/NN
5/CD decrease/NN metabolites/NNS months/NNS hyperprolactinemia/NN
hydroxyindoleacetic/JJ acid/NN metabolites/NNS months/NNS hyperprolactinemia/NN
acid/NN metabolites/NNS months/NNS hyperprolactinemia/NN
5/CD acid/NN metabolites/NNS months/NNS hyperprolactinemia/NN
HIAA/NNP 5/CD acid/NN metabolites/NNS months/NNS hyperprolactinemia/NN
5/CD acid/NN metabolites/NNS months/NNS hyperprolactinemia/NN
HIAA/NNP 5/CD acid/NN metabolites/NNS months/NNS hyperprolactinemia/NN
DA/NNP levels/NNS change/NN metabolites/NNS months/NNS hyperprolactinemia/NN
DA/NNP levels/NNS change/NN metabolites/NNS months/NNS hyperprolactinemia/NN
DA/NNP concentrations/NNS increase/NN months/NNS hyperprolactinemia/NN
DA/NNP concentrations/NNS increase/NN months/NNS metabolites/NNS months/NNS hyperprolactinemia/NN
serotonin/NN norepinephrine/NN change/NN metabolites/NNS months/NNS hyperprolactinemia/NN
serotonin/NN norepinephrine/NN change/NN metabolites/NNS months/NNS hyperprolactinemia/NN
5/CD serotonin/NN norepinephrine/NN change/NN metabolites/NNS months/NNS hyperprolactinemia/NN
HT/NNP 5/CD serotonin/NN norepinephrine/NN change/NN metabolites/NNS months/NNS hyperprolactinemia/NN
5/CD serotonin/NN norepinephrine/NN change/NN metabolites/NNS months/NNS hyperprolactinemia/NN
HT/NNP 5/CD serotonin/NN norepinephrine/NN change/NN metabolites/NNS months/NNS hyperprolactinemia/NN
guanethidine/NN reduced/VBN potentiated/VBD inhibited/VBD enlargement/NN
guanethidine/NN reduced/VBN potentiated/VBD inhibited/VBD enlargement/NN pulse/NN of/IN
guanethidine/NN reduced/VBN potentiated/VBD inhibited/VBD enlargement/NN pulse/NN
guanethidine/NN reduced/VBN potentiated/VBD inhibited/VBD pressure/NN
propranolol/JJ i/FW v/VBP i/FW inhibited/VBD enlargement/NN
propranolol/JJ i/FW v/VBP i/FW inhibited/VBD enlargement/NN pulse/NN of/IN
propranolol/JJ i/FW v/VBP i/FW inhibited/VBD enlargement/NN pulse/NN
propranolol/JJ i/FW v/VBP i/FW inhibited/VBD pressure/NN
phentolamine/NN guanethidine/NN reduced/VBN potentiated/VBD inhibited/VBD enlargement/NN
phentolamine/NN guanethidine/NN reduced/VBN potentiated/VBD inhibited/VBD enlargement/NN pulse/NN of/IN
phentolamine/NN guanethidine/NN reduced/VBN potentiated/VBD inhibited/VBD enlargement/NN pulse/NN
phentolamine/NN guanethidine/NN reduced/VBN potentiated/VBD inhibited/VBD pressure/NN
phentolamine/NN guanethidine/NN reduced/VBN potentiated/VBD inhibited/VBD pressure/NN tachycardia/NN
guanethidine/NN reduced/VBN potentiated/VBD inhibited/VBD pressure/NN tachycardia/NN
propranolol/JJ i/FW v/VBP i/FW inhibited/VBD pressure/NN tachycardia/NN
hexamethonium/NN guanethidine/NN reduced/VBN potentiated/VBD inhibited/VBD pressure/NN tachycardia/NN
hexamethonium/NN guanethidine/NN reduced/VBN potentiated/VBD inhibited/VBD enlargement/NN
hexamethonium/NN guanethidine/NN reduced/VBN potentiated/VBD inhibited/VBD enlargement/NN pulse/NN of/IN
hexamethonium/NN guanethidine/NN reduced/VBN potentiated/VBD inhibited/VBD enlargement/NN pulse/NN
hexamethonium/NN guanethidine/NN reduced/VBN potentiated/VBD inhibited/VBD pressure/NN
desmethylimipramine/JJ mg/NN i/FW inhibited/VBD pressure/NN tachycardia/NN
sirolimus/JJ cyclosporine/NN Conversion/NNP induced/VBN nephropathy/RB
sirolimus/NNS A/NN conversion/NN Protocols/NNS used/VBN prevent/VB CsA/NNP induced/VBN nephropathy/RB
SRL/NNP sirolimus/NNS A/NN conversion/NN Protocols/NNS used/VBN prevent/VB CsA/NNP induced/VBN nephropathy/RB
hematoxylin/NN analyzed/VBN lesions/NNS Renal/JJ
hematoxylin/NN analyzed/VBN lesions/NNS
eosin/NN hematoxylin/NN analyzed/VBN lesions/NNS Renal/JJ
eosin/NN hematoxylin/NN analyzed/VBN lesions/NNS
SRL/NNP treated/VBN rats/NNS presented/VBN markers/NNS impairment/NN renal/JJ
SRL/NNP treated/VBN rats/NNS presented/VBN markers/NNS impairment/NN
SRL/NNP Conversion/NNP prevented/VBD CsA/NNP induced/VBN evolution/NN renal/JJ
SRL/NNP Conversion/NNP prevented/VBD CsA/NNP induced/VBN evolution/NN damage/NN
SRL/NNP biomarker/NN seems/VBZ induced/VBN evolution/NN renal/JJ
SRL/NNP biomarker/NN seems/VBZ induced/VBN evolution/NN damage/NN
triglycerides/NN decrease/NN hepatomegaly/NN
glucose/NN triglycerides/NN decrease/NN hepatomegaly/NN
amiodarone/NN mice/NNS resulted/VBD rate/NN extent/NN loss/NN weight/NN
amiodarone/NN mice/NNS resulted/VBD rate/NN extent/NN loss/NN
amiodarone/JJ cells/NNS hepatoma/JJ
amiodarone/NN effects/NNS indirect/JJ indicates/VBZ inability/NN cells/NNS hepatoma/JJ
ecstasy/RB explained/VBN manifested/VBD deficit/NN
ecstasy/RB explained/VBN manifested/VBD deficit/NN accuracy/NN in/IN
ecstasy/RB explained/VBN manifested/VBD deficit/NN accuracy/NN fear/NN
ecstasy/RB explained/VBN manifested/VBD deficit/NN accuracy/NN recognition/NN
dexamphetamine/NN trazodone/NN effect/NN METHODS/NNP induced/VBN stereotypies/NNS oral/JJ
dexamphetamine/NN trazodone/NN effect/NN METHODS/NNP induced/VBN stereotypies/NNS
ergometrine/JJ haloperidol/JJ behavior/NN induced/VBN catalepsy/NN
apomorphine/NN dexamphetamine/NN trazodone/NN effect/NN METHODS/NNP induced/VBN stereotypies/NNS oral/JJ
apomorphine/NN dexamphetamine/NN trazodone/NN effect/NN METHODS/NNP induced/VBN stereotypies/NNS
apomorphine/JJ haloperidol/JJ behavior/NN induced/VBN catalepsy/NN induced/VBN stereotypies/NNS oral/JJ
apomorphine/JJ haloperidol/JJ behavior/NN induced/VBN catalepsy/NN induced/VBN stereotypies/NNS
trazodone/NN effect/NN METHODS/NNP induced/VBN catalepsy/NN
haloperidol/JJ behavior/NN induced/VBN catalepsy/NN induced/VBN stereotypies/NNS oral/JJ
haloperidol/JJ behavior/NN induced/VBN catalepsy/NN induced/VBN stereotypies/NNS
fluoxetine/NN METHODS/NNP induced/VBN catalepsy/NN
ergometrine/JJ haloperidol/JJ behavior/NN induced/VBN catalepsy/NN induced/VBN stereotypies/NNS oral/JJ
ergometrine/JJ haloperidol/JJ behavior/NN induced/VBN catalepsy/NN induced/VBN stereotypies/NNS
fluoxetine/NN METHODS/NNP induced/VBN stereotypies/NNS oral/JJ
fluoxetine/NN METHODS/NNP induced/VBN stereotypies/NNS
dexamphetamine/NN trazodone/NN effect/NN METHODS/NNP induced/VBN catalepsy/NN
trazodone/NN effect/NN METHODS/NNP induced/VBN stereotypies/NNS oral/JJ
trazodone/NN effect/NN METHODS/NNP induced/VBN stereotypies/NNS
trazodone/NN induces/VBZ catalepsy/RB
Trazodone/NNP induce/VB catalepsy/RB
Trazodone/NNP induce/VB RESULTS/NNS induced/VBN catalepsy/RB
ergometrine/NN enhanced/VBN antagonized/VBN catalepsy/NN
trazodone/VBP enhanced/VBN antagonized/VBN catalepsy/NN
fluoxetine/NN behavior/NN ergometrine/NN enhanced/VBN antagonized/VBN catalepsy/NN
dexamphetamine/JJ enhanced/VBN antagonized/VBN catalepsy/NN
Trazodone/JJ mg/NN induced/VBN catalepsy/RB
dexamphetamine/JJ apomorphine/JJ stereotypies/NNS antagonized/VBN induced/VBN catalepsy/RB
5/CD blocking/VBG trazodone/NN releases/VBZ suggest/VBP dexamphetamine/VBP antagonizes/VBZ catalepsy/NN
HT/NNP receptors/NNP 5/CD blocking/VBG trazodone/NN releases/VBZ suggest/VBP dexamphetamine/VBP antagonizes/VBZ catalepsy/NN
5/CD caused/VBN inhibition/NN releases/VBZ suggest/VBP dexamphetamine/VBP antagonizes/VBZ catalepsy/NN
HT/RB releases/VBZ suggest/VBP dexamphetamine/VBP antagonizes/VBZ catalepsy/NN
trazodone/NN releases/VBZ suggest/VBP dexamphetamine/VBP antagonizes/VBZ catalepsy/NN
dexamphetamine/VBP antagonizes/VBZ catalepsy/NN
dexamethasone/NN mice/NNS Treatment/NNP led/VBD elevation/NN pressure/NN loss/NN cells/NNS retinal/JJ
dexamethasone/NN mice/NNS Treatment/NNP led/VBD elevation/NN pressure/NN loss/NN cells/NNS ganglion/NN
sodium/NN TM/NNP induced/VBN hypertension/NN ocular/NN
sodium/NN TM/NNP induced/VBN hypertension/NN
4/CD sodium/NN TM/NNP induced/VBN hypertension/NN ocular/NN
4/CD sodium/NN TM/NNP induced/VBN hypertension/NN
phenylbutyrate/NN TM/NNP induced/VBN hypertension/NN ocular/NN
phenylbutyrate/NN TM/NNP induced/VBN hypertension/NN
levodopa/JJ effects/NNS Parkinson/NNP
levodopa/JJ effects/NNS Parkinson/NNP '/POS
levodopa/JJ effects/NNS gene/NN variants/NNS Association/NNP patients/NNS s/VBZ
levodopa/JJ effects/NNS gene/NN variants/NNS Association/NNP patients/NNS disease/NN
Levodopa/NNP therapy/NN disease/NN Parkinson/NNP
Levodopa/NNP therapy/NN disease/NN Parkinson/NNP '/POS
Levodopa/NNP therapy/NN disease/NN s/JJ
Levodopa/NNP therapy/NN disease/NN
doxorubicin/NN induced/VBN cardiotoxicity/RB
doxorubicin/NN model/NN utilized/VBN provide/VB underlying/VBG toxicity/NN
DOX/NNP doxorubicin/NN model/NN utilized/VBN provide/VB underlying/VBG toxicity/NN
gadolinium/NN correlated/VBD enhancement/NN dysfunction/NN diastolic/JJ
gadolinium/NN correlated/VBD enhancement/NN dysfunction/NN
nicergoline/JJ lysine/NN due/JJ occlusion/NN retinal/JJ
nicergoline/JJ lysine/NN due/JJ occlusion/NN vein/NN
nicergoline/JJ lysine/NN due/JJ occlusion/NN
bendazac/JJ nicergoline/JJ lysine/NN due/JJ occlusion/NN retinal/JJ
bendazac/JJ nicergoline/JJ lysine/NN due/JJ occlusion/NN vein/NN
bendazac/JJ nicergoline/JJ lysine/NN due/JJ occlusion/NN
lysine/NN due/JJ occlusion/NN retinal/JJ
lysine/NN due/JJ occlusion/NN vein/NN
lysine/NN due/JJ occlusion/NN
acetaminophen/NN 2004/CD undergone/VBN patients/NNS outcomes/NNS severity/NN LT/NN disease/NN chronic/JJ
acetaminophen/NN 2004/CD undergone/VBN patients/NNS outcomes/NNS severity/NN LT/NN disease/NN liver/NN
acetaminophen/NN 2004/CD undergone/VBN patients/NNS outcomes/NNS severity/NN LT/NN disease/NN
acetaminophen/NN 2004/CD undergone/VBN patients/NNS outcomes/NNS severity/NN LT/NN disease/NN CLD/NNP
acetaminophen/NN severity/NN LT/NN disease/NN chronic/JJ
acetaminophen/NN severity/NN LT/NN disease/NN liver/NN
acetaminophen/NN severity/NN LT/NN disease/NN
acetaminophen/NN severity/NN LT/NN disease/NN CLD/NNP
acetaminophen/VBZ had/VBD had/VBD LT/NNP non/NN 01/NNP 0/NNP 35/CD =/NNP CLD/NNP
acetaminophen/NNP 01/NNP 0/NNP 35/CD =/NNP CLD/NNP
acetaminophen/NNP ALF/NNP years/NNS CLD/NNP
acetaminophen/NN non/NN years/NNS CLD/NNP
acetaminophen/NN transplanted/VBD comparable/JJ CLD/NNP
acetaminophen/NN transplanted/NN comparable/JJ CLD/NNP
epinephrine/JJ infusion/NN required/VBD treat/VB hypotension/NN
d/SYM use/NN Efficacy/NN proarrhythmia/NN
l/NN d/SYM use/NN Efficacy/NN proarrhythmia/NN
sotalol/NN Efficacy/NN proarrhythmia/NN
d/SYM use/NN Efficacy/NN sotalol/NN tachyarrhythmias/NNS ventricular/NN
d/SYM use/NN Efficacy/NN sotalol/NN tachyarrhythmias/NNS
l/NN d/SYM use/NN Efficacy/NN sotalol/NN tachyarrhythmias/NNS ventricular/NN
l/NN d/SYM use/NN Efficacy/NN sotalol/NN tachyarrhythmias/NNS
sotalol/NN tachyarrhythmias/NNS ventricular/NN
sotalol/NN tachyarrhythmias/NNS
d/SYM treated/VBN patients/NNS pointes/NNS efficacy/NN evaluated/VBN study/NN sotalol/NN tachyarrhythmias/NNS ventricular/NN
d/SYM treated/VBN patients/NNS pointes/NNS efficacy/NN evaluated/VBN study/NN sotalol/NN tachyarrhythmias/NNS
l/NN d/SYM treated/VBN patients/NNS pointes/NNS efficacy/NN evaluated/VBN study/NN sotalol/NN tachyarrhythmias/NNS ventricular/NN
l/NN d/SYM treated/VBN patients/NNS pointes/NNS efficacy/NN evaluated/VBN study/NN sotalol/NN tachyarrhythmias/NNS
sotalol/NN tachyarrhythmias/NNS ventricular/NN
sotalol/NN tachyarrhythmias/NNS
d/NNS received/VBD sustained/VBD patients/NNS 54/CD disease/NN coronary/JJ
d/NNS received/VBD sustained/VBD patients/NNS 54/CD disease/NN artery/NN
d/NNS received/VBD sustained/VBD patients/NNS 54/CD disease/NN
l/CD d/NNS received/VBD sustained/VBD patients/NNS 54/CD disease/NN coronary/JJ
l/CD d/NNS received/VBD sustained/VBD patients/NNS 54/CD disease/NN artery/NN
l/CD d/NNS received/VBD sustained/VBD patients/NNS 54/CD disease/NN
sotalol/JJ l/CD d/NNS received/VBD sustained/VBD patients/NNS 54/CD disease/NN coronary/JJ
sotalol/JJ l/CD d/NNS received/VBD sustained/VBD patients/NNS 54/CD disease/NN artery/NN
sotalol/JJ l/CD d/NNS received/VBD sustained/VBD patients/NNS 54/CD disease/NN
d/NNS received/VBD sustained/VBD patients/NNS 54/CD 20/CD cardiomyopathy/NN dilated/JJ
d/NNS received/VBD sustained/VBD patients/NNS 54/CD 20/CD cardiomyopathy/NN
l/CD d/NNS received/VBD sustained/VBD patients/NNS 54/CD 20/CD cardiomyopathy/NN dilated/JJ
l/CD d/NNS received/VBD sustained/VBD patients/NNS 54/CD 20/CD cardiomyopathy/NN
sotalol/JJ l/CD d/NNS received/VBD sustained/VBD patients/NNS 54/CD 20/CD cardiomyopathy/NN dilated/JJ
sotalol/JJ l/CD d/NNS received/VBD sustained/VBD patients/NNS 54/CD 20/CD cardiomyopathy/NN
d/NNS received/VBD tachycardia/NN fibrillation/NNS ventricular/NN
d/NNS received/VBD tachycardia/NN fibrillation/NNS
l/CD d/NNS received/VBD tachycardia/NN fibrillation/NNS ventricular/NN
l/CD d/NNS received/VBD tachycardia/NN fibrillation/NNS
sotalol/JJ l/CD d/NNS received/VBD tachycardia/NN fibrillation/NNS ventricular/NN
sotalol/JJ l/CD d/NNS received/VBD tachycardia/NN fibrillation/NNS
d/NNS received/VBD tachycardia/NN ventricular/NN
d/NNS received/VBD tachycardia/NN
l/CD d/NNS received/VBD tachycardia/NN ventricular/NN
l/CD d/NNS received/VBD tachycardia/NN
sotalol/JJ l/CD d/NNS received/VBD tachycardia/NN ventricular/NN
sotalol/JJ l/CD d/NNS received/VBD tachycardia/NN
d/NNS l/CD sotalol/JJ prevent/VB induction/NN tachyarrhythmia/NN ventricular/NN
d/NNS l/CD sotalol/JJ prevent/VB induction/NN tachyarrhythmia/NN
l/CD sotalol/JJ prevent/VB induction/NN tachyarrhythmia/NN ventricular/NN
l/CD sotalol/JJ prevent/VB induction/NN tachyarrhythmia/NN
sotalol/JJ prevent/VB induction/NN tachyarrhythmia/NN ventricular/NN
sotalol/JJ prevent/VB induction/NN tachyarrhythmia/NN
d/NN prevented/VBD discharged/VBN induction/NN tachycardia/NN fibrillation/NNS ventricular/NN
d/NN prevented/VBD discharged/VBN induction/NN tachycardia/NN fibrillation/NNS
l/NN d/NN prevented/VBD discharged/VBN induction/NN tachycardia/NN fibrillation/NNS ventricular/NN
l/NN d/NN prevented/VBD discharged/VBN induction/NN tachycardia/NN fibrillation/NNS
sotalol/NN prevented/VBD discharged/VBN induction/NN tachycardia/NN fibrillation/NNS ventricular/NN
sotalol/NN prevented/VBD discharged/VBN induction/NN tachycardia/NN fibrillation/NNS
d/NN prevented/VBD discharged/VBN induction/NN tachycardia/NN ventricular/NN
d/NN prevented/VBD discharged/VBN induction/NN tachycardia/NN
l/NN d/NN prevented/VBD discharged/VBN induction/NN tachycardia/NN ventricular/NN
l/NN d/NN prevented/VBD discharged/VBN induction/NN tachycardia/NN
sotalol/NN prevented/VBD discharged/VBN induction/NN tachycardia/NN ventricular/NN
sotalol/NN prevented/VBD discharged/VBN induction/NN tachycardia/NN
d/JJ l/JJ patients/NNS prevented/VBN Induction/NNP tachyarrhythmia/NN ventricular/NN
d/JJ l/JJ patients/NNS prevented/VBN Induction/NNP tachyarrhythmia/NN
l/JJ patients/NNS prevented/VBN Induction/NNP tachyarrhythmia/NN ventricular/NN
l/JJ patients/NNS prevented/VBN Induction/NNP tachyarrhythmia/NN
sotalol/NN l/JJ patients/NNS prevented/VBN Induction/NNP tachyarrhythmia/NN ventricular/NN
sotalol/NN l/JJ patients/NNS prevented/VBN Induction/NNP tachyarrhythmia/NN
d/JJ l/JJ patients/NNS prevented/VBN remained/VBD tachyarrhythmia/NN ventricular/NN
d/JJ l/JJ patients/NNS prevented/VBN remained/VBD tachyarrhythmia/NN
l/JJ patients/NNS prevented/VBN remained/VBD tachyarrhythmia/NN ventricular/NN
l/JJ patients/NNS prevented/VBN remained/VBD tachyarrhythmia/NN
sotalol/NN l/JJ patients/NNS prevented/VBN remained/VBD tachyarrhythmia/NN ventricular/NN
sotalol/NN l/JJ patients/NNS prevented/VBN remained/VBD tachyarrhythmia/NN
d/SYM mg/NN tolerate/VB prevented/VBN Induction/NNP tachyarrhythmia/NN ventricular/NN
d/SYM mg/NN tolerate/VB prevented/VBN Induction/NNP tachyarrhythmia/NN
l/NN d/SYM mg/NN tolerate/VB prevented/VBN Induction/NNP tachyarrhythmia/NN ventricular/NN
l/NN d/SYM mg/NN tolerate/VB prevented/VBN Induction/NNP tachyarrhythmia/NN
sotalol/VB tolerate/VB prevented/VBN Induction/NNP tachyarrhythmia/NN ventricular/NN
sotalol/VB tolerate/VB prevented/VBN Induction/NNP tachyarrhythmia/NN
d/SYM mg/NN tolerate/VB prevented/VBN remained/VBD tachyarrhythmia/NN ventricular/NN
d/SYM mg/NN tolerate/VB prevented/VBN remained/VBD tachyarrhythmia/NN
l/NN d/SYM mg/NN tolerate/VB prevented/VBN remained/VBD tachyarrhythmia/NN ventricular/NN
l/NN d/SYM mg/NN tolerate/VB prevented/VBN remained/VBD tachyarrhythmia/NN
sotalol/VB tolerate/VB prevented/VBN remained/VBD tachyarrhythmia/NN ventricular/NN
sotalol/VB tolerate/VB prevented/VBN remained/VBD tachyarrhythmia/NN
d/SYM treatment/NN years/NNS had/VBD patient/NN disease/NN cardiac/JJ
d/SYM treatment/NN years/NNS had/VBD patient/NN disease/NN
l/NN d/SYM treatment/NN years/NNS had/VBD patient/NN disease/NN cardiac/JJ
l/NN d/SYM treatment/NN years/NNS had/VBD patient/NN disease/NN
sotalol/NN l/NN d/SYM treatment/NN years/NNS had/VBD patient/NN disease/NN cardiac/JJ
sotalol/NN l/NN d/SYM treatment/NN years/NNS had/VBD patient/NN disease/NN
citrate/NN anticoagulation/NN carries/VBZ risk/NN toxicity/NN
citrate/JJ toxicity/NN
citrate/JJ dialysate/NN anticoagulated/VBN transplantation/NN underwent/VBD AKI/NNP induced/VBN failure/NN fulminant/JJ
citrate/JJ dialysate/NN anticoagulated/VBN transplantation/NN underwent/VBD AKI/NNP induced/VBN failure/NN liver/NN
citrate/JJ dialysate/NN anticoagulated/VBN transplantation/NN underwent/VBD AKI/NNP induced/VBN failure/NN
citrate/JJ dialysate/NN anticoagulated/VBN transplantation/NN underwent/VBD AKI/NNP
citrate/JJ toxicity/NN
Citrate/JJ dialysate/NN alternative/NN support/NN transplantation/NN failure/NN fulminant/JJ
Citrate/JJ dialysate/NN alternative/NN support/NN transplantation/NN failure/NN liver/NN
Citrate/JJ dialysate/NN alternative/NN support/NN transplantation/NN failure/NN
steroid/JJ injection/NN neuropathy/VBD
steroid/JJ injection/NN occurred/VBD neuropathy/NN
steroid/JJ injection/NN occurred/VBD treat/VB epicondylitis/NNS lateral/JJ
steroid/JJ injection/NN occurred/VBD treat/VB epicondylitis/NNS
steroid/JJ injection/NN treatment/NN epicondylitis/NNS lateral/JJ
steroid/JJ injection/NN treatment/NN epicondylitis/NNS
dopamine/JJ levodopa/NN Administration/NNP enhances/VBZ learning/VBG subjects/NNS patients/NNS stroke/NN
levodopa/NN Administration/NNP enhances/VBZ learning/VBG subjects/NNS patients/NNS stroke/NN
dopamine/NN agonist/VBP word/NN impaired/JJ
dopamine/NN agonist/VBP word/NN novel/NN
dopamine/NN agonist/VBP word/NN
dopamine/NN agonist/VBP learning/VBG
dopamine/NN enhances/VBZ associative/NN learning/VBG subjects/NNS patients/NNS stroke/NN
dithiothreitol/NN affected/VBN sites/NNS mice/NNS seizure/JJ
quinine/JJ sulfate/NN cramps/NNS leg/NN
quinine/JJ sulfate/NN cramps/NNS
sulfate/NN cramps/NNS leg/NN
sulfate/NN cramps/NNS
quinine/JJ toxicity/NN
beclomethasone/NN placed/VBN patients/NNS asthmatic/JJ
beclomethasone/NN prednisone/NN use/NN increase/VB risk/NN developing/VBG hoarseness/NNS candidiasis/NNS
prednisone/NN use/NN increase/VB risk/NN developing/VBG hoarseness/NNS candidiasis/NNS
prednisone/NN use/NN increase/VB risk/NN developing/VBG hoarseness/NNS
methadone/JJ therapy/NN male/NN Rhabdomyolysis/NNS stroke/NN ischemic/JJ
methadone/JJ therapy/NN male/NN Rhabdomyolysis/NNS stroke/NN
heroin/NN stroke/NN ischemic/JJ
heroin/NN stroke/NN
heroin/NN presented/VBN rhabdomyolysis/NNS stroke/NN ischemic/JJ
heroin/NN presented/VBN rhabdomyolysis/NNS stroke/NN
methadone/NN using/VBG Those/DT CONCLUSION/NNP increase/VB risk/NN rhabdomyolysis/NNS stroke/NN ischemic/JJ
methadone/NN using/VBG Those/DT CONCLUSION/NNP increase/VB risk/NN rhabdomyolysis/NNS stroke/NN
heroin/NN methadone/NN using/VBG Those/DT CONCLUSION/NNP increase/VB risk/NN rhabdomyolysis/NNS stroke/NN ischemic/JJ
heroin/NN methadone/NN using/VBG Those/DT CONCLUSION/NNP increase/VB risk/NN rhabdomyolysis/NNS stroke/NN
tacrolimus/JJ ointment/NN dermatitis/VBZ treatment/NN dermatoses/NNS facial/JJ
tacrolimus/JJ ointment/NN dermatitis/VBZ treatment/NN dermatoses/NNS inflammatory/JJ
tacrolimus/JJ ointment/NN dermatitis/VBZ treatment/NN dermatoses/NNS
tacrolimus/JJ ointment/NN dermatitis/VBZ
steroid/JJ effective/JJ aggravated/VBN dermatitis/NNS rosacea/NN
steroid/JJ effective/JJ aggravated/VBN dermatitis/NNS rosacea/NN perioral/NN
steroid/JJ effective/JJ aggravated/VBN dermatitis/NNS
Tacrolimus/NNP ointment/NNP used/VBN indicate/VBP effective/JJ aggravated/VBN dermatitis/NNS rosacea/NN perioral/NN
Tacrolimus/NNP ointment/NNP used/VBN indicate/VBP effective/JJ aggravated/VBN dermatitis/NNS
tacrolimus/JJ ointment/NN report/VBP dermatitis/NNS
tacrolimus/JJ ointment/NN treated/VBN patients/NNS dermatoses/NNS inflammatory/JJ
tacrolimus/JJ ointment/NN treated/VBN patients/NNS dermatoses/NNS facial/JJ
tacrolimus/JJ ointment/NN treated/VBN patients/NNS dermatoses/NNS
tacrolimus/JJ ointment/NN treatment/NN complication/NN dermatitis/NNS
Ifosfamide/JJ encephalopathy/NN
Ifosfamide/NNP agent/NN useful/JJ treatment/NN range/NN cancers/NNS cancers/NNS sarcomas/NNS
Ifosfamide/NNP agent/NN useful/JJ treatment/NN range/NN cancers/NNS cancers/NNS sarcomas/NNS lymphoma/NN
Ifosfamide/NNP agent/NN useful/JJ treatment/NN range/NN cancers/NNS
Ifosfamide/NNP agent/NN useful/JJ treatment/NN range/NN cancers/NNS cancers/NNS sarcomas/NNS gynecologic/NN
Ifosfamide/NNP agent/NN useful/JJ treatment/NN range/NN cancers/NNS cancers/NNS sarcomas/NNS and/CC
Ifosfamide/NNP agent/NN useful/JJ treatment/NN range/NN cancers/NNS cancers/NNS sarcomas/NNS testicular/NN
Ifosfamide/NNP agent/NN useful/JJ treatment/NN range/NN cancers/NNS cancers/NNS
ifosfamide/VBP reported/VBN Encephalopathy/NNP
ifosfamide/JJ encephalopathy/NN
ifosfamide/JJ encephalopathy/NN developed/VBD patients/NNS admitted/VBN Center/NNP Cancer/NNP
ifosfamide/JJ encephalopathy/NN
ifosfamide/NN soon/RB encephalopathy/NN
ifosfamide/JJ correlates/NNS encephalopathy/NN
ifosfamide/NN develop/VBP features/NNS encephalopathy/NN
cyclophosphamide/NN toxicity/NN
CY/NNP toxicity/NNP
CY/NNP toxicity/NN
Procaterol/VB terbutaline/VB asthma/NN bronchial/JJ
Procaterol/VB terbutaline/VB asthma/NN
terbutaline/VB asthma/NN bronchial/JJ
terbutaline/VB asthma/NN
Procaterol/NNP cross/VBP patients/NNS asthma/NN bronchial/JJ
Procaterol/NNP cross/VBP patients/NNS asthma/NN
procaterol/NN effects/NNS asthmatic/JJ
anthraquinones/NNS containing/VBG slimming/VBG intake/NN associated/VBN failure/NN Acute/JJ
anthraquinones/NNS containing/VBG slimming/VBG intake/NN associated/VBN failure/NN renal/JJ
anthraquinones/NNS containing/VBG slimming/VBG intake/NN associated/VBN failure/NN
Chinese/JJ herbs/NNS caused/VBN Nephropathy/RB
herbs/NNS caused/VBN Nephropathy/RB
aristolochic/JJ acids/NNS use/NN caused/VBN Nephropathy/RB
acids/NNS use/NN caused/VBN Nephropathy/RB
anthraquinone/JJ derivatives/NNS contained/VBD pill/NN use/NN failure/NN acute/JJ
anthraquinone/JJ derivatives/NNS contained/VBD pill/NN use/NN failure/NN renal/JJ
anthraquinone/JJ derivatives/NNS contained/VBD pill/NN use/NN failure/NN
anthraquinone/NN use/NN containing/VBG agent/NN remains/NNS renal/JJ
anthraquinone/NN use/NN containing/VBG agent/NN remains/NNS injury/NN
anthraquinone/NN use/NN relationship/NN associated/JJ nephropathy/NN
anthraquinone/NN use/NN relationship/NN associated/JJ considered/VBN patients/NNS present/VBP failure/NN renal/JJ
anthraquinone/NN use/NN relationship/NN associated/JJ considered/VBN patients/NNS present/VBP failure/NN
methoxamine/NN Effect/NN incontinence/NN stress/NN
methoxamine/NN Effect/NN incontinence/NN
methoxamine/NN doses/NNS administered/VBN group/NN women/NNS incontinence/NN stress/NN
methoxamine/NN doses/NNS administered/VBN group/NN women/NNS incontinence/NN
propranolol/NN atenolol/NN tachycardia/NN
atenolol/NN tachycardia/NN
atropine/JJ mg/NN determined/VBN effects/NNS tachycardia/NN
Tranexamic/JJ overdosage/NN seizure/NN failure/NN renal/JJ
Tranexamic/JJ overdosage/NN seizure/NN failure/NN
acid/JJ overdosage/NN seizure/NN failure/NN renal/JJ
acid/JJ overdosage/NN seizure/NN failure/NN
Tranexamic/JJ overdosage/NN seizure/NN
acid/JJ overdosage/NN seizure/NN
Tranexamic/JJ acid/NN administered/VBN control/VB bleeding/NN
acid/NN administered/VBN control/VB bleeding/NN
TNA/NNP acid/NN administered/VBN control/VB bleeding/NN
TNA/NNP overdose/NN believed/VBN cause/NN convulsions/NNS
TNA/NNP overdose/NN
crack/NN cocaine/NN Smoking/NN infection/NN HIV/NN
crack/NN cocaine/NN Smoking/NN infection/NN
cocaine/NN Smoking/NN infection/NN HIV/NN
cocaine/NN Smoking/NN infection/NN
crack/NN cocaine/NN incidence/NN infection/NN HIV/NN
crack/NN cocaine/NN incidence/NN infection/NN
cocaine/NN incidence/NN infection/NN HIV/NN
cocaine/NN incidence/NN infection/NN
crack/NN cocaine/NN use/NN sought/VBD examine/VB become/VBN factor/NN infection/NN HIV/NN
crack/NN cocaine/NN use/NN sought/VBD examine/VB become/VBN factor/NN infection/NN
cocaine/NN use/NN sought/VBD examine/VB become/VBN factor/NN infection/NN HIV/NN
cocaine/NN use/NN sought/VBD examine/VB become/VBN factor/NN infection/NN
rocuronium/NN fasciculation/NN myalgia/NN
rocuronium/NN fasciculation/NN
rocuronium/NN dose/NN identified/VBN induced/VBN fasciculation/NN myalgia/NN
rocuronium/NN influence/NN evaluated/VBN identified/VBN induced/VBN fasciculation/NN myalgia/NN
rocuronium/NN dose/NN identified/VBN induced/VBN fasciculation/NN
rocuronium/NN influence/NN evaluated/VBN identified/VBN induced/VBN fasciculation/NN
rocuronium/NN dose/NN amount/NN increasing/VBG less/JJR incidence/NN fasciculation/NN muscle/NN
rocuronium/NN dose/NN amount/NN increasing/VBG less/JJR incidence/NN fasciculation/NN
rocuronium/NN dose/NN amount/NN increasing/VBG decrease/VB tend/VBP Those/DT myalgia/NN
rocuronium/NN dose/NN considering/VBG reduction/NN incidence/NN fasciculation/NN myalgia/NN
rocuronium/NN dose/NN considering/VBG reduction/NN incidence/NN fasciculation/NN
ribavirin/NNP contributing/VBG induced/VBN anemia/NN
Interferon/NNP produces/VBZ therapy/NN C/NNP chronic/JJ
Interferon/NNP produces/VBZ therapy/NN C/NNP hepatitis/NNP
Interferon/NNP produces/VBZ therapy/NN C/NNP
ribavirin/NNP Interferon/NNP produces/VBZ therapy/NN C/NNP chronic/JJ
ribavirin/NNP Interferon/NNP produces/VBZ therapy/NN C/NNP hepatitis/NNP
ribavirin/NNP Interferon/NNP produces/VBZ therapy/NN C/NNP
ribavirin/NNP contributing/VBG factors/NNS identify/VB conducted/VBN anemia/NN
interferon/JJ received/VBD C/NNP chronic/JJ
interferon/JJ received/VBD C/NNP hepatitis/NNP
interferon/JJ received/VBD C/NNP
alpha/NN interferon/JJ received/VBD C/NNP chronic/JJ
alpha/NN interferon/JJ received/VBD C/NNP hepatitis/NNP
alpha/NN interferon/JJ received/VBD C/NNP
2/LS b/SYM C/NNP chronic/JJ
2/LS b/SYM C/NNP hepatitis/NNP
2/LS b/SYM C/NNP
b/SYM C/NNP chronic/JJ
b/SYM C/NNP hepatitis/NNP
b/SYM C/NNP
ribavirin/NNP administered/VBN MU/NN dose/NN b/SYM C/NNP chronic/JJ
ribavirin/NNP administered/VBN MU/NN dose/NN b/SYM C/NNP hepatitis/NNP
ribavirin/NNP administered/VBN MU/NN dose/NN b/SYM C/NNP
ribavirin/NNP defined/VBN g/VBP anemia/NN
Ribavirin/NNP anemia/NN
thiol/JJ groups/NNS nephropathy/NN
sulfhydryl/JJ reagent/NN Chloroacetaldehyde/NNP role/NN groups/NNS nephropathy/NN
Chloroacetaldehyde/NNP role/NN groups/NNS nephropathy/NN
ifosfamide/NN anti/NNS therapy/NN tumor/NN
IFO/NNP ifosfamide/NN anti/NNS therapy/NN tumor/NN
IFO/NNP therapy/NN tumor/NN
Chloroacetaldehyde/NNP metabolite/NN ifosfamide/NN anti/NNS therapy/NN tumor/NN
CAA/NNP Chloroacetaldehyde/NNP metabolite/NN ifosfamide/NN anti/NNS therapy/NN tumor/NN
Chloroacetaldehyde/NNP metabolite/NN ifosfamide/NN anti/NNS responsible/JJ damage/NN renal/JJ
Chloroacetaldehyde/NNP metabolite/NN ifosfamide/NN anti/NNS responsible/JJ damage/NN
CAA/NNP Chloroacetaldehyde/NNP metabolite/NN ifosfamide/NN anti/NNS responsible/JJ damage/NN renal/JJ
CAA/NNP Chloroacetaldehyde/NNP metabolite/NN ifosfamide/NN anti/NNS responsible/JJ damage/NN
trypan/JJ exclusion/NN content/NN determined/VBN Toxicity/NNP
blue/JJ exclusion/NN content/NN determined/VBN Toxicity/NNP
CAA/NNP Toxicity/NNP
thiols/NNS loss/NN increase/NN markers/NNS necrosis/JJ
CAA/NNP reduced/VBD number/NN induced/VBN loss/NN increase/NN markers/NNS necrosis/JJ
thiol/JJ donors/NNS slowed/VBD Acidification/NNP attenuate/VB markers/NNS necrosis/JJ
thiol/JJ depletion/NN markers/NNS necrosis/JJ
CAA/NNP reaction/NN slowed/VBD Acidification/NNP attenuate/VB markers/NNS necrosis/JJ
CAA/NNP effects/NNS attenuate/VB markers/NNS necrosis/JJ
cysteine/JJ inhibition/NN depletion/NN markers/NNS necrosis/JJ
thiols/VBZ mediating/VBG toxicity/NN
CAA/NNP reacts/VBZ thiols/VBZ mediating/VBG toxicity/NN
lomustine/NN Tolerability/NNP cyclophosphamide/NN dogs/NNS lymphoma/NN
cyclophosphamide/NN dogs/NNS lymphoma/NN
lomustine/NN protocol/NN associated/VBN dogs/NNS lymphoma/NN
CCNU/NNP lomustine/NN protocol/NN associated/VBN dogs/NNS lymphoma/NN
cyclophosphamide/NN lomustine/NN protocol/NN associated/VBN toxicity/NN
CTX/NNP lomustine/NN protocol/NN associated/VBN toxicity/NN
lomustine/NN protocol/NN associated/VBN toxicity/NN
CCNU/NNP lomustine/NN protocol/NN associated/VBN toxicity/NN
cyclophosphamide/NN lomustine/NN protocol/NN associated/VBN dogs/NNS lymphoma/NN
CTX/NNP lomustine/NN protocol/NN associated/VBN dogs/NNS lymphoma/NN
CTX/NNP m/NN tolerable/JJ tumor/NN
CCNU/NNP m/NN combined/VBN mg/NN bearing/VBG tolerable/JJ tumor/NN
bile/NN neutral/JJ synthesis/NN inhibition/NN associated/VBN cholestasis/NNS intrahepatic/JJ
bile/NN neutral/JJ synthesis/NN inhibition/NN associated/VBN cholestasis/NNS
salt/NN synthesis/NN inhibition/NN associated/VBN cholestasis/NNS intrahepatic/JJ
salt/NN synthesis/NN inhibition/NN associated/VBN cholestasis/NNS
BS/NNP synthesis/NN inhibition/NN associated/VBN cholestasis/NNS intrahepatic/JJ
BS/NNP synthesis/NN inhibition/NN associated/VBN cholestasis/NNS
Gemfibrozil/NNP therapy/NN hyperlipoproteinemias/NNS
lovastatin/NN therapy/NN hyperlipoproteinemias/NNS
lovastatin/NN treatment/NN patients/NNS hyperlipidemia/NN
gemfibrozil/NN label/NN safety/NN treatment/NN patients/NNS hyperlipidemia/NN
lovastatin/NN treatment/NN safety/NN %/NN had/VBD disease/NN atherosclerotic/JJ
lovastatin/NN treatment/NN safety/NN %/NN had/VBD disease/NN vascular/NN
lovastatin/NN treatment/NN safety/NN %/NN had/VBD disease/NN
gemfibrozil/NN label/NN safety/NN %/NN had/VBD disease/NN atherosclerotic/JJ
gemfibrozil/NN label/NN safety/NN %/NN had/VBD disease/NN vascular/NN
gemfibrozil/NN label/NN safety/NN %/NN had/VBD disease/NN
creatine/JJ phosphokinase/NN occurred/VBD Myositis/NNS
creatine/JJ phosphokinase/NN occurred/VBD had/VBD rhabdomyolysis/NNS
creatine/JJ phosphokinase/NN occurred/VBD had/VBD rhabdomyolysis/NNS ABSTRACT/NNP myoglobinuria/NNP
CCK/NNP induced/VBN decreases/NNS amnesia/JJ
8/CD morphine/NN CCK/NNP induced/VBN decreases/NNS amnesia/JJ
morphine/NN effect/NN attenuates/VBZ 8/CD CCK/NNP induced/VBN impairment/NN memory/NN
morphine/NN effect/NN attenuates/VBZ 8/CD CCK/NNP induced/VBN impairment/NN
morphine/NN 8/CD 8/CD CCK/NNP induced/VBN impairment/NN memory/NN
morphine/NN 8/CD 8/CD CCK/NNP induced/VBN impairment/NN
CCK/NNP induced/VBN impairment/NN memory/NN
CCK/NNP induced/VBN impairment/NN
8/CD CCK/NNP induced/VBN impairment/NN memory/NN
8/CD CCK/NNP induced/VBN impairment/NN
CCK/NNP function/NN suggest/VBP attenuates/VBZ 8/CD CCK/NNP induced/VBN impairment/NN memory/NN
CCK/NNP function/NN suggest/VBP attenuates/VBZ 8/CD CCK/NNP induced/VBN impairment/NN
8/CD 8/CD CCK/NNP induced/VBN impairment/NN memory/NN
8/CD 8/CD CCK/NNP induced/VBN impairment/NN
propylthiouracil/NN carbimazole/NN prescribed/VBN treatment/NN hyperthyroidism/NN
PTU/NNP carbimazole/NN prescribed/VBN treatment/NN hyperthyroidism/NN
Anti/NNP drugs/NNS prescribed/VBN treatment/NN hyperthyroidism/NN
thyroid/NN drugs/NNS prescribed/VBN treatment/NN hyperthyroidism/NN
drugs/NNS prescribed/VBN treatment/NN hyperthyroidism/NN
carbimazole/NN prescribed/VBN treatment/NN hyperthyroidism/NN
carbimazole/NN developed/VBD patient/NN disease/NN Graves/NNP
carbimazole/NN developed/VBD patient/NN disease/NN Graves/NNP '/POS
carbimazole/NN developed/VBD patient/NN disease/NN
carbimazole/NN induced/VBN vasculitis/NNS
carbimazole/NN induced/VBN case/NN vasculitis/JJ
misoprostol/NN effect/NN dose/NN dysfunction/NN cirrhosis/NNS
misoprostol/NN effect/NN dose/NN dysfunction/NN renal/JJ
misoprostol/NN effect/NN dose/NN dysfunction/NN
indomethacin/NN misoprostol/NN effect/NN dose/NN dysfunction/NN cirrhosis/NNS
Misoprostol/NNP shown/VBN counteract/VB indomethacin/NN induced/VBN patients/NNS cirrhotic/JJ
Misoprostol/NNP shown/VBN counteract/VB indomethacin/NN induced/VBN dysfunction/NN renal/JJ
Misoprostol/NNP shown/VBN counteract/VB indomethacin/NN induced/VBN dysfunction/NN
indomethacin/NN induced/VBN patients/NNS cirrhotic/JJ
misoprostol/NN doses/NNS mg/NN combination/NN assessed/VBN techniques/NNS patients/NNS cirrhotic/JJ
indomethacin/NN mg/NN combination/NN assessed/VBN techniques/NNS patients/NNS cirrhotic/JJ
sodium/NN hemodynamics/NNS Parameters/NNS assessed/VBN techniques/NNS patients/NNS cirrhotic/JJ
misoprostol/NN micrograms/NNS ability/NN confirmed/VBN prudent/JJ avoid/VB cirrhosis/NNS
indomethacin/NN effects/NNS prevent/VB micrograms/NNS ability/NN confirmed/VBN prudent/JJ avoid/VB cirrhosis/NNS
oxygen/NN consumption/NN pressure/NN accompanied/VBN Hypotension/NNP
oxygen/NN difference/NN pressure/NN observed/VBN hypotension/NN
doxorubicin/NN study/NN squamous/VBZ
doxorubicin/NN study/NN squamous/VBZ carcinoma/NN cell/NN
doxorubicin/NN study/NN squamous/VBZ carcinoma/NN
doxorubicin/NN study/NN squamous/VBZ carcinoma/NN cervix/NN of/IN
doxorubicin/NN study/NN squamous/VBZ carcinoma/NN cervix/NN the/DT
doxorubicin/NN study/NN squamous/VBZ carcinoma/NN cervix/NN
carboplatin/NN doxorubicin/NN study/NN squamous/VBZ
carboplatin/NN doxorubicin/NN study/NN squamous/VBZ carcinoma/NN cell/NN
carboplatin/NN doxorubicin/NN study/NN squamous/VBZ carcinoma/NN
carboplatin/NN doxorubicin/NN study/NN squamous/VBZ carcinoma/NN cervix/NN of/IN
carboplatin/NN doxorubicin/NN study/NN squamous/VBZ carcinoma/NN cervix/NN the/DT
carboplatin/NN doxorubicin/NN study/NN squamous/VBZ carcinoma/NN cervix/NN
doxorubicin/NN combination/NN activity/NN tested/VBN study/NN patients/NNS carcinoma/NN cervical/JJ
doxorubicin/NN combination/NN activity/NN tested/VBN study/NN patients/NNS carcinoma/NN
carboplatin/NN doxorubicin/NN combination/NN activity/NN tested/VBN study/NN patients/NNS carcinoma/NN cervical/JJ
carboplatin/NN doxorubicin/NN combination/NN activity/NN tested/VBN study/NN patients/NNS carcinoma/NN
carboplatin/NN combination/NN METHODS/NNS administered/VBN determine/VB activity/NN profile/NN toxicity/NN
doxorubicin/NN combination/NN METHODS/NNS administered/VBN carcinoma/NNS squamous/NN
doxorubicin/NN combination/NN METHODS/NNS administered/VBN carcinoma/NNS cell/NN
doxorubicin/NN combination/NN METHODS/NNS administered/VBN carcinoma/NNS cervical/JJ
doxorubicin/NN combination/NN METHODS/NNS administered/VBN carcinoma/NNS
Doxil/NNP doxorubicin/NN combination/NN METHODS/NNS administered/VBN carcinoma/NNS squamous/NN
Doxil/NNP doxorubicin/NN combination/NN METHODS/NNS administered/VBN carcinoma/NNS cell/NN
Doxil/NNP doxorubicin/NN combination/NN METHODS/NNS administered/VBN carcinoma/NNS cervical/JJ
Doxil/NNP doxorubicin/NN combination/NN METHODS/NNS administered/VBN carcinoma/NNS
doxorubicin/NN combination/NN METHODS/NNS administered/VBN determine/VB activity/NN profile/NN toxicity/NN
Doxil/NNP doxorubicin/NN combination/NN METHODS/NNS administered/VBN determine/VB activity/NN profile/NN toxicity/NN
carboplatin/NN combination/NN METHODS/NNS administered/VBN carcinoma/NNS squamous/NN
carboplatin/NN combination/NN METHODS/NNS administered/VBN carcinoma/NNS cell/NN
carboplatin/NN combination/NN METHODS/NNS administered/VBN carcinoma/NNS cervical/JJ
carboplatin/NN combination/NN METHODS/NNS administered/VBN carcinoma/NNS
doxorubicin/NN combination/NN has/VBZ activity/NN patients/NNS carcinoma/NN cervical/JJ
doxorubicin/NN combination/NN has/VBZ activity/NN patients/NNS carcinoma/NN
carboplatin/NN doxorubicin/NN combination/NN has/VBZ activity/NN patients/NNS carcinoma/NN cervical/JJ
carboplatin/NN doxorubicin/NN combination/NN has/VBZ activity/NN patients/NNS carcinoma/NN
Sulfadiazine/NNP acute/NNP reviving/VBG use/NN toxoplasmosis/NNS
sulfadiazine/NN treatment/NN developed/VBD failure/NN renal/JJ
sulfadiazine/NN treatment/NN developed/VBD failure/NN
sulfadiazine/NN treatment/NN developed/VBD failure/NN abdominal/JJ
sulfadiazine/NN treatment/NN developed/VBD failure/NN pain/NN
sulfadiazine/NN treatment/NN developed/VBD failure/NN oliguria/NN
Glibenclamide/NNP hypotension/NN
glibenclamide/NN attenuated/VBN Hypotension/NNP
K/NNP channels/NNS activation/NN attributable/JJ hypotension/NN
K/NNP channels/NNS activation/NN attributable/JJ hypotension/NN
glibenclamide/NN activation/NN attributable/JJ hypotension/NN
ATP/NNP K/NNP channels/NNS activation/NN attributable/JJ hypotension/NN
nitric/JJ oxide/NN seem/VB produced/VBD hypotension/NN
oxide/NN seem/VB produced/VBD hypotension/NN
Mesna/NNP reduces/VBZ s/VBZ genotoxicity/RB
IFO/NNP s/VBZ genotoxicity/RB
everolimus/NNS Efficacy/NNP patients/NNS NSCLC/NN
RAD/NNP Efficacy/NNP patients/NNS NSCLC/NN
001/CD RAD/NNP Efficacy/NNP patients/NNS NSCLC/NN
RAD/NNP shown/VBN phase/VB NSCLC/NNP
001/CD RAD/NNP shown/VBN phase/VB NSCLC/NNP
rapamycin/NN target/NN inhibitor/NN RAD/NNP shown/VBN phase/VB NSCLC/NNP
tyrosine/JJ inhibitors/NNS received/VBN day/NN toxicity/NN
platinum/NN IIIb/NNP inhibitors/NNS received/VBN day/NN toxicity/NN
RAD/NNP received/VBN inhibitors/NNS IIIb/NNP patients/NNS NSCLC/NNP
001/CD RAD/NNP received/VBN inhibitors/NNS IIIb/NNP patients/NNS NSCLC/NNP
platinum/NN IIIb/NNP patients/NNS NSCLC/NNP
RAD/NNP received/VBN day/NN toxicity/NN
001/CD RAD/NNP received/VBN day/NN toxicity/NN
tyrosine/JJ inhibitors/NNS IIIb/NNP patients/NNS NSCLC/NNP
RAD/NNP CONCLUSIONS/NNS tolerated/JJ showing/VBG NSCLC/NN
001/CD 10/CD mg/NN RAD/NNP CONCLUSIONS/NNS tolerated/JJ showing/VBG NSCLC/NN
RAD/NNP Evaluation/NNP therapy/NN NSCLC/NN
001/CD RAD/NNP Evaluation/NNP therapy/NN NSCLC/NN
Streptozotocin/NNP events/NNS neurotoxicity/NN
Streptozotocin/NNP activation/NN toxicity/NN
STZ/NNP role/NN activation/NN toxicity/NN
nitrite/JJ Ca/JJ level/NN increased/VBD reduced/VBD preparation/NN illustrating/VBG generation/NN excitotoxicity/NN
STZ/NNP increased/VBD reduced/VBD preparation/NN illustrating/VBG generation/NN excitotoxicity/NN
Ca/JJ level/NN increased/VBD reduced/VBD preparation/NN illustrating/VBG generation/NN excitotoxicity/NN
STZ/NNP treatment/NN showed/VBD remains/VBZ indicating/VBG neurotoxicity/RB
STZ/NNP induced/NNP glial/VBP death/NN neurotoxicity/NN
Memantine/NNP treatment/NN attenuated/VBD glial/VBP death/NN neurotoxicity/NN
Ibuprofen/NNP Memantine/NNP treatment/NN attenuated/VBD glial/VBP death/NN neurotoxicity/NN
STZ/NNP impairment/NN factors/NNS activation/NN neurotoxicity/NN
propranolol/NN Use/NN treatment/NN hypotension/NN idiopathic/JJ
propranolol/NN Use/NN treatment/NN hypotension/NN orthostatic/JJ
propranolol/NN Use/NN treatment/NN hypotension/NN
norepinephrine/NN effects/NNS marked/VBN hypersensitivity/RB
catecholamines/NNS reduced/VBD marked/VBN hypersensitivity/RB
propranolol/NN drug/NN patients/NNS hypotension/NN idiopathic/JJ
propranolol/NN drug/NN patients/NNS hypotension/NN orthostatic/JJ
propranolol/NN drug/NN patients/NNS hypotension/NN
pilocarpine/NN caused/VBN maneuver/NN hyperventilation/NN
sodium/NN hypotension/NNP
MPTP/NNP model/NN disease/NN Parkinson/NNP
MPTP/NNP model/NN disease/NN Parkinson/NNP '/POS
MPTP/NNP model/NN disease/NN s/JJ
MPTP/NNP model/NN disease/NN
levodopa/NN lesioned/VBD used/VBN model/NN symptoms/NNS neuropsychiatric/JJ
levodopa/NN lesioned/VBD used/VBN model/NN symptoms/NNS
levodopa/NN lesioned/VBD used/VBN model/NN symptoms/NNS patients/NNS PD/NNP
MPTP/NNP treated/VBN levodopa/NN lesioned/VBD used/VBN model/NN symptoms/NNS neuropsychiatric/JJ
MPTP/NNP treated/VBN levodopa/NN lesioned/VBD used/VBN model/NN symptoms/NNS
MPTP/NNP treated/VBN levodopa/NN lesioned/VBD used/VBN model/NN symptoms/NNS patients/NNS PD/NNP
levodopa/NN course/NN induced/VBN neuropsychiatric/JJ
levodopa/NN course/NN induced/VBN determine/VB like/IN
levodopa/NN course/NN induced/VBN determine/VB behaviors/NNS
1/CD administered/VBN methyl/NN tetrahydropyridine/VBN resulting/VBG parkinsonism/NN
methyl/NN tetrahydropyridine/VBN resulting/VBG parkinsonism/NN
4/CD methyl/NN tetrahydropyridine/VBN resulting/VBG parkinsonism/NN
phenyl/NNP -/NNP 4/CD methyl/NN tetrahydropyridine/VBN resulting/VBG parkinsonism/NN
-/NNP 4/CD methyl/NN tetrahydropyridine/VBN resulting/VBG parkinsonism/NN
1/CD -/NNP 4/CD methyl/NN tetrahydropyridine/VBN resulting/VBG parkinsonism/NN
2/CD -/NNP 4/CD methyl/NN tetrahydropyridine/VBN resulting/VBG parkinsonism/NN
3/CD -/NNP 4/CD methyl/NN tetrahydropyridine/VBN resulting/VBG parkinsonism/NN
6/CD -/NNP 4/CD methyl/NN tetrahydropyridine/VBN resulting/VBG parkinsonism/NN
tetrahydropyridine/VBN resulting/VBG parkinsonism/NN
levodopa/NN prior/RB neuropsychiatric/JJ
levodopa/NN prior/RB neuropsychiatric/JJ behaviors/NNS like/IN
levodopa/NN prior/RB neuropsychiatric/JJ behaviors/NNS
levodopa/NN prior/RB neuropsychiatric/JJ evaluated/JJ time/NN disability/NN parkinsonian/NN
levodopa/NN prior/RB neuropsychiatric/JJ evaluated/JJ time/NN disability/NN
levodopa/NN induced/VBN neuropsychiatric/JJ
levodopa/NN like/VBP
levodopa/NN like/VBP present/JJ behaviors/NNS
levodopa/NN treatment/NN Day/NNP present/JJ like/VBP levodopa/NN induced/VBN neuropsychiatric/JJ
levodopa/NN treatment/NN Day/NNP present/JJ like/VBP
levodopa/NN treatment/NN Day/NNP present/JJ behaviors/NNS
levodopa/NN interaction/NN disorders/NNS neuropsychiatric/JJ
levodopa/NN interaction/NN disorders/NNS
levodopa/NN interaction/NN disorders/NNS PD/NNP
tobramycin/NN combined/VBD infections/NNS
tobramycin/NN combined/VBD infections/NNS patients/NNS cancer/NN
carbenicillin/NN combined/VBD infections/NNS
carbenicillin/NN combined/VBD infections/NNS patients/NNS cancer/NN
tobramycin/NN given/VBN overcome/VB effects/NNS neutropenia/NN
carbenicillin/NN combined/VBN given/VBN overcome/VB effects/NNS neutropenia/NN
creatinine/NN serum/NN greater/JJR mg/NN dl/NN azotemia/NN
doxorubicin/NN cardiomyopathy/NN repair/NN cardiomyopathy/NN disease/NN congenital/JJ
doxorubicin/NN cardiomyopathy/NN repair/NN cardiomyopathy/NN disease/NN heart/NN
doxorubicin/NN cardiomyopathy/NN repair/NN cardiomyopathy/NN disease/NN
doxorubicin/NN cardiomyopathy/NN repair/NN cardiomyopathy/NN hypertrophic/JJ
doxorubicin/NN cardiomyopathy/NN repair/NN cardiomyopathy/NN
doxorubicin/NN cardiomyopathy/NN repair/NN disease/NN valvular/NN
doxorubicin/NN cardiomyopathy/NN repair/NN disease/NN heart/NN
doxorubicin/NN cardiomyopathy/NN repair/NN disease/NN
doxorubicin/NN cardiomyopathy/NN repair/NN cardiomyopathy/NN idiopathic/JJ
doxorubicin/NN cardiomyopathy/NN repair/NN cardiomyopathy/NN
ganciclovir/NN treated/VBN infections/NNS Cytomegalovirus/JJ
ganciclovir/NN treated/VBN infections/NNS
6/CD vulnerability/NN dyskinesias/NNS
hydroxydopamine/JJ lesion/NN vulnerability/NN dyskinesias/NNS
L/NNP Treatment/NNP benserazide/NNP resulted/VBN dyskinesias/NNS
DOPA/NNP benserazide/NNP resulted/VBN dyskinesias/NNS
+/NNP benserazide/NNP resulted/VBN dyskinesias/NNS
benserazide/NNP resulted/VBN dyskinesias/NNS
DA/NNP lesion/NNP impairment/NN severity/NN increased/VBD reduced/VBD dyskinesias/NNS
CM/NNP toxicity/NNP
all/DT complications/NNS leukemia/NN acute/JJ
all/DT complications/NNS leukemia/NN promyelocytic/JJ
all/DT complications/NNS leukemia/NN
trans/NNS complications/NNS leukemia/NN acute/JJ
trans/NNS complications/NNS leukemia/NN promyelocytic/JJ
trans/NNS complications/NNS leukemia/NN
retinoic/JJ therapy/NN trans/NNS complications/NNS leukemia/NN acute/JJ
retinoic/JJ therapy/NN trans/NNS complications/NNS leukemia/NN promyelocytic/JJ
retinoic/JJ therapy/NN trans/NNS complications/NNS leukemia/NN
acid/JJ therapy/NN trans/NNS complications/NNS leukemia/NN acute/JJ
acid/JJ therapy/NN trans/NNS complications/NNS leukemia/NN promyelocytic/JJ
acid/JJ therapy/NN trans/NNS complications/NNS leukemia/NN
all/DT treated/VBN occlusion/NN vessels/NNS leukemia/NN patient/JJ acute/JJ
all/DT treated/VBN occlusion/NN vessels/NNS leukemia/NN promyelocytic/JJ
all/DT treated/VBN occlusion/NN vessels/NNS leukemia/NN
trans/NNS all/DT treated/VBN occlusion/NN vessels/NNS leukemia/NN patient/JJ acute/JJ
trans/NNS all/DT treated/VBN occlusion/NN vessels/NNS leukemia/NN promyelocytic/JJ
trans/NNS all/DT treated/VBN occlusion/NN vessels/NNS leukemia/NN
retinoic/JJ acid/NN all/DT treated/VBN occlusion/NN vessels/NNS leukemia/NN patient/JJ acute/JJ
retinoic/JJ acid/NN all/DT treated/VBN occlusion/NN vessels/NNS leukemia/NN promyelocytic/JJ
retinoic/JJ acid/NN all/DT treated/VBN occlusion/NN vessels/NNS leukemia/NN
acid/NN all/DT treated/VBN occlusion/NN vessels/NNS leukemia/NN patient/JJ acute/JJ
acid/NN all/DT treated/VBN occlusion/NN vessels/NNS leukemia/NN promyelocytic/JJ
acid/NN all/DT treated/VBN occlusion/NN vessels/NNS leukemia/NN
all/DT treated/VBN occlusion/NN vessels/NNS leukemia/NN APL/NNP
trans/NNS all/DT treated/VBN occlusion/NN vessels/NNS leukemia/NN APL/NNP
retinoic/JJ acid/NN all/DT treated/VBN occlusion/NN vessels/NNS leukemia/NN APL/NNP
acid/NN all/DT treated/VBN occlusion/NN vessels/NNS leukemia/NN APL/NNP
ATRA/NNP acid/NN all/DT treated/VBN occlusion/NN vessels/NNS leukemia/NN patient/JJ acute/JJ
ATRA/NNP acid/NN all/DT treated/VBN occlusion/NN vessels/NNS leukemia/NN promyelocytic/JJ
ATRA/NNP acid/NN all/DT treated/VBN occlusion/NN vessels/NNS leukemia/NN
ATRA/NNP acid/NN all/DT treated/VBN occlusion/NN vessels/NNS leukemia/NN APL/NNP
all/DT treated/VBN occlusion/NN
all/DT treated/VBN occlusion/NN vessels/NNS of/IN
all/DT treated/VBN occlusion/NN vessels/NNS renal/JJ
all/DT treated/VBN occlusion/NN vessels/NNS
trans/NNS all/DT treated/VBN occlusion/NN
trans/NNS all/DT treated/VBN occlusion/NN vessels/NNS of/IN
trans/NNS all/DT treated/VBN occlusion/NN vessels/NNS renal/JJ
trans/NNS all/DT treated/VBN occlusion/NN vessels/NNS
retinoic/JJ acid/NN all/DT treated/VBN occlusion/NN
retinoic/JJ acid/NN all/DT treated/VBN occlusion/NN vessels/NNS of/IN
retinoic/JJ acid/NN all/DT treated/VBN occlusion/NN vessels/NNS renal/JJ
retinoic/JJ acid/NN all/DT treated/VBN occlusion/NN vessels/NNS
acid/NN all/DT treated/VBN occlusion/NN
acid/NN all/DT treated/VBN occlusion/NN vessels/NNS of/IN
acid/NN all/DT treated/VBN occlusion/NN vessels/NNS renal/JJ
acid/NN all/DT treated/VBN occlusion/NN vessels/NNS
ATRA/NNP acid/NN all/DT treated/VBN occlusion/NN
ATRA/NNP acid/NN all/DT treated/VBN occlusion/NN vessels/NNS of/IN
ATRA/NNP acid/NN all/DT treated/VBN occlusion/NN vessels/NNS renal/JJ
ATRA/NNP acid/NN all/DT treated/VBN occlusion/NN vessels/NNS
tranexamic/JJ acid/NN all/DT treated/VBN occlusion/NN due/JJ failure/NN acute/JJ
tranexamic/JJ acid/NN all/DT treated/VBN occlusion/NN due/JJ failure/NN renal/JJ
tranexamic/JJ acid/NN all/DT treated/VBN occlusion/NN due/JJ failure/NN
acid/NN all/DT treated/VBN occlusion/NN due/JJ failure/NN acute/JJ
acid/NN all/DT treated/VBN occlusion/NN due/JJ failure/NN renal/JJ
acid/NN all/DT treated/VBN occlusion/NN due/JJ failure/NN
tranexamic/JJ acid/NN all/DT treated/VBN occlusion/NN vessels/NNS leukemia/NN patient/JJ acute/JJ
tranexamic/JJ acid/NN all/DT treated/VBN occlusion/NN vessels/NNS leukemia/NN promyelocytic/JJ
tranexamic/JJ acid/NN all/DT treated/VBN occlusion/NN vessels/NNS leukemia/NN
acid/NN all/DT treated/VBN occlusion/NN vessels/NNS leukemia/NN patient/JJ acute/JJ
acid/NN all/DT treated/VBN occlusion/NN vessels/NNS leukemia/NN promyelocytic/JJ
acid/NN all/DT treated/VBN occlusion/NN vessels/NNS leukemia/NN
tranexamic/JJ acid/NN all/DT treated/VBN occlusion/NN vessels/NNS leukemia/NN APL/NNP
acid/NN all/DT treated/VBN occlusion/NN vessels/NNS leukemia/NN APL/NNP
tranexamic/JJ acid/NN all/DT treated/VBN occlusion/NN
tranexamic/JJ acid/NN all/DT treated/VBN occlusion/NN vessels/NNS of/IN
tranexamic/JJ acid/NN all/DT treated/VBN occlusion/NN vessels/NNS renal/JJ
tranexamic/JJ acid/NN all/DT treated/VBN occlusion/NN vessels/NNS
acid/NN all/DT treated/VBN occlusion/NN
acid/NN all/DT treated/VBN occlusion/NN vessels/NNS of/IN
acid/NN all/DT treated/VBN occlusion/NN vessels/NNS renal/JJ
acid/NN all/DT treated/VBN occlusion/NN vessels/NNS
ATRA/NNP treated/VBN patient/NN APL/NNP
ATRA/NNP therapy/NN associated/VBN patients/NNS APL/NNP
ATRA/NNP therapy/NN associated/VBN complications/NNS thromboembolic/JJ
ATRA/NNP included/VBN presented/VBD signs/NNS APL/NNP
ATRA/NNP choice/NN patients/NNS APL/NNP
heparin/NN low/JJ using/VBG avoided/VBN events/NNS Thrombotic/JJ
Theophylline/VB neurotoxicity/RB
theophylline/NN neurotoxicity/NN
theophylline/VB response/NN neurotoxic/JJ
lithium/NN therapy/NN term/NN CONCLUSION/NNP hyperparathyroidism/NN Primary/JJ
lithium/NN therapy/NN term/NN CONCLUSION/NNP hyperparathyroidism/NN
methamphetamine/NN diagnosis/NN Patients/NNS based/VBN interviewed/VBN using/VBG Interview/NNP disorders/NNS psychiatric/JJ
methamphetamine/NN diagnosis/NN Patients/NNS based/VBN interviewed/VBN using/VBG Interview/NNP disorders/NNS
methamphetamine/JJ disorders/NNS psychiatric/JJ
methamphetamine/JJ disorders/NNS
methamphetamine/NN use/NN co/NN disorder/NN affective/NN
methamphetamine/NN use/NN co/NN disorder/NN
Ca/JJ causes/VBZ apoptosis/NNS arrhythmia/NN
Na/NN channels/NNS have/VBP roles/NNS cardiotoxicity/NN
Ca/JJ role/NN available/JJ poisoning/NN
Ca/JJ signaling/NNS importance/NN explored/VBD poisoning/NN
Ca/JJ lead/NN found/VBD caused/VBD arrhythmia/NN
aconitine/NN effects/NNS investigate/VB performed/VBD assay/NN cytotoxicity/JJ
aconitine/NN effects/NNS investigate/VB injury/NN myocardial/JJ
aconitine/NN effects/NNS investigate/VB injury/NN
lactate/JJ level/NN myocytes/NNS performed/VBD investigate/VB injury/NN myocardial/JJ
lactate/JJ level/NN myocytes/NNS performed/VBD investigate/VB injury/NN
lactate/JJ level/NN myocytes/NNS performed/VBD assay/NN cytotoxicity/JJ
aconitine/NN resulted/VBD injury/NN myocardial/JJ
aconitine/NN resulted/VBD injury/NN
Ca/JJ overload/NN aggravates/VBZ causes/VBZ arrhythmia/NN
beta/JJ adrenergic/NN affected/VBN abolished/VBN tachycardia/NNP
adrenergic/NN affected/VBN abolished/VBN tachycardia/NNP
and/CC adrenergic/NN affected/VBN abolished/VBN tachycardia/NNP
muscarinic/JJ blockade/NN adrenergic/NN affected/VBN abolished/VBN tachycardia/NNP
receptors/VBG blockade/NN adrenergic/NN affected/VBN abolished/VBN tachycardia/NNP
blockade/NN adrenergic/NN affected/VBN abolished/VBN tachycardia/NNP
beta/JJ adrenergic/NN affected/VBN Vasodilation/NNP vessels/NNS hypotension/NN
adrenergic/NN affected/VBN Vasodilation/NNP vessels/NNS hypotension/NN
and/CC adrenergic/NN affected/VBN Vasodilation/NNP vessels/NNS hypotension/NN
muscarinic/JJ blockade/NN adrenergic/NN affected/VBN Vasodilation/NNP vessels/NNS hypotension/NN
receptors/VBG blockade/NN adrenergic/NN affected/VBN Vasodilation/NNP vessels/NNS hypotension/NN
blockade/NN adrenergic/NN affected/VBN Vasodilation/NNP vessels/NNS hypotension/NN
Caffeine/JJ challenge/NN test/VBP disorder/NN depression/NN
caffeine/NN test/NN respond/VB patients/NNS disorder/NN patients/NNS depression/NN attacks/NNS Manual/NNP Disorders/NNP Mental/NNP
caffeine/NN test/NN respond/VB patients/NNS disorder/NN patients/NNS depression/NN attacks/NNS Manual/NNP Disorders/NNP
caffeine/NN test/NN respond/VB patients/NNS disorder/NN patients/NNS depression/NN attacks/NNS MDP/NNP
caffeine/NN test/NN respond/VB patients/NNS disorder/NN patients/NNS depression/NN major/JJ
caffeine/NN test/NN respond/VB patients/NNS disorder/NN patients/NNS depression/NN
caffeine/NN administered/VBN applied/VBN scales/NNS anxiety/NN
caffeine/NN caffeine/NN administered/VBN applied/VBN scales/NNS anxiety/NN
caffeine/NN sensitive/JJ patients/NNS PD/NNP MDP/NNP
caffeine/NN sensitive/JJ patients/NNS MD/NNP
caffeine/NN test/NN associated/VBN' associated/VBN PD/NNP MDP/NNP
trimethoprim/NN induced/VBN crisis/NN had/VBD girl/NN year/NN sulfomethoxazole/VBD resulting/VBG anoxia/NN cerebral/JJ
trimethoprim/NN induced/VBN crisis/NN had/VBD girl/NN year/NN sulfomethoxazole/VBD resulting/VBG anoxia/NN
sulfomethoxazole/VBD resulting/VBG anoxia/NN cerebral/JJ
sulfomethoxazole/VBD resulting/VBG anoxia/NN
dobutamine/NN occurs/VBZ patients/NNS disease/NN coronary/JJ
dobutamine/NN occurs/VBZ patients/NNS disease/NN artery/NN
dobutamine/NN occurs/VBZ patients/NNS disease/NN
dobutamine/NN induced/VBN ischaemia/NN myocardial/JJ
dobutamine/NN induced/VBN ischaemia/NN
dobutamine/NN exercise/NN ischaemia/NN
dobutamine/JJ results/NNS left/VBD patients/NNS disease/NN coronary/JJ
dobutamine/JJ results/NNS left/VBD patients/NNS disease/NN artery/NN
dobutamine/JJ results/NNS left/VBD patients/NNS disease/NN
dobutamine/JJ results/NNS ischaemia/NN
Dobutamine/NNP ischaemia/NNP used/VBN study/VB patients/NNS disease/NN coronary/JJ
Dobutamine/NNP ischaemia/NNP used/VBN study/VB patients/NNS disease/NN artery/NN
Dobutamine/NNP ischaemia/NNP used/VBN study/VB patients/NNS disease/NN
Dobutamine/NNP ischaemia/NNP
paracetamol/NNP due/JJ failure/NN patients/NNS Fas/NN overdose/VBP
paracetamol/NNP overdose/NNP
albuterol/JJ exacerbations/NNS asthma/NN
albuterol/NN reported/VBN received/VBD patients/NNS admitted/VBN unit/NN exacerbations/NNS asthma/NN
albuterol/JJ treatments/NNS albuterol/NN reported/VBN received/VBD patients/NNS admitted/VBN unit/NN exacerbations/NNS asthma/NN
ibuprofen/NN administration/NN trial/NN treatment/NN ductus/NNS patent/NN
ibuprofen/NN administration/NN trial/NN treatment/NN ductus/NNS
ibuprofen/NN administration/NN arteriosus/VBZ
ibuprofen/NN arteriosus/VBZ administration/NN trial/NN treatment/NN ductus/NNS patent/NN
ibuprofen/NN arteriosus/VBZ administration/NN trial/NN treatment/NN ductus/NNS
ibuprofen/NN arteriosus/VBZ
nitric/JJ therapy/NN resolved/VBD Hypoxaemia/NNP
oxide/NN therapy/NN resolved/VBD Hypoxaemia/NNP
bromocriptine/NN treated/VBN oligomenorrhea/NN
bromocriptine/NN treated/VBN outpatients/NNS hyperprolactinemia/NN amenorrhea/NN
bromocriptine/NN treated/VBN outpatients/NNS hyperprolactinemia/NN
neuroleptic/JJ galactorrhea/NNS
bromocriptine/NN evaluated/VBN therapy/NN galactorrhea/NNS hyperprolactinemia/NN amenorrhea/NN
bromocriptine/NN evaluated/VBN therapy/NN galactorrhea/NNS hyperprolactinemia/NN
bromocriptine/NN evaluated/VBN therapy/NN galactorrhea/NNS
Rifampicin/NNP administered/VBN developed/VBD nausea/NN fever/NN
Rifampicin/NNP administered/VBN developed/VBD nausea/NN vomiting/NN
Rifampicin/NNP administered/VBN developed/VBD nausea/NN
desferrioxamine/NN therapy/NN occurring/VBG failure/NN Acute/JJ
desferrioxamine/NN therapy/NN occurring/VBG failure/NN renal/JJ
desferrioxamine/NN therapy/NN occurring/VBG failure/NN
desferrioxamine/NN treatment/NN undergoing/VBG thalassemia/NNP
DFX/NNP treatment/NN undergoing/VBG thalassemia/NNP
desferrioxamine/NN caused/VBN failure/NN acute/JJ
desferrioxamine/NN caused/VBN failure/NN renal/JJ
desferrioxamine/NN caused/VBN failure/NN
metolachlor/NN use/NN incidence/NN Cancer/NNP
metolachlor/NN using/VBG reported/VBD %/NN applicators/NNS evaluated/VBN incidence/NN cancer/NN
metolachlor/NN use/NN incidence/NN cancer/NN
metolachlor/NN use/NN association/NN cancers/NNS
metolachlor/NN use/NN association/NN cancers/NNS site/NN cancers/NNS
metolachlor/NN use/NN levels/NNS risk/NN lung/NN
metolachlor/NN use/NN levels/NNS risk/NN cancer/NN
metolachlor/NN use/NN effects/NNS up/RB follow/VB warrant/VBP findings/NNS cancer/NN lymphoma/NN
bupivacaine/NN precipitate/VB dysrhythmias/NNS
bupivacaine/NN circulating/VBG potentiate/VB precipitate/VB dysrhythmias/NNS
epinephrine/NN bupivacaine/NN precipitate/VB dysrhythmias/NNS
epinephrine/NN effects/NNS potentiate/VB precipitate/VB dysrhythmias/NNS
epinephrine/NN administration/NN dysrhythmogenicity/NN alters/VBZ alters/VBZ' dogs/NNS infarction/NN myocardial/JJ
epinephrine/NN administration/NN dysrhythmogenicity/NN alters/VBZ alters/VBZ' dogs/NNS infarction/NN
bupivacaine/NN alters/VBZ alters/VBZ' dogs/NNS infarction/NN myocardial/JJ
bupivacaine/NN alters/VBZ alters/VBZ' dogs/NNS infarction/NN
epinephrine/NN min/VBP day/NN kg/VBP infarction/NN myocardial/JJ
epinephrine/NN min/VBP day/NN kg/VBP infarction/NN
halothane/NN kg/VBP infarction/NN myocardial/JJ
halothane/NN kg/VBP infarction/NN
halothane/NN kg/VBP day/NN min/VBP epinephrine/NN appeared/VBD VT/NNP
Bupivacaine/JJ antagonizes/NNS epinephrine/VBP dogs/NNS susceptible/JJ VT/NNP
Bupivacaine/JJ antagonizes/NNS epinephrine/VBP epinephrine/VBP' dogs/NNS dysrhythmias/NNS
epinephrine/VBP epinephrine/VBP' dogs/NNS dysrhythmias/NNS
Vigabatrin/NNP changes/NNS elected/VBD continue/VB medication/NN control/NN seizure/NN
Vigabatrin/NNP pathogenesis/NNS reaction/NN dose/NN toxicity/NN
dipyridamole/JJ infusion/NN surface/VBP detection/NN disease/NN coronary/JJ
dipyridamole/JJ infusion/NN surface/VBP detection/NN disease/NN artery/NN
dipyridamole/JJ infusion/NN surface/VBP detection/NN disease/NN
dipyridamole/JJ infusion/NN changes/NNS studied/VBN patients/NNS disease/NN coronary/JJ
dipyridamole/JJ infusion/NN changes/NNS studied/VBN patients/NNS disease/NN artery/NN
dipyridamole/JJ infusion/NN changes/NNS studied/VBN patients/NNS disease/NN
dipyridamole/NN observed/VBN ST/NN depression/NN
dipyridamole/NN observed/VBN %/NN group/NN MI/NNP
dipyridamole/NN observed/VBN ST/NN ischemic/JJ
dipyridamole/NN observed/VBN %/NN group/NN %/NN INF/NNP
dipyridamole/NN observed/VBN %/NN MI/NNP
dipyridamole/NN observed/VBN %/NN group/NN %/NN ANT/NNP
dipyridamole/NN observed/VBN %/NN group/NN MI/NNP
dipyridamole/JJ test/NN useful/JJ test/NN assessment/NN disease/NN coronary/JJ
dipyridamole/JJ test/NN useful/JJ test/NN assessment/NN disease/NN artery/NN
dipyridamole/JJ test/NN useful/JJ test/NN assessment/NN disease/NN
eslicarbazepine/JJ acetate/NN seizures/NNS
acetate/NN seizures/NNS
BIA/NNP acetate/NN seizures/NNS
2/CD BIA/NNP acetate/NN seizures/NNS
093/CD BIA/NNP acetate/NN seizures/NNS
eslicarbazepine/JJ acetate/NN elicited/VBN seizures/NNS
acetate/NN elicited/VBN seizures/NNS
eslicarbazepine/JJ acetate/NN elicited/VBN changes/NNS patterns/NNS threshold/NN seizure/NN
acetate/NN elicited/VBN changes/NNS patterns/NNS threshold/NN seizure/NN
Rifampicin/NNP glomerulonephritis/NNS endocarditis/NNS staphylococcal/JJ
Rifampicin/NNP glomerulonephritis/NNS endocarditis/NNS
rifampicin/NN therapy/NN complication/NN reported/VBN patients/NNS receiving/VBG treatment/NN tuberculosis/NNP
rifampicin/NN infections/NNS Staphylococcal/NNP
rifampicin/NN infections/NNS
rifampicin/NN use/NN increase/NN led/VBN epidemiology/NN infections/NNS endocarditis/NNS infective/JJ
rifampicin/NN use/NN increase/NN led/VBN epidemiology/NN infections/NNS endocarditis/NNS
rifampicin/NN use/NN increase/NN led/VBN epidemiology/NN IE/NNP
rifampicin/NN use/NN increase/NN led/VBN epidemiology/NN infections/NNS
rifampicin/NN treated/VBN developed/VBD IE/NNP Staphylococcal/NNP
rifampicin/NN treated/VBN developed/VBD IE/NNP
rifampicin/NN therapy/NN complication/NN literature/NN review/VB treated/VBN developed/VBD IE/NNP Staphylococcal/NNP
rifampicin/NN therapy/NN complication/NN literature/NN review/VB treated/VBN developed/VBD IE/NNP
nitric/JJ synthase/NN expression/NN irritation/NN bladder/NN
nitric/JJ synthase/NN expression/NN irritation/NN
oxide/NN synthase/NN expression/NN irritation/NN bladder/NN
oxide/NN synthase/NN expression/NN irritation/NN
nitric/JJ synthase/NN expression/NN alterations/NNS examine/VB pathways/NNS irritation/NN
nitric/JJ synthase/NN expression/NN alterations/NNS examine/VB pathways/NNS irritation/NN tract/NN of/IN
nitric/JJ synthase/NN expression/NN alterations/NNS examine/VB pathways/NNS irritation/NN tract/NN the/DT
nitric/JJ synthase/NN expression/NN alterations/NNS examine/VB pathways/NNS irritation/NN tract/NN urinary/JJ
nitric/JJ synthase/NN expression/NN alterations/NNS examine/VB pathways/NNS irritation/NN tract/NN
oxide/NN synthase/NN expression/NN alterations/NNS examine/VB pathways/NNS irritation/NN
oxide/NN synthase/NN expression/NN alterations/NNS examine/VB pathways/NNS irritation/NN tract/NN of/IN
oxide/NN synthase/NN expression/NN alterations/NNS examine/VB pathways/NNS irritation/NN tract/NN the/DT
oxide/NN synthase/NN expression/NN alterations/NNS examine/VB pathways/NNS irritation/NN tract/NN urinary/JJ
oxide/NN synthase/NN expression/NN alterations/NNS examine/VB pathways/NNS irritation/NN tract/NN
acrolein/NN metabolized/VBN cyclophosphamide/NN induced/VBN cystitis/NNS
aminonucleoside/JJ nephrosis/NNS
protamine/JJ sulfate/NN aminonucleoside/NN administration/NN developed/VBN model/NN sclerosis/NN focal/JJ
protamine/JJ sulfate/NN aminonucleoside/NN administration/NN developed/VBN model/NN sclerosis/NN segmental/JJ
protamine/JJ sulfate/NN aminonucleoside/NN administration/NN developed/VBN model/NN sclerosis/NN glomerular/NN
protamine/JJ sulfate/NN aminonucleoside/NN administration/NN developed/VBN model/NN sclerosis/NN
sulfate/NN aminonucleoside/NN administration/NN developed/VBN model/NN sclerosis/NN focal/JJ
sulfate/NN aminonucleoside/NN administration/NN developed/VBN model/NN sclerosis/NN segmental/JJ
sulfate/NN aminonucleoside/NN administration/NN developed/VBN model/NN sclerosis/NN glomerular/NN
sulfate/NN aminonucleoside/NN administration/NN developed/VBN model/NN sclerosis/NN
protamine/JJ sulfate/NN aminonucleoside/NN administration/NN developed/VBN model/NN sclerosis/NN FSGS/NNP
sulfate/NN aminonucleoside/NN administration/NN developed/VBN model/NN sclerosis/NN FSGS/NNP
PS/NNP sulfate/NN aminonucleoside/NN administration/NN developed/VBN model/NN sclerosis/NN focal/JJ
PS/NNP sulfate/NN aminonucleoside/NN administration/NN developed/VBN model/NN sclerosis/NN segmental/JJ
PS/NNP sulfate/NN aminonucleoside/NN administration/NN developed/VBN model/NN sclerosis/NN glomerular/NN
PS/NNP sulfate/NN aminonucleoside/NN administration/NN developed/VBN model/NN sclerosis/NN
PS/NNP sulfate/NN aminonucleoside/NN administration/NN developed/VBN model/NN sclerosis/NN FSGS/NNP
AMNS/NNS toxicity/NN
PS/NNP administration/NN enhances/VBZ produces/VBZ FSGS/NNS
PS/NNP administration/NN enhances/VBZ produces/VBZ rats/NNS resulting/VBG end/NN
PS/NNP administration/NN enhances/VBZ produces/VBZ rats/NNS disease/NN stage/NN
PS/NNP administration/NN enhances/VBZ produces/VBZ rats/NNS disease/NN renal/JJ
PS/NNP administration/NN enhances/VBZ produces/VBZ rats/NNS disease/NN
PS/NNP administration/NN enhances/VBZ toxicity/NN
ethambutol/JJ overtreatment/NN due/JJ Optochiasmatic/NNP neuropathy/NN peripheral/JJ
ethambutol/JJ overtreatment/NN due/JJ Optochiasmatic/NNP neuropathy/NN
ethambutol/JJ toxicity/NN
thalidomide/NN treated/VBN erythematosus/NNS amplitude/JJ patients/NNS lupus/NNS cutaneous/NNS
thalidomide/NN treated/VBN erythematosus/NNS amplitude/JJ patients/NNS lupus/NNS
thalidomide/NN treated/VBN erythematosus/NNS
thalidomide/NN treated/VBN erythematosus/NNS CLE/NNP
thalidomide/NN potential/NN identify/VB use/VB measure/VB variations/NNS erythematosus/NNS amplitude/JJ patients/NNS lupus/NNS cutaneous/NNS
thalidomide/NN potential/NN identify/VB use/VB measure/VB variations/NNS erythematosus/NNS amplitude/JJ patients/NNS lupus/NNS
thalidomide/NN potential/NN identify/VB use/VB measure/VB variations/NNS erythematosus/NNS
thalidomide/NN potential/NN identify/VB use/VB measure/VB variations/NNS erythematosus/NNS CLE/NNP
thalidomide/NN treated/VBN erythematosus/NNS variations/NNS measure/VB use/VB identify/VB potential/NN neurotoxic/JJ
thalidomide/NN potential/NN neurotoxic/JJ
thalidomide/NN treatment/NN data/NNS patients/NNS CLE/NNP
thalidomide/NN potential/NN neurotoxic/JJ
vincristine/JJ sulfate/NN given/VBN monkeys/NNS 2/CD inoculation/NN resulted/VBD infection/NN
sulfate/NN given/VBN monkeys/NNS 2/CD inoculation/NN resulted/VBD infection/NN
corticosteroid/JJ suspensions/NNS long/JJ studies/NNS injection/NN artery/NN retinal/JJ
corticosteroid/JJ suspensions/NNS long/JJ studies/NNS injection/NN artery/NN
corticosteroid/JJ suspensions/NNS long/JJ studies/NNS injection/NN artery/NN and/CC
corticosteroid/JJ suspensions/NNS long/JJ studies/NNS injection/NN artery/NN occlusion/NN choriocapillaris/NNS
corticosteroid/JJ suspensions/NNS long/JJ studies/NNS injection/NN artery/NN occlusion/NN
epinephrine/NN lidocaine/NN combination/NN acetate/NN injection/NN reported/VBN Two/CD occlusions/VBZ blindness/NN
penicillin/NN lidocaine/NN combination/NN acetate/NN injection/NN reported/VBN Two/CD occlusions/VBZ blindness/NN
lidocaine/NN combination/NN acetate/NN injection/NN reported/VBN Two/CD occlusions/VBZ cases/NNS artery/NN retinal/JJ
lidocaine/NN combination/NN acetate/NN injection/NN reported/VBN Two/CD occlusions/VBZ cases/NNS artery/NN
lidocaine/NN combination/NN acetate/NN injection/NN reported/VBN Two/CD occlusions/VBZ cases/NNS artery/NN and/CC
lidocaine/NN combination/NN acetate/NN injection/NN reported/VBN Two/CD occlusions/VBZ cases/NNS artery/NN choriocapillaris/NNS
lidocaine/NN combination/NN acetate/NN injection/NN reported/VBN Two/CD occlusions/VBZ
methylprednisolone/JJ acetate/NN injection/NN reported/VBN Two/CD occlusions/VBZ blindness/NN
acetate/NN injection/NN reported/VBN Two/CD occlusions/VBZ blindness/NN
epinephrine/NN lidocaine/NN combination/NN acetate/NN injection/NN reported/VBN Two/CD occlusions/VBZ cases/NNS artery/NN retinal/JJ
epinephrine/NN lidocaine/NN combination/NN acetate/NN injection/NN reported/VBN Two/CD occlusions/VBZ cases/NNS artery/NN
epinephrine/NN lidocaine/NN combination/NN acetate/NN injection/NN reported/VBN Two/CD occlusions/VBZ cases/NNS artery/NN and/CC
epinephrine/NN lidocaine/NN combination/NN acetate/NN injection/NN reported/VBN Two/CD occlusions/VBZ cases/NNS artery/NN choriocapillaris/NNS
epinephrine/NN lidocaine/NN combination/NN acetate/NN injection/NN reported/VBN Two/CD occlusions/VBZ
penicillin/NN lidocaine/NN combination/NN acetate/NN injection/NN reported/VBN Two/CD occlusions/VBZ cases/NNS artery/NN retinal/JJ
penicillin/NN lidocaine/NN combination/NN acetate/NN injection/NN reported/VBN Two/CD occlusions/VBZ cases/NNS artery/NN
penicillin/NN lidocaine/NN combination/NN acetate/NN injection/NN reported/VBN Two/CD occlusions/VBZ cases/NNS artery/NN and/CC
penicillin/NN lidocaine/NN combination/NN acetate/NN injection/NN reported/VBN Two/CD occlusions/VBZ cases/NNS artery/NN choriocapillaris/NNS
penicillin/NN lidocaine/NN combination/NN acetate/NN injection/NN reported/VBN Two/CD occlusions/VBZ
lidocaine/NN combination/NN acetate/NN injection/NN reported/VBN Two/CD occlusions/VBZ blindness/NN
propylthiouracil/NN treated/VBN antibody/NN patients/NNS Graves/NNP
propylthiouracil/NN treated/VBN antibody/NN patients/NNS Graves/NNP '/POS
propylthiouracil/NN treated/VBN antibody/NN patients/NNS disease/NN
propylthiouracil/NN treated/VBN patients/NNS reported/VBN vasculitis/NNS
PTU/NNP propylthiouracil/NN treated/VBN patients/NNS reported/VBN vasculitis/NNS
propylthiouracil/NN treated/VBN patients/NNS disease/NN Graves/NNP
propylthiouracil/NN treated/VBN patients/NNS disease/NN Graves/NNP '/POS
propylthiouracil/NN treated/VBN patients/NNS disease/NN
PTU/NNP propylthiouracil/NN treated/VBN patients/NNS disease/NN Graves/NNP
PTU/NNP propylthiouracil/NN treated/VBN patients/NNS disease/NN Graves/NNP '/POS
PTU/NNP propylthiouracil/NN treated/VBN patients/NNS disease/NN
PTU/NNP therapy/NN vasculitis/NNS
PTU/NNP therapy/NN vasculitis/NNS ANCA/NNP appearance/NN ANCA/NNP patients/NNS Graves/NNP
PTU/NNP therapy/NN vasculitis/NNS ANCA/NNP appearance/NN ANCA/NNP patients/NNS Graves/NNP '/POS
PTU/NNP therapy/NN vasculitis/NNS ANCA/NNP appearance/NN ANCA/NNP patients/NNS disease/NN
PTU/NNP therapy/NN starting/VBG investigated/VBD vasculitis/NNS
PTU/NNP therapy/NN starting/VBG investigated/VBD vasculitis/NNS hyperthyroidism/JJ
PTU/NNP therapy/NN starting/VBG investigated/VBD vasculitis/NNS due/JJ disease/NN Graves/NNP
PTU/NNP therapy/NN starting/VBG investigated/VBD vasculitis/NNS due/JJ disease/NN Graves/NNP '/POS
PTU/NNP therapy/NN starting/VBG investigated/VBD vasculitis/NNS due/JJ disease/NN
PTU/NNP therapy/NN ml/VBP developed/VBD disorders/NNS vasculitic/JJ
PTU/NNP therapy/NN ml/VBP developed/VBD disorders/NNS
PTU/NNP therapy/NN related/VBN appear/VB related/VBN vasculitis/NNS
dehydroepiandrosterone/NN Effects/NNPS models/NNS schizophrenia/NN
dehydroepiandrosterone/NN effects/NNS examine/VB models/NNS schizophrenia/NN
DHEA/NNP dehydroepiandrosterone/NN effects/NNS examine/VB models/NNS schizophrenia/NN
Amphetamine/NNP induced/VBN locomotion/NN hyper/JJ
Amphetamine/NNP induced/VBN apomorphine/NN haloperidol/NN induced/VBN used/VBN tests/NNS catalepsy/JJ
haloperidol/NN apomorphine/NN induced/VBN locomotion/NN hyper/JJ
apomorphine/NN haloperidol/NN induced/VBN used/VBN tests/NNS catalepsy/JJ
apomorphine/NN induced/VBN locomotion/NN hyper/JJ
DHEA/NNP reduced/VBD increased/VBD catalepsy/RB
DHEA/NNP displays/VBZ used/VBN treatment/NN schizophrenia/NN
lithium/NN polydipsia/NN
lithium/NN treating/VBG induced/VBN developed/VBN secondary/JJ trauma/NN brain/NN
lithium/NN treating/VBG induced/VBN developed/VBN secondary/JJ trauma/NN
ibuprofen/NN took/VBD fever/NN
aspirin/NN put/VBN took/VBD fever/NN
beta/NN kg/FW 05/VBD reduced/VBN binding/NNP convulsions/NNS
carboline/JJ reduced/VBN binding/NNP convulsions/NNS
-LSB-/NNP increase/NN markedly/VBZ reduced/VBN binding/NNP convulsions/NNS
35/CD -LSB-/NNP increase/NN markedly/VBZ reduced/VBN binding/NNP convulsions/NNS
S/NNP binding/NNP convulsions/NNS
-RSB-/NNP binding/NNP convulsions/NNS
TBPS/NNP binding/NNP convulsions/NNS
pancuronium/NN pretreatment/NN occur/VB rigidity/NN prolonged/JJ
pancuronium/NN pretreatment/NN occur/VB rigidity/NN jaw/NN
pancuronium/NN pretreatment/NN occur/VB rigidity/NN
pancuronium/NN pretreatment/NN occur/VB rigidity/NN myalgia/NN
cocaine/NN year/NN 30/CD man/NN became/VBD manic/JJ
DEP/NNP different/JJ changes/NNS power/NN oscillation/NN pupillary/JJ
DEP/NNP different/JJ changes/NNS power/NN oscillation/NN
1/CD induced/VBN patient/NN hypoparathyroidism/NN
25/CD 1/CD induced/VBN patient/NN hypoparathyroidism/NN
OH/NNP 1/CD induced/VBN patient/NN hypoparathyroidism/NN
2/CD D/NNS 1/CD induced/VBN patient/NN hypoparathyroidism/NN
D/NNS 1/CD induced/VBN patient/NN hypoparathyroidism/NN
calcium/NN amounts/NNS described/VBN context/NN treatment/NN disease/NN peptic/JJ
calcium/NN amounts/NNS described/VBN context/NN treatment/NN disease/NN ulcer/NN
calcium/NN amounts/NNS described/VBN context/NN treatment/NN disease/NN
alkali/NN calcium/NN amounts/NNS described/VBN context/NN treatment/NN disease/NN peptic/JJ
alkali/NN calcium/NN amounts/NNS described/VBN context/NN treatment/NN disease/NN ulcer/NN
alkali/NN calcium/NN amounts/NNS described/VBN context/NN treatment/NN disease/NN
omeprazole/NN blockers/NNS H/NNP therapy/NN ulcer/NN
sucralfate/NN blockers/NNS H/NNP therapy/NN decreased/VBN remains/VBZ triad/NN hypercalcemia/NN alkalosis/NNS
omeprazole/NN blockers/NNS H/NNP therapy/NN decreased/VBN remains/VBZ triad/NN hypercalcemia/NN impairment/NN renal/JJ
omeprazole/NN blockers/NNS H/NNP therapy/NN decreased/VBN remains/VBZ triad/NN hypercalcemia/NN impairment/NN
sucralfate/NN blockers/NNS H/NNP therapy/NN ulcer/NN
omeprazole/NN blockers/NNS H/NNP therapy/NN decreased/VBN frequency/NN milk/NN
omeprazole/NN blockers/NNS H/NNP therapy/NN decreased/VBN syndrome/NN alkali/NN
omeprazole/NN blockers/NNS H/NNP therapy/NN decreased/VBN syndrome/NN
omeprazole/NN blockers/NNS H/NNP therapy/NN decreased/VBN remains/VBZ triad/NN hypercalcemia/NN
sucralfate/NN blockers/NNS H/NNP therapy/NN decreased/VBN frequency/NN milk/NN
sucralfate/NN blockers/NNS H/NNP therapy/NN decreased/VBN syndrome/NN alkali/NN
sucralfate/NN blockers/NNS H/NNP therapy/NN decreased/VBN syndrome/NN
sucralfate/NN blockers/NNS H/NNP therapy/NN decreased/VBN remains/VBZ triad/NN hypercalcemia/NN
sucralfate/NN blockers/NNS H/NNP therapy/NN decreased/VBN remains/VBZ triad/NN hypercalcemia/NN impairment/NN renal/JJ
sucralfate/NN blockers/NNS H/NNP therapy/NN decreased/VBN remains/VBZ triad/NN hypercalcemia/NN impairment/NN
omeprazole/NN blockers/NNS H/NNP therapy/NN decreased/VBN remains/VBZ triad/NN hypercalcemia/NN alkalosis/NNS
calcium/NN carbonate/NN treated/VBN hypoparathyroidism/NN
carbonate/NN treated/VBN hypoparathyroidism/NN
calcitriol/NN carbonate/NN treated/VBN hypoparathyroidism/NN
pamidronate/NN illustrates/VBZ tool/NN presents/VBZ milk/NN
pamidronate/NN illustrates/VBZ tool/NN presents/VBZ milk/NN syndrome/NN alkali/JJ
pamidronate/NN illustrates/VBZ tool/NN presents/VBZ milk/NN syndrome/NN
pamidronate/NN illustrates/VBZ tool/NN presents/VBZ emergency/NN hypercalcemic/JJ
pamidronate/NN illustrates/VBZ tool/NN presents/VBZ emergency/NN
epirubicin/NN exposure/NN predict/VB dysfunction/NN cardiac/JJ
epirubicin/NN exposure/NN predict/VB dysfunction/NN
epirubicin/NN exposure/NN predict/VB T/NN alterations/NNS strain/NN myocardial/JJ
epirubicin/NN exposure/NN predict/VB T/NN alterations/NNS strain/NN
epirubicin/NN treated/VBN lymphoma/NNP patients/NNS non/NN
epirubicin/NN treated/VBN lymphoma/NNP Hodgkin/NNP
epirubicin/NN treated/VBN lymphoma/NNP
anthracycline/NN receiving/VBG patients/NNS predict/VB dysfunction/NN cardiac/JJ
anthracycline/NN receiving/VBG patients/NNS predict/VB dysfunction/NN
isoproterenol/NN rats/NNS diabetic/JJ
streptozotocin/JJ rats/NNS isoproterenol/NN effect/NN cardiotoxic/JJ
isoproterenol/NN effect/NN cardiotoxic/JJ
isoproterenol/NN doses/NNS effect/NN diabetes/NN
ISO/NNP isoproterenol/NN doses/NNS effect/NN diabetes/NN
streptozotocin/NN diabetes/NN effect/NN cardiotoxic/JJ
isoproterenol/NN doses/NNS effect/NN cardiotoxic/JJ
ISO/NNP isoproterenol/NN doses/NNS effect/NN cardiotoxic/JJ
glucose/NN fall/NN slope/NN correlation/NN appeared/VBD analyzed/VBN fibrosis/NNP
catecholamines/NNS content/NN estimated/VBN rats/NNS diabetic/JJ
ISO/NNP resistance/NN causes/VBZ points/VBZ effect/NN sensitivity/NN rats/NNS diabetic/JJ
catecholamine/NN sensitivity/NN rats/NNS diabetic/JJ
1/CD 3/CD CML/NNP
3/CD CML/NNP
Butadiene/NNP CML/NNP
1/CD studies/NNS UNASSIGNED/NNP suggest/VBP associated/VBN leukemia/NN chronic/JJ
1/CD studies/NNS UNASSIGNED/NNP suggest/VBP associated/VBN leukemia/NN myeloid/JJ
1/CD studies/NNS UNASSIGNED/NNP suggest/VBP associated/VBN leukemia/NN
3/CD 1/CD studies/NNS UNASSIGNED/NNP suggest/VBP associated/VBN leukemia/NN chronic/JJ
3/CD 1/CD studies/NNS UNASSIGNED/NNP suggest/VBP associated/VBN leukemia/NN myeloid/JJ
3/CD 1/CD studies/NNS UNASSIGNED/NNP suggest/VBP associated/VBN leukemia/NN
butadiene/RB suggest/VBP associated/VBN leukemia/NN chronic/JJ
butadiene/RB suggest/VBP associated/VBN leukemia/NN myeloid/JJ
butadiene/RB suggest/VBP associated/VBN leukemia/NN
1/CD studies/NNS UNASSIGNED/NNP suggest/VBP associated/VBN leukemia/NN CML/NNP
3/CD 1/CD studies/NNS UNASSIGNED/NNP suggest/VBP associated/VBN leukemia/NN CML/NNP
butadiene/RB suggest/VBP associated/VBN leukemia/NN CML/NNP
PAN/NNP nephropathy/NN rats/NNS failure/NN growth/NN
PAN/NNP nephropathy/NN rats/NNS failure/NN
malondialdehyde/NN content/NN glomerulosclerosis/NNS injury/NN tubulointerstitial/JJ
malondialdehyde/NN content/NN glomerulosclerosis/NNS injury/NN
malondialdehyde/NN content/NN glomerulosclerosis/NNS
malondialdehyde/NN content/NN glomerulosclerosis/NNS increased/VBD associated/VBN hypertrophy/NN glomerular/NN
malondialdehyde/NN content/NN glomerulosclerosis/NNS increased/VBD associated/VBN hypertrophy/NN
malondialdehyde/NN content/NN gain/NN damage/NN glomerular/NN tubulointerstitial/NN
malondialdehyde/NN content/NN gain/NN damage/NN
malondialdehyde/NN content/NN gain/NN proteinuria/NN
fluorescein/NN angiography/NN Convulsion/NNP
Quinine/NNP induced/VBN malaria/NN severe/JJ
Quinine/NNP induced/VBN malaria/NN
Quinine/NNP induced/VBN arrhythmia/NN
quinine/JJ infusion/NN getting/VBG reported/VBN presented/VBD case/NN patient/NN jaundice/NN
quinine/JJ infusion/NN getting/VBG reported/VBN presented/VBD case/NN patient/NN severe/JJ
quinine/JJ infusion/NN getting/VBG reported/VBN presented/VBD case/NN patient/NN malaria/NN
quinine/JJ infusion/NN getting/VBG reported/VBN presented/VBD arrhythmia/NN
dextrose/NN got/VBD diagnosed/VBN jaundice/NN
bilirubin/NN falciparum/NNP diagnosed/VBN jaundice/NN
bilirubin/NN mg/NN mg/NN falciparum/NNP diagnosed/VBN jaundice/NN
bilirubin/NN mg/NN mg/NN mg/NN falciparum/NNP diagnosed/VBN jaundice/NN
quinine/JJ infusion/NN got/VBD diagnosed/VBN jaundice/NN
potassium/CD 3/CD mg/NN mg/NN mg/NN falciparum/NNP diagnosed/VBN jaundice/NN
dextrose/NN got/VBD diagnosed/VBN malaria/NN severe/JJ
dextrose/NN got/VBD diagnosed/VBN malaria/NN
quinine/JJ infusion/NN got/VBD diagnosed/VBN malaria/NN severe/JJ
quinine/JJ infusion/NN got/VBD diagnosed/VBN malaria/NN
potassium/CD 3/CD mg/NN mg/NN mg/NN falciparum/NNP diagnosed/VBN malaria/NN severe/JJ
potassium/CD 3/CD mg/NN mg/NN mg/NN falciparum/NNP diagnosed/VBN malaria/NN
bilirubin/NN falciparum/NNP diagnosed/VBN malaria/NN severe/JJ
bilirubin/NN falciparum/NNP diagnosed/VBN malaria/NN
bilirubin/NN mg/NN mg/NN falciparum/NNP diagnosed/VBN malaria/NN severe/JJ
bilirubin/NN mg/NN mg/NN falciparum/NNP diagnosed/VBN malaria/NN
bilirubin/NN mg/NN mg/NN mg/NN falciparum/NNP diagnosed/VBN malaria/NN severe/JJ
bilirubin/NN mg/NN mg/NN mg/NN falciparum/NNP diagnosed/VBN malaria/NN
quinine/JJ infusion/NN hours/NNS felt/VBD showed/VBD palpitation/NN
quinine/JJ infusion/NN hours/NNS felt/VBD showed/VBD >/VBD 5/CD minute/NN wave/NN sinoatrial/JJ
quinine/JJ infusion/NN hours/NNS felt/VBD showed/VBD >/VBD 5/CD minute/NN wave/NN block/NN
potassium/NN level/NN meq/NN felt/VBD reduced/VBD frequency/NN PVC/NNP
quinidine/NN alkaloid/NN property/NN arrhythmic/JJ
quinidine/NN alkaloid/NN arrhythmic/JJ
quinidine/NN alkaloid/NN arrhythmias/NNS
quinidine/NN alkaloid/NN arrhythmia/NN
Quinine/RB alkaloid/NN property/NN arrhythmic/JJ
Quinine/RB alkaloid/NN arrhythmic/JJ
Quinine/RB alkaloid/NN arrhythmias/NNS
Quinine/RB alkaloid/NN arrhythmia/NN
quinidine/NN alkaloid/NN arrhythmia/NN PVC/NNP
quinine/NN Administration/NNP done/VBN patients/NNS have/VBP diseases/NNS heart/NN
quinine/NN Administration/NNP done/VBN patients/NNS have/VBP diseases/NNS
quinine/NN Administration/NNP done/VBN patients/NNS have/VBP diseases/NNS occurs/VBZ due/JJ and/CC cases/NNS malaria/NN
quinine/NN Administration/NNP done/VBN patients/NNS have/VBP diseases/NNS occurs/VBZ due/JJ and/CC vomiting/NN
quinine/NN Administration/NNP done/VBN patients/NNS have/VBP diseases/NNS hypokalemia/NNP
quinine/NN Administration/NNP done/VBN patients/NNS have/VBP diseases/NNS disorder/NN electrolyte/JJ
quinine/NN Administration/NNP done/VBN patients/NNS have/VBP diseases/NNS disorder/NN
quinine/NN Administration/NNP done/VBN and/CC observation/NN effect/NN arrhythmic/NN
quinine/NN Administration/NNP done/VBN patients/NNS have/VBP diseases/NNS occurs/VBZ due/JJ and/CC diarrhea/NN
Fazadinium/NNP dose/NN mg/NN abolition/NN fasciculations/NNS
Fazadinium/NNP dose/NN mg/NN abolition/NN influence/VB occurrence/NN pain/NN
bromide/NN chloride/NN used/VBD affected/VBD incidence/NN pain/NN
chloride/NN used/VBD affected/VBD incidence/NN pain/NN
Althesin/NNP agent/NN type/NN used/VBD affected/VBD incidence/NN pain/NN
Thiopentone/NNP Althesin/NNP agent/NN type/NN used/VBD affected/VBD incidence/NN pain/NN
Propranolol/JJ antagonism/NN hypertension/NN
Phenylpropanolamine/NNP cause/VB hypertension/NN hemorrhage/NN intracerebral/JJ
Phenylpropanolamine/NNP cause/VB hypertension/NN hemorrhage/NN
PPA/NNP Phenylpropanolamine/NNP cause/VB hypertension/NN hemorrhage/NN intracerebral/JJ
PPA/NNP Phenylpropanolamine/NNP cause/VB hypertension/NN hemorrhage/NN
Phenylpropanolamine/NNP cause/VB overdose/RB
PPA/NNP Phenylpropanolamine/NNP cause/VB overdose/RB
propranolol/NN efficacy/NN studied/VBD treatment/NN hypertension/NN
PPA/NNP increased/VBD volume/NN stroke/NN
Lamivudine/NNP effective/JJ suppressing/VBG DNA/NN hepatitis/NNP
Lamivudine/NNP effective/JJ suppressing/VBG DNA/NN B/NNP
Lamivudine/NNP novel/NN 3/CD analogue/NN has/VBZ effects/NNS replication/NN hepatitis/NNP
Lamivudine/NNP novel/NN 3/CD analogue/NN has/VBZ effects/NNS replication/NN B/NNP
2/CD novel/NN 3/CD analogue/NN has/VBZ effects/NNS replication/NN hepatitis/NNP
2/CD novel/NN 3/CD analogue/NN has/VBZ effects/NNS replication/NN B/NNP
3/CD analogue/NN has/VBZ effects/NNS replication/NN hepatitis/NNP
3/CD analogue/NN has/VBZ effects/NNS replication/NN B/NNP
dideoxy/RB cytosine/JJ analogue/NN has/VBZ effects/NNS replication/NN hepatitis/NNP
dideoxy/RB cytosine/JJ analogue/NN has/VBZ effects/NNS replication/NN B/NNP
cytosine/JJ analogue/NN has/VBZ effects/NNS replication/NN hepatitis/NNP
cytosine/JJ analogue/NN has/VBZ effects/NNS replication/NN B/NNP
lamivudine/NN receiving/VBG had/VBD decrease/NN virus/NN hepatitis/NNP
lamivudine/NN receiving/VBG had/VBD decrease/NN virus/NN B/NNP
methimazole/NN case/NN hepatitis/NN
methimazole/NN case/NN hepatitis/NN cases/NNS associated/VBN lupus/NNS
methimazole/NN case/NN hepatitis/NN cases/NNS described/VBN syndrome/NN like/IN
methimazole/NN case/NN hepatitis/NN cases/NNS described/VBN syndrome/NN
propylthiouracil/NN cases/NNS necrosis/NNS hepatocellular/NN
propylthiouracil/NN cases/NNS necrosis/NNS
propylthiouracil/NN case/NN necrosis/NNS hepatocellular/NN
propylthiouracil/NN case/NN necrosis/NNS
fluconazole/NN initiation/NN suppression/NN bone/NN
fluconazole/NN initiation/NN suppression/NN marrow/NN
fluconazole/NN initiation/NN suppression/NN
Indomethacin/NNP induced/VBN arthritis/NN gouty/JJ
Indomethacin/NNP induced/VBN arthritis/NN
indomethacin/NN developed/VBD treatment/NN arthritis/NN gouty/JJ
indomethacin/NN developed/VBD treatment/NN arthritis/NN
prostaglandin/NN synthesis/NN hypoaidosteronism/NN hyporeninemic/JJ
prostaglandin/NN synthesis/NN hypoaidosteronism/NN
potassium/NN balance/NN function/NN attention/NN particularly/RB preexisting/VBG disease/NN renal/JJ
potassium/NN balance/NN function/NN attention/NN particularly/RB preexisting/VBG disease/NN
indomethacin/NN receiving/VBG patients/NNS function/NN attention/NN particularly/RB patients/NNS mellitus/NNS diabetes/NN
indomethacin/NN receiving/VBG patients/NNS function/NN attention/NN particularly/RB patients/NNS mellitus/NNS
potassium/NN balance/NN function/NN attention/NN particularly/RB patients/NNS mellitus/NNS diabetes/NN
potassium/NN balance/NN function/NN attention/NN particularly/RB patients/NNS mellitus/NNS
indomethacin/NN receiving/VBG patients/NNS function/NN attention/NN particularly/RB preexisting/VBG disease/NN renal/JJ
indomethacin/NN receiving/VBG patients/NNS function/NN attention/NN particularly/RB preexisting/VBG disease/NN
cephalothin/NN therapy/NN receiving/VBG anemia/NN Coombs/NNP developed/VBD patient/NN disease/NN renal/JJ
cephalothin/NN therapy/NN receiving/VBG anemia/NN Coombs/NNP developed/VBD patient/NN disease/NN
levodopa/NN patients/NNS disease/NN Parkinson/NNP
levodopa/NN patients/NNS disease/NN Parkinson/NNP '/POS
levodopa/NN patients/NNS disease/NN s/JJ
levodopa/NN patients/NNS disease/NN
levodopa/NN patients/NNS disease/NN PD/NNP
celecoxib/JJ patients/NNS reactions/NNS skin/NN
celecoxib/JJ patients/NNS reactions/NNS
CE/NNP tolerability/NN evaluated/VBN group/NN patients/NNS history/NN reactions/NNS cutaneous/NNS
CE/NNP tolerability/NN evaluated/VBN group/NN patients/NNS history/NN reactions/NNS
P/NNP studied/VBD patients/NNS hypersensitivity/NN
N/NNP P/NNP studied/VBD patients/NNS hypersensitivity/NN
P/NN documented/VBN reaction/NN hypersensitivity/JJ
CE/NNP reaction/NN hypersensitivity/JJ
N/NNP P/NN documented/VBN reaction/NN hypersensitivity/JJ
CO/NNP pulses/NNS means/NNS applied/VBN pain/NN
2/CD CO/NNP pulses/NNS means/NNS applied/VBN pain/NN
CO/NNP pulses/NNS means/NNS applied/VBN induced/VBN pain/NN
2/CD CO/NNP pulses/NNS means/NNS applied/VBN induced/VBN pain/NN
CO/JJ stimuli/NNS obtained/VBN CSSEPs/NNPS correlates/NNS pain/NN
2/CD stimuli/NNS obtained/VBN CSSEPs/NNPS correlates/NNS pain/NN
lamivudine/NN combined/VBD globulin/NN hepatitis/NNP
lamivudine/NN combined/VBD globulin/NN B/NNP
lamivudine/NN prevention/NN recurrence/NN hepatitis/NNP
lamivudine/NN prevention/NN recurrence/NN B/NNP
lamivudine/JJ patients/NNS globulin/NN hepatitis/NNP
lamivudine/JJ patients/NNS globulin/NN B/NNP
lamivudine/JJ prophylaxis/NNS recurrence/NN B/NNP hepatitis/NNP
lamivudine/JJ prophylaxis/NNS recurrence/NN B/NNP
HBsAg/NNP survival/NN improved/VBN B/NNP recurrence/NN prophylaxis/NNS lamivudine/JJ patients/NNS globulin/NN hepatitis/NNP
HBsAg/NNP survival/NN improved/VBN B/NNP recurrence/NN prophylaxis/NNS lamivudine/JJ patients/NNS globulin/NN B/NNP
HBsAg/NNP survival/NN improved/VBN B/NNP hepatitis/NNP
HBsAg/NNP survival/NN improved/VBN B/NNP
Verapamil/JJ test/NN hyperprolactinemia/NN
Verapamil/NNP test/NN investigated/VBN tool/NN diagnosis/NN hyperprolactinemia/NN
verapamil/NN value/NN investigate/VB population/NN screened/VBD macroprolactinemia/NN
verapamil/VB hyperprolactinemia/NN
Verapamil/NNP increased/VBD controls/NNS N/NNP macroprolactinoma/NNP
risperidone/NN pseudoprolactinoma/NN
Verapamil/NNP responsiveness/NNS finding/NN diagnosis/NN hyperprolactinemia/NN
verapamil/JJ unresponsiveness/NNS discriminates/VBZ causes/NNS hyperprolactinemia/NN
oxygen/NN nitrative/VBP reported/VBD present/JJ adriamycin/NN cardiotoxicity/NN
adriamycin/NN cardiotoxicity/NN
ADR/NNP adriamycin/NN cardiotoxicity/NN
nitrogen/NN species/NNS reported/VBD present/JJ adriamycin/NN cardiotoxicity/NN
4/CD HNE/NNP showed/VBD point/NN appeared/VBD injury/NN mitochondrial/JJ
4/CD HNE/NNP showed/VBD point/NN appeared/VBD injury/NN
HNE/NNP showed/VBD point/NN appeared/VBD injury/NN mitochondrial/JJ
HNE/NNP showed/VBD point/NN appeared/VBD injury/NN
sodium/NN mmol/NN mosmol/NN SIADH/NNP
sodium/NN osmolality/NN mosmol/NN SIADH/NNP
zinc/NN induced/VBN hearing/VBG
zinc/NN induced/VBN hearing/VBG loss/NN
superoxide/JJ protects/NNS zinc/NN induced/VBN hearing/VBG
superoxide/JJ protects/NNS zinc/NN induced/VBN hearing/VBG loss/NN
copper/NN Overexpression/VBN zinc/NN induced/VBN hearing/VBG
copper/NN Overexpression/VBN zinc/NN induced/VBN hearing/VBG loss/NN
superoxide/JJ radicals/NNS formation/NN catalyze/VBP aminoglycoside/VBP observations/NNS deduced/VBN participation/NN species/NNS aminoglycoside/NN induced/VBN ototoxicity/RB
superoxide/JJ radicals/NNS formation/NN catalyze/VBP attenuate/VBP ototoxicity/RB
aminoglycoside/NN induced/VBN ototoxicity/RB
aminoglycoside/NN species/NNS participation/NN deduced/VBN observations/NNS aminoglycoside/VBP catalyze/VBP attenuate/VBP ototoxicity/RB
aminoglycoside/VBP observations/NNS deduced/VBN participation/NN species/NNS aminoglycoside/NN induced/VBN ototoxicity/RB
aminoglycoside/VBP catalyze/VBP attenuate/VBP ototoxicity/RB
oxygen/NN species/NNS aminoglycoside/NN induced/VBN ototoxicity/RB
oxygen/NN species/NNS participation/NN deduced/VBN observations/NNS aminoglycoside/VBP catalyze/VBP attenuate/VBP ototoxicity/RB
iron/NN complexes/NNS catalyze/VBP aminoglycoside/VBP observations/NNS deduced/VBN participation/NN species/NNS aminoglycoside/NN induced/VBN ototoxicity/RB
iron/NN complexes/NNS catalyze/VBP attenuate/VBP ototoxicity/RB
Zn/NNP overexpression/NN hypothesized/VBN protect/VB ototoxicity/NN
superoxide/JJ dismutase/NN protect/VB ototoxicity/NN
Cu/NNP Zn/NNP overexpression/NN hypothesized/VBN protect/VB ototoxicity/NN
superoxide/JJ dismutase/NN overexpression/NN protection/NN supports/VBZ plays/VBZ role/NN aminoglycoside/NN induced/VBN ototoxicity/RB
aminoglycoside/NN induced/VBN ototoxicity/RB
Clonazepam/VB epilepsy/NN
clonazepam/NN treated/VBN patients/NNS types/NNS epilepsy/NN spasms/NNS infantile/JJ
clonazepam/NN treated/VBN patients/NNS types/NNS epilepsy/NN spasms/NNS
clonazepam/NN treated/VBN patients/NNS types/NNS epilepsy/NN
carboplatin/NN combined/VBN directed/VBD patients/NNS non/NN
carboplatin/NN combined/VBN directed/VBD patients/NNS small/JJ
carboplatin/NN combined/VBN directed/VBD patients/NNS cancer/NN cell/NN
carboplatin/NN combined/VBN directed/VBD patients/NNS cancer/NN lung/NN
carboplatin/NN combined/VBN directed/VBD patients/NNS cancer/NN
Paclitaxel/NNP directed/VBD patients/NNS non/NN
Paclitaxel/NNP directed/VBD patients/NNS small/JJ
Paclitaxel/NNP directed/VBD patients/NNS cancer/NN cell/NN
Paclitaxel/NNP directed/VBD patients/NNS cancer/NN lung/NN
Paclitaxel/NNP directed/VBD patients/NNS cancer/NN
Taxol/NNP Bristol/NNP Paclitaxel/NNP directed/VBD patients/NNS non/NN
Taxol/NNP Bristol/NNP Paclitaxel/NNP directed/VBD patients/NNS small/JJ
Taxol/NNP Bristol/NNP Paclitaxel/NNP directed/VBD patients/NNS cancer/NN cell/NN
Taxol/NNP Bristol/NNP Paclitaxel/NNP directed/VBD patients/NNS cancer/NN lung/NN
Taxol/NNP Bristol/NNP Paclitaxel/NNP directed/VBD patients/NNS cancer/NN
paclitaxel/NN trial/NN patients/NNS cohort/NN compared/VBN Toxicities/NNS
Carboplatin/NNP appear/VB add/VB toxicities/NNS hematologic/JJ
Carboplatin/NNP appear/VB add/VB toxicities/NNS
carboplatin/NN combination/NN dosed/VBN appear/VB add/VB toxicities/NNS hematologic/JJ
carboplatin/NN combination/NN dosed/VBN appear/VB add/VB toxicities/NNS
platinum/JJ ovarian/NN m/NN trial/NN carcinoma/NN
platinum/JJ ovarian/NN m/NN trial/NN carcinoma/NN peritoneum/NN of/IN
platinum/JJ ovarian/NN m/NN trial/NN carcinoma/NN peritoneum/NN the/DT
platinum/JJ ovarian/NN m/NN trial/NN carcinoma/NN peritoneum/NN
platinum/JJ ovarian/NN
platinum/JJ ovarian/NN and/CC
platinum/JJ ovarian/NN cancers/NNS fallopian/NN
platinum/JJ ovarian/NN cancers/NNS tube/NN
platinum/JJ ovarian/NN cancers/NNS
doxorubicin/NN trial/NN carcinoma/NN
doxorubicin/NN trial/NN carcinoma/NN peritoneum/NN of/IN
doxorubicin/NN trial/NN carcinoma/NN peritoneum/NN the/DT
doxorubicin/NN trial/NN carcinoma/NN peritoneum/NN
paclitaxel/JJ ovarian/NN
paclitaxel/JJ ovarian/NN and/CC
paclitaxel/JJ ovarian/NN cancers/NNS fallopian/NN
paclitaxel/JJ ovarian/NN cancers/NNS tube/NN
paclitaxel/JJ ovarian/NN cancers/NNS
paclitaxel/JJ ovarian/NN m/NN trial/NN carcinoma/NN
paclitaxel/JJ ovarian/NN m/NN trial/NN carcinoma/NN peritoneum/NN of/IN
paclitaxel/JJ ovarian/NN m/NN trial/NN carcinoma/NN peritoneum/NN the/DT
paclitaxel/JJ ovarian/NN m/NN trial/NN carcinoma/NN peritoneum/NN
doxorubicin/NN trial/NN m/NN ovarian/NN
doxorubicin/NN trial/NN m/NN ovarian/NN and/CC
doxorubicin/NN trial/NN m/NN ovarian/NN cancers/NNS fallopian/NN
doxorubicin/NN trial/NN m/NN ovarian/NN cancers/NNS tube/NN
doxorubicin/NN trial/NN m/NN ovarian/NN cancers/NNS
doxorubicin/NN demonstrated/VBN agent/NN platinum/NN cancer/NN ovarian/JJ
doxorubicin/NN demonstrated/VBN agent/NN platinum/NN cancer/NN
Doxil/NNP doxorubicin/NN demonstrated/VBN agent/NN platinum/NN cancer/NN ovarian/JJ
Doxil/NNP doxorubicin/NN demonstrated/VBN agent/NN platinum/NN cancer/NN
platinum/NN agent/NN limiting/VBG erythrodysesthesia/NN
platinum/NN agent/NN demonstrated/VBN hand/VB
platinum/NN agent/NN demonstrated/VBN hand/VB foot/NN -/JJ
platinum/NN agent/NN demonstrated/VBN hand/VB foot/NN
platinum/NN agent/NN demonstrated/VBN hand/VB syndrome/NN
platinum/NN agent/NN limiting/VBG toxicity/NN
platinum/NN cancer/NN ovarian/JJ
platinum/NN cancer/NN
doxorubicin/NN demonstrated/VBN agent/NN limiting/VBG toxicity/NN
Doxil/NNP doxorubicin/NN demonstrated/VBN agent/NN limiting/VBG toxicity/NN
platinum/NN agent/NN demonstrated/VBN stomatitis/VBZ
platinum/NN carcinoma/NN peritoneal/JJ
platinum/NN carcinoma/NN
platinum/NN carcinoma/NN Patients/NNS cancers/NNS ovarian/NN
platinum/NN carcinoma/NN Patients/NNS cancers/NNS ovarian/NN or/CC
platinum/NN carcinoma/NN Patients/NNS cancers/NNS ovarian/NN fallopian/NN
platinum/NN carcinoma/NN Patients/NNS cancers/NNS tube/NN
platinum/NN carcinoma/NN Patients/NNS cancers/NNS
doxorubicin/NN treated/VBN METHODS/NNP Patients/NNS carcinoma/NN peritoneal/JJ
doxorubicin/NN treated/VBN METHODS/NNP Patients/NNS carcinoma/NN
paclitaxel/NN treated/VBN METHODS/NNP Patients/NNS cancers/NNS ovarian/NN
paclitaxel/NN treated/VBN METHODS/NNP Patients/NNS cancers/NNS ovarian/NN or/CC
paclitaxel/NN treated/VBN METHODS/NNP Patients/NNS cancers/NNS ovarian/NN fallopian/NN
paclitaxel/NN treated/VBN METHODS/NNP Patients/NNS cancers/NNS tube/NN
paclitaxel/NN treated/VBN METHODS/NNP Patients/NNS cancers/NNS
paclitaxel/NN treated/VBN METHODS/NNP Patients/NNS carcinoma/NN peritoneal/JJ
paclitaxel/NN treated/VBN METHODS/NNP Patients/NNS carcinoma/NN
doxorubicin/NN treated/VBN METHODS/NNP Patients/NNS cancers/NNS ovarian/NN
doxorubicin/NN treated/VBN METHODS/NNP Patients/NNS cancers/NNS ovarian/NN or/CC
doxorubicin/NN treated/VBN METHODS/NNP Patients/NNS cancers/NNS ovarian/NN fallopian/NN
doxorubicin/NN treated/VBN METHODS/NNP Patients/NNS cancers/NNS tube/NN
doxorubicin/NN treated/VBN METHODS/NNP Patients/NNS cancers/NNS
doxorubicin/NN results/NNS toxicity/NN
platinum/NN well/JJ cancer/NN ovarian/NN
platinum/NN well/JJ cancer/NN
paclitaxel/JJ well/JJ cancer/NN ovarian/NN
paclitaxel/JJ well/JJ cancer/NN
zidovudine/NNP patient/NN induced/VBN AIDS/NNP
caffeine/NN exposure/NN induced/VBN offspring/NN glomerulosclerosis/NNS
creatinine/NN levels/NNS accompanied/VBN exhibited/VBD glomerulosclerosis/NNS
creatinine/NN levels/NNS accompanied/VBN exhibited/VBD glomerulosclerosis/NNS fibrosis/NN interstitial/JJ
creatinine/NN levels/NNS accompanied/VBN exhibited/VBD glomerulosclerosis/NNS fibrosis/NN
isotretinoin/NN drug/NN treatment/NN acne/NN
Isotretinoin/NNP contraindicated/VBN use/NN microphthalmos/NNS hypoplasia/NN optic/JJ
Isotretinoin/NNP contraindicated/VBN use/NN microphthalmos/NNS hypoplasia/NN nerve/NN
Isotretinoin/NNP contraindicated/VBN use/NN microphthalmos/NNS hypoplasia/NN
Isotretinoin/NNP contraindicated/VBN pregnancy/NN abnormalities/NNS congenital/JJ
Isotretinoin/NNP contraindicated/VBN pregnancy/NN abnormalities/NNS
Isotretinoin/NNP contraindicated/VBN use/NN microphthalmos/NNS hypertelorism/NN
Isotretinoin/NNP contraindicated/VBN use/NN microphthalmos/NNS
Sotalol/NNP induced/VBN patient/NN cardiomyopathy/NN dilated/JJ
Sotalol/NNP induced/VBN patient/NN cardiomyopathy/NN
Sotalol/NNP induced/VBN patient/NN cardiomyopathy/NN associated/VBN tachycardia/NN ventricular/NN
Sotalol/NNP induced/VBN patient/NN cardiomyopathy/NN associated/VBN tachycardia/NN
nifekalant/JJ hydrochloride/NN administration/NN terminated/VBN VT/NNP
hydrochloride/NN administration/NN terminated/VBN VT/NNP
sotalol/NN agent/NN effective/JJ prevention/NN VT/NNP
atropine/JJ sulphate/NN rectified/VBN experienced/VBD drop/NN
atropine/JJ sulphate/NN rectified/VBN experienced/VBD pressure/NN in/IN
atropine/JJ sulphate/NN rectified/VBN experienced/VBD pressure/NN blood/NN
atropine/JJ sulphate/NN rectified/VBN experienced/VBD pressure/NN
sulphate/NN rectified/VBN experienced/VBD drop/NN
sulphate/NN rectified/VBN experienced/VBD pressure/NN in/IN
sulphate/NN rectified/VBN experienced/VBD pressure/NN blood/NN
sulphate/NN rectified/VBN experienced/VBD pressure/NN
Isradipine/JJ treatment/NN hypertension/NN
isradipine/NN reported/VBD frequent/JJ headache/NN palpitation/NN
propofol/NN formulations/NNS using/VBG depression/NN cardiovascular/JJ
propofol/NN formulations/NNS using/VBG depression/NN
bupivacaine/NN treatment/NN Pre/NNP induced/VBN depression/NN cardiovascular/JJ
bupivacaine/NN treatment/NN Pre/NNP induced/VBN depression/NN
propofol/NN content/NN alleviate/VB shown/VBN Pre/VBN induced/VBN cardiotoxicity/RB
propofol/NN effects/NNS investigate/VB bupivacaine/NN induced/VBN cardiotoxicity/RB
bupivacaine/JJ consumption/NN amount/NN asystole/VB time/NN mean/VB recorded/VBD occurrence/NN dysrhythmia/NN
propofol/NN treatment/NN pre/NN induced/VBN effects/NNS cardiotoxic/JJ
propofol/NN treatment/NN pre/NN induced/VBN effects/NNS cardiotoxic/JJ
phenylephrine/NN effect/NN ischemia/NN cerebral/JJ
phenylephrine/NN effect/NN ischemia/NN
phenylephrine/NN effect/NN induced/VBN injury/NN ischemic/JJ
phenylephrine/NN effect/NN induced/VBN injury/NN brain/NN
phenylephrine/NN effect/NN induced/VBN injury/NN
phenylephrine/NN effect/NN determined/VBN min/NN occlusion/NN middle/JJ
phenylephrine/NN effect/NN determined/VBN min/NN occlusion/NN cerebral/JJ
phenylephrine/NN effect/NN determined/VBN min/NN occlusion/NN artery/NN
phenylephrine/NN effect/NN determined/VBN min/NN occlusion/NN
2/CD using/VBG staining/VBG evaluated/VBN evaluated/VBN 3/CD 5/CD chloride/NN edema/NN
3/CD 5/CD chloride/NN edema/NN
5/CD chloride/NN edema/NN
triphenyltetrazolium/NN chloride/NN edema/NN
chloride/NN edema/NN
2/CD using/VBG staining/VBG evaluated/VBN rats/NNS injury/NN brain/NN
2/CD using/VBG staining/VBG evaluated/VBN rats/NNS injury/NN
3/CD evaluated/VBN evaluated/VBN rats/NNS injury/NN brain/NN
3/CD evaluated/VBN evaluated/VBN rats/NNS injury/NN
5/CD 3/CD evaluated/VBN evaluated/VBN rats/NNS injury/NN brain/NN
5/CD 3/CD evaluated/VBN evaluated/VBN rats/NNS injury/NN
triphenyltetrazolium/NN chloride/NN 5/CD 3/CD evaluated/VBN evaluated/VBN rats/NNS injury/NN brain/NN
triphenyltetrazolium/NN chloride/NN 5/CD 3/CD evaluated/VBN evaluated/VBN rats/NNS injury/NN
chloride/NN 5/CD 3/CD evaluated/VBN evaluated/VBN rats/NNS injury/NN brain/NN
chloride/NN 5/CD 3/CD evaluated/VBN evaluated/VBN rats/NNS injury/NN
Evans/NNP Blue/NNP greater/JJR group/NN HTN/NNP
Blue/NNP greater/JJR group/NN HTN/NNP
Evans/NNP Blue/NNP greater/JJR group/NN greater/JJR group/NN HTN/NNP
Blue/NNP greater/JJR group/NN greater/JJR group/NN HTN/NNP
androgen/NN thalidomide/NN study/NN prostate/NN
androgen/NN thalidomide/NN study/NN prostate/NN cancer/NN
thalidomide/NN study/NN prostate/NN
thalidomide/NN study/NN prostate/NN cancer/NN
thalidomide/NN effects/NNS assessed/VBN trials/NNS patients/NNS malignancies/NNS solid/JJ haematological/JJ
thalidomide/NN effects/NNS assessed/VBN trials/NNS patients/NNS malignancies/NNS
androgen/NN men/NNS cancer/NN prostate/NN
androgen/NN men/NNS cancer/NN
thalidomide/NN mg/NN using/VBG men/NNS cancer/NN prostate/NN
thalidomide/NN mg/NN using/VBG men/NNS cancer/NN
dexamethasone/NN bortezomib/NN fasciitis/NNS containing/VBG patient/NN macroglobulinaemia/NNP Waldenstrom/NNP
dexamethasone/NN bortezomib/NN fasciitis/NNS containing/VBG patient/NN macroglobulinaemia/NNP
bortezomib/NN fasciitis/NNS containing/VBG patient/NN macroglobulinaemia/NNP Waldenstrom/NNP
bortezomib/NN fasciitis/NNS containing/VBG patient/NN macroglobulinaemia/NNP
Bortezomib/JJ dose/NN dexamethasone/VBP containing/VBG considered/VBN tolerable/JJ infections/NNS bacterial/JJ
Bortezomib/JJ dose/NN dexamethasone/VBP containing/VBG considered/VBN tolerable/JJ infections/NNS
dexamethasone/VBP containing/VBG considered/VBN tolerable/JJ infections/NNS bacterial/JJ
dexamethasone/VBP containing/VBG considered/VBN tolerable/JJ infections/NNS
Bortezomib/JJ dose/NN dexamethasone/VBP malignancies/NNS
dexamethasone/VBP malignancies/NNS
dexamethasone/JJ dose/NN treatment/NN suffered/VBD neutropenia/NN
bortezomib/JJ dose/NN treatment/NN suffered/VBD neutropenia/NN
dexamethasone/JJ dose/NN treatment/NN suffered/VBD case/NN 76/CD man/NN macroglobulinaemia/NNP Waldenstrom/NNP
dexamethasone/JJ dose/NN treatment/NN suffered/VBD case/NN 76/CD man/NN macroglobulinaemia/NNP
bortezomib/JJ dose/NN treatment/NN suffered/VBD case/NN 76/CD man/NN macroglobulinaemia/NNP Waldenstrom/NNP
bortezomib/JJ dose/NN treatment/NN suffered/VBD case/NN 76/CD man/NN macroglobulinaemia/NNP
bortezomib/VB related/VBN infections/NNS bacterial/JJ
bortezomib/VB related/VBN infections/NNS
dexamethasone/NN high/JJ bortezomib/VB related/VBN infections/NNS bacterial/JJ
dexamethasone/NN high/JJ bortezomib/VB related/VBN infections/NNS
angiotensin/NN doses/NNS Toleration/NNP inhibitors/NNS patients/NNS failure/NN heart/NN
angiotensin/NN doses/NNS Toleration/NNP inhibitors/NNS patients/NNS failure/NN
converting/JJ inhibitors/NNS patients/NNS failure/NN heart/NN
converting/JJ inhibitors/NNS patients/NNS failure/NN
enzyme/NN inhibitors/NNS patients/NNS failure/NN heart/NN
enzyme/NN inhibitors/NNS patients/NNS failure/NN
inhibitors/NNS patients/NNS failure/NN heart/NN
inhibitors/NNS patients/NNS failure/NN
angiotensin/NN Treatment/NNP BACKGROUND/NNP reduces/VBZ patients/NNS failure/NN heart/NN
angiotensin/NN Treatment/NNP BACKGROUND/NNP reduces/VBZ patients/NNS failure/NN
converting/VBG reduces/VBZ patients/NNS failure/NN heart/NN
converting/VBG reduces/VBZ patients/NNS failure/NN
enzyme/JJ inhibitors/NNS converting/VBG reduces/VBZ patients/NNS failure/NN heart/NN
enzyme/JJ inhibitors/NNS converting/VBG reduces/VBZ patients/NNS failure/NN
ACE/NNP inhibitors/NNS converting/VBG reduces/VBZ patients/NNS failure/NN heart/NN
ACE/NNP inhibitors/NNS converting/VBG reduces/VBZ patients/NNS failure/NN
inhibitors/NNS converting/VBG reduces/VBZ patients/NNS failure/NN heart/NN
inhibitors/NNS converting/VBG reduces/VBZ patients/NNS failure/NN
angiotensin/NN Treatment/NNP BACKGROUND/NNP reduces/VBZ patients/NNS failure/NN CHF/NNP
converting/VBG reduces/VBZ patients/NNS failure/NN CHF/NNP
enzyme/JJ inhibitors/NNS converting/VBG reduces/VBZ patients/NNS failure/NN CHF/NNP
ACE/NNP inhibitors/NNS converting/VBG reduces/VBZ patients/NNS failure/NN CHF/NNP
inhibitors/NNS converting/VBG reduces/VBZ patients/NNS failure/NN CHF/NNP
lisinopril/NN CHF/NNP
ACE/NNP inhibitor/NN receiving/VBG titrated/VBN doses/NNS required/VBN symptoms/NNS related/VBN hypotension/NN 2/CD because/RB dysfunction/NN renal/JJ
ACE/NNP inhibitor/NN receiving/VBG titrated/VBN doses/NNS required/VBN symptoms/NNS related/VBN hypotension/NN 2/CD because/RB dysfunction/NN
inhibitor/NN receiving/VBG titrated/VBN doses/NNS required/VBN symptoms/NNS related/VBN hypotension/NN 2/CD because/RB dysfunction/NN renal/JJ
inhibitor/NN receiving/VBG titrated/VBN doses/NNS required/VBN symptoms/NNS related/VBN hypotension/NN 2/CD because/RB dysfunction/NN
ACE/NNP inhibitor/NN receiving/VBG titrated/VBN doses/NNS required/VBN symptoms/NNS related/VBN hypotension/NN
inhibitor/NN receiving/VBG titrated/VBN doses/NNS required/VBN symptoms/NNS related/VBN hypotension/NN
ACE/NNP inhibitor/NN receiving/VBG titrated/VBN doses/NNS required/VBN symptoms/NNS related/VBN hypotension/NN 2/CD because/RB dysfunction/NN hyperkalemia/NN
inhibitor/NN receiving/VBG titrated/VBN doses/NNS required/VBN symptoms/NNS related/VBN hypotension/NN 2/CD because/RB dysfunction/NN hyperkalemia/NN
creatinine/JJ >/JJ Hg/NNP pressure/NN >/VBZ -RSB-/NNS patients/NNS diabetes/NN
ACE/NNP intolerance/NN risk/NN tolerated/VBN >/VBZ -RSB-/NNS patients/NNS diabetes/NN
inhibitor/NN intolerance/NN risk/NN tolerated/VBN >/VBZ -RSB-/NNS patients/NNS diabetes/NN
ACE/NNP therapy/NN patients/NNS CHF/NNP
inhibitor/NN therapy/NN patients/NNS CHF/NNP
argatroban/NN therapy/NN considerations/NNS harm/NN Reducing/VBG induced/VBN thrombocytopenia/NN
heparin/NN therapy/NN considerations/NNS harm/NN Reducing/VBG induced/VBN thrombocytopenia/NN
Argatroban/NNP hepatically/NN inhibitor/NN used/VBN prophylaxis/NNS thrombosis/NNS
Argatroban/NNP hepatically/NN thrombocytopenia/NN
Argatroban/NNP hepatically/NN thrombocytopenia/NN HIT/NNP
Argatroban/NNP hepatically/NN patients/NNS HIT/NNP
heparin/NN thrombosis/NNS
heparin/NN thrombosis/NNS prophylaxis/NNS used/VBN inhibitor/NN hepatically/NN thrombocytopenia/NN
heparin/NN thrombosis/NNS prophylaxis/NNS used/VBN inhibitor/NN hepatically/NN thrombocytopenia/NN HIT/NNP
heparin/NN thrombosis/NNS prophylaxis/NNS used/VBN inhibitor/NN hepatically/NN patients/NNS HIT/NNP
argatroban/NN therapy/NN considerations/NNS summarize/VB HIT/NNP
argatroban/NN dose/NN HIT/NNP
argatroban/NN dose/NN HIT/NNP microg/NN reduced/VBN patients/NNS impairment/NN hepatic/JJ
argatroban/NN dose/NN HIT/NNP microg/NN reduced/VBN patients/NNS impairment/NN
argatroban/NN investigated/VBN unnecessary/JJ age/NN obesity/NN
argatroban/NN therapy/NN HIT/NNP
argatroban/NN therapy/NN professionals/NNS familiarity/NN facilitate/VB reduction/NN harm/NN associated/VBN HIT/NNP
argatroban/NN errors/NNS g/NNP e/NNP HIT/NNP associated/VBN harm/NN reduction/NN facilitate/VB familiarity/NN professionals/NNS therapy/NN HIT/NNP
argatroban/NN errors/NNS g/NNP e/NNP HIT/NNP
cisplatin/NN receiving/VBG patients/NNS Hypotension/NNP cardiotoxicity/NN
5/CD cisplatin/NN receiving/VBG patients/NNS Hypotension/NNP cardiotoxicity/NN
fluorouracil/VBP Hypotension/NNP cardiotoxicity/NN
5/CD cisplatin/NN treated/VBN developed/VBD patients/NNS carcinoma/NN colorectal/JJ
5/CD cisplatin/NN treated/VBN developed/VBD patients/NNS carcinoma/NN
fluorouracil/NN 5/CD cisplatin/NN treated/VBN developed/VBD patients/NNS carcinoma/NN colorectal/JJ
fluorouracil/NN 5/CD cisplatin/NN treated/VBN developed/VBD patients/NNS carcinoma/NN
5/CD fluorouracil/NN 5/CD cisplatin/NN treated/VBN developed/VBD patients/NNS carcinoma/NN colorectal/JJ
5/CD fluorouracil/NN 5/CD cisplatin/NN treated/VBN developed/VBD patients/NNS carcinoma/NN
FU/NNP 5/CD fluorouracil/NN 5/CD cisplatin/NN treated/VBN developed/VBD patients/NNS carcinoma/NN colorectal/JJ
FU/NNP 5/CD fluorouracil/NN 5/CD cisplatin/NN treated/VBN developed/VBD patients/NNS carcinoma/NN
cisplatin/NN treated/VBN developed/VBD patients/NNS carcinoma/NN colorectal/JJ
cisplatin/NN treated/VBN developed/VBD patients/NNS carcinoma/NN
CDDP/NNP cisplatin/NN treated/VBN developed/VBD patients/NNS carcinoma/NN colorectal/JJ
CDDP/NNP cisplatin/NN treated/VBN developed/VBD patients/NNS carcinoma/NN
CDDP/NNP influenced/VBN cardiotoxicity/NN
5/CD manifestations/NNS cardiotoxicity/NN
FU/NNP cardiotoxicity/NN
dexamethasone/NN days/NNS 4/CD treated/VBN woman/NN myeloma/NN multiple/JJ
dexamethasone/NN days/NNS 4/CD treated/VBN woman/NN myeloma/NN
vincristine/NN infusion/NN 4/CD treated/VBN woman/NN myeloma/NN multiple/JJ
vincristine/NN infusion/NN 4/CD treated/VBN woman/NN myeloma/NN
doxorubicin/NN vincristine/NN infusion/NN 4/CD treated/VBN woman/NN myeloma/NN multiple/JJ
doxorubicin/NN vincristine/NN infusion/NN 4/CD treated/VBN woman/NN myeloma/NN
Minocycline/NNP induced/VBN vasculitis/NNS
minocycline/NN taking/VBG pustulosis/NNS developed/VBN fever/NN pain/NN testicular/NN
minocycline/NN taking/VBG pustulosis/NNS developed/VBN fever/NN pain/NN
minocycline/NN taking/VBG pustulosis/NNS palmoplantar/NN
minocycline/NN taking/VBG pustulosis/NNS
minocycline/NN taking/VBG pustulosis/NNS developed/VBN fever/NN polyneuropathy/NN
minocycline/NN taking/VBG pustulosis/NNS developed/VBN fever/NN myalgias/NNS
minocycline/NN taking/VBG pustulosis/NNS developed/VBN fever/NN
minocycline/NN case/NN vasculitis/NNS
Fluoxetine/NNP gaining/VBG acceptance/NN treatment/NN depression/NN
serotonin/NN inhibitor/NN Fluoxetine/NNP gaining/VBG acceptance/NN treatment/NN depression/NN
fluoxetine/NN developed/VBD cases/NNS adolescents/NNS depressed/JJ
fluoxetine/JJ pharmacotherapy/NN mania/NN development/NN factors/NNS combination/NN attention/NN
fluoxetine/JJ pharmacotherapy/NN mania/NN development/NN factors/NNS combination/NN disorder/NN deficit/NN
fluoxetine/JJ pharmacotherapy/NN mania/NN development/NN factors/NNS combination/NN disorder/NN hyperactivity/NN
fluoxetine/JJ pharmacotherapy/NN mania/NN development/NN factors/NNS combination/NN disorder/NN
fluoxetine/JJ pharmacotherapy/NN mania/NN development/NN factors/NNS combination/NN depression/NN
fluoxetine/JJ pharmacotherapy/NN mania/NN development/NN factors/NNS combination/NN depression/NN features/NNS psychotic/JJ
fluoxetine/JJ pharmacotherapy/NN mania/NN development/NN factors/NNS combination/NN history/NN disorder/NN affective/JJ
fluoxetine/JJ pharmacotherapy/NN mania/NN development/NN factors/NNS combination/NN history/NN disorder/NN
amphetamine/NN influenced/VBN hyperactivity/NN
amphetamine/NN influenced/VBN induced/VBN Cocaine/NNP induced/VBN hyperactivity/RB
Cocaine/NNP induced/VBN influenced/VBN hyperactivity/NN
Cocaine/NNP induced/VBN hyperactivity/RB
adenosine/JJ agonists/NNS influenced/VBN hyperactivity/NN
adenosine/JJ agonists/NNS influenced/VBN induced/VBN Cocaine/NNP induced/VBN hyperactivity/RB
amphetamine/JJ induced/VBN cocaine/NN agonists/NNS influence/NN examined/VBN hyperactivity/RB
cocaine/NN agonists/NNS influence/NN examined/VBN hyperactivity/RB
adenosine/JJ agonists/NNS influence/NN examined/VBN hyperactivity/RB
adenosine/JJ agonists/NNS decreased/VBD
adenosine/JJ agonists/NNS decreased/VBD activity/NN the/DT
adenosine/JJ agonists/NNS decreased/VBD activity/NN locomotor/NN
adenosine/JJ agonists/NNS decreased/VBD activity/NN
amphetamine/NN induced/VBN hyperactivity/RB
amphetamine/NN induced/VBN hyperactivity/RB
cocaine/NN active/JJ those/DT doses/NNS induced/VBN hyperactivity/RB
cocaine/NN active/JJ those/DT doses/NNS induced/VBN amphetamine/NN induced/VBN hyperactivity/RB
adenosine/JJ receptor/NN agonists/VBZ amphetamine/NN induced/VBN hyperactivity/RB
adenosine/JJ receptor/NN agonists/VBZ amphetamine/NN induced/VBN hyperactivity/RB
amphetamine/VBN shown/VBN induced/VBN influenced/VBN hyperactivity/NN
amphetamine/VBN shown/VBN induced/VBN hyperactivity/RB
amphetamine/NN influenced/VBN hyperactivity/NN
amphetamine/NN influenced/VBN induced/VBN shown/VBN induced/VBN hyperactivity/RB
cocaine/NN reduce/VB adenosine/VBP shown/VBN induced/VBN influenced/VBN hyperactivity/NN
cocaine/NN reduce/VB adenosine/VBP shown/VBN induced/VBN hyperactivity/RB
cocaine/NN indicate/VBP induced/VBN shown/VBN induced/VBN influenced/VBN hyperactivity/NN
cocaine/NN indicate/VBP induced/VBN shown/VBN induced/VBN hyperactivity/RB
adenosine/VBP shown/VBN induced/VBN influenced/VBN hyperactivity/NN
adenosine/VBP shown/VBN induced/VBN hyperactivity/RB
adenosine/JJ agonists/NNS influenced/VBN hyperactivity/NN
adenosine/JJ agonists/NNS influenced/VBN induced/VBN shown/VBN induced/VBN hyperactivity/RB
sumatriptan/NN subcutaneously/NN headache/NN cluster/NN
sumatriptan/NN subcutaneously/NN headache/NN
warfarin/NN induced/VBN epiphyses/NNS nasal/JJ
warfarin/NN induced/VBN epiphyses/NNS hypoplasia/JJ
warfarin/NN induced/VBN embryopathy/RB
warfarin/NN treated/VBN mothers/NNS born/VBN infants/NNS reported/VBN hypoplasia/NN Nasal/JJ
warfarin/NN treated/VBN mothers/NNS born/VBN infants/NNS reported/VBN hypoplasia/NN
Histamine/JJ antagonists/NNS induced/VBN hypotension/NN
MT/NNP induction/NN effect/NN explore/VB aimed/VBN study/NN dysfunction/NN cognitive/NN
MT/NNP induction/NN effect/NN explore/VB aimed/VBN study/NN dysfunction/NN
BCNU/JJ administration/NN resulted/VBD deterioration/NN
BCNU/JJ administration/NN resulted/VBD deterioration/NN memory/NN of/IN
BCNU/JJ administration/NN resulted/VBD deterioration/NN memory/NN learning/NN
BCNU/JJ administration/NN resulted/VBD deterioration/NN memory/NN learning/NN and/CC
BCNU/JJ administration/NN resulted/VBD deterioration/NN memory/NN learning/NN short/JJ
BCNU/JJ administration/NN resulted/VBD deterioration/NN memory/NN term/NN
BCNU/JJ administration/NN resulted/VBD deterioration/NN memory/NN
glutathione/VBP resulted/VBD deterioration/NN
glutathione/VBP resulted/VBD deterioration/NN memory/NN of/IN
glutathione/VBP resulted/VBD deterioration/NN memory/NN learning/NN
glutathione/VBP resulted/VBD deterioration/NN memory/NN learning/NN and/CC
glutathione/VBP resulted/VBD deterioration/NN memory/NN learning/NN short/JJ
glutathione/VBP resulted/VBD deterioration/NN memory/NN term/NN
glutathione/VBP resulted/VBD deterioration/NN memory/NN
glutathione/NN activity/NN content/JJ glutathione/VBP resulted/VBD deterioration/NN
glutathione/NN activity/NN content/JJ glutathione/VBP resulted/VBD deterioration/NN memory/NN of/IN
glutathione/NN activity/NN content/JJ glutathione/VBP resulted/VBD deterioration/NN memory/NN learning/NN
glutathione/NN activity/NN content/JJ glutathione/VBP resulted/VBD deterioration/NN memory/NN learning/NN and/CC
glutathione/NN activity/NN content/JJ glutathione/VBP resulted/VBD deterioration/NN memory/NN learning/NN short/JJ
glutathione/NN activity/NN content/JJ glutathione/VBP resulted/VBD deterioration/NN memory/NN term/NN
glutathione/NN activity/NN content/JJ glutathione/VBP resulted/VBD deterioration/NN memory/NN
GSH/NNP glutathione/NN activity/NN content/JJ glutathione/VBP resulted/VBD deterioration/NN
GSH/NNP glutathione/NN activity/NN content/JJ glutathione/VBP resulted/VBD deterioration/NN memory/NN of/IN
GSH/NNP glutathione/NN activity/NN content/JJ glutathione/VBP resulted/VBD deterioration/NN memory/NN learning/NN
GSH/NNP glutathione/NN activity/NN content/JJ glutathione/VBP resulted/VBD deterioration/NN memory/NN learning/NN and/CC
GSH/NNP glutathione/NN activity/NN content/JJ glutathione/VBP resulted/VBD deterioration/NN memory/NN learning/NN short/JJ
GSH/NNP glutathione/NN activity/NN content/JJ glutathione/VBP resulted/VBD deterioration/NN memory/NN term/NN
GSH/NNP glutathione/NN activity/NN content/JJ glutathione/VBP resulted/VBD deterioration/NN memory/NN
MT/NNP alpha/NNP factor/NN tumor/NN
BCNU/JJ administration/NN increased/VBD factor/NN necrosis/NNS
malondialdehyde/NN contents/NNS MT/NNP alpha/NNP factor/NN necrosis/NNS
MDA/NNP contents/NNS MT/NNP alpha/NNP factor/NN necrosis/NNS
MT/NNP alpha/NNP factor/NN necrosis/NNS
BCNU/JJ administration/NN increased/VBD factor/NN tumor/NN
malondialdehyde/NN contents/NNS MT/NNP alpha/NNP factor/NN tumor/NN
MDA/NNP contents/NNS MT/NNP alpha/NNP factor/NN tumor/NN
MDA/NNP TNFalpha/NNP levels/NNS counteracted/VBN induced/VBN toxicity/NN
GSH/NNP depletion/NN inhibition/NNP prevented/VBD induced/VBN toxicity/NN
MT/NNP halts/NNS BCNU/VBD induced/VBN toxicity/NN
BCNU/VBD induced/VBN toxicity/NN
biperiden/NN lactate/NN application/NN led/VBD long/JJ reaction/NN characterized/VBN bradycardia/NN dysphagia/NN
lactate/NN application/NN led/VBD long/JJ reaction/NN characterized/VBN bradycardia/NN dysphagia/NN
biperiden/NN lactate/NN application/NN led/VBD long/JJ reaction/NN characterized/VBN bradycardia/NN
lactate/NN application/NN led/VBD long/JJ reaction/NN characterized/VBN bradycardia/NN
biperiden/NN lactate/NN application/NN led/VBD long/JJ reaction/NN characterized/VBN bradycardia/NN dysarthria/NN
lactate/NN application/NN led/VBD long/JJ reaction/NN characterized/VBN bradycardia/NN dysarthria/NN
biperiden/NN lactate/NN application/NN led/VBD 38/CD suffering/NN neuralgia/NN postzosteric/JJ
lactate/NN application/NN led/VBD 38/CD suffering/NN neuralgia/NN postzosteric/JJ
biperiden/NN lactate/NN application/NN led/VBD 38/CD suffering/NN neuralgia/NN trigeminal/NN
biperiden/NN lactate/NN application/NN led/VBD 38/CD suffering/NN neuralgia/NN
lactate/NN application/NN led/VBD 38/CD suffering/NN neuralgia/NN trigeminal/NN
lactate/NN application/NN led/VBD 38/CD suffering/NN neuralgia/NN
atropine/NN effect/NN dose/NN attributed/VBN' attributed/VBN Bradycardia/NNP
muscarine/JJ receptors/NNS drugs/NNS effect/NN dose/NN attributed/VBN' attributed/VBN Bradycardia/NNP
spironolactone/JJ d/SYM d/NNP treated/VBN woman/NN hyperaldosteronism/NN
verapamil/JJ d/NNP treated/VBN woman/NN hyperaldosteronism/NN
melphalan/VBN patients/NNS amyloidosis/NNS primary/JJ
melphalan/VBN patients/NNS amyloidosis/NNS systemic/JJ
melphalan/VBN patients/NNS amyloidosis/NNS
creatinine/NN level/NN dL/NN mg/VBN 5/CD insufficiency/NN Acute/JJ
creatinine/NN level/NN dL/NN mg/VBN 5/CD insufficiency/NN renal/JJ
creatinine/NN level/NN dL/NN mg/VBN 5/CD insufficiency/NN
creatinine/NN level/NN dL/NN mg/VBN 5/CD insufficiency/NN ARI/NNP
melphalan/NN injury/NN prerequisite/NN Ongoing/VBG injury/NN tubular/JJ
melphalan/NN injury/NN prerequisite/NN Ongoing/VBG injury/NN
bis/JJ phosphate/NN effect/NN role/NN induced/NNP nephrotoxicity/NN
p/NN phosphate/NN effect/NN role/NN induced/NNP nephrotoxicity/NN
nitrophenyl/NN p/NN phosphate/NN effect/NN role/NN induced/NNP nephrotoxicity/NN
phosphate/NN effect/NN role/NN induced/NNP nephrotoxicity/NN
bis/JJ phosphate/NN effect/NN role/NN nephrotoxicity/NN
p/NN phosphate/NN effect/NN role/NN nephrotoxicity/NN
nitrophenyl/NN p/NN phosphate/NN effect/NN role/NN nephrotoxicity/NN
phosphate/NN effect/NN role/NN nephrotoxicity/NN
acetaminophen/NN aminophenol/NN role/NN induced/NNP nephrotoxicity/NN
acetaminophen/NN aminophenol/NN role/NN nephrotoxicity/NN
acetaminophen/NN phosphate/NN effect/NN role/NN induced/NNP nephrotoxicity/NN
acetaminophen/NN phosphate/NN effect/NN role/NN nephrotoxicity/NN
p/NN role/NN induced/NNP nephrotoxicity/NN
aminophenol/NN role/NN induced/NNP nephrotoxicity/NN
p/NN role/NN nephrotoxicity/NN
aminophenol/NN role/NN nephrotoxicity/NN
p/NN acetaminophen/NN phosphate/NN effect/NN role/NN induced/NNP nephrotoxicity/NN
aminophenol/JJ nephrotoxicity/NN role/NN induced/NNP nephrotoxicity/NN
p/NN acetaminophen/NN phosphate/NN effect/NN role/NN nephrotoxicity/NN
aminophenol/JJ nephrotoxicity/NN
APAP/NNP induced/VBN nephrotoxicity/RB
PAP/NNP formation/NN step/NN APAP/NNP induced/VBN nephrotoxicity/RB
bis/NNP phosphate/NN effect/NN nephrotoxicity/NN
p/NN phosphate/NN effect/NN nephrotoxicity/NN
nitrophenyl/NN p/NN phosphate/NN effect/NN nephrotoxicity/NN
phosphate/NN effect/NN nephrotoxicity/NN
BNPP/NNP effect/NN nephrotoxicity/NN
APAP/NNP effect/NN nephrotoxicity/NN
PAP/NNP nephrotoxicity/NN
BNPP/NNP animals/NNS Pretreatment/NNP resulted/VBD reduction/NN nephrotoxicity/NN
BNPP/NNP animals/NNS Pretreatment/NNP resulted/VBD nephrotoxicity/RB
APAP/NNP prior/RB animals/NNS Pretreatment/NNP resulted/VBD reduction/NN nephrotoxicity/NN
APAP/NNP prior/RB animals/NNS Pretreatment/NNP resulted/VBD nephrotoxicity/RB
APAP/NNP nephrotoxicity/NN
APAP/NNP nephrotoxicity/NN reduction/NN resulted/VBD nephrotoxicity/RB
PAP/NNP APAP/NNP prior/RB animals/NNS Pretreatment/NNP resulted/VBD reduction/NN nephrotoxicity/NN
PAP/NNP APAP/NNP prior/RB animals/NNS Pretreatment/NNP resulted/VBD nephrotoxicity/RB
PAP/NNP reduction/NN nephrotoxicity/NN
PAP/NNP reduction/NN resulted/VBD nephrotoxicity/RB
BNPP/NNP appears/VBZ nephrotoxicity/RB
APAP/NNP reduction/NN BNPP/NNP appears/VBZ nephrotoxicity/RB
APAP/NNP deacetylation/NN inhibition/NN due/JJ appears/VBZ nephrotoxicity/RB
aminocaproic/JJ therapy/NN thrombosis/NNS acute/JJ
aminocaproic/JJ therapy/NN thrombosis/NNS renal/JJ
aminocaproic/JJ therapy/NN thrombosis/NNS artery/NN
aminocaproic/JJ therapy/NN thrombosis/NNS
acid/JJ therapy/NN thrombosis/NNS acute/JJ
acid/JJ therapy/NN thrombosis/NNS renal/JJ
acid/JJ therapy/NN thrombosis/NNS artery/NN
acid/JJ therapy/NN thrombosis/NNS
aminocaproic/JJ therapy/NN associated/VBN hemorrhage/NN subarachnoid/VBD
aminocaproic/JJ therapy/NN associated/VBN hemorrhage/NN
acid/JJ therapy/NN associated/VBN hemorrhage/NN subarachnoid/VBD
acid/JJ therapy/NN associated/VBN hemorrhage/NN
EACA/NNP phenomena/NNS thromboembolic/JJ
EACA/NNP phenomena/NNS
EACA/NNP implicated/VBN patients/NNS coagulation/NN disseminated/JJ
EACA/NNP implicated/VBN patients/NNS coagulation/NN intravascular/NN
EACA/NNP implicated/VBN patients/NNS coagulation/NN
EACA/NNP implicated/VBN patients/NNS coagulation/NN coagulopathies/NNS consumption/NN
EACA/NNP implicated/VBN patients/NNS coagulation/NN coagulopathies/NNS
acetaminophen/NN found/VBN unresponsive/JJ toxicity/NN
acetaminophen/NN overdose/NN edema/NN patients/NNS used/VBN hypothermia/NN
acetaminophen/NN overdose/NN
ketoconazole/NN induced/VBN syndrome/NN Baboon/NN
ketoconazole/NN induced/VBN syndrome/NN
ketoconazole/NN included/VBD history/NN based/VBN syndrome/NN baboon/NN
ketoconazole/NN included/VBD history/NN based/VBN syndrome/NN
ketoconazole/NN case/NN syndrome/NN baboon/NN
ketoconazole/NN case/NN syndrome/NN
Nelarabine/JJ neurotoxicity/NN
nelarabine/VBP neurotoxicity/RB
nelarabine/NN caused/VBN neurotoxicity/NN
cyclosporine/NN patients/NNS had/VBD bacteremias/JJ
Aza/NNP patients/NNS had/VBD occurred/VBD infections/NNS fungal/JJ
Aza/NNP patients/NNS had/VBD occurred/VBD infections/NNS
Aza/NNP patients/NNS had/VBD infections/NNS staphylococcal/JJ
Aza/NNP patients/NNS had/VBD infections/NNS
cyclosporine/JJ patients/NNS had/VBD symptoms/NNS related/VBN infection/NN CMV/NNP
cyclosporine/JJ patients/NNS had/VBD symptoms/NNS related/VBN infection/NN
cyclosporine/JJ patients/NNS %/NN found/VBN evidence/NN infection/NN Epstein/NNP
cyclosporine/JJ patients/NNS %/NN found/VBN evidence/NN infection/NN Barr/NNP
cyclosporine/JJ patients/NNS %/NN found/VBN evidence/NN infection/NN Virus/NNP
cyclosporine/JJ patients/NNS %/NN found/VBN evidence/NN infection/NN
monosodium/NN glutamate/NN injection/NN treated/VBN mice/NNS thresholds/NNS seizure/NN
glutamate/NN injection/NN treated/VBN mice/NNS thresholds/NNS seizure/NN
monosodium/NN glutamate/NN injection/NN treated/VBN mice/NNS thresholds/NNS evaluation/NN parameters/NNS testing/NN seizure/NN
glutamate/NN injection/NN treated/VBN mice/NNS thresholds/NNS evaluation/NN parameters/NNS testing/NN seizure/NN
MSG/NNP glutamate/NN injection/NN treated/VBN mice/NNS thresholds/NNS seizure/NN
MSG/NNP glutamate/NN injection/NN treated/VBN mice/NNS thresholds/NNS evaluation/NN parameters/NNS testing/NN seizure/NN
Flurothyl/JJ thresholds/NNS seizure/NN
Flurothyl/JJ thresholds/NNS evaluation/NN parameters/NNS testing/NN seizure/NN
flurothyl/JJ testing/NN parameters/NNS evaluation/NN thresholds/NNS seizure/NN
flurothyl/JJ testing/NN seizure/NN
Monosodium/RB produces/VBZ convulsions/NNS
glutamate/JJ administration/NN produces/VBZ convulsions/NNS
MSG/NNP administration/NN produces/VBZ convulsions/NNS
MSG/NNP administration/NN produced/VBD susceptibility/NN seizure/NN
ether/NN technique/NN seizure/NN
ether/NN technique/NN used/VBN evaluate/VB susceptibility/NN seizure/NN
MSG/NNP injections/NNS received/VBD susceptibility/NN evaluate/VB used/VBN technique/NN seizure/NN
MSG/NNP injections/NNS received/VBD susceptibility/NN seizure/NN
flurothyl/JJ technique/NN seizure/NN
flurothyl/JJ technique/NN used/VBN evaluate/VB susceptibility/NN seizure/NN
MSG/NNP treatment/NN resulted/VBD alter/VB threshold/NN seizure/NN
MSG/NNP control/NN thresholds/NNS seizure/NN
naloxone/JJ challenge/NN ineffective/JJ altering/VBG thresholds/NNS seizure/NN
ether/NN produced/VBD unclear/JJ relationship/NN hypothermia/NN induction/NN seizure/NN
Flurothyl/JJ ether/NN produced/VBD unclear/JJ relationship/NN hypothermia/NN induction/NN seizure/NN
flurothyl/JJ exposure/NN duration/NN correlated/VBN hypothermia/NN produced/VBD unclear/JJ relationship/NN hypothermia/NN induction/NN seizure/NN
ether/NN produced/VBD hypothermia/NN
ether/NN produced/VBD unclear/JJ relationship/NN hypothermia/NN
Flurothyl/JJ testing/NN seizure/NN
Flurothyl/JJ testing/NN proved/VBD technique/NN evaluate/VB seizure/NN
aspirin/NN associated/VBN ESRD/NNP risk/NN related/VBN high/JJ subset/NN patients/NNS nephropathy/NN
5/CD injection/NN produced/VBN nerves/NNS destruction/NN reduced/VBD magnitude/NN vasodepressor/NN responses/NNS bradycardiac/JJ
7/CD destruction/NN reduced/VBD magnitude/NN vasodepressor/NN responses/NNS bradycardiac/JJ
dihydroxytryptamine/NN 7/CD destruction/NN reduced/VBD magnitude/NN vasodepressor/NN responses/NNS bradycardiac/JJ
5/CD destruction/NN reduced/VBD magnitude/NN vasodepressor/NN responses/NNS bradycardiac/JJ
HT/NNP nerves/NNS destruction/NN reduced/VBD magnitude/NN vasodepressor/NN responses/NNS bradycardiac/JJ
danazol/NN women/NNS angioedema/NN hereditary/JJ
danazol/NN women/NNS angioedema/NN
danazol/NN safety/NN investigated/VBD performing/VBG angioedema/NN hereditary/JJ
danazol/NN safety/NN investigated/VBD performing/VBG angioedema/NN
danazol/JJ treated/VBN angioedema/NN hereditary/JJ
danazol/JJ treated/VBN angioedema/NN
heparin/NN aspects/NNS thrombocytopenia/NN thrombosis/NNS
heparin/NN therapy/NN thrombocytopenia/NN thrombosis/NNS
Heparin/NNP used/VBN treat/VB thrombosis/NNS
heparin/NN remains/VBZ treat/VB episodes/NNS thrombotic/JJ
heparin/NN effect/NN Bleeding/NNP
heparin/NN therapy/NN receiving/VBG patients/NNS concern/NN bleeding/NN
heparin/NN use/NN common/JJ HITT/JJ
cocaine/NN hydrochloride/NN infusion/NN fraction/NN volumes/NNS min/VBP measured/VBD patients/NNS referred/VBN catheterization/NN evaluation/NN pain/NN chest/NN
cocaine/NN hydrochloride/NN infusion/NN fraction/NN volumes/NNS min/VBP measured/VBD patients/NNS referred/VBN catheterization/NN evaluation/NN pain/NN
hydrochloride/NN infusion/NN fraction/NN volumes/NNS min/VBP measured/VBD patients/NNS referred/VBN catheterization/NN evaluation/NN pain/NN chest/NN
hydrochloride/NN infusion/NN fraction/NN volumes/NNS min/VBP measured/VBD patients/NNS referred/VBN catheterization/NN evaluation/NN pain/NN
digoxin/NN beneficial/JJ patients/NNS fibrillation/NN atrial/JJ
digoxin/NN beneficial/JJ patients/NNS fibrillation/NN
digoxin/NN increase/VB infarction/NN myocardial/JJ
digoxin/NN increase/VB infarction/NN
digoxin/NN increase/VB infarction/NN MI/NNP
fludrocortisone/NN reversed/VBN induced/VBN Hyperkalemia/NNP
mefenamic/JJ nephropathy/NN history/NN caused/VBN hypoaldosteronism/NN hyperkalemia/JJ
acid/JJ nephropathy/NN history/NN caused/VBN hypoaldosteronism/NN hyperkalemia/JJ
naproxen/NN indomethacin/NN caused/VBN history/NN arthritis/NN rheumatoid/JJ
naproxen/NN indomethacin/NN caused/VBN history/NN arthritis/NN
indomethacin/NN caused/VBN history/NN arthritis/NN rheumatoid/JJ
indomethacin/NN caused/VBN history/NN arthritis/NN
naproxen/NN indomethacin/NN caused/VBN history/NN nephropathy/NN
mefenamic/JJ nephropathy/NN history/NN arthritis/NN rheumatoid/JJ
mefenamic/JJ nephropathy/NN history/NN arthritis/NN
acid/JJ nephropathy/NN history/NN arthritis/NN rheumatoid/JJ
acid/JJ nephropathy/NN history/NN arthritis/NN
indomethacin/NN caused/VBN history/NN nephropathy/NN
mefenamic/JJ nephropathy/NN history/NN caused/VBN hypoaldosteronism/NN
acid/JJ nephropathy/NN history/NN caused/VBN hypoaldosteronism/NN
prostaglandin/NN inhibitors/NNS predisposed/VBD acidosis/NNS IV/NN type/NN
prostaglandin/NN inhibitors/NNS predisposed/VBD acidosis/NNS IV/NN
prostaglandin/NN inhibitors/NNS predisposed/VBD acidosis/NNS renal/JJ
prostaglandin/NN inhibitors/NNS predisposed/VBD acidosis/NNS tubular/JJ
prostaglandin/NN inhibitors/NNS predisposed/VBD acidosis/NNS
prostaglandin/NN inhibitors/NNS predisposed/VBD disease/NN renal/JJ
prostaglandin/NN inhibitors/NNS predisposed/VBD disease/NN
fludrocortisone/NN added/VBN correcting/VBG hyperkalemia/NN
amisulpride/JJ overdose/NN
amisulpride/NN g/NN cases/NNS poisoning/NN
calcium/RB gluconate/JJ administration/NN respond/VB appeared/VBD prolongation/NN QT/NNP
calcium/RB gluconate/JJ administration/NN respond/VB appeared/VBD prolongation/NN
gluconate/JJ administration/NN respond/VB appeared/VBD prolongation/NN QT/NNP
gluconate/JJ administration/NN respond/VB appeared/VBD prolongation/NN
caffeine/NN disorders/NNS panic/NN
caffeine/NN disorders/NNS
caffeine/NN administration/NN effects/NNS determined/VBN meeting/VBG attacks/NNS panic/NN
caffeine/NN administration/NN effects/NNS determined/VBN meeting/VBG attacks/NNS
caffeine/NN administration/NN effects/NNS determined/VBN meeting/VBG attacks/NNS disorder/NN panic/NN
caffeine/NN administration/NN effects/NNS determined/VBN meeting/VBG attacks/NNS disorder/NN
3/CD pressure/NN ratings/NNS caffeine/NN administration/NN effects/NNS determined/VBN meeting/VBG attacks/NNS panic/NN
3/CD pressure/NN ratings/NNS caffeine/NN administration/NN effects/NNS determined/VBN meeting/VBG attacks/NNS
methoxy/NN ratings/NNS caffeine/NN administration/NN effects/NNS determined/VBN meeting/VBG attacks/NNS panic/NN
methoxy/NN ratings/NNS caffeine/NN administration/NN effects/NNS determined/VBN meeting/VBG attacks/NNS
4/CD ratings/NNS caffeine/NN administration/NN effects/NNS determined/VBN meeting/VBG attacks/NNS panic/NN
4/CD ratings/NNS caffeine/NN administration/NN effects/NNS determined/VBN meeting/VBG attacks/NNS
hydroxyphenethyleneglycol/NN ratings/NNS caffeine/NN administration/NN effects/NNS determined/VBN meeting/VBG attacks/NNS panic/NN
hydroxyphenethyleneglycol/NN ratings/NNS caffeine/NN administration/NN effects/NNS determined/VBN meeting/VBG attacks/NNS
3/CD pressure/NN ratings/NNS caffeine/NN administration/NN effects/NNS determined/VBN meeting/VBG attacks/NNS disorder/NN panic/NN
3/CD pressure/NN ratings/NNS caffeine/NN administration/NN effects/NNS determined/VBN meeting/VBG attacks/NNS disorder/NN
methoxy/NN ratings/NNS caffeine/NN administration/NN effects/NNS determined/VBN meeting/VBG attacks/NNS disorder/NN panic/NN
methoxy/NN ratings/NNS caffeine/NN administration/NN effects/NNS determined/VBN meeting/VBG attacks/NNS disorder/NN
4/CD ratings/NNS caffeine/NN administration/NN effects/NNS determined/VBN meeting/VBG attacks/NNS disorder/NN panic/NN
4/CD ratings/NNS caffeine/NN administration/NN effects/NNS determined/VBN meeting/VBG attacks/NNS disorder/NN
hydroxyphenethyleneglycol/NN ratings/NNS caffeine/NN administration/NN effects/NNS determined/VBN meeting/VBG attacks/NNS disorder/NN panic/NN
hydroxyphenethyleneglycol/NN ratings/NNS caffeine/NN administration/NN effects/NNS determined/VBN meeting/VBG attacks/NNS disorder/NN
MHPG/NNP hydroxyphenethyleneglycol/NN ratings/NNS caffeine/NN administration/NN effects/NNS determined/VBN meeting/VBG attacks/NNS panic/NN
MHPG/NNP hydroxyphenethyleneglycol/NN ratings/NNS caffeine/NN administration/NN effects/NNS determined/VBN meeting/VBG attacks/NNS
MHPG/NNP hydroxyphenethyleneglycol/NN ratings/NNS caffeine/NN administration/NN effects/NNS determined/VBN meeting/VBG attacks/NNS disorder/NN panic/NN
MHPG/NNP hydroxyphenethyleneglycol/NN ratings/NNS caffeine/NN administration/NN effects/NNS determined/VBN meeting/VBG attacks/NNS disorder/NN
caffeine/NN administration/NN effects/NNS determined/VBN meeting/VBG DSM/NNP criteria/NNS agoraphobia/NN
cortisol/NN ratings/NNS caffeine/NN administration/NN effects/NNS determined/VBN meeting/VBG DSM/NNP criteria/NNS agoraphobia/NN
cortisol/NN ratings/NNS caffeine/NN administration/NN effects/NNS determined/VBN meeting/VBG attacks/NNS panic/NN
cortisol/NN ratings/NNS caffeine/NN administration/NN effects/NNS determined/VBN meeting/VBG attacks/NNS
cortisol/NN ratings/NNS caffeine/NN administration/NN effects/NNS determined/VBN meeting/VBG attacks/NNS disorder/NN panic/NN
cortisol/NN ratings/NNS caffeine/NN administration/NN effects/NNS determined/VBN meeting/VBG attacks/NNS disorder/NN
3/CD pressure/NN ratings/NNS caffeine/NN administration/NN effects/NNS determined/VBN meeting/VBG DSM/NNP criteria/NNS agoraphobia/NN
methoxy/NN ratings/NNS caffeine/NN administration/NN effects/NNS determined/VBN meeting/VBG DSM/NNP criteria/NNS agoraphobia/NN
4/CD ratings/NNS caffeine/NN administration/NN effects/NNS determined/VBN meeting/VBG DSM/NNP criteria/NNS agoraphobia/NN
hydroxyphenethyleneglycol/NN ratings/NNS caffeine/NN administration/NN effects/NNS determined/VBN meeting/VBG DSM/NNP criteria/NNS agoraphobia/NN
MHPG/NNP hydroxyphenethyleneglycol/NN ratings/NNS caffeine/NN administration/NN effects/NNS determined/VBN meeting/VBG DSM/NNP criteria/NNS agoraphobia/NN
Caffeine/NNP produced/VBD subject/JJ anxiety/NN palpitations/NNS
Caffeine/NNP produced/VBD subject/JJ anxiety/NN restlessness/NNS
caffeine/NN effects/NNS similar/JJ those/DT experienced/VBN attacks/NNS panic/NN
caffeine/NN effects/NNS similar/JJ those/DT experienced/VBN attacks/NNS
caffeine/NN antagonist/NN suggest/VBP have/VB patients/NNS panic/NN
caffeine/NN antagonist/NN suggest/VBP have/VB patients/NNS disorder/NN
caffeine/NN antagonist/NN suggest/VBP have/VB abnormalities/NNS
caffeine/NN antagonist/NN suggest/VBP have/VB abnormalities/NNS systems/NNS in/IN
caffeine/NN antagonist/NN suggest/VBP have/VB abnormalities/NNS systems/NNS neuronal/JJ
caffeine/NN antagonist/NN suggest/VBP have/VB abnormalities/NNS systems/NNS
adenosine/JJ antagonist/NN suggest/VBP have/VB abnormalities/NNS
adenosine/JJ antagonist/NN suggest/VBP have/VB abnormalities/NNS systems/NNS in/IN
adenosine/JJ antagonist/NN suggest/VBP have/VB abnormalities/NNS systems/NNS neuronal/JJ
adenosine/JJ antagonist/NN suggest/VBP have/VB abnormalities/NNS systems/NNS
adenosine/NN involving/VBG systems/NNS abnormalities/NNS
adenosine/NN involving/VBG systems/NNS in/IN
adenosine/NN involving/VBG systems/NNS neuronal/JJ
adenosine/NN involving/VBG systems/NNS
adenosine/JJ antagonist/NN suggest/VBP have/VB patients/NNS panic/NN
adenosine/JJ antagonist/NN suggest/VBP have/VB patients/NNS disorder/NN
adenosine/NN involving/VBG systems/NNS abnormalities/NNS have/VB patients/NNS panic/NN
adenosine/NN involving/VBG systems/NNS abnormalities/NNS have/VB patients/NNS disorder/NN
levodopa/NN factors/NNS dyskinesia/NN Malaysians/NNS disease/NN Parkinson/NNP
levodopa/NN factors/NNS dyskinesia/NN Malaysians/NNS disease/NN Parkinson/NNP '/POS
levodopa/NN factors/NNS dyskinesia/NN Malaysians/NNS disease/NN s/JJ
levodopa/NN factors/NNS dyskinesia/NN Malaysians/NNS disease/NN
levodopa/NN therapy/NN disease/NN Parkinson/NNP
levodopa/NN therapy/NN disease/NN Parkinson/NNP '/POS
levodopa/NN therapy/NN disease/NN s/JJ
levodopa/NN therapy/NN disease/NN
levodopa/NN therapy/NN disease/NN PD/NNP
levodopa/NN predictors/NNS prevalence/NN studied/VBD PD/NNP
levodopa/NN therapy/NN involving/VBG patients/NNS PD/NNP
tranexamic/JJ acid/NN aorta/NN arrest/NN hypothermic/JJ
acid/NN aorta/NN arrest/NN hypothermic/JJ
tranexamic/JJ acid/NN aorta/NN failure/NN congestive/JJ
tranexamic/JJ acid/NN aorta/NN failure/NN heart/NN
tranexamic/JJ acid/NN aorta/NN failure/NN
acid/NN aorta/NN failure/NN congestive/JJ
acid/NN aorta/NN failure/NN heart/NN
acid/NN aorta/NN failure/NN
anthracycline/VBP cardiotoxicity/RB
Doxorubicin/NNP anti/NN therapeutic/NNS cancer/NN
DOX/NNP Doxorubicin/NNP anti/NN therapeutic/NNS cancer/NN
Doxorubicin/NNP anti/NN associated/VBN cardiotoxicity/NN
DOX/NNP Doxorubicin/NNP anti/NN associated/VBN cardiotoxicity/NN
DOX/NNP examined/VBN cardiotoxicity/RB
Methyldopa/NNP induced/VBN old/JJ presenting/VBG near/JJ syncope/JJ
Methyldopa/NNP causes/VBZ anemia/NN autoimmune/JJ
Methyldopa/NNP causes/VBZ anemia/NN hemolytic/JJ
Methyldopa/NNP causes/VBZ anemia/NN
methyldopa/NN case/NN report/VBP syncope/VBP anemia/NN boy/NN presented/VBD department/NN emergency/NN
methyldopa/NN case/NN report/VBP syncope/VBP anemia/NN boy/NN presented/VBD department/NN
methyldopa/NN case/NN report/VBP syncope/VBP
methyldopa/NN treated/VBN admission/NN trauma/NN
thiabendazole/JJ administration/NN duct/VBP bile/NN
thiabendazole/JJ administration/NN duct/VBP
thiabendazole/JJ administration/NN duct/VBP injury/NN
thiabendazole/VB developed/VBN wk/NN jaundice/NN
lamivudine/NN mutants/NNS Rate/NNP patients/NNS infection/NN chronic/JJ
lamivudine/NN mutants/NNS Rate/NNP patients/NNS infection/NN hepatitis/NNP
lamivudine/NN mutants/NNS Rate/NNP patients/NNS infection/NN B/NNP
lamivudine/NN mutants/NNS Rate/NNP patients/NNS infection/NN virus/NN
lamivudine/NN mutants/NNS Rate/NNP patients/NNS infection/NN
Lamivudine/NNP used/VBN treatment/NN patients/NNS chronic/JJ
Lamivudine/NNP used/VBN treatment/NN patients/NNS hepatitis/NNP
Lamivudine/NNP used/VBN treatment/NN patients/NNS B/NNP
lamivudine/NN occur/VBP mutants/NNS virus/NN hepatitis/NN
lamivudine/NN occur/VBP mutants/NNS virus/NN B/NN
lamivudine/NN occur/VBP patients/NNS chronic/JJ
lamivudine/NN occur/VBP patients/NNS hepatitis/NNP
lamivudine/NN occur/VBP patients/NNS B/NNP
lamivudine/NN mutants/NNS rate/NN patients/NNS chronic/JJ
lamivudine/NN mutants/NNS rate/NN patients/NNS hepatitis/NNP
lamivudine/NN mutants/NNS rate/NN patients/NNS B/NNP
lamivudine/NN treated/VBN patients/NNS chronic/JJ
lamivudine/NN treated/VBN patients/NNS hepatitis/NNP
lamivudine/NN treated/VBN patients/NNS B/NNP
lamivudine/NN mutants/NNS patients/NNS B/NNP chronic/JJ
lamivudine/NN mutants/NNS patients/NNS B/NNP hepatitis/NNP
lamivudine/NN mutants/NNS patients/NNS B/NNP
lamivudine/NN mutants/NNS occurrence/NN reported/VBN detected/VBN patients/NNS chronic/JJ
lamivudine/NN mutants/NNS occurrence/NN reported/VBN detected/VBN patients/NNS hepatitis/NNP
lamivudine/NN mutants/NNS occurrence/NN reported/VBN detected/VBN patients/NNS B/NNP
lamivudine/NN detected/VBN reported/VBN occurrence/NN mutants/NNS patients/NNS B/NNP chronic/JJ
lamivudine/NN detected/VBN reported/VBN occurrence/NN mutants/NNS patients/NNS B/NNP hepatitis/NNP
lamivudine/NN detected/VBN reported/VBN occurrence/NN mutants/NNS patients/NNS B/NNP
lamivudine/NN detected/VBN patients/NNS chronic/JJ
lamivudine/NN detected/VBN patients/NNS hepatitis/NNP
lamivudine/NN detected/VBN patients/NNS B/NNP
Vasopressin/NNP hypertension/NN
vasopressin/NN agent/NN process/NN hypertensive/JJ
DOCA/NNP pathogenesis/NNS plays/VBZ hypertension/NN treated/VBN insipidus/NNS diabetes/NN
DOCA/NNP pathogenesis/NNS plays/VBZ hypertension/NN treated/VBN insipidus/NNS
DOCA/NNP treated/VBN insipidus/NNS diabetes/NN
DOCA/NNP treated/VBN insipidus/NNS
Vasopressin/NNP plays/VBZ hypertension/NN treated/VBN insipidus/NNS diabetes/NN
Vasopressin/NNP plays/VBZ hypertension/NN treated/VBN insipidus/NNS
lithium/NN rats/NNS substantial/JJ hypertension/NN
Vasopressin/NNP plays/VBZ hypertension/NN
vasopressin/NN action/NN appears/VBZ important/JJ development/NN model/NN hypertension/NN
vasopressin/NN action/NN appears/VBZ important/JJ observed/VBN stage/NN hypertension/NN
vasopressin/NN secretion/NN promotes/VBZ function/NN hormone/NN factor/NN hypertension/NN
vasopressin/NN role/NN remains/VBZ determined/VBN hypertension/NN
warfarin/NN due/JJ hematoma/NN
warfarin/NN induced/VBN coagulopathy/RB
warfarin/NN causing/VBG coagulopathy/RB
piroxicam/NN interaction/NN exacerbated/VBN coagulopathy/NN
levobupivacaine/JJ block/NN administration/NN toxicity/NN nervous/JJ Central/JJ
levobupivacaine/JJ block/NN administration/NN toxicity/NN nervous/JJ
levobupivacaine/JJ block/NN administration/NN toxicity/NN system/NN
levobupivacaine/JJ block/NN administration/NN toxicity/NN
epinephrine/JJ 2/CD %/NN microgram/NN mL/NN administration/NN developed/VBD seizures/NNS grand/JJ
epinephrine/JJ 2/CD %/NN microgram/NN mL/NN administration/NN developed/VBD seizures/NNS mal/NN
epinephrine/JJ 2/CD %/NN microgram/NN mL/NN administration/NN developed/VBD seizures/NNS
epinephrine/NN administration/NN signs/NNS blood/NN developed/VBD seizures/NNS grand/JJ
epinephrine/NN administration/NN signs/NNS blood/NN developed/VBD seizures/NNS mal/NN
epinephrine/NN administration/NN signs/NNS blood/NN developed/VBD seizures/NNS
succinylcholine/VB treated/VBN seizures/NNS
sodium/NN thiopental/NN treated/VBN seizures/NNS
thiopental/NN treated/VBN seizures/NNS
bupivacaine/NN have/VB profile/NN cardiac/JJ
bupivacaine/NN have/VB profile/NN toxicity/NN
levobupivacaine/NN have/VB result/VB convulsions/NNS
levobupivacaine/NN amounts/NNS reach/VBP have/VB result/VB convulsions/NNS
levobupivacaine/NN have/VB profile/NN cardiac/JJ
levobupivacaine/NN have/VB profile/NN toxicity/NN
levobupivacaine/NN amounts/NNS reach/VBP have/VB profile/NN cardiac/JJ
levobupivacaine/NN amounts/NNS reach/VBP have/VB profile/NN toxicity/NN
bupivacaine/NN have/VB result/VB convulsions/NNS
K/NNP neither/DT blockers/VBZ morphine/NN induced/VBN hypoactivity/RB
K/NNP induced/VBN hypoactivity/RB
morphine/NN induced/VBN hypoactivity/RB
morphine/JJ prevented/VBN blockers/NNS K/NNP induced/VBN hypoactivity/RB
K/NNP neither/DT blockers/VBZ morphine/NN induced/VBN hyperactivity/NN
K/NNP induced/VBN morphine/NN induced/VBN hyperactivity/NN
quinine/JJ K/NN connected/VBN seems/VBZ morphine/JJ hypoactivity/RB
K/NNP blockade/NN sufficient/JJ suggested/VBN induced/VBN morphine/JJ hypoactivity/RB
K/NN connected/VBN seems/VBZ morphine/JJ hypoactivity/RB
4/CD -/NNS aminopyridine/JJ quinine/JJ K/NN connected/VBN seems/VBZ hyperactivity/RB
-/NNS aminopyridine/JJ quinine/JJ K/NN connected/VBN seems/VBZ hyperactivity/RB
aminopyridine/JJ quinine/JJ K/NN connected/VBN seems/VBZ hyperactivity/RB
4/CD -/NNS aminopyridine/JJ quinine/JJ K/NN connected/VBN seems/VBZ morphine/JJ hypoactivity/RB
-/NNS aminopyridine/JJ quinine/JJ K/NN connected/VBN seems/VBZ morphine/JJ hypoactivity/RB
aminopyridine/JJ quinine/JJ K/NN connected/VBN seems/VBZ morphine/JJ hypoactivity/RB
quinine/JJ K/NN connected/VBN seems/VBZ hyperactivity/RB
morphine/NN prevent/VB sufficient/JJ suggested/VBN induced/VBN morphine/JJ hypoactivity/RB
morphine/JJ hypoactivity/RB
K/NNP blockade/NN sufficient/JJ suggested/VBN induced/VBN morphine/JJ seems/VBZ hyperactivity/RB
K/NN connected/VBN seems/VBZ hyperactivity/RB
temsirolimus/NNS lymphoma/NN mantle/NN
temsirolimus/NNS lymphoma/NN cell/NN
temsirolimus/NNS lymphoma/NN
temsirolimus/NNS treated/VBD reported/VBN MCL/NNP
temsirolimus/NNS treated/VBD had/VBD opportunity/NN study/VB case/NN MCL/NNP
temsirolimus/JJ treatment/NN had/VBD case/NN study/VB opportunity/NN had/VBD treated/VBD reported/VBN MCL/NNP
temsirolimus/JJ treatment/NN had/VBD case/NN MCL/NNP
temsirolimus/NNS treated/VBD had/VBD opportunity/NN study/VB case/NN had/VBD regression/NN tumor/NN
temsirolimus/JJ treatment/NN had/VBD regression/NN tumor/NN
temsirolimus/NNS inhibited/VBD proliferation/NN tumor/NN
temsirolimus/NNS inhibited/VBD induce/VB number/NN cells/NNS tumor/NN
temsirolimus/NNS had/VBD effect/NN decrease/NN density/NN tumor/NN
temsirolimus/JJ reduced/VBD contribute/VB efficiency/NN MCL/NNP
temsirolimus/NNS effect/NN contribute/VB efficiency/NN MCL/NNP
temsirolimus/JJ reduced/VBD burden/NN tumor/NN
temsirolimus/JJ reduced/VBD contribute/VB effect/NN temsirolimus/NNS tissue/NN tumor/NN
temsirolimus/NNS effect/NN contribute/VB reduced/VBD burden/NN tumor/NN
temsirolimus/NNS tissue/NN tumor/NN
triphenyltetrazolium/JJ staining/NN using/VBG evaluated/VBN BBB/NNP destroy/VB used/VBN hypertension/NN
TTC/NNP staining/NN using/VBG evaluated/VBN BBB/NNP destroy/VB used/VBN hypertension/NN
TTC/NNP exhibited/VBD s/NNP giving/VBG using/VBG evaluated/VBN BBB/NNP destroy/VB used/VBN hypertension/NN
glutathione/NN ischemia/NN injury/NN reperfusion/NN
glutathione/NN ischemia/NN injury/NN
glutathione/NN ischemia/NN
epinephrine/NN lipid/NN Resuscitation/NNP toxicity/NN cardiac/JJ
epinephrine/NN lipid/NN Resuscitation/NNP toxicity/NN
levobupivacaine/NN both/DT lipid/NN Resuscitation/NNP toxicity/NN cardiac/JJ
levobupivacaine/NN both/DT lipid/NN Resuscitation/NNP toxicity/NN
epinephrine/NN emulsion/NN regimens/NNS determined/VBN neonates/NNS cases/NNS toxicity/NN
Nefiracetam/NNP reverses/VBZ effects/NNS apomorphine/JJ amnesia/NN
DM/NNP Nefiracetam/NNP reverses/VBZ effects/NNS apomorphine/JJ amnesia/NN
9384/CD DM/NNP Nefiracetam/NNP reverses/VBZ effects/NNS apomorphine/JJ amnesia/NN
pyrrolidone/NN derivative/NN induced/VBN learning/VBG
pyrrolidone/NN derivative/NN induced/VBN and/CC
pyrrolidone/NN derivative/NN induced/VBN post/NN
pyrrolidone/NN derivative/NN induced/VBN training/VBG
pyrrolidone/NN derivative/NN induced/VBN training/VBG deficits/NNS consolidation/NN
pyrrolidone/NN derivative/NN induced/VBN training/VBG deficits/NNS
Nefiracetam/NNP derivative/NN induced/VBN learning/VBG
Nefiracetam/NNP derivative/NN induced/VBN and/CC
Nefiracetam/NNP derivative/NN induced/VBN post/NN
Nefiracetam/NNP derivative/NN induced/VBN training/VBG
Nefiracetam/NNP derivative/NN induced/VBN training/VBG deficits/NNS consolidation/NN
Nefiracetam/NNP derivative/NN induced/VBN training/VBG deficits/NNS
nefiracetam/NN ability/NN evaluated/VBN amnesia/NN
nefiracetam/NN administration/NN reversed/VBD amnesia/NN
chloride/NN function/NN cause/VB depolarisation/NN sustained/JJ
chloride/NN function/NN cause/VB depolarisation/NN membrane/JJ
chloride/NN function/NN cause/VB depolarisation/NN
chloride/NN function/NN defect/NN caused/VBN congenita/NNP Myotonia/NNP
chloride/NN function/NN defect/NN caused/VBN congenita/NNP
chloride/NN function/NN defect/NN caused/VBN congenita/NNP MC/NNP
Vasurix/NNP Hexabrix/NNP polyvidone/VBP considered/VBN preferred/VBN toxicity/NN
polyvidone/VBP considered/VBN preferred/VBN toxicity/NN
Hexabrix/NNP polyvidone/VBP considered/VBN preferred/VBN toxicity/NN
Hexabrix/NNP preferred/VBN toxicity/NN
contrast/NN media/NNS considered/VBN preferred/VBN toxicity/NN
media/NNS considered/VBN preferred/VBN toxicity/NN
Quetiapine/NNP induced/VBN carcinoma/NN hepatocellular/NN
Quetiapine/NNP induced/VBN carcinoma/NN
Quetiapine/NNP induced/VBN neutropenia/NN patient/NN bipolar/NNP
clozapine/JJ derivative/NN has/VBZ risk/NN causing/VBG dyscrasias/NNS neutropenia/NN
Quetiapine/NNP derivative/NN has/VBZ risk/NN causing/VBG dyscrasias/NNS blood/NN
Quetiapine/NNP derivative/NN has/VBZ risk/NN causing/VBG dyscrasias/NNS
clozapine/JJ derivative/NN has/VBZ risk/NN causing/VBG dyscrasias/NNS blood/NN
clozapine/JJ derivative/NN has/VBZ risk/NN causing/VBG dyscrasias/NNS
quetiapine/NN developed/VBD patient/NN carcinoma/NN hepatocellular/NN
quetiapine/NN developed/VBD patient/NN carcinoma/NN
quetiapine/VB marker/NN one/CD dysfunction/NN Hepatic/JJ
quetiapine/VB marker/NN one/CD dysfunction/NN
glutamate/NN variability/NN hyperalgesia/NN
glutamate/NN variability/NN hyperalgesia/NN allodynia/NN
capsaicin/NN glutamate/NN injections/NNS attractive/JJ use/VB mimic/VBP aspects/NNS disorders/NNS pain/NN
capsaicin/NN glutamate/NN injections/NNS attractive/JJ use/VB mimic/VBP aspects/NNS disorders/NNS
glutamate/NN injections/NNS attractive/JJ use/VB mimic/VBP aspects/NNS disorders/NNS pain/NN
glutamate/NN injections/NNS attractive/JJ use/VB mimic/VBP aspects/NNS disorders/NNS
glutamate/NN injections/NNS attractive/JJ use/VB mimic/VBP hyperalgesia/NN
glutamate/NN injections/NNS attractive/JJ use/VB mimic/VBP hyperalgesia/NN allodynia/NN
glutamate/NN injections/NNS attractive/JJ use/VB models/NNS pain/NN
capsaicin/NN glutamate/NN injections/NNS attractive/JJ use/VB models/NNS pain/NN
glutamate/JJ injection/NN gauges/VBZ scale/NN increase/NN observed/VBN hyperalgesia/NN
glutamate/NN conclusion/NN yield/VB hyperalgesic/JJ
glutamate/NN conclusion/NN yield/VB hyperalgesic/JJ responses/NNS allodynic/JJ
bepridil/JJ administration/NN evaluation/NN fibrillation/NN atrial/JJ
bepridil/JJ administration/NN evaluation/NN fibrillation/NN
bepridil/JJ administration/NN evaluation/NN fibrillation/NN and/CC
bepridil/JJ administration/NN evaluation/NN fibrillation/NN flutter/NN
Bepridil/NNP hydrochloride/NNP attracted/VBN drug/NN fibrillation/NN atrial/JJ
Bepridil/NNP hydrochloride/NNP attracted/VBN drug/NN fibrillation/NN
hydrochloride/NNP attracted/VBN drug/NN fibrillation/NN atrial/JJ
hydrochloride/NNP attracted/VBN drug/NN fibrillation/NN
Bepridil/NNP hydrochloride/NNP attracted/VBN drug/NN fibrillation/NN AF/NNP
hydrochloride/NNP attracted/VBN drug/NN fibrillation/NN AF/NNP
Bpd/NNP hydrochloride/NNP attracted/VBN drug/NN fibrillation/NN atrial/JJ
Bpd/NNP hydrochloride/NNP attracted/VBN drug/NN fibrillation/NN
Bpd/NNP hydrochloride/NNP attracted/VBN drug/NN fibrillation/NN AF/NNP
Bepridil/NNP hydrochloride/NNP attracted/VBN drug/NN fibrillation/NN flutter/NN atrial/JJ
Bepridil/NNP hydrochloride/NNP attracted/VBN drug/NN fibrillation/NN flutter/NN
hydrochloride/NNP attracted/VBN drug/NN fibrillation/NN flutter/NN atrial/JJ
hydrochloride/NNP attracted/VBN drug/NN fibrillation/NN flutter/NN
Bepridil/NNP hydrochloride/NNP attracted/VBN drug/NN fibrillation/NN AFL/NNP
hydrochloride/NNP attracted/VBN drug/NN fibrillation/NN AFL/NNP
Bpd/NNP hydrochloride/NNP attracted/VBN drug/NN fibrillation/NN flutter/NN atrial/JJ
Bpd/NNP hydrochloride/NNP attracted/VBN drug/NN fibrillation/NN flutter/NN
Bpd/NNP hydrochloride/NNP attracted/VBN drug/NN fibrillation/NN AFL/NNP
Bpd/NNP administered/VBN patients/NNS comprising/VBG AF/NNP
Bpd/NNP administered/VBN patients/NNS comprising/VBG AF/NNP cases/NNS AFL/NNP
GEM/NNP active/JJ treatment/NN lymphoma/NN Hodgkin/NNP
GEM/NNP active/JJ treatment/NN lymphoma/NN
Gemcitabine/NN have/VBP activity/NN HL/NNP non/NN toxicity/NN
Gemcitabine/NN have/VBP activity/NN HL/NNP
cisplatin/NN Gemcitabine/NN have/VBP activity/NN HL/NNP
cisplatin/NN Gemcitabine/NN have/VBP activity/NN HL/NNP non/NN toxicity/NN
methylprednisolone/JJ m/NN analysis/NN patients/NNS treated/NNS HL/NN
gemcitabine/JJ 1/CD treated/NNS HL/NN
GEM/NNP days/NNS included/VBN m/NN analysis/NN patients/NNS treated/NNS HL/NN
cisplatin/JJ D/NNP m/NN analysis/NN patients/NNS treated/NNS HL/NN
GEM/NNP chemotherapy/NN rates/NNS treatment/NN HL/NN
androgen/NN treated/VBN Fanconi/NNP
androgen/NN treated/VBN Fanconi/NNP '/POS
androgen/NN treated/VBN s/VBZ
androgen/NN treated/VBN anemia/RB
corticosteroid/VBD treated/VBN Fanconi/NNP
corticosteroid/VBD treated/VBN Fanconi/NNP '/POS
corticosteroid/VBD treated/VBN s/VBZ
corticosteroid/VBD treated/VBN anemia/RB
androgens/NNS treated/VBN reported/VBN known/VBN have/VB anemia/NN Fanconi/NNP
androgens/NNS treated/VBN reported/VBN known/VBN have/VB anemia/NN Fanconi/NNP '/POS
androgens/NNS treated/VBN reported/VBN known/VBN have/VB anemia/NN s/JJ
androgens/NNS treated/VBN reported/VBN known/VBN have/VB anemia/NN
corticosteroids/NNS androgens/NNS treated/VBN reported/VBN known/VBN have/VB anemia/NN Fanconi/NNP
corticosteroids/NNS androgens/NNS treated/VBN reported/VBN known/VBN have/VB anemia/NN Fanconi/NNP '/POS
corticosteroids/NNS androgens/NNS treated/VBN reported/VBN known/VBN have/VB anemia/NN s/JJ
corticosteroids/NNS androgens/NNS treated/VBN reported/VBN known/VBN have/VB anemia/NN
androgen/NN patients/NNS develop/VB metastasizing/VBG non/VBP corticosteroid/VBD treated/VBN anemia/NN Fanconi/NNP
androgen/NN patients/NNS develop/VB metastasizing/VBG non/VBP corticosteroid/VBD treated/VBN anemia/NN Fanconi/NNP '/POS
androgen/NN patients/NNS develop/VB metastasizing/VBG non/VBP corticosteroid/VBD treated/VBN anemia/NN s/JJ
androgen/NN patients/NNS develop/VB metastasizing/VBG non/VBP corticosteroid/VBD treated/VBN anemia/NN
androgen/NN patients/NNS develop/VB neoplasms/NNS hepatic/JJ
androgen/NN patients/NNS develop/VB neoplasms/NNS
corticosteroid/VBD non/VBP metastasizing/VBG develop/VB neoplasms/NNS hepatic/JJ
corticosteroid/VBD non/VBP metastasizing/VBG develop/VB neoplasms/NNS
corticosteroid/VBD treated/VBN anemia/NN Fanconi/NNP
corticosteroid/VBD treated/VBN anemia/NN Fanconi/NNP '/POS
corticosteroid/VBD treated/VBN anemia/NN s/JJ
corticosteroid/VBD treated/VBN anemia/NN
VGB/NNP exposure/NN current/JJ therapy/NN basis/NN grouped/VBN people/NNS epilepsy/NN
garcinielliptone/JJ FC/NNP pretreated/VBD pilocarpine/NN seizures/NNS
FC/NNP pretreated/VBD pilocarpine/NN seizures/NNS
aspartate/JJ glutamine/JJ acid/NN r/SYM levels/NNS activity/NN determine/VB mg/VBP parameters/NNS seizure/NN
aspartate/JJ glutamine/JJ acid/NN r/SYM levels/NNS activity/NN determine/VB seizures/NNS
amino/JJ levels/NNS activity/NN determine/VB mg/VBP parameters/NNS seizure/NN
acid/JJ levels/NNS activity/NN determine/VB mg/VBP parameters/NNS seizure/NN
amino/JJ levels/NNS activity/NN determine/VB seizures/NNS
acid/JJ levels/NNS activity/NN determine/VB seizures/NNS
glutathione/JJ glutamine/JJ acid/NN r/SYM levels/NNS activity/NN determine/VB mg/VBP parameters/NNS seizure/NN
glutathione/JJ glutamine/JJ acid/NN r/SYM levels/NNS activity/NN determine/VB seizures/NNS
GFC/NNP effects/NNS evaluate/VB aimed/VBN study/NN mg/VBP parameters/NNS seizure/NN
GFC/NNP effects/NNS evaluate/VB aimed/VBN study/NN mg/VBP determine/VB seizures/NNS
glutamine/JJ acid/NN r/SYM levels/NNS activity/NN determine/VB mg/VBP parameters/NNS seizure/NN
glutamine/JJ acid/NN r/SYM levels/NNS activity/NN determine/VB seizures/NNS
r/SYM levels/NNS activity/NN determine/VB mg/VBP parameters/NNS seizure/NN
aminobutyric/JJ acid/NN r/SYM levels/NNS activity/NN determine/VB mg/VBP parameters/NNS seizure/NN
acid/NN r/SYM levels/NNS activity/NN determine/VB mg/VBP parameters/NNS seizure/NN
r/SYM levels/NNS activity/NN determine/VB seizures/NNS
aminobutyric/JJ acid/NN r/SYM levels/NNS activity/NN determine/VB seizures/NNS
acid/NN r/SYM levels/NNS activity/NN determine/VB seizures/NNS
GABA/NNP acid/NN r/SYM levels/NNS activity/NN determine/VB mg/VBP parameters/NNS seizure/NN
GABA/NNP acid/NN r/SYM levels/NNS activity/NN determine/VB seizures/NNS
GFC/NNP produced/VBD kg/NN latency/JJ seizure/NN
GFC/NNP exert/VB reduce/VB frequency/NN epilepticus/NNS status/NN
GFC/NNP exert/VB reduce/VB frequency/NN epilepticus/NNS
GFC/NNP exert/VB reduce/VB frequency/NN epilepticus/NNS demonstrated/VBD seizure/NN
acetaminophen/NN NSAIDs/NNP using/VBG bleeding/VBG risks/NNS hospitalization/NN AMI/NNP
COX/NNP NSAIDs/NNP using/VBG bleeding/VBG risks/NNS hospitalization/NN AMI/NNP GI/NNP
COX/NNP NSAIDs/NNP using/VBG bleeding/VBG
2/CD inhibitors/NNS NSAIDs/NNP using/VBG bleeding/VBG risks/NNS hospitalization/NN AMI/NNP GI/NNP
2/CD inhibitors/NNS NSAIDs/NNP using/VBG bleeding/VBG
inhibitors/NNS NSAIDs/NNP using/VBG bleeding/VBG risks/NNS hospitalization/NN AMI/NNP GI/NNP
inhibitors/NNS NSAIDs/NNP using/VBG bleeding/VBG
acetaminophen/NN NSAIDs/NNP using/VBG bleeding/VBG risks/NNS hospitalization/NN AMI/NNP GI/NNP
acetaminophen/NN NSAIDs/NNP using/VBG bleeding/VBG
diclofenac/JJ 1/CD 1/CD 59/CD group/NN acetaminophen/NN GI/VBP non/NN users/NNS aspirin/NN ratios/NNS hospitalization/NN AMI/NNP
acetaminophen/NN GI/VBP non/NN users/NNS aspirin/NN ratios/NNS hospitalization/NN AMI/NNP
aspirin/NN ratios/NNS hospitalization/NN AMI/NNP
aspirin/NN acetaminophen/NN GI/VBP non/NN users/NNS aspirin/NN ratios/NNS hospitalization/NN AMI/NNP
ibuprofen/NN 0/CD 17/CD group/NN acetaminophen/NN GI/VBP non/NN users/NNS aspirin/NN ratios/NNS hospitalization/NN AMI/NNP
celecoxib/NN 1/CD 27/CD group/NN acetaminophen/NN GI/VBP non/NN users/NNS aspirin/NN ratios/NNS hospitalization/NN AMI/NNP
aspirin/NN users/NNS naproxen/NN seemed/VBN carry/VB risk/NN GI/NNP AMI/NNP
aspirin/NN users/NNS naproxen/NN seemed/VBN carry/VB risk/NN GI/NNP
aspirin/NN users/NNS naproxen/NN seemed/VBN carry/VB risk/NN GI/NNP bleeding/VBG
acetaminophen/NN that/DT similar/JJ AMI/NNP
rofecoxib/NNP those/DT better/JJR seemed/VBD similar/JJ toxicity/NNP
celecoxib/NN toxicity/NNP
acetaminophen/NN that/DT similar/JJ toxicity/NNP
celecoxib/NN toxicity/NNP similar/JJ AMI/NNP
methothexate/NN concentration/NN leakage/NN development/NN predispose/VB inappropriately/VB calculations/NNS presence/NN preservatives/NNS neurotoxic/JJ
methotrexate/NN doses/NNS inappropriately/VB calculations/NNS presence/NN preservatives/NNS neurotoxic/JJ
methotrexate/JJ preparations/NNS preservatives/NNS neurotoxic/JJ
methotrexate/JJ diluents/NNS use/NN calculations/NNS presence/NN preservatives/NNS neurotoxic/JJ
methothexate/NN concentration/NN leakage/NN development/NN dynamics/NNS related/VBN presence/NN leukemia/NN central/JJ
methothexate/NN concentration/NN leakage/NN development/NN dynamics/NNS related/VBN presence/NN leukemia/NN nervous/JJ
methothexate/NN concentration/NN leakage/NN development/NN dynamics/NNS related/VBN presence/NN leukemia/NN system/NN
methothexate/NN concentration/NN leakage/NN development/NN dynamics/NNS related/VBN presence/NN leukemia/NN
methotrexate/NN doses/NNS inappropriately/VB predispose/VB development/NN dynamics/NNS related/VBN presence/NN leukemia/NN central/JJ
methotrexate/NN doses/NNS inappropriately/VB predispose/VB development/NN dynamics/NNS related/VBN presence/NN leukemia/NN nervous/JJ
methotrexate/NN doses/NNS inappropriately/VB predispose/VB development/NN dynamics/NNS related/VBN presence/NN leukemia/NN system/NN
methotrexate/NN doses/NNS inappropriately/VB predispose/VB development/NN dynamics/NNS related/VBN presence/NN leukemia/NN
methotrexate/JJ preparations/NNS preservatives/NNS presence/NN calculations/NNS inappropriately/VB predispose/VB development/NN dynamics/NNS related/VBN presence/NN leukemia/NN central/JJ
methotrexate/JJ preparations/NNS preservatives/NNS presence/NN calculations/NNS inappropriately/VB predispose/VB development/NN dynamics/NNS related/VBN presence/NN leukemia/NN nervous/JJ
methotrexate/JJ preparations/NNS preservatives/NNS presence/NN calculations/NNS inappropriately/VB predispose/VB development/NN dynamics/NNS related/VBN presence/NN leukemia/NN system/NN
methotrexate/JJ preparations/NNS preservatives/NNS presence/NN calculations/NNS inappropriately/VB predispose/VB development/NN dynamics/NNS related/VBN presence/NN leukemia/NN
methotrexate/JJ diluents/NNS use/NN calculations/NNS inappropriately/VB predispose/VB development/NN dynamics/NNS related/VBN presence/NN leukemia/NN central/JJ
methotrexate/JJ diluents/NNS use/NN calculations/NNS inappropriately/VB predispose/VB development/NN dynamics/NNS related/VBN presence/NN leukemia/NN nervous/JJ
methotrexate/JJ diluents/NNS use/NN calculations/NNS inappropriately/VB predispose/VB development/NN dynamics/NNS related/VBN presence/NN leukemia/NN system/NN
methotrexate/JJ diluents/NNS use/NN calculations/NNS inappropriately/VB predispose/VB development/NN dynamics/NNS related/VBN presence/NN leukemia/NN
methotrexate/JJ contaminants/NNS irradiation/NN pathogenesis/NNS toxicity/NN
methotrexate/NN toxicity/NN
methotrexate/JJ contaminants/NNS deficiency/NN folate/NN
methotrexate/JJ contaminants/NNS deficiency/NN
methotrexate/NN toxicity/NN pathogenesis/NNS irradiation/NN contaminants/NNS deficiency/NN folate/NN
methotrexate/NN toxicity/NN pathogenesis/NNS irradiation/NN contaminants/NNS deficiency/NN
methotrexate/NN doses/NNS employing/VBG reduced/VBN incidence/NN neurotoxicity/NN
methotrexate/NN doses/NNS employing/VBG presence/NN leukemia/NN central/JJ
methotrexate/NN doses/NNS employing/VBG presence/NN leukemia/NN nervous/JJ
methotrexate/NN doses/NNS employing/VBG presence/NN leukemia/NN system/NN
methotrexate/NN doses/NNS employing/VBG presence/NN leukemia/NN
methotrexate/NN levels/NNS monitoring/NN predictive/JJ development/NN neurotoxicity/NN
5/CD infusion/NN received/VBD Risk/NN encephalopathy/NN patients/NNS cancer/NN
fluorouracil/NN Risk/NN encephalopathy/NN patients/NNS cancer/NN
5/CD infusion/NN received/VBD Risk/NN fluorouracil/NN complication/NN dehydration/NN infection/NN
fluorouracil/NN complication/NN dehydration/NN infection/NN
5/CD infusion/NN received/VBD Risk/NN encephalopathy/NN hyperammonemic/JJ
5/CD infusion/NN received/VBD Risk/NN encephalopathy/NN
fluorouracil/NN Risk/NN encephalopathy/NN hyperammonemic/JJ
fluorouracil/NN Risk/NN encephalopathy/NN
5/CD infusion/NN received/VBD Risk/NN fluorouracil/NN complication/NN dehydration/NN
fluorouracil/NN complication/NN dehydration/NN
5/CD infusion/NN related/VBN patients/NNS cancer/NN
fluorouracil/NN identified/VBN related/VBN patients/NNS cancer/NN
5/CD fluorouracil/NN identified/VBN related/VBN patients/NNS cancer/NN
FU/NNP 5/CD fluorouracil/NN identified/VBN related/VBN patients/NNS cancer/NN
5/CD infusion/NN related/VBN patients/NNS had/VBD episodes/NNS encephalopathy/NN hyperammonemic/JJ
5/CD infusion/NN related/VBN patients/NNS had/VBD episodes/NNS encephalopathy/NN
fluorouracil/NN identified/VBN related/VBN patients/NNS had/VBD episodes/NNS encephalopathy/NN hyperammonemic/JJ
fluorouracil/NN identified/VBN related/VBN patients/NNS had/VBD episodes/NNS encephalopathy/NN
5/CD fluorouracil/NN identified/VBN related/VBN patients/NNS had/VBD episodes/NNS encephalopathy/NN hyperammonemic/JJ
5/CD fluorouracil/NN identified/VBN related/VBN patients/NNS had/VBD episodes/NNS encephalopathy/NN
FU/NNP 5/CD fluorouracil/NN identified/VBN related/VBN patients/NNS had/VBD episodes/NNS encephalopathy/NN hyperammonemic/JJ
FU/NNP 5/CD fluorouracil/NN identified/VBN related/VBN patients/NNS had/VBD episodes/NNS encephalopathy/NN
ammonium/NN levels/NNS seen/VBN patients/NNS infections/NNS bacterial/JJ
ammonium/NN levels/NNS seen/VBN patients/NNS infections/NNS
ammonium/NN levels/NNS onset/NN hyperammonemia/NN
5/CD doses/NNS receiving/VBG patients/NNS patients/NNS' patients/NNS infections/NNS bacterial/JJ
5/CD doses/NNS receiving/VBG patients/NNS patients/NNS' patients/NNS infections/NNS
FU/NNP doses/NNS receiving/VBG patients/NNS patients/NNS' patients/NNS infections/NNS bacterial/JJ
FU/NNP doses/NNS receiving/VBG patients/NNS patients/NNS' patients/NNS infections/NNS
5/CD infusion/NN receiving/VBG patients/NNS occur/VB encephalopathy/NN hyperammonemic/JJ
5/CD infusion/NN receiving/VBG patients/NNS occur/VB encephalopathy/NN
FU/NNP infusion/NN receiving/VBG patients/NNS occur/VB encephalopathy/NN hyperammonemic/JJ
FU/NNP infusion/NN receiving/VBG patients/NNS occur/VB encephalopathy/NN
levodopa/NN rigidity/NN
levodopa/NN rigidity/NN bradykinesia/JJ
levodopa/NN rigidity/NN Twenty/CD patients/NNS suffering/VBG disease/NN Parkinson/NNP
levodopa/NN rigidity/NN Twenty/CD patients/NNS suffering/VBG disease/NN Parkinson/NNP '/POS
levodopa/NN rigidity/NN Twenty/CD patients/NNS suffering/VBG disease/NN s/JJ
levodopa/NN rigidity/NN Twenty/CD patients/NNS suffering/VBG disease/NN
cyclophosphamide/JJ therapy/NN pelvis/NNS carcinoma/NN
cyclophosphamide/JJ therapy/NN pelvis/NNS of/IN
cyclophosphamide/JJ therapy/NN pelvis/NNS the/DT
cyclophosphamide/JJ therapy/NN pelvis/NNS renal/JJ
cyclophosphamide/JJ therapy/NN pelvis/NNS
cyclophosphamide/NN treated/VBN had/VBN obstruction/NN due/JJ woman/NN hydroureteronephrosis/NNS
cyclophosphamide/NN treated/VBN had/VBN vasculitis/NNS cerebral/JJ
cyclophosphamide/NN treated/VBN had/VBN vasculitis/NNS
cyclophosphamide/JJ abnormalities/NNS ability/NN known/VBN appreciated/VBN associated/VBN carcinoma/NN
cyclophosphamide/JJ abnormalities/NNS ability/NN known/VBN appreciated/VBN associated/VBN carcinoma/NN tract/NN of/IN
cyclophosphamide/JJ abnormalities/NNS ability/NN known/VBN appreciated/VBN associated/VBN carcinoma/NN tract/NN the/DT
cyclophosphamide/JJ abnormalities/NNS ability/NN known/VBN appreciated/VBN associated/VBN carcinoma/NN tract/NN urinary/JJ
cyclophosphamide/JJ abnormalities/NNS ability/NN known/VBN appreciated/VBN associated/VBN carcinoma/NN tract/NN
cyclophosphamide/JJ cause/VB cystitis/NNS hemorrhagic/JJ
cyclophosphamide/JJ cause/VB cystitis/NNS
cyclophosphamide/JJ treatment/NN reported/VBN pelvis/NNS carcinoma/NN
cyclophosphamide/JJ treatment/NN reported/VBN pelvis/NNS of/IN
cyclophosphamide/JJ treatment/NN reported/VBN pelvis/NNS the/DT
cyclophosphamide/JJ treatment/NN reported/VBN pelvis/NNS renal/JJ
cyclophosphamide/JJ treatment/NN reported/VBN pelvis/NNS
cyclophosphamide/JJ treatment/NN reported/VBN cancer/NN urinary/JJ
cyclophosphamide/JJ treatment/NN reported/VBN cancer/NN tract/NN
cyclophosphamide/JJ treatment/NN reported/VBN cancer/NN
cyclophosphamide/VB intensified/VBD prolonged/VBZ suggests/VBZ association/NN tumor/NN
cyclophosphamide/VB intensified/VBD prolonged/VBZ suggests/VBZ association/NN tumor/NN hydroureteronephrosis/NNS
cyclophosphamide/NN treatment/NN evaluated/VBN uropathy/NN obstructive/JJ
cyclophosphamide/NN treatment/NN evaluated/VBN uropathy/NN
VNR/NNP comparing/VBG analysis/NN treatment/NN malignancies/NNS
VNR/NNP drugs/NNS treatment/NN cancer/NN
gemcitabine/JJ -RSB-/NNS drugs/NNS cardiotoxic/JJ
GEM/NNP -RSB-/NNS drugs/NNS cardiotoxic/JJ
anthracyclines/JJ fluorouracil/JJ -RSB-/NNS drugs/NNS cardiotoxic/JJ
fluorouracil/JJ -RSB-/NNS drugs/NNS cardiotoxic/JJ
vindesine/VB VDS/NNP drugs/NNS cardiotoxic/JJ
VDS/NNP drugs/NNS cardiotoxic/JJ
serotonin/NN complication/NN reuptake/VBP important/JJ aware/JJ cause/VB hypertension/NN
daptomycin/NN meningitis/NNS
daptomycin/NN high/JJ concentrations/NNS treated/VBN bacteremia/NNP
daptomycin/NN high/JJ concentrations/NNS treated/VBN bacteremia/NNP meningitis/NNS
methicillin/NN case/NN report/VB sensitive/JJ treated/VBN bacteremia/NNP
methicillin/NN case/NN report/VB sensitive/JJ treated/VBN bacteremia/NNP meningitis/NNS
creatinine/NN mg/NN developed/VBD failure/NN acute/JJ
creatinine/NN mg/NN developed/VBD failure/NN renal/JJ
creatinine/NN mg/NN developed/VBD failure/NN
daptomycin/VBN discontinued/VBN Nafcillin/NNP initiated/VBN meningitis/NNS
Nafcillin/NNP initiated/VBN meningitis/NNS
nafcillin/NN nephritis/NNS bacteremia/NN
Daptomycin/NNP initiated/VBN nafcillin/NN nephritis/NNS bacteremia/NN
Daptomycin/NNP initiated/VBN nafcillin/NN nephritis/NNS interstitial/JJ
Daptomycin/NNP initiated/VBN nafcillin/NN nephritis/NNS
daptomycin/NN option/NN bacteremia/NNP
quetiapine/VBN schizo/NN
quetiapine/VBN doses/NNS high/JJ add/VBP disorder/NN affective/JJ
quetiapine/VBN doses/NNS high/JJ add/VBP disorder/NN
lithium/NN case/NN year/NN suffering/NN schizo/NN
lithium/NN case/NN disorder/NN affective/JJ
lithium/NN case/NN disorder/NN
lithium/NNP 0/NNP lithium/NN case/NN year/NN suffering/NN schizo/NN
lithium/NNP 0/NNP lithium/NN case/NN disorder/NN affective/JJ
lithium/NNP 0/NNP lithium/NN case/NN disorder/NN
zuclopenthixol/NN antipsychotics/NNS case/NN year/NN suffering/NN schizo/NN
zuclopenthixol/NN antipsychotics/NNS case/NN disorder/NN affective/JJ
zuclopenthixol/NN antipsychotics/NNS case/NN disorder/NN
quetiapine/NN introduction/NN h/NN presented/VBD contrasting/VBG absence/NN history/NN disorder/NN aggressiveness/NN
quetiapine/NN introduction/NN h/NN presented/VBD contrasting/VBG absence/NN history/NN disorder/NN aggressiveness/NN personality/NN
quetiapine/NN introduction/NN h/NN presented/VBD contrasting/VBG absence/NN history/NN disorder/NN
sulphonylurea/NN treatment/NN patients/NNS type/NN
sulphonylurea/NN treatment/NN patients/NNS type/NN 2/CD
sulphonylurea/NN treatment/NN associated/VBN disease/NN Risk/NN diabetes/VBZ
sulphonylurea/NN treatment/NN associated/VBN disease/NN coronary/JJ
sulphonylurea/NN treatment/NN associated/VBN disease/NN artery/NN
sulphonylurea/NN treatment/NN associated/VBN disease/NN
sulphonylureas/NNS associated/VBN treatment/NN diabetes/NN type/NN
sulphonylureas/NNS associated/VBN treatment/NN diabetes/NN 2/CD
sulphonylureas/NNS associated/VBN treatment/NN diabetes/NN
sulphonylureas/NNS associated/VBN disease/NN coronary/JJ
sulphonylureas/NNS associated/VBN disease/NN artery/NN
sulphonylureas/NNS associated/VBN disease/NN
sulphonylureas/NNS associated/VBN disease/NN CAD/NNP
glipizide/NN 0/CD fold/NNP fold/NNP 4/CD treatment/NN associated/VBN hazard/NN developing/VBG CAD/NNP
metformin/NN unchanged/JJ associated/VBN hazard/NN developing/VBG CAD/NNP
gliclazide/VB risk/NN CAD/NNP
glimepiride/VB gliclazide/VB risk/NN CAD/NNP
glimepiride/VB gliclazide/VB risk/NN associated/VBN CONCLUSIONS/NNS treatment/NN diabetes/NN type/NN
glimepiride/VB gliclazide/VB risk/NN associated/VBN CONCLUSIONS/NNS treatment/NN diabetes/NN 2/CD
glimepiride/VB gliclazide/VB risk/NN associated/VBN CONCLUSIONS/NNS treatment/NN diabetes/NN
glipizide/NN glibenclamide/NN treatment/NN CONCLUSIONS/NNS associated/VBN risk/NN CAD/NNP
gliclazide/VB risk/NN associated/VBN CONCLUSIONS/NNS treatment/NN diabetes/NN type/NN
gliclazide/VB risk/NN associated/VBN CONCLUSIONS/NNS treatment/NN diabetes/NN 2/CD
gliclazide/VB risk/NN associated/VBN CONCLUSIONS/NNS treatment/NN diabetes/NN
glipizide/NN glibenclamide/NN treatment/NN diabetes/NN type/NN
glipizide/NN glibenclamide/NN treatment/NN diabetes/NN 2/CD
glipizide/NN glibenclamide/NN treatment/NN diabetes/NN
glibenclamide/NN treatment/NN diabetes/NN type/NN
glibenclamide/NN treatment/NN diabetes/NN 2/CD
glibenclamide/NN treatment/NN diabetes/NN
carboplatin/NN chemotherapy/NN retinoblastoma/NN
carboplatin/NN injections/NNS used/VBN Focal/NNP BACKGROUND/NNP adjunct/NN chemotherapy/NN retinoblastoma/NN
carboplatin/NN injections/NNS used/VBN toxicity/NN
carboplatin/NN received/VBN retinoblastoma/NN
carboplatin/NN injections/NNS treated/VBN retinoblastoma/NN
carboplatin/NNP free/JJ toxicity/NN
heparin/NN patient/NN alteplase/NN thrombolysis/NNS
heparin/NN patient/NN alteplase/NN thrombolysis/NNS Use/NN thrombocytopenia/NN thrombosis/NNS
argatroban/NN Use/NN thrombocytopenia/NN thrombosis/NNS
argatroban/NN Use/NN thrombocytopenia/NN
argatroban/NN Use/NN thrombolysis/NNS
heparin/NN directed/VBD presented/VBN thrombolysis/NNS
heparin/NN induced/VBN thrombosis/NNS
argatroban/NN treated/VBN induced/VBN thrombosis/NNS
argatroban/NN treated/VBN induced/VBN thrombocytopenia/NN
argatroban/NN treated/VBN induced/VBN heparin/NN directed/VBD presented/VBN thrombolysis/NNS
argatroban/NN treated/VBN induced/VBN thrombosis/NNS HITT/NNP
heparin/NN induced/VBN thrombosis/NNS HITT/NNP
heparin/NN embolism/NN venous/NNS upper/NN undergoing/VBG amyloidosis/NNS
heparin/NN embolism/NN venous/NNS upper/NN
heparin/NN embolism/NN venous/NNS extremity/JJ
heparin/NN embolism/NN venous/NNS deep/JJ
heparin/NN embolism/NN venous/NNS
heparin/NN embolism/NN venous/NNS thrombosis/NNS
argatroban/NN restarted/VBN resolved/VBD epistaxis/NNS
argatroban/NN treated/VBN year/NN man/NN amyloidosis/NNS
argatroban/NN treated/VBN year/NN syndrome/NN secondary/JJ HITT/NNP
argatroban/NN treated/VBN year/NN syndrome/NN SVC/NNP
argatroban/NN treated/VBN year/NN syndrome/NN
nocistatin/VBP FQ/VBP impairment/NN learning/NN
nocistatin/VBP FQ/VBP impairment/NN learning/NN and/CC
nocistatin/VBP FQ/VBP impairment/NN learning/NN memory/NN
nocistatin/VBP FQ/VBP impairment/NN
scopolamine/NN induced/VBN impairment/NN learning/NN
scopolamine/NN induced/VBN impairment/NN learning/NN and/CC
scopolamine/NN induced/VBN impairment/NN learning/NN memory/NN
scopolamine/NN induced/VBN impairment/NN
Nociceptin/NNP FQ/VBP impairment/NN learning/NN
Nociceptin/NNP FQ/VBP impairment/NN learning/NN and/CC
Nociceptin/NNP FQ/VBP impairment/NN learning/NN memory/NN
Nociceptin/NNP FQ/VBP impairment/NN
orphanin/NN FQ/VBP impairment/NN learning/NN
orphanin/NN FQ/VBP impairment/NN learning/NN and/CC
orphanin/NN FQ/VBP impairment/NN learning/NN memory/NN
orphanin/NN FQ/VBP impairment/NN
FQ/VBP impairment/NN learning/NN
FQ/VBP impairment/NN learning/NN and/CC
FQ/VBP impairment/NN learning/NN memory/NN
FQ/VBP impairment/NN
nocistatin/NN isolated/VBN nociceptin/NN induced/VBN allodynia/NN
nocistatin/NN isolated/VBN nociceptin/NN induced/VBN allodynia/NN hyperalgesia/NN
nociceptin/NN nociceptin/NN induced/VBN allodynia/NN
nociceptin/NN nociceptin/NN induced/VBN allodynia/NN hyperalgesia/NN
nociceptin/NN induced/VBN allodynia/NN
nociceptin/NN induced/VBN allodynia/NN hyperalgesia/NN
nocistatin/NN FQ/NN modulate/VB impairment/NN
nocistatin/NN FQ/NN modulate/VB impairment/NN learning/NN of/IN
nocistatin/NN FQ/NN modulate/VB impairment/NN learning/NN
nocistatin/NN FQ/NN modulate/VB impairment/NN learning/NN and/CC
nocistatin/NN FQ/NN modulate/VB impairment/NN learning/NN memory/NN
scopolamine/NN using/VBG induced/VBN impairment/NN
scopolamine/NN using/VBG induced/VBN impairment/NN learning/NN of/IN
scopolamine/NN using/VBG induced/VBN impairment/NN learning/NN
scopolamine/NN using/VBG induced/VBN impairment/NN learning/NN and/CC
scopolamine/NN using/VBG induced/VBN impairment/NN learning/NN memory/NN
nociceptin/NN FQ/NN modulate/VB impairment/NN
nociceptin/NN FQ/NN modulate/VB impairment/NN learning/NN of/IN
nociceptin/NN FQ/NN modulate/VB impairment/NN learning/NN
nociceptin/NN FQ/NN modulate/VB impairment/NN learning/NN and/CC
nociceptin/NN FQ/NN modulate/VB impairment/NN learning/NN memory/NN
orphanin/NN FQ/NN modulate/VB impairment/NN
orphanin/NN FQ/NN modulate/VB impairment/NN learning/NN of/IN
orphanin/NN FQ/NN modulate/VB impairment/NN learning/NN
orphanin/NN FQ/NN modulate/VB impairment/NN learning/NN and/CC
orphanin/NN FQ/NN modulate/VB impairment/NN learning/NN memory/NN
FQ/NN modulate/VB impairment/NN
FQ/NN modulate/VB impairment/NN learning/NN of/IN
FQ/NN modulate/VB impairment/NN learning/NN
FQ/NN modulate/VB impairment/NN learning/NN and/CC
FQ/NN modulate/VB impairment/NN learning/NN memory/NN
valproic/JJ year/NN Reversible/VB man/NN epilepsy/NN
acid/JJ year/NN Reversible/VB man/NN epilepsy/NN
Haloperidol/NNP failed/VBD prevent/VB amphetamine/NN seizures/NNS
Haloperidol/NNP decreased/VBD incidence/NN seizures/NNS
haloperidol/NN role/NN suggest/VBP amphetamine/VBP reducing/VBG incidence/NN seizures/NNS
dopamine/JJ haloperidol/NN role/NN suggest/VBP amphetamine/VBP reducing/VBG incidence/NN seizures/NNS
haloperidol/NN demonstrated/VBD ability/NN reduce/VB cocaine/NN induced/VBN seizures/NNS
cocaethylene/VB Cocaine/VB cardiotoxity/NN
Cocaine/VB cardiotoxity/NN
cocaethylene/VB Cocaine/VB model/NN abuse/NN cocaine/NN
cocaethylene/VB Cocaine/VB model/NN abuse/NN cocaine/NN and/CC
cocaethylene/VB Cocaine/VB model/NN abuse/NN cocaine/NN ethanol/NN
cocaethylene/VB Cocaine/VB model/NN abuse/NN
Cocaine/VB model/NN abuse/NN cocaine/NN
Cocaine/VB model/NN abuse/NN cocaine/NN and/CC
Cocaine/VB model/NN abuse/NN cocaine/NN ethanol/NN
Cocaine/VB model/NN abuse/NN
ethanol/UH Cocaine/VB cardiotoxity/NN
ethanol/UH Cocaine/VB model/NN abuse/NN cocaine/NN
ethanol/UH Cocaine/VB model/NN abuse/NN cocaine/NN and/CC
ethanol/UH Cocaine/VB model/NN abuse/NN cocaine/NN ethanol/NN
ethanol/UH Cocaine/VB model/NN abuse/NN
cocaethylene/VB due/JJ formed/VBD due/JJ toxicity/NN cardiac/JJ
cocaethylene/VB due/JJ formed/VBD due/JJ toxicity/NN
CE/NNP cocaethylene/VB due/JJ formed/VBD due/JJ toxicity/NN cardiac/JJ
CE/NNP cocaethylene/VB due/JJ formed/VBD due/JJ toxicity/NN
cocaine/NN metabolite/NN formed/VBD due/JJ toxicity/NN cardiac/JJ
cocaine/NN metabolite/NN formed/VBD due/JJ toxicity/NN
ethanol/NN presence/NN formed/VBD due/JJ toxicity/NN cardiac/JJ
ethanol/NN presence/NN formed/VBD due/JJ toxicity/NN
CE/NNP role/NN delineate/VB cardiotoxicity/NN
cocaine/NN cardiotoxicity/NN
ethanol/NN cocaine/NN cardiotoxicity/NN
cocaethylene/NN concentrations/NNS associated/VBN depression/NN myocardial/JJ
cocaethylene/NN concentrations/NNS associated/VBN depression/NN
alkylxanthines/NNS testing/NN toxicity/NN
cycloheximide/NN treated/VBN rats/NNS epileptic/JJ
cycloheximide/NN subject/JJ epilepticus/NNS status/NN
cycloheximide/NN subject/JJ epilepticus/NNS
CHX/NNP layer/NN subject/JJ epilepticus/NNS status/NN
CHX/NNP layer/NN subject/JJ epilepticus/NNS
carbamazepine/NN had/VBD had/VBD had/VBD hemosiderosis/NNS resulting/VBG shock/NN cardiogenic/JJ
carbamazepine/NN had/VBD had/VBD had/VBD hemosiderosis/NNS resulting/VBG shock/NN
carbamazepine/NN induced/VBN myocarditis/NNS eosinophilic/JJ
carbamazepine/NN induced/VBN myocarditis/NNS
propranolol/JJ therapy/NN correlated/JJ invariable/JJ conclude/VBP reported/VBD apnea/NN hypoglycemia/NN
propranolol/JJ therapy/NN correlated/JJ invariable/JJ bradycardia/NN
propranolol/JJ therapy/NN correlated/JJ invariable/JJ conclude/VBP reported/VBD apnea/NN neonatal/JJ
propranolol/JJ therapy/NN correlated/JJ invariable/JJ conclude/VBP reported/VBD apnea/NN
propranolol/JJ therapy/NN correlated/JJ invariable/JJ conclude/VBP reported/VBD apnea/NN hyperbilirubinemia/NN
propranolol/JJ therapy/NN correlated/JJ invariable/JJ conclude/VBP reported/VBD apnea/NN polycythemia/NN
Crocin/NNP reduced/VBD inhibition/NN activation/NN hyperlipemia/NN
Crocin/NNP considered/VBN agent/NN diazinon/NN induced/VBN hyperlipemia/NN
losartan/NN treated/VBN progression/NN nephropathy/NN
losartan/NN treated/VBN progression/NN nephropathy/NN rats/NNS hypertensive/NN
adriamycin/NN nephropathy/NN rats/NNS hypertensive/NN
adriamycin/NN nephropathy/NN
losartan/NN blocker/NN effects/NNS investigate/VB slowing/VBG progression/NN renal/JJ
losartan/NN blocker/NN effects/NNS investigate/VB slowing/VBG progression/NN disease/NN
losartan/NN blocker/NN effects/NNS investigate/VB slowing/VBG nephropathy/RB
losartan/NN blocker/NN effects/NNS investigate/VB slowing/VBG progression/NN rats/NNS hypertensive/JJ
adriamycin/NN progression/NN rats/NNS hypertensive/JJ
ADR/NNP adriamycin/NN progression/NN rats/NNS hypertensive/JJ
angiotensin/NNP type/NN effects/NNS investigate/VB slowing/VBG progression/NN rats/NNS hypertensive/JJ
II/NNP type/NN effects/NNS investigate/VB slowing/VBG progression/NN rats/NNS hypertensive/JJ
adriamycin/NN progression/NN renal/JJ
adriamycin/NN progression/NN disease/NN
adriamycin/NN progression/NN slowing/VBG nephropathy/RB
ADR/NNP adriamycin/NN progression/NN renal/JJ
ADR/NNP adriamycin/NN progression/NN disease/NN
ADR/NNP adriamycin/NN progression/NN slowing/VBG nephropathy/RB
angiotensin/NNP type/NN effects/NNS investigate/VB slowing/VBG progression/NN renal/JJ
angiotensin/NNP type/NN effects/NNS investigate/VB slowing/VBG progression/NN disease/NN
II/NNP type/NN effects/NNS investigate/VB slowing/VBG progression/NN renal/JJ
II/NNP type/NN effects/NNS investigate/VB slowing/VBG progression/NN disease/NN
angiotensin/NNP type/NN effects/NNS investigate/VB slowing/VBG nephropathy/RB
II/NNP type/NN effects/NNS investigate/VB slowing/VBG nephropathy/RB
losartan/NN treatment/NN Short/NNP glomerulosclerosis/NNS
losartan/NN treatment/NN Short/NNP glomerulosclerosis/NNS resulting/VBG proteinuria/NN
losartan/NN treatment/NN showed/VBD reduction/NN glomerulosclerosis/NNS associated/VBN preventing/VBG proteinuria/NN failure/NN chronic/JJ
losartan/NN treatment/NN showed/VBD reduction/NN glomerulosclerosis/NNS associated/VBN preventing/VBG proteinuria/NN failure/NN renal/JJ
losartan/NN treatment/NN showed/VBD reduction/NN glomerulosclerosis/NNS associated/VBN preventing/VBG proteinuria/NN failure/NN
losartan/NN treatment/NN showed/VBD reduction/NN glomerulosclerosis/NNS associated/VBN progression/NN atrophy/NN fibrosis/NN interstitial/NN
losartan/NN treatment/NN showed/VBD reduction/NN glomerulosclerosis/NNS associated/VBN progression/NN atrophy/NN fibrosis/NN
losartan/NN treatment/NN showed/VBD reduction/NN glomerulosclerosis/NNS
losartan/NN treatment/NN showed/VBD reduction/NN glomerulosclerosis/NNS associated/VBN preventing/VBG proteinuria/NN
losartan/NN treatment/NN showed/VBD reduction/NN glomerulosclerosis/NNS associated/VBN progression/NN atrophy/NN
Losartan/NNP reduced/VBD clearance/NN nephropathy/NN
ADR/NNP nephropathy/NN
urea/NN clearance/NN uraemia/NN
urea/NN clearance/NN nephropathy/NN
Losartan/NNP reduced/VBD clearance/NN uraemia/NN
ADR/NNP infiltration/NN atrophy/JJ
losartan/NN prevent/VB nephropathy/RB
ADR/NNP infiltration/NN prevent/VB nephropathy/RB
losartan/NN prevent/VB infiltration/NN fibrosis/NN
losartan/NN prevent/VB infiltration/NN atrophy/JJ
ADR/NNP infiltration/NN fibrosis/NN
Losartan/NNP reduces/VBZ rate/NN induced/VBN end/VB
Losartan/NNP reduces/VBZ rate/NN disease/NN stage/NN
Losartan/NNP reduces/VBZ rate/NN disease/NN renal/JJ
Losartan/NNP reduces/VBZ rate/NN disease/NN
ADR/NNP progression/NN rate/NN induced/VBN end/VB
ADR/NNP progression/NN rate/NN disease/NN stage/NN
ADR/NNP progression/NN rate/NN disease/NN renal/JJ
ADR/NNP progression/NN rate/NN disease/NN
Losartan/NNP reduces/VBZ rate/NN induced/VBN glomerulosclerosis/NNS focal/JJ
Losartan/NNP reduces/VBZ rate/NN induced/VBN glomerulosclerosis/NNS segmental/JJ
Losartan/NNP reduces/VBZ rate/NN induced/VBN glomerulosclerosis/NNS
phenylephrine/NN determined/VBN hypotension/NN
Phe/NNP phenylephrine/NN determined/VBN hypotension/NN
sodium/NN hypertension/NN
nitroprusside/NN hypertension/NN
SN/NNP nitroprusside/NN hypertension/NN
AVP/NNP administration/NN reduced/VBN hypotension/NN
neuroleptic/NN expression/NN intact/JJ need/VBP promotes/VBZ catalepsy/RB
neuroleptic/NN induced/VBN catalepsy/RB
atropine/NN blocker/NN disrupted/VBD haloperidol/NN induced/VBN catalepsy/RB
acetylcholine/JJ inhibitor/NN injection/NN prevented/VBD catalepsy/NN
hemicholinium/NN injection/NN prevented/VBD catalepsy/NN
neuroleptics/NNS produced/VBN catalepsy/NN
lithium/NN therapy/NN developed/VBD bradyarrhythmia/NN
lithium/NN conduct/VB prompted/VBD findings/NNS patient/NN receiving/VBG therapy/NN developed/VBD bradyarrhythmia/NN
lithium/NN therapy/NN receiving/VBG patient/NN bipolar/JJ
lithium/NN therapy/NN receiving/VBG patient/NN findings/NNS prompted/VBD conduct/VB study/NN patients/NNS bipolar/NNP
lithium/NN conduct/VB prompted/VBD findings/NNS patient/NN bipolar/JJ
lithium/NN conduct/VB study/NN patients/NNS bipolar/NNP
lithium/NN non/NN treated/VBN hypercalcemias/NNS related/VBN malignancies/NNS
lithium/NN patients/NNS conditions/NNS malignancies/NNS
lithium/NN sex/NN age/NN treated/VBN patients/NNS bipolar/JJ
lithium/NN sex/NN age/NN included/VBD group/NN included/VBD patients/NNS bipolar/JJ
lithium/NN resulting/VBG diseases/NNS patients/NNS bipolar/JJ
botox/NN injection/NN Abductor/VB paralysis/NN
Botox/NNP injections/NNS paralysis/NN
Botox/NNP injections/NNS dysphonia/NN spasmodic/JJ
Botox/NNP injections/NNS dysphonia/NN
Botox/NNP dose/NN noted/VBN patients/NNS paralysis/NN
Botox/NNP dose/NN paralysis/NN
Botox/NN dose/NN dose/NN noted/VBN patients/NNS paralysis/NN
Botox/NN dose/NN dose/NN paralysis/NN
Botox/NNP injection/NN paralysis/NN
Botox/NNP injections/NNS complication/NN paralysis/NN
Botox/NNP diffusion/NN mechanism/NN paralysis/NN
statins/NNS are/VBP reported/VBN tolerated/VBD drugs/NNS cases/NNS drug/NN
statins/NNS are/VBP reported/VBN injury/NN induced/JJ
statins/NNS are/VBP reported/VBN injury/NN liver/NN
statins/NNS are/VBP reported/VBN injury/NN
S/NNP d/SYM 312/CD 312/CD S/NNP showed/VBD convulsions/NNS audiogenic/JJ
S/NNP d/SYM 312/CD 312/CD S/NNP showed/VBD convulsions/NNS tonic/NN
S/NNP d/SYM 312/CD 312/CD S/NNP showed/VBD convulsions/NNS
312/CD 312/CD 312/CD S/NNP showed/VBD convulsions/NNS audiogenic/JJ
312/CD 312/CD 312/CD S/NNP showed/VBD convulsions/NNS tonic/NN
312/CD 312/CD 312/CD S/NNP showed/VBD convulsions/NNS
l/NN 312/CD S/NNP showed/VBD convulsions/NNS audiogenic/JJ
l/NN 312/CD S/NNP showed/VBD convulsions/NNS tonic/NN
l/NN 312/CD S/NNP showed/VBD convulsions/NNS
S/NNP showed/VBD convulsions/NNS audiogenic/JJ
S/NNP showed/VBD convulsions/NNS tonic/NN
S/NNP showed/VBD convulsions/NNS
312/CD S/NNP showed/VBD convulsions/NNS audiogenic/JJ
312/CD S/NNP showed/VBD convulsions/NNS tonic/NN
312/CD S/NNP showed/VBD convulsions/NNS
S/NNP 312/CD S/NNP showed/VBD convulsions/NNS audiogenic/JJ
S/NNP 312/CD S/NNP showed/VBD convulsions/NNS tonic/NN
S/NNP 312/CD S/NNP showed/VBD convulsions/NNS
312/CD 312/CD S/NNP showed/VBD convulsions/NNS audiogenic/JJ
312/CD 312/CD S/NNP showed/VBD convulsions/NNS tonic/NN
312/CD 312/CD S/NNP showed/VBD convulsions/NNS
d/SYM 312/CD 312/CD S/NNP showed/VBD convulsions/NNS audiogenic/JJ
d/SYM 312/CD 312/CD S/NNP showed/VBD convulsions/NNS tonic/NN
d/SYM 312/CD 312/CD S/NNP showed/VBD convulsions/NNS
calcium/NN antagonists/NNS S/NNP showed/VBD convulsions/NNS audiogenic/JJ
calcium/NN antagonists/NNS S/NNP showed/VBD convulsions/NNS tonic/NN
calcium/NN antagonists/NNS S/NNP showed/VBD convulsions/NNS
flunarizine/NN that/DT 34/CD o/NNP convulsions/NNS audiogenic/JJ
flunarizine/NN that/DT 34/CD o/NNP convulsions/NNS tonic/NN
flunarizine/NN that/DT 34/CD o/NNP convulsions/NNS
S/NNP effects/NNS observed/VBN convulsions/NNS
312/CD S/NNP effects/NNS observed/VBN convulsions/NNS
d/SYM S/NNP effects/NNS observed/VBN convulsions/NNS
S/NNP effects/NNS observed/VBN observed/VBN convulsions/NNS
312/CD S/NNP effects/NNS observed/VBN observed/VBN convulsions/NNS
d/SYM S/NNP effects/NNS observed/VBN observed/VBN convulsions/NNS
N/NNP induced/VBN convulsions/NNS observed/VBN observed/VBN convulsions/NNS
methyl/NN N/NNP induced/VBN convulsions/NNS observed/VBN observed/VBN convulsions/NNS
D/NNP N/NNP induced/VBN convulsions/NNS observed/VBN observed/VBN convulsions/NNS
aspartate/NN N/NNP induced/VBN convulsions/NNS observed/VBN observed/VBN convulsions/NNS
N/NNP induced/VBN convulsions/NNS
methyl/NN N/NNP induced/VBN convulsions/NNS
D/NNP N/NNP induced/VBN convulsions/NNS
aspartate/NN N/NNP induced/VBN convulsions/NNS
S/NNP useful/JJ therapy/NN types/NNS epilepsy/NN
312/CD S/NNP useful/JJ therapy/NN types/NNS epilepsy/NN
d/SYM useful/JJ therapy/NN types/NNS epilepsy/NN
aracytine/NN dose/NN edema/NN C/NNP lymphoma/NN
C/NNP lymphoma/NN
Ara/NNP developed/VBD C/NNP lymphomas/NNS
C/NNP lymphomas/NNS
Ara/NNP C/NNS associated/VBN hypothesize/VBP thought/VBN involved/VBN development/NN shock/NN syndrome/NN adult/JJ
Ara/NNP C/NNS associated/VBN hypothesize/VBP thought/VBN involved/VBN development/NN shock/NN syndrome/NN respiratory/JJ
Ara/NNP C/NNS associated/VBN hypothesize/VBP thought/VBN involved/VBN development/NN shock/NN syndrome/NN distress/NN
Ara/NNP C/NNS associated/VBN hypothesize/VBP thought/VBN involved/VBN development/NN shock/NN syndrome/NN
C/NNS associated/VBN hypothesize/VBP thought/VBN involved/VBN development/NN shock/NN syndrome/NN adult/JJ
C/NNS associated/VBN hypothesize/VBP thought/VBN involved/VBN development/NN shock/NN syndrome/NN respiratory/JJ
C/NNS associated/VBN hypothesize/VBP thought/VBN involved/VBN development/NN shock/NN syndrome/NN distress/NN
C/NNS associated/VBN hypothesize/VBP thought/VBN involved/VBN development/NN shock/NN syndrome/NN
phosphatidylserine/NN exposure/NN characterized/VBN eryptosis/NNS death/NN result/VB anemia/NN
PS/NNP phosphatidylserine/NN exposure/NN characterized/VBN eryptosis/NNS death/NN result/VB anemia/NN
estrogen/JJ sites/NNS evidence/NN induced/VBN carcinomas/NNS renal/JJ
estrogen/JJ sites/NNS evidence/NN induced/VBN carcinomas/NNS
Estrogen/JJ sites/NNS demonstrated/VBN autoradiography/NN diethylstilbesterol/NN induced/VBN carcinomas/NNS renal/JJ
Estrogen/JJ sites/NNS demonstrated/VBN autoradiography/NN diethylstilbesterol/NN induced/VBN carcinomas/NNS
estradiol/NN H/NNP injection/NN Radiolabelling/NN increased/VBN nuclei/NN cells/NNS tumor/NN
silver/NN grains/NNS nuclei/NN cells/NNS tumor/NN
estrogen/NN nuclei/NNS cells/NNS carcinomas/NNS renal/JJ
estrogen/NN nuclei/NNS cells/NNS carcinomas/NNS
estrogen/JJ carcinomas/NNS renal/JJ
estrogen/JJ carcinomas/NNS
tenofovir/VB exposed/VBN persons/NNS investigation/NN pattern/NN injury/NN kidney/NN
tenofovir/VB exposed/VBN persons/NNS investigation/NN pattern/NN injury/NN
disoproxil/JJ fumarate/NN tenofovir/VB exposed/VBN persons/NNS investigation/NN pattern/NN injury/NN kidney/NN
disoproxil/JJ fumarate/NN tenofovir/VB exposed/VBN persons/NNS investigation/NN pattern/NN injury/NN
fumarate/NN tenofovir/VB exposed/VBN persons/NNS investigation/NN pattern/NN injury/NN kidney/NN
fumarate/NN tenofovir/VB exposed/VBN persons/NNS investigation/NN pattern/NN injury/NN
TDF/NNP criteria/NNS records/NNS disease/NN kidney/NN
TDF/NNP criteria/NNS records/NNS disease/NN
TDF/NNP criteria/NNS records/NNS disease/NN had/VBD features/NNS dysfunction/NN kidney/NN
TDF/NNP criteria/NNS records/NNS disease/NN had/VBD features/NNS dysfunction/NN tubular/JJ
TDF/NNP criteria/NNS records/NNS disease/NN had/VBD features/NNS dysfunction/NN
TDF/NNP criteria/NNS records/NNS found/VBN have/VB features/NNS dysfunction/NN glomerular/NN
TDF/NNP criteria/NNS records/NNS found/VBN have/VB features/NNS dysfunction/NN
carbamazepine/NN associated/VBN cases/NNS nystagmus/NNS downbeat/NN
carbamazepine/NN associated/VBN cases/NNS nystagmus/NNS
carbamazepine/VB related/VBN nystagmus/NNS downbeat/JJ
carbamazepine/VB related/VBN nystagmus/NNS
carbamazepine/JJ levels/NNS reduction/NN resolved/VBN nystagmus/NNS
lead/NN regulation/NN learning/NN exposed/VBD produces/VBZ impairment/NN cognitive/NN
lead/NN regulation/NN learning/NN exposed/VBD produces/VBZ impairment/NN
lead/JJ exposure/NN absence/NN produces/VBZ impairment/NN cognitive/NN
lead/JJ exposure/NN absence/NN produces/VBZ impairment/NN
Pb/NN exposure/NN model/NN using/VBG succimer/NN agent/NN treatment/NN poisoning/NN Pb/NNP
Pb/NN exposure/NN model/NN using/VBG succimer/NN agent/NN treatment/NN poisoning/NN
succimer/NN agent/NN treatment/NN poisoning/NN Pb/NNP
succimer/NN agent/NN treatment/NN poisoning/NN
Pb/NNP exposure/NN produced/VBN impairments/NNS
Pb/NNP exposure/NN produced/VBN impairments/NNS learning/NN in/IN
Pb/NNP exposure/NN produced/VBN impairments/NNS learning/NN
Pb/NNP exposure/NN produced/VBN impairments/NNS learning/NN attention/NN
Pb/NNP exposure/NN produced/VBN impairments/NNS learning/NN control/NN inhibitory/JJ
Pb/NNP exposure/NN produced/VBN impairments/NNS learning/NN control/NN
Pb/NNP exposure/NN produced/VBN impairments/NNS learning/NN and/CC
Pb/NNP exposure/NN produced/VBN impairments/NNS learning/NN regulation/NN arousal/JJ
Pb/NNP exposure/NN produced/VBN impairments/NNS learning/NN regulation/NN
Pb/NNP seen/VBN dysfunction/NN areas/NNS paralleling/VBG produced/VBN impairments/NNS
Pb/NNP seen/VBN dysfunction/NN areas/NNS paralleling/VBG produced/VBN impairments/NNS learning/NN in/IN
Pb/NNP seen/VBN dysfunction/NN areas/NNS paralleling/VBG produced/VBN impairments/NNS learning/NN
Pb/NNP seen/VBN dysfunction/NN areas/NNS paralleling/VBG produced/VBN impairments/NNS learning/NN attention/NN
Pb/NNP seen/VBN dysfunction/NN areas/NNS paralleling/VBG produced/VBN impairments/NNS learning/NN control/NN inhibitory/JJ
Pb/NNP seen/VBN dysfunction/NN areas/NNS paralleling/VBG produced/VBN impairments/NNS learning/NN control/NN
Pb/NNP seen/VBN dysfunction/NN areas/NNS paralleling/VBG produced/VBN impairments/NNS learning/NN and/CC
Pb/NNP seen/VBN dysfunction/NN areas/NNS paralleling/VBG produced/VBN impairments/NNS learning/NN regulation/NN arousal/JJ
Pb/NNP seen/VBN dysfunction/NN areas/NNS paralleling/VBG produced/VBN impairments/NNS learning/NN regulation/NN
succimer/NN treatment/NN produced/VBD dysfunction/NN cognitive/JJ
succimer/NN treatment/NN produced/VBD dysfunction/NN cognitive/JJ and/CC
succimer/NN treatment/NN produced/VBD dysfunction/NN cognitive/JJ affective/JJ
succimer/NN treatment/NN produced/VBD dysfunction/NN
Pb/NNP exposed/VBN rats/NNS treatment/NN produced/VBD dysfunction/NN cognitive/JJ
Pb/NNP exposed/VBN rats/NNS treatment/NN produced/VBD dysfunction/NN cognitive/JJ and/CC
Pb/NNP exposed/VBN rats/NNS treatment/NN produced/VBD dysfunction/NN cognitive/JJ affective/JJ
Pb/NNP exposed/VBN rats/NNS treatment/NN produced/VBD dysfunction/NN
Pb/NN regimen/NN produced/VBN that/DT produced/VBD dysfunction/NN cognitive/JJ
Pb/NN regimen/NN produced/VBN that/DT produced/VBD dysfunction/NN cognitive/JJ and/CC
Pb/NN regimen/NN produced/VBN that/DT produced/VBD dysfunction/NN cognitive/JJ affective/JJ
Pb/NN regimen/NN produced/VBN that/DT produced/VBD dysfunction/NN
Pb/NNP exposure/NN due/JJ deficits/NNS cognitive/JJ
Pb/NNP exposure/NN due/JJ deficits/NNS
rifampicin/NN antibodies/NNS failure/NN renal/JJ
rifampicin/NN antibodies/NNS failure/NN
rifampicin/NN reintroduction/NN induced/VBN failure/NN acute/JJ
rifampicin/NN reintroduction/NN induced/VBN failure/NN renal/JJ
rifampicin/NN reintroduction/NN induced/VBN failure/NN
ethanol/NN extract/NN effect/NN isoproterenol/NN induced/VBN infarction/NN myocardial/JJ
ethanol/NN extract/NN effect/NN isoproterenol/NN induced/VBN infarction/NN
Terminalia/NNP chebula/NNP injury/NN myocardial/JJ
Terminalia/NNP chebula/NNP injury/NN
chebula/NNP injury/NN myocardial/JJ
chebula/NNP injury/NN
ethanolic/JJ extract/NNS effect/NN examined/VBN isoproterenol/NN induced/VBN damage/NN myocardial/JJ
ethanolic/JJ extract/NNS effect/NN examined/VBN isoproterenol/NN induced/VBN damage/NN
extract/NNS effect/NN examined/VBN isoproterenol/NN induced/VBN damage/NN myocardial/JJ
extract/NNS effect/NN examined/VBN isoproterenol/NN induced/VBN damage/NN
of/IN fruits/NNS extract/NNS effect/NN examined/VBN isoproterenol/NN induced/VBN damage/NN myocardial/JJ
of/IN fruits/NNS extract/NNS effect/NN examined/VBN isoproterenol/NN induced/VBN damage/NN
Terminalia/NNP fruits/NNS extract/NNS effect/NN examined/VBN isoproterenol/NN induced/VBN damage/NN myocardial/JJ
Terminalia/NNP fruits/NNS extract/NNS effect/NN examined/VBN isoproterenol/NN induced/VBN damage/NN
chebula/NN fruits/NNS extract/NNS effect/NN examined/VBN isoproterenol/NN induced/VBN damage/NN myocardial/JJ
chebula/NN fruits/NNS extract/NNS effect/NN examined/VBN isoproterenol/NN induced/VBN damage/NN
fruits/NNS extract/NNS effect/NN examined/VBN isoproterenol/NN induced/VBN damage/NN myocardial/JJ
fruits/NNS extract/NNS effect/NN examined/VBN isoproterenol/NN induced/VBN damage/NN
L/NNP effect/NN treatment/NN patients/NNS parkinsonian/NN
dopa/NN treatment/NN patients/NNS parkinsonian/NN
L/NNP treated/VBN patients/NNS parkinsonian/NN
dopa/NNP L/NNP treated/VBN patients/NNS parkinsonian/NN
potassium/NN excretion/NN dopa/NN L/NNP influence/NN studied/VBN patients/NNS hypokalemia/NN
potassium/NN concentration/NN flow/NN determination/NN studied/VBN patients/NNS hypokalemia/NN
potassium/NN excretion/NN flow/NN determination/NN studied/VBN patients/NNS hypokalemia/NN
sodium/NN flow/NN determination/NN studied/VBN patients/NNS hypokalemia/NN
sodium/NN potassium/NN excretion/NN flow/NN determination/NN studied/VBN patients/NNS hypokalemia/NN
aldosterone/NN potassium/NN excretion/NN flow/NN determination/NN studied/VBN patients/NNS hypokalemia/NN
corticotropin/NN releasing/VBG releasing/VBG modulate/VBP response/NN hypercapnic/JJ
thyrotropin/NN hormone/NN releasing/VBG releasing/VBG modulate/VBP response/NN hypercapnic/JJ
diethylcarbamazine/NN loiasis/NNS
diethylcarbamazine/NN treatment/NN cases/NNS observed/VBN filariasis/NNS
DEC/NNP diethylcarbamazine/NN treatment/NN cases/NNS observed/VBN filariasis/NNS
Vincristine/NNP given/VBN child/NN leukaemia/NN
domperidone/NN potentiate/VB mirtazapine/NN associated/VBN syndrome/NN restless/JJ
domperidone/NN potentiate/VB mirtazapine/NN associated/VBN syndrome/NN legs/NNS
domperidone/NN potentiate/VB mirtazapine/NN associated/VBN syndrome/NN
levodopa/NN agonists/NNS improved/VBN symptoms/NNS RLS/NNP
levodopa/NN agonists/NNS improved/VBN induce/VB symptoms/NNS RLS/NNP
dopamine/NN levodopa/NN agonists/NNS improved/VBN symptoms/NNS RLS/NNP
dopamine/NN levodopa/NN agonists/NNS improved/VBN induce/VB symptoms/NNS RLS/NNP
dopamine/NNP antagonists/NNS induce/VB improved/VBN symptoms/NNS RLS/NNP
dopamine/NNP antagonists/NNS induce/VB symptoms/NNS RLS/NNP
domperidone/NN induce/VB symptoms/NNS RLS/NNP
dopamine/JJ antagonist/NN domperidone/NN induce/VB symptoms/NNS RLS/NNP
domperidone/JJ therapy/NN added/VBN developed/VBD dyspepsia/NN postprandial/JJ
domperidone/JJ therapy/NN added/VBN developed/VBD dyspepsia/NN
mirtazapine/NN RLS/NNP added/VBN developed/VBD dyspepsia/NN postprandial/JJ
mirtazapine/NN RLS/NNP added/VBN developed/VBD dyspepsia/NN
domperidone/JJ therapy/NN added/VBN RLS/NNP
domperione/NN effect/NN support/VB relationship/NN use/NN symptoms/NNS RLS/NNP
domperione/NN RLS/NNP
dopamine/JJ antagonists/NNS individuals/NNS associated/VBN RLS/NNP
vitamin/NN E/NN lack/NN due/JJ Myopathy/RB
E/NN lack/NN due/JJ Myopathy/RB
vitamin/NN E/NN lack/NN due/JJ induced/VBN myopathy/RB
E/NN lack/NN due/JJ induced/VBN myopathy/RB
steroids/NNS using/VBG obtained/VBN departments/NNS patients/NNS myopathic/JJ
steroids/NNS using/VBG obtained/VBN results/NNS encouraged/VBN investigate/VB doses/NNS rats/NNS rendered/VBN myopathic/JJ
CIBA/NNP Dianabol/NNP agent/NN effects/NNS investigate/VB encouraged/VBN results/NNS obtained/VBN departments/NNS patients/NNS myopathic/JJ
CIBA/NNP Dianabol/NNP agent/NN effects/NNS investigate/VB doses/NNS rats/NNS rendered/VBN myopathic/JJ
vitamin/NN E/NN rendered/VBN rats/NNS doses/NNS investigate/VB encouraged/VBN results/NNS obtained/VBN departments/NNS patients/NNS myopathic/JJ
E/NN rendered/VBN rats/NNS doses/NNS investigate/VB encouraged/VBN results/NNS obtained/VBN departments/NNS patients/NNS myopathic/JJ
vitamin/NN E/NN rendered/VBN myopathic/JJ
E/NN rendered/VBN myopathic/JJ
Dianabol/NNP agent/NN effects/NNS investigate/VB encouraged/VBN results/NNS obtained/VBN departments/NNS patients/NNS myopathic/JJ
Dianabol/NNP agent/NN effects/NNS investigate/VB doses/NNS rats/NNS rendered/VBN myopathic/JJ
steroids/NNS disease/NN myopathic/JJ
steroids/NNS disease/NN
vitamin/NNP E/NNP certainly/RB unknown/JJ carried/VBN have/VBP conclude/VBP affirming/VBG efficacy/NN steroids/NNS disease/NN myopathic/JJ
vitamin/NNP E/NNP certainly/RB unknown/JJ carried/VBN have/VBP conclude/VBP affirming/VBG efficacy/NN steroids/NNS disease/NN
E/NNP certainly/RB unknown/JJ carried/VBN have/VBP conclude/VBP affirming/VBG efficacy/NN steroids/NNS disease/NN myopathic/JJ
E/NNP certainly/RB unknown/JJ carried/VBN have/VBP conclude/VBP affirming/VBG efficacy/NN steroids/NNS disease/NN
oral/JJ contraceptives/NNS hypertension/NN association/NN artery/NN aneurysm/NN case/NN reported/VBN patient/NN locked/NN
oral/JJ contraceptives/NNS hypertension/NN association/NN artery/NN aneurysm/NN case/NN reported/VBN syndrome/NN in/IN
oral/JJ contraceptives/NNS hypertension/NN association/NN artery/NN aneurysm/NN case/NN reported/VBN syndrome/NN
contraceptives/NNS hypertension/NN association/NN artery/NN aneurysm/NN case/NN reported/VBN patient/NN locked/NN
contraceptives/NNS hypertension/NN association/NN artery/NN aneurysm/NN case/NN reported/VBN syndrome/NN in/IN
contraceptives/NNS hypertension/NN association/NN artery/NN aneurysm/NN case/NN reported/VBN syndrome/NN
oral/JJ contraceptives/NNS hypertension/NN
contraceptives/NNS hypertension/NN
adriamycin/NN ribose/NN d/SYM effect/NN evaluation/NN evoked/VBD cardiotoxicity/RB
d/SYM effect/NN evaluation/NN evoked/VBD cardiotoxicity/RB
ribose/NN d/SYM effect/NN evaluation/NN evoked/VBD cardiotoxicity/RB
d/SYM induced/VBN myocardiopathy/RB
ribose/JJ d/SYM induced/VBN myocardiopathy/RB
Adriamycin/NNP evoked/VBD toxicity/NN cardiac/JJ
Adriamycin/NNP evoked/VBD toxicity/NN
ADR/NNP influence/VB cardiotoxicity/RB
D/NNP influence/VB cardiotoxicity/RB
ribose/JJ D/NNP influence/VB cardiotoxicity/RB
Famotidine/NNP H/NNP used/VBD prevention/NN ulcers/NNS
propofol/NN delirium/NN
nitric/JJ oxide/NN convulsions/NNS
oxide/NN convulsions/NNS
GABA/NNP receptors/NNP blockage/NN trough/VBZ convulsions/NNS
L/NNP arginine/NN NAME/NNP effects/NNS due/JJ role/NN observed/VBN models/NNS epilepsy/NN
NAME/NNP effects/NNS due/JJ role/NN observed/VBN models/NNS epilepsy/NN
Nitric/JJ oxide/NN has/VBZ role/NN observed/VBN models/NNS epilepsy/NN
oxide/NN has/VBZ role/NN observed/VBN models/NNS epilepsy/NN
NO/RB oxide/NN has/VBZ role/NN observed/VBN models/NNS epilepsy/NN
NO/DT syntheses/NNS precursor/NN arginine/NN NAME/NNP effects/NNS due/JJ role/NN observed/VBN models/NNS epilepsy/NN
L/NNP NAME/NNP effects/NNS due/JJ role/NN observed/VBN models/NNS epilepsy/NN
arginine/NN NAME/NNP effects/NNS due/JJ role/NN observed/VBN models/NNS epilepsy/NN
NO/RB effects/NNS determine/VB characteristics/NNS epilepsy/NNP
lindane/NN characteristics/NNS epilepsy/NNP
L/NNP administration/NN arginine/VBP increased/VBN incidence/NN convulsion/JJ
arginine/VBP increased/VBN incidence/NN convulsion/JJ
L/NNP administration/NN arginine/VBP increased/VBN shortened/VBN convulsion/NN
arginine/VBP increased/VBN shortened/VBN convulsion/NN
L/NNP pretreatment/NN decreased/VBD incidence/NN convulsion/NN
NAME/JJ L/NNP pretreatment/NN decreased/VBD incidence/NN convulsion/NN
L/NNP pretreatment/NN decreased/VBD convulsion/VB
NAME/JJ L/NNP pretreatment/NN decreased/VBD convulsion/VB
L/NNP pretreatment/NN decreased/VBD convulsion/VB dose/NN convulsive/JJ
NAME/JJ L/NNP pretreatment/NN decreased/VBD convulsion/VB dose/NN convulsive/JJ
NO/NNP plays/VBZ model/NN seizures/NNS
glucose/NN transport/NN followed/VBN system/NN dysfunction/NN associated/VBN dementia/NN
glucose/NN GLUT/NNP transport/NN followed/VBN system/NN dysfunction/NN associated/VBN dementia/NN
glucose/NN metabolism/NN dysfunction/NN associated/VBN dementia/NN
galactose/NN injections/NNS induce/VB deterioration/NN memory/NN
galactose/NN injections/NNS induce/VB deterioration/NN
galactose/NN treatment/NN effects/NNS tested/VBN induce/VB deterioration/NN memory/NN
galactose/NN treatment/NN effects/NNS tested/VBN induce/VB deterioration/NN
galactose/NN exposure/NN have/VB worth/JJ investigating/VBG improvement/NN deficits/NNS associated/VBN hypometabolism/NN AD/NNP
galactose/NN exposure/NN have/VB worth/JJ investigating/VBG improvement/NN deficits/NNS associated/VBN hypometabolism/NN glucose/NN
galactose/NN exposure/NN have/VB worth/JJ investigating/VBG improvement/NN deficits/NNS associated/VBN hypometabolism/NN
betaine/JJ isoproterenol/NN pathways/NNS transducer/NN Regulation/NN injury/NN myocardial/JJ
betaine/JJ isoproterenol/NN pathways/NNS transducer/NN Regulation/NN injury/NN
isoproterenol/NN pathways/NNS transducer/NN Regulation/NN injury/NN myocardial/JJ
isoproterenol/NN pathways/NNS transducer/NN Regulation/NN injury/NN
betaine/NN effects/NNS investigate/VB ischemia/NN myocardial/JJ
betaine/NN effects/NNS investigate/VB ischemia/NN
betaine/NN administration/NN reduced/VBD prevented/VBD remodeling/NN ventricular/NN
betaine/NN administration/NN reduced/VBD prevented/VBD remodeling/NN
betaine/NN damage/NN myocardial/JJ
betaine/NN damage/NN
betaine/JJ pretreatment/NN attenuated/VBD isoproterenol/NN induced/VBN ischemia/NN myocardial/JJ
betaine/JJ pretreatment/NN attenuated/VBD isoproterenol/NN induced/VBN ischemia/NN
Temocapril/NNP modulates/VBZ injury/NN nephrosis/NNS
puromycin/NN nephrosis/NNS injury/NN glomerular/NN
puromycin/NN nephrosis/NNS injury/NN
aminonucleoside/NN nephrosis/NNS injury/NN glomerular/NN
aminonucleoside/NN nephrosis/NNS injury/NN
angiotensin/NN SH/NN Temocapril/NNP modulates/VBZ injury/NN nephrosis/NNS
Temocapril/NNP modulates/VBZ injury/NN glomerular/NN
Temocapril/NNP modulates/VBZ injury/NN
angiotensin/NN SH/NN Temocapril/NNP modulates/VBZ injury/NN glomerular/NN
angiotensin/NN SH/NN Temocapril/NNP modulates/VBZ injury/NN
temocapril/NN administration/NN acting/VBG inhibited/VBD hypertrophy/RB
temocapril/NN administration/NN acting/VBG inhibited/VBD angiotensin/NN converting/VBG inhibitor/NN proteinuria/NN
angiotensin/NN converting/VBG inhibitor/NN proteinuria/NN
angiotensin/NN inhibited/VBD acting/VBG induced/VBN rats/NNS nephrotic/JJ
temocapril/NN administration/NN acting/VBG induced/VBN rats/NNS nephrotic/JJ
puromycin/NN aminonucleoside/NN prevented/VBD glomerulosclerosis/NNS
aminonucleoside/NN prevented/VBD glomerulosclerosis/NNS
PAN/NNP aminonucleoside/NN prevented/VBD glomerulosclerosis/NNS
angiotensin/NN inhibited/VBD hypertrophy/RB
temocapril/NN administration/NN acting/VBG inhibited/VBD prevented/VBD glomerulosclerosis/NNS
puromycin/NN aminonucleoside/NN prevented/VBD inhibited/VBD acting/VBG induced/VBN rats/NNS nephrotic/JJ
aminonucleoside/NN prevented/VBD inhibited/VBD acting/VBG induced/VBN rats/NNS nephrotic/JJ
PAN/NNP aminonucleoside/NN prevented/VBD inhibited/VBD acting/VBG induced/VBN rats/NNS nephrotic/JJ
angiotensin/NN inhibited/VBD prevented/VBD glomerulosclerosis/NNS
puromycin/NN aminonucleoside/NN prevented/VBD inhibited/VBD hypertrophy/RB
aminonucleoside/NN prevented/VBD inhibited/VBD hypertrophy/RB
PAN/NNP aminonucleoside/NN prevented/VBD inhibited/VBD hypertrophy/RB
Temocapril/NNP attenuate/VB proteinuria/NN
PAN/NNP group/NN weeks/NNS %/NN was/VBD index/NN glomerulosclerosis/JJ
temocapril/NN effective/JJ protected/VBD rats/NNS neprotic/JJ
folinic/JJ acid/NN C/NNP treatment/NN cancer/NN gastric/JJ
folinic/JJ acid/NN C/NNP treatment/NN cancer/NN
acid/NN C/NNP treatment/NN cancer/NN gastric/JJ
acid/NN C/NNP treatment/NN cancer/NN
5/CD dose/NN High/NNP acid/NN C/NNP treatment/NN cancer/NN gastric/JJ
5/CD dose/NN High/NNP acid/NN C/NNP treatment/NN cancer/NN
fluorouracil/NN High/NNP acid/NN C/NNP treatment/NN cancer/NN gastric/JJ
fluorouracil/NN High/NNP acid/NN C/NNP treatment/NN cancer/NN
mitomycin/NN C/NNP treatment/NN cancer/NN gastric/JJ
mitomycin/NN C/NNP treatment/NN cancer/NN
C/NNP treatment/NN cancer/NN gastric/JJ
C/NNP treatment/NN cancer/NN
folinic/JJ acid/NN fluorouracil/NN BACKGROUND/NNP shown/VBN effective/JJ toxicity/NN
acid/NN fluorouracil/NN BACKGROUND/NNP shown/VBN effective/JJ toxicity/NN
FA/NNP acid/NN fluorouracil/NN BACKGROUND/NNP shown/VBN effective/JJ toxicity/NN
folinic/JJ acid/NN part/NN regimens/NNS cancer/NN gastric/JJ
folinic/JJ acid/NN part/NN regimens/NNS cancer/NN
acid/NN part/NN regimens/NNS cancer/NN gastric/JJ
acid/NN part/NN regimens/NNS cancer/NN
folinic/JJ acid/NN fluorouracil/NN BACKGROUND/NNP AGC/NNP
acid/NN fluorouracil/NN BACKGROUND/NNP AGC/NNP
FA/NNP acid/NN part/NN regimens/NNS cancer/NN gastric/JJ
FA/NNP acid/NN part/NN regimens/NNS cancer/NN
FA/NNP acid/NN fluorouracil/NN BACKGROUND/NNP AGC/NNP
5/CD infusion/NN BACKGROUND/NNP fluorouracil/NN acid/NN part/NN regimens/NNS cancer/NN gastric/JJ
5/CD infusion/NN BACKGROUND/NNP fluorouracil/NN acid/NN part/NN regimens/NNS cancer/NN
fluorouracil/NN acid/NN part/NN regimens/NNS cancer/NN gastric/JJ
fluorouracil/NN acid/NN part/NN regimens/NNS cancer/NN
5/CD infusion/NN BACKGROUND/NNP AGC/NNP
fluorouracil/NN BACKGROUND/NNP AGC/NNP
5/CD fluorouracil/NN acid/NN part/NN regimens/NNS cancer/NN gastric/JJ
5/CD fluorouracil/NN acid/NN part/NN regimens/NNS cancer/NN
FU/NNP 5/CD fluorouracil/NN acid/NN part/NN regimens/NNS cancer/NN gastric/JJ
FU/NNP 5/CD fluorouracil/NN acid/NN part/NN regimens/NNS cancer/NN
5/CD fluorouracil/NN BACKGROUND/NNP AGC/NNP
FU/NNP 5/CD fluorouracil/NN BACKGROUND/NNP AGC/NNP
5/CD infusion/NN BACKGROUND/NNP shown/VBN effective/JJ toxicity/NN
fluorouracil/NN BACKGROUND/NNP shown/VBN effective/JJ toxicity/NN
5/CD fluorouracil/NN BACKGROUND/NNP shown/VBN effective/JJ toxicity/NN
FU/NNP 5/CD fluorouracil/NN BACKGROUND/NNP shown/VBN effective/JJ toxicity/NN
FA/NNP FU/NNP study/NN found/VBD rate/NN toxicity/NN
mitomycin/NNP C/NNP FU/NNP study/NN found/VBD rate/NN toxicity/NN
C/NNP FU/NNP study/NN found/VBD rate/NN toxicity/NN
MMC/NNP study/NN found/VBD rate/NN toxicity/NN
5/CD bolus/NNS study/NN found/VBD rate/NN toxicity/NN
FU/NNP study/NN found/VBD rate/NN toxicity/NN
FA/NNP hour/NN 2000/CD recruited/VBD AGC/NNP
5/CD preceded/NNS 2000/CD recruited/VBD AGC/NNP
FU/NNP mg/JJ preceded/NNS 2000/CD recruited/VBD AGC/NNP
FA/NNP CONCLUSIONS/NNS regimen/NN AGC/NNP
5/CD dose/NN High/NNP CONCLUSIONS/NNS regimen/NN AGC/NNP
FU/NNP FA/NNP CONCLUSIONS/NNS regimen/NN AGC/NNP
MMC/NNP regimen/NN AGC/NNP
cisplatin/VB alternative/NN serve/VB has/VBZ considered/VBN occur/VB HUS/NNP
galantamine/NN disorder/NN autistic/JJ
galantamine/NN disorder/NN
galantamine/NN use/NN assess/VB treatment/NN interfering/VBG children/NNS autism/NN
galantamine/NN trial/NN METHODS/NNS children/NNS autism/NN
galantamine/NN was/VBD appeared/VBD beneficial/JJ treatment/NN interfering/VBG children/NNS autism/NN dyscontrol/NN behavioral/JJ
galantamine/NN was/VBD appeared/VBD beneficial/JJ treatment/NN interfering/VBG children/NNS autism/NN dyscontrol/NN
galantamine/NN was/VBD appeared/VBD beneficial/JJ treatment/NN interfering/VBG children/NNS autism/NN aggression/NN
galantamine/NN was/VBD appeared/VBD beneficial/JJ treatment/NN interfering/VBG children/NNS autism/NN inattention/NN
galantamine/NN was/VBD appeared/VBD beneficial/JJ treatment/NN interfering/VBG children/NNS autism/NN
Valproate/NNP induced/VBN encephalopathy/NN
Valproate/NNP induced/VBN effect/NN encephalopathy/NN
valproate/JJ treatment/NN effect/NN encephalopathy/NN
valproate/NN due/JJ epilepsy/NN
DSP/NNP pretreatment/NN reduced/VBN induced/VBN hyperactivity/NN
4/CD pretreatment/NN reduced/VBN induced/VBN hyperactivity/NN
DSP/NNP blocked/VBN rearings/NNS amphetamine/NN stereotypies/NNS
4/CD DSP/NNP blocked/VBN rearings/NNS amphetamine/NN stereotypies/NNS
amphetamine/NN stereotypies/NNS
amphetamine/JJ hyperactivity/NN reduction/NN blocked/VBN noradrenaline/NN uptake/NN blocking/VBG agent/NN prevents/VBZ action/NN neurotoxic/JJ
desipramine/NN agent/NN prevents/VBZ action/NN neurotoxic/JJ
noradrenaline/NN blocked/VBN reduction/NN hyperactivity/NN
noradrenaline/NN uptake/NN blocking/VBG agent/NN prevents/VBZ action/NN neurotoxic/JJ
DSP/NNP induced/VBN hyperactivity/NN reduction/NN blocked/VBN noradrenaline/NN uptake/NN blocking/VBG agent/NN prevents/VBZ action/NN neurotoxic/JJ
4/CD DSP/NNP induced/VBN hyperactivity/NN reduction/NN blocked/VBN noradrenaline/NN uptake/NN blocking/VBG agent/NN prevents/VBZ action/NN neurotoxic/JJ
DSP/NNP action/NN neurotoxic/JJ
4/CD DSP/NNP action/NN neurotoxic/JJ
DSP/NNP induced/VBN hyperactivity/NN
4/CD DSP/NNP induced/VBN hyperactivity/NN
DSP/NNP action/NN prevents/VBZ agent/NN blocking/VBG uptake/NN noradrenaline/NN blocked/VBN reduction/NN hyperactivity/NN
4/CD DSP/NNP action/NN prevents/VBZ agent/NN blocking/VBG uptake/NN noradrenaline/NN blocked/VBN reduction/NN hyperactivity/NN
amphetamine/JJ hyperactivity/NN
desipramine/NN agent/NN blocking/VBG uptake/NN noradrenaline/NN blocked/VBN reduction/NN hyperactivity/NN
barium/NN ingestion/NN induced/VBN dysfunction/NN hypersensitivity/NN
chloride/NN ingestion/NN induced/VBN dysfunction/NN hypersensitivity/NN
barium/NN ingestion/NN induced/VBN dysfunction/NN Cardiovascular/NNP
barium/NN ingestion/NN induced/VBN dysfunction/NN
chloride/NN ingestion/NN induced/VBN dysfunction/NN Cardiovascular/NNP
chloride/NN ingestion/NN induced/VBN dysfunction/NN
sodium/NN pentobarbital/NN dysfunction/NN hypersensitivity/NN
pentobarbital/NN dysfunction/NN hypersensitivity/NN
sodium/NN pentobarbital/NN dysfunction/NN Cardiovascular/NNP
sodium/NN pentobarbital/NN dysfunction/NN
pentobarbital/NN dysfunction/NN Cardiovascular/NNP
pentobarbital/NN dysfunction/NN
Barium/RB hooded/VBD characterized/VBN hypertension/NN
barium/NNP treatment/NN month/NN evident/JJ hypertension/NN
barium/NN induced/VBN disturbances/NNS
barium/NN induced/VBN system/NN within/IN
barium/NN induced/VBN system/NN the/DT
barium/NN induced/VBN system/NN cardiovascular/JJ
barium/NN induced/VBN system/NN
sodium/NN pentobarbital/NN system/NN hypersensitivity/NN
pentobarbital/NN system/NN hypersensitivity/NN
barium/NN effect/NN aspect/NN hypersensitivity/NN
barium/NN exposure/NN induced/VBN disorder/NN existence/NN suggest/VBP contractility/NN disturbances/NNS metabolic/JJ
barium/NN exposure/NN induced/VBN disorder/NN existence/NN suggest/VBP contractility/NN disturbances/NNS
sodium/NN pentobarbital/NN system/NN hypersensitivity/NN contractility/NN disturbances/NNS metabolic/JJ
sodium/NN pentobarbital/NN system/NN hypersensitivity/NN contractility/NN disturbances/NNS
pentobarbital/NN system/NN hypersensitivity/NN contractility/NN disturbances/NNS metabolic/JJ
pentobarbital/NN system/NN hypersensitivity/NN contractility/NN disturbances/NNS
sodium/NN pentobarbital/NN system/NN hypersensitivity/NN
pentobarbital/NN system/NN hypersensitivity/NN
barium/NN exposure/NN induced/VBN disorder/NN cardiomyopathic/JJ
barium/NN exposure/NN induced/VBN disorder/NN
sodium/NN pentobarbital/NN system/NN hypersensitivity/NN contractility/NN suggest/VBP existence/NN disorder/NN cardiomyopathic/JJ
sodium/NN pentobarbital/NN system/NN hypersensitivity/NN contractility/NN suggest/VBP existence/NN disorder/NN
pentobarbital/NN system/NN hypersensitivity/NN contractility/NN suggest/VBP existence/NN disorder/NN cardiomyopathic/JJ
pentobarbital/NN system/NN hypersensitivity/NN contractility/NN suggest/VBP existence/NN disorder/NN
barium/NN exposure/NN induced/VBN disorder/NN existence/NN suggest/VBP contractility/NN hypersensitivity/NN
Amiodarone/NNP mass/NN glomerulonephritis/NNS disease/NN patient/JJ valvular/NN
Amiodarone/NNP mass/NN glomerulonephritis/NNS disease/NN heart/NN
Amiodarone/NNP mass/NN glomerulonephritis/NNS disease/NN
Amiodarone/NNP is/VBZ threatening/VBG tachycardia/NN
Amiodarone/NNP is/VBZ threatening/VBG anti/NN drug/NN arrhythmic/JJ
amiodarone/NN developed/VBD mass/NN proteinuria/NN
amiodarone/NN developed/VBD patient/NN case/NN disease/NN valvular/NN
amiodarone/NN developed/VBD patient/NN case/NN disease/NN heart/NN
amiodarone/NN developed/VBD patient/NN case/NN disease/NN
amiodarone/NN lesion/NN indicating/VBG containing/VBG composed/VBN suspected/VBN cancer/NN lung/NN
amiodarone/NN lesion/NN indicating/VBG containing/VBG composed/VBN suspected/VBN cancer/NN
amiodarone/NN lesion/NN neoplasm/NN
amiodarone/JJ treatment/NN complication/NN suggests/VBZ difficult/JJ diagnosis/NN amiodarone/NN lesion/NN neoplasm/NN
